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1001-69 Aspirin Before Reperfusion Blunts the Infarct Size 
Limiting Effect of Atorvastatin
Yochai Birnbaum, Yu Lin, Yumei Ye, Juan D. Martinez, Ming-He Huang, Jose R. Perez-
Polo, Barry F. Uretsky, University Of Texas Medical Branch, Galveston, TX
Background: Aspirin (ASA) has a strong anti-platelet activity and reduces mortality 
in patients with acute myocardial infarction. Statins reduce infarct size (IS). This dose-
dependent effect is mediated by upregulation of cycloxygenase-2 (COX2). Selective 
COX2 inhibitors block the IS-limiting effect of atorvastatin (ATV). We assess whether ASA, 
administered before reperfusion, abrogates the infarct size (IS) limiting effect of ATV.
Methods: Sprague-Dawley rats received 3-day oral ATV (10mg/kg/d) or water alone. 
Rats underwent 30min coronary artery occlusion and 4h reperfusion (n=8 in each group). 
At 27 min of ischemia rats received intravenous ASA (5, 10, or 20 mg/kg) or saline. Area 
at risk (AR) was assessed by blue dye and IS by triphenyl-tetrazolium-chloride (TTC).
Results: ATV reduced IS compared with controls. Intravenous ASA alone did not affect 
IS; however, ASA dose-dependely attenuated the protective effect of ATV (Figure. * 
p<0.01 vs. control and ASA; # p<0.02 vs ATV). COX2 activity was as follows: control: 
8.93±0.90 pg/mg; ATV: 75.85±1.08 pg/mg; ATV+ASA 5: 34.39±1.48 pg/mg; ATV+ASA 10: 
19.87±1.10 pg/mg; and ATV+ASA 20: 9.36±0.94 pg/mg.
Conclusions: ASA, administered before reperfusion in doses comparable to those used 
in the clinical setting, abrogates the IS-limiting effect of statins in a model with mechanical 
occlusion of the coronary artery. This potential adverse interaction should be further 
investigated in the clinical setting of acute coronary syndromes. 
10:00 a.m.
1001-70 The Role of Adenosine in Activation of Endothelial 
Nitric Oxide Synthase (eNOS) by Atorvastatin: 
Adenosine, Generated By Ecto-5’-Nucleotidase, is 
Needed for Akt Phosphorylation by Phosphorylated 3-
Phosphoinositide-Dependent Kinase 1
Yumei Ye, Merla Ramanna, Yu Lin, Juan D. Martinez, Barry F. Uretsky, Jose R. Perez-
Polo, Yochai Birnbaum, University Of Texas Medical Branch, Galveston, TX
Background: The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors 
(statins) activate Phosphatidylinositol 3-Kinase (PI3K) that activates both ecto-5’-
nucleotidase (E5N) and phosphorylates 3-Phosphoinositide-Dependent Kinase 1 
(PDK1). Phosphorylated PDK1 phosphorylates Akt that phosphorylates endothelial 
nitric oxide synthase (eNOS). However, it is unclear whether the cardioprotective effects 
of adenosine, generated by E5N, are independent of eNOS activation. We assessed 
whether theophylline, a non-selective adenosine receptor inhibitor, affects the induction 
of phosphorylation (P-) of PDK1, Akt and eNOS by atorvastatin (ATV).
Methods: Mice received intra-peritoneal ATV (20 mg/kg), theophylline (T, 50 mg/kg), their 
combination (T+ATV), or saline alone. Six hours later the hearts were explanted and 
assessed for myocardial expression of PDK1, P-PDK1, Akt, P-Akt, eNOS, and P-eNOS 
(% of the expression in the controls).
Results: ATV increased the expression of P-PDK1, P-Akt, and P-eNOS. T alone had no 
effect on the expression of the enzymes; however, T blocked the ATV-induced increased 
expression of P-Akt and P-eNOS.
Conclusions: The ATV-induced Akt and eNOS phosphorylation by P-PDK1 is 
dependent on adenosine.
Protein Expression (% of controls)
Control T ATV T+ATV p value
PDK1 100.0+0.5 98.0+1.5 98.0+0.5 101.5+0.1 ns
P-PDK1 100.0+5.5 97.0+2.5 1198.5+1.5 1037.8+1 <0.001
Akt 100.0+1.0 96.5+2.5 96.0+0.1 95.5+0.5 ns
P-Akt 100.0+0.1 100.5+1.5 217.0+2.0 101.5+0.5 <0.001
eNOS 100.0+0.5 94.5+0.1 100.5+1.0 95.5+0.1 0.003
P-eNOS 100.0+0.1 98.0+1.0 204.5+4.5 91.5+0.5 <0.001
10:00 a.m.
1001-71 Potent mitochondria-targeted Peptides reduce 
Myocardial Infarctionin Rats
Janghyun Cho, Kyungheon Won, DunLi Wu, Yi Soong, Shaoyi Liu, Hazel H. Szeto, Mun 
K. Hong, Weill Cornell Medical College, Cornell, New York, NY, St. Carollo Hospita, 
Suncheon, Jeonnam, South Korea
Background: Previously we demonstrated that a novel opiate peptide, 2’,6’-
dimethyltyrosine(Dmt)-D-Arg-Phe-Lys-NH2, provided cardioprotection against myocardial 
stunning in vivo. We subsequently showed that this peptide targeted mitochondria and can 
scavenge reactive oxygen species (ROS). The objective of this study was to determine 
the role of opioid versus antioxidant activity in cardioprotection.
Methods: We compared two mitochondria-targeted peptide analogues that lacked opioid 
activity: SS-31 (D-Arg-Dmt-Lys-Phe-NH2) and SS-20 (Phe-D-Arg-Phe-Lys-NH2). They 
differ in that only SS-31 has scavenging ability. Rats (n = 8/group) were randomized to SS-
31, SS-20, or placebo. The drugs (3 mg/kg) or saline was administered intraperitoneally 
(IP) 30 minutes prior to ligation of left anterior descending artery for 60 minutes, and 
another dose given IP 5 minutes before reperfusion for 60 minutes. Study endpoints 
included myocardial infarct size, cardiac arrhythmia, and myocardial lipid peroxidation.
Results: The area at risk was similar among the groups. However, the infarct area/area 
at risk was significantly smaller in the treatment groups (53.9 ± 1.1% in SS-31 group, 
47.1 ± 1.4% in SS-20 group, versus 59.9±1% in the controls, p<0.01). Lipid peroxidation 
was significantly reduced by both SS-31 and SS-20 treatment. Arrhythmia occurred only 
during early period of coronary occlusion and was less frequent and less severe in the 
peptide treatment groups versus the controls (Lambeth score 5 points, 3 points, versus 
13 points in the contols, p<0.05).
Conclusions: This study shows that pretreatment with both SS-31 and SS-20 significantly 
reduced myocardial lipid peroxidation and infarct size in ischemia reperfusion injury, and 
suggests that the cardioprotective properties of (Dmt)-D-Arg-Phe-Lys-NH2) was primarily 
mediated by its antioxidant properties. Since SS-20 does not scavenge ROS, it most 
likely reduces ROS production during ischemia-reperfusion.
10:00 a.m.
1001-72 Circulating Human Monocytes Express a Characteristic 
Proteome Profile During the Acute Coronary Syndrome
Jose Tunon, Maria G. Barderas, Veronica M. Darde, Fernando De La Cuesta, Jose J. 
Jimenez-Nacher, Maria C. Duran, Alberto Lazaro, Julio Gallego-Delgado, Nieves Tarin, 
Lorenzo Lopez-Bescos, Jesús Egido, Fernando Vivanco, Fundacion Jimenez Diaz, 
Madrid, Spain, Universidad Complutense de Madrid, Madrid, Spain
Background: Monocyte-macrophages participate in the genesis of non-ST-elevation 
acute coronary syndromes (NSTEACS). Assessment of monocyte protein expression 
in NSTEACS may disclose new pathways in the pathophysiology of these syndromes. 
Novel proteomic techniques combining two-dimensional electrophoresis and mass 
spectrometry allow to analyze the expression of multiple proteins at once.
Methods: Proteomic analysis was performed in circulating monocytes from 18 patients with 
NSTEACS (on admission, at 4 days, 2 months and 6 months), 10 patients with stable coronary 
artery disease (SCAD) and 12 healthy controls without significant differences in age and sex.
Results: The monocytes from patients with NSTEACS displayed significantly different 
expression of 17 proteins as compared to those of SCAD subjects. The number of 
differentially expressed proteins was maximal on admission and decreased progressively 
on succesive examinations. At six months there was not differential protein expression, 
suggesting a stabilization in the proteome of circulating monocytes. Proteins whose 
expression was changed are involved in energetic and metabolic processes (chain A 
triosephosphate isomerase, mannose 6 phosphate receptor, protein disulfide isomerase, 
piruvate kinase M2 isozyme, alpha 1 enolase, chain A nuclease DNAse/RNAse sugar 
non-specific, chain A endonuclease, nuclease, adenosin triphosphate synthase and 
Glutathione transferase), hydrolysis (mature cathepsin D, cathepsin D proform, and uracil 
DNA glycosylase), blood transport of different substances (albumin precursor), contraction 
(vimentin), inflammation (S100 Calcium binding protein A8) and neoangiogenesis 
(Thymidine phosphorylase precursor).
Conclusion: Proteomic analysis allowed to identify 17 proteins with differential expression 
in the circulating monocytes of NSTEACS as compared to SCAD subjects. Further 
studies are required to explore if these variations have a role in the pathophysiology of 
this disorder and whether changes in serum levels of any of these proteins may have 
prognostic implications.
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1001-73 Manganese Superoxide Dismutase Polymorphism is 
Associated with Acute Coronary Syndrome
Hajime Fujimoto, Ryozo Nagai, Minoru Ohno, Toranomon Hospital, Tokyo, Japan, 
University of Tokyo, Tokyo, Japan
Background: Oxidative stress plays an important role in atherogenesis. Manganese 
superoxide dismutase (MnSOD) is an antioxidant enzyme localized in the mitochondria, 
where it catalyzes the conversion of superoxide radicals. There are two genetic variants of 
MnSOD arising from a valine-to-alanine substitution in the signal peptide. We previously 
reported that the alanine variant of MnSOD increases the mitochondrial MnSOD activity, 
and protects macrophage against the oxidized low density lipoprotein(oxLDL)-induced 
apoptosis. So, we hypothesized that MnSOD polymorphism may affect the vulnerability 
of the plaque and occurrence of acute coronary syndrome (ACS). In this study, we 
investigated the association between MnSOD genotype and ACS.
Methods: Blood samples were collected from 641 healthy subjects who did not have any 
symptoms and evidence suggesting coronary artery disease and 87 ACS patients. ACS 
patients underwent coronary angiography (CAG) and diagnosed to be non-ST elevated 
myocardial infarction (NSTEMI) or ST elevated myocardial infarction (STEMI) from CAG, 
ECG, and laboratory findings. MnSOD genotype of each subject was analyzed by real-
time polymerase chain reaction.
Results: Among the 87 ACS patients, 44 were NSTEMI, and 43 were STEMI. The valine 
allele frequency was higher in the ACS patients (0.929) than in the healthy subjects 
(0.835) (odds ratio [OR] = 2.56, P = 0.0016 by chi-square analysis). MnSOD genotype 
distribution in healthy subjects was as follows; alaine/alanine 2.2%, alanine/valine 28.5%, 
and valine/valine 69.3%, and was compatible with Hardy-Weinberg equilibrium. In ACS 
patients the genotype distribution was: alanine/alanine 0.0%, alanine/valine 13.8%, and 
valine/valine 86.2% (ACS patients, P = 0.0037 by chi-square analysis). Multivariate 
logistic regression analysis revealed the valine/valine homozygocity to be a genetic risk 
factor for ACS independent of other coronary risk factors (OR = 2.73, 95% CI (1.38, 5.41); 
P = 0.0041). Conclusion: The alanine variant of MnSOD signal peptide reduces the risk 
of ACS. This may be related to the fact that alanine variant increases the tolerence of 
macrophages against oxLDL-induced apoptosis.
10:00 a.m.
1001-74 Transradial Approach In Percutaneaous Coronary 
Intervention Following Pre-hospital Fibrinolysis 
Reduce Vascular Access Site Complication: Data From 
The French National OPTIMAL Study
Christophe LOUBEYRE, Loic BELLE, Dominique SAVARY, Meyer ELBAZ, Sandrine 
CHARPENTIER, Yves COTTIN, Louis SOULAT, Vanina BONGARD, Darko MILJKOVIC, 
Philippe Gabriel STEG, Jacques PUEL, On behalf of the OPTIMAL Study Group, 
University Hospital, Toulouse, France, Boehringer Ingelheim France, Reims, France
Trans Radial Approach in Percutaneous Coronary Intervention Following Pre-
Hospital Fibrinolysis Reduces Bleeding Compared to the Femoral Route: Data from 
the French National OPTIMAL study.
Background: Early post lysis angiography and percutaneous coronary intervention (PCI) 
is largely used in ST elevation myocardial infarction (STEMI). Bleeding, particularly at the 
access site is a major concern and the impact of radial route as not been assessed.
Methods: From Nov 2004 to Nov 2005 a prospective study was conducted in France with 
STEMI patients treated by PHT and who underwent coronary angiography within 6 hours 
after lysis. The vascular access site was left to the operator’s discretion.
Results: Data were available for analysis in 948 patients. 937 underwent early PCI. Mean 
age was 60.3 years, 82% were males. Arterial access was radial in 39% of cases. Baseline 
characteristics were similar in the two groups, except for cardiogenic shock more common 
in the femoral group (9.1 vs 1.6%, p<0.001). Radial access was associated with more 
frequent use of GP IIb/IIIa inhibitors (18.9 vs 13.7%, p=0.04). The rate of early discharge 
(<3 days) was 44% after trans-radial PCI vs 34 % after transfemoral PCI (p=0.004). 
Femoral (%) Radial (%) OR 95% CI p
Any bleeding 9.44 4.38 2.28 [1.16:4.49] 0.020
Minor bleeding 7.28 3.32 2.29 [1.05:4.97] 0.035
Major bleeding 2.27 1.11 2.06 [0.54:7.84] 0.365
ICH and Stroke 1.78 2.20 0.80 [0.28:2.31] 0.788
Hospital Death: 7.43 2.43 3.22 [1.46:7.10] 0.002
Major bleeding includes tranfusion and/or surgery
Conclusion: Radial approach in early PCI post lysis is associated with a low bleeding 
risk as compared to the femoral route. The radial approach may reduce hospitalization 
stay duration and enables the adjunctive use of a GP IIb/IIIa inhibitors when necessary.
10:00 a.m.
1001-75 Direct Collagen Injection To Thicken The Infarct Scar: 
Collagen Density Determines Angiogenesis
Wangde Dai, Gregory L. Kay, Aarne J. Jyrala, Robert A. Kloner, Heart Institute in the 
Good Samaritan Hospital, Los Angeles, CA
Background: We have reported that implantation of dense collagen (Col) thickened the 
scar of myocardial infarcts in rats, but no angiogenesis developed within the Col implant 
(Col-I). We determined whether the Col density could affect angiogenesis within the Col-I.
Methods: Low density (LD, 35mg/ml) and high density (HD, 65mg/ml) Col were used. Col 
or saline (100 μl) was injected into the scar of 1-week-old myocardial infarcts in rats (n=3 
LD Col; n=11 HD Col; n=13 Saline). Rats were euthanized at 1 week (n=3 LD Col; n=2 
saline) or 6 weeks (n=11 HD Col; n=11 saline), and hearts processed for histology.
Results: Compared with hearts that received saline, Col-I was easily identified 
histologically as homogeneous bright red staining by picrosirius red. H&E staining 
demonstrated capillary-like tubular structures containing erythrocytes within the Col-
I in 3/3 hearts that received LD Col at 1 week (Fig A:40× and C:400×; black arrows; 
435±78 blood vessels/mm2 within the Col-I). The capillary-like tubular structures were not 
observed within the Col-I in 11/11 hearts that received HD Col at 6 weeks (Fig B:40× and 
D:400×). LD and HD Col were associated with thicker scars, but only LD Col reduced LV 
volume (31±5mm2) compared to saline (47±0.2mm2, p=0.03)
Conclusions: Blood vessels developed within LD Col-I at 1 week and were associated with 
less LV remodeling, but did not appear within HD Col-I even at 6 weeks. The results suggest 
that the density of Col significantly affects the development of angiogenesis and remodeling. 
10:00 a.m.
1001-90 Enhanced External Counterpulstion Inhibits Intimal 
Hyperplasia by Downregulating Proliferative Signaling 
Proteins
Yan Zhang, Hong Ma, Gui-Fu Wu, Xiao-Hong He, Xiao-Lin Chen, Dong-Hong Liu, Zhi-
Min Du, Yu-Gan Dong, Ya-Fei Jin, Dian-Qiu Fang, Jin-Yun Luo, Yan Xiong, Kui-Jian 
Wang, William E. Lawson, John CK Hui, Zhen-Sheng Zheng, The Key Laboratory on 
Assisted Circulation, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, 
People’s Republic of China, Cardiology Division, State University of New York at Stony 
Brook, Stony Brook, NY
Background: Hypercholesterolemia promotes intimal hyperplasia (IH). Enhanced 
external counterpulsation (EECP) increases shear stress, improves endothelial function. 
This study hypothesizes that EECP reduces IH by downregulating the VSMCs proliferative 
signaling pathway, altering atherogenesis due to hypercholesterolemia.
Methods: 48 male pigs were randomly assigned to usual diet (N; n=7), high cholesterol 
diet (Chol; n=18), or Chol+EECP (34 hrs of EECP last 7 wks, n=23) for 15 wks. Blood 
lipids, viscosity, hemodynamic parameters were measured. Animals were sacrificed at 15 
wks and their LAD stained with hematoxylin/eosin to assess IH by intima-to-media area 
ratio (IMR) and wall-to-lumen ratio (WLR). VSMCs proliferation index was measured by 
the Elivsion immunohistochemical technique incubated with mouse anti-proliferating cell 
nuclear antigen (PCNA) Ab. Proliferative signaling protein expression were monitored 
by incubating LAD cross sections with rabbit polyclonal phospho-AKT Ab and by indirect 
immunofluorescence using rabbit polyclonal NF-κBp65 Ab. Statistical analysis was by 
Kruskal-Wallis and Mann-Whitney tests.
Results: Cholesterol of CHOL and CHOL+EECP groups were higher than N (9.2±2.8 
and 8.5±3.6 vs 1.9±0.3 mmol/L, p<0.001). Doppler diastolic peak flow in the brachial 
artery increased with EECP (59.5±13.6 vs 24.6±4.7 cm/sec, p<0.001), increasing arterial 
wall shear stress > 2X (54.4±12.5 vs 23.9±7.3 dynes/cm2, p<0.001). EECP decreased 
IMR and WLR (N: 19.7±9.0, 18.0±8.2; CHOL: 36.4±16.6, 24.0±4.4; CHOL+EECP: 
21.3±10.0, 17.6±4.7%, p<0.001), a finding supported by reduction of VSMCs proliferation 
index (N: 0.4±0.2, CHOL: 0.7±0.2, CHOL+EECP: 0.5±0.1; p<0.05), with supression of 
protein kinase AKT (N: 1.0±0.2, CHOL: 14.6±9.5, CHOL+EECP: 1.6±0.5, p<0.05) and 
transcription factor NF-κB (3,893±116, 19,448±3,071, 7,153±1,469, p<0.05) by EECP.
Conclusions: EECP increased shear stress, suppressed activity of VSMC proliferation 
signaling proteins, and decreased intimal hyperplasia due to hypercholesterolemia. This 
paradigm suggests that EECP offers a novel modality for prevention and treatment of 
cardiovascular disease.
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1001-91 Cardioprotective Effect Of Cannabidiol, A Non-
psychoactive Cannabis Constituent, In Ischemic 
Reperfusion Injury
Ronen Durst, Haim Danenberg, Ruth Galilee, Rafael Mechoulam, Ronen Beeri, Keren 
Meir, Ester Grad, Elizabet Axelrod, Thea Pugatch, Chaim Lotan, Hadassah hebrew 
University Medical Center, Jerusalem, Israel, Pharmacology Faculty hebrew University, 
Jerusalem, Israel
Background: Cannabidiol (CBD) is a major, non-psychoactive cannabis constituent with 
anti-inflammatory activity, that is presumably mediated by enhancement of adenosine 
signaling through inhibition of its uptake. As adenosine receptors are promising 
pharmaceutical targets in a wide range of conditions, including cardiac ischemic diseases, 
we tested CBD in rats for cardiac protection from ischemia, both in vivo and in an isolated 
heart model.
Methods: All animals received either CBD (IP, 5mg/kg) or solvent as a control. For the in 
vivo studies the left anterior descending artery was ligated for 30 minutes, the rats were 
allowed to recover and were subsequently treated for 7 days with CBD or solvent. Their 
heart function was studied by echocardiography prior to sacrifice and histological analysis 
of the hearts. For the ex vivo model animals received CBD 24 and 1 hour prior to sacrifice, 
the hearts were removed and mounted on a Langendorff apparatus for physiological 
measurements. Percent necrotic area was determined by conventional triphenyl-
tetrazolium staining. Hematoxilin and eosin stainings were used to assess myocardial 
inflammatory response.
Results: In the in vivo model, the reduction in shortening fraction ratio was significantly 
smaller in CBD treated animals (from 47.21±7.71% to 37.36±6.49 % and from 46.64±5.85 
% to 31.64±9.12 % in the CBD and the controls respectively, P<0.05). Mean infarct 
size was significantly reduced in CBD treated animals, despite nearly identical areas 
at risk (9.6±3.9% vs. 28.2±7.0% in CBD and control arm respectively, P <0.001) and 
was associated with reduced myocardial inflammation. In isolated hearts no significant 
difference could be detected between CBD and control hearts in either infarct size, left 
ventricular developed pressures during ischemia and reperfusion or in coronary flow.
Conclusion: our study shows that CBD induces a substantial in vivo cardioprotective 
effect from ischemia, that could not be observed in an ex vivo model. The mechanism 
seems to be indirect and may be mediated by a reduced inflammatory response. As CBD 
has previously been administered to humans without side effects, it may represent a 
promising novel treatment for ischemia.
10:00 a.m.
1001-92 Value of Serial Measurements of C-Reactive Protein in 
Non-ST-Segment Elevation Acute Coronary Syndromes
Masami Kosuge, Kazuo Kimura, Toshiaki Ebina, Kiyoshi Hibi, Kengo Tukahara, Jyun 
Okuda, Kazuaki Uchino, Satoshi Umemura, Yokohama City University Medical Center, 
Yokohama, Japan
Background: Elevated C-reactive protein level (CRP) at admission is associated with 
poor outcomes in non-ST-segment elevation acute coronary syndrome (NSTE-ACS). 
However, the value of serial measurements of CRP for risk analysis remains unclear.
Methods: We measured high-sensitivity CRP at admission and 24 h later in 215 NSTE-
ACS patients. An elevated CRP at admission (admission elevation) was defined as CRP 
of > 0.300 mg/dl. An increase in CRP after admission (late increase) was considered 
present when CRP 24 h later was higher than CRP at admission. Patients were divided 
into 4 groups according to changes in CRP after admission. Coronary angiography was 
performed a median of 4 days after admission.
Results: There were no significant differences in age, sex, coronary risk factors, 
or multivessel disease in the 4 groups. On multivariate analysis, admission elevation 
(OR1.50, p<0.05) and late increase (OR 6.56, p=0.03) were independent predictors 
of 30-day events (death, (re)infarction, or urgent revascularization). Other significant 
predictors were positive-troponin T (OR 2.30, p=0.03) and ST-segment depression on 
admission at admission (OR 4.26, p=0.03).
Conclusions: In patients with NSTE-ACS, the highest risk of 30-day events is associated 
with an elevated CRP at admission followed by an increase in CRP 24 h later. Patients 
with either of these findings are at moderate risk, and those with neither of these findings 
are at low risk. Serial measurements of CRP after admission are useful for risk analysis.
10:00 a.m.
1001-93 Activated Partial Thromboplastin Time Measurement Is 
Not Associated With Clinical Outcomes in Patients With 
High-risk Non-ST-segment Elevation Acute Coronary 
Syndromes Treated With Unfractionated Heparin
Shaun G. Goodman, Kenneth W. Mahaffey, Karen Chiswell, Marc Cohen, Michael C. 
Kontos, Elliott M. Antman, James J. Ferguson, Robert M. Califf, Richard Becker, Duke 
Clinical Research Institute, Durham, NC
Background: aPTT, bleeding and coronary events have been shown to be related, but 
findings were reported when multi-targeted platelet-directed therapies and early coronary 
revascularization were not common in daily practice.
Methods: We studied the association of aPTT with recurrent ischemic events (7-day 
death, [re]infarction, stroke, recurrent angina requiring revascularization) and non-
coronary artery bypass surgery-related TIMI major bleeding in 4985 pts with high-risk 
NSTE ACS participating in SYNERGY, which emulated current practice where UFH 
is given intravenously and titrated according to a weight-adjusted dosing nomogram 
to a target aPTT of 1.5-2 times ULN (ie, 50-70 sec). Aspirin was given to 95% of pts, 
clopidogrel to 63%, GP IIb/IIIa inhibitors to 58%, early coronary angiography to 92%, 
and revascularization to 66%. aPTT was used as a time-dependent covariate and 
evaluated as a predictor of time to ischemic or major hemorrhagic events in proportional 
hazards regression models. Using discrete variable analysis, aPTT was categorized as 
persistently below a lower threshold of anticoagulation (<50 vs ≥50 sec) for recurrent 
ischemic events and above an upper threshold (>70 vs ≤70 sec) for hemorrhage.
Results: UFH treatment lasted a median of 35 (17, 70) hr. At >6-12 (n=3021), >12-24 
(n=3406) and >24-48 (n=2497) hr, 34%, 41% and 46% of pts achieved the target aPTT 
range. After adjusting for baseline predictors of anticoagulant response and risk score 
(age, hypertension, diabetes, smoking, ST depression, renal function), no significant 
relationship between aPTT values and recurrent ischemic events or major bleeding was 
found. No relationship was seen between clinical outcomes and aPTT values persistently 
above or below the thresholds.
Conclusions: aPTT values were not associated with clinical outcomes in high-risk NSTE 
ACS pts treated with UFH. The required intensity of UFH therapy when administered with 
multisite platelet-directed therapy in patients undergoing early coronary revascularization 
may be relatively modest. Patient characteristics have a powerful effect on the interface 
between traditional laboratory-based measures of anticoagulation and clinical outcomes.
10:00 a.m.
1001-94 Global Outcomes of STEMI: Comparisons of the 
ExTRACT-TIMI 25 Registry and Trial
Benjamin A. Steinberg, Nazanin Moghbeli, Jacqueline L. Buros, Michelle Lew, Sabina 
A. Murphy, Carolyn H. McCabe, Armando García-Castillo, Marianna Janion, José C. 
Nicolau, Keith A A Fox, C. Michael Gibson, David A. Morrow, Elliott M. Antman, Brigham 
and Women’s Hospital & Harvard Medical School, Boston, MA
Background: Outcomes in patients with ST-elevation MI (STEMI) differ between those 
in clinical trials and those in routine practice, as well as across different regions. We 
hypothesized that adjustment for baseline risk would minimize such variations.
Methods: The ExTRACT-TIMI 25 Registry was an observational study of STEMI patients 
presenting to hospitals participating in the ExTRACT-TIMI 25 clinical trial. Consecutive 
STEMI patients not randomized into the trial were registered. Baseline data, in-hospital 
therapies, and events were collected. Baseline risk was assessed by the TIMI Risk Index 
(TRI). To adjust for differences among the countries from which the patients presented, 
the gross national income per capita (GNI) was used.
Results: A total of 3,726 patients were registered from 109 sites in 25 countries. Patients 
in the registry had a higher baseline risk than those in the trial (panel A). Unadjusted 
in-hospital mortality was higher in the registry (8.3%) than in the trial (6.6%) (HR 1.35, 
p<0.001); mortality adjusted for TRI was similar in the two groups (HR=1.02, p=0.92) 
(panel B). GNI was not significantly predictive of in-hospital mortality in the multivariable 
model of the registry population, which included reperfusion.
Conclusion: Patients in the registry had higher mortality than those in the trial, which is 
explained by a higher baseline risk. After adjusting for baseline risk, the GNI of the country 
in which the patient presented did not contribute to predicting in-hospital mortality.
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1001-95 The Prognostic Value of the 12-Lead Electrocardiogram 
(ECG) in Patients Presenting with Acute Coronary 
Syndromes (ACS): Insights from the Global Registry of 
Acute Coronary Events (GRACE) ECG Substudy
Mircea Petrina, Kim A. Eagle, José López-Sendón, Ph Gabriel Steg, Keith A. Fox, 
Martin Stiles, Ann Quill, Shaun G. Goodman, for the GRACE Investigators, University of 
Michigan Medical Center, Ann Arbor, MI, Center for Outcomes Research, University of 
Massachusetts Medical School, Worcester, MA
Background: Recently, there has been an increased interest in non-invasive modalities, 
including ECG, that identify and influence the management of high-risk ACS patients. 
There is limited data on the value of multiple ECG characteristics in predicting outcome 
across the spectrum of ACS, including STEMI (ST elevation MI), non-STEMI, and 
unstable angina.
Methods: We evaluated the predictive value of the initial 12-lead ECG in 4,991 patients 
with suspected ACS at 39 hospitals in 11 countries as part of a prospective substudy of 
GRACE. ECG characteristics included bradycardia, tachycardia, atrial fibrillation (AF) or 
flutter, ventricular tachycardia, left ventricular hypertrophy, atrioventricular (AV) blocks, 
fascicular blocks, left bundle branch block, right bundle branch block, pathologic Q-waves, 
ST-segment and T-wave changes, and QRS duration. All ECGs were interpreted at a core 
laboratory by one of three full-time trained physicians blinded to site interpretation, patient 
characteristics and outcome.
Results: Logistic stepwise regression identified ECG parameters (Table) independently 
predictive of in-hospital mortality.
Conclusions: Tachycardia, ST-segment deviations, atrial fibrillation and prolonged QRS 
duration were the most clinically relevant ECG parameters predictive of poor outcome. 
Reducing the current large number of ECG parameters predictive of outcome after ACS could 
allow the clinician to easier risk stratify and better individualize evidence-based therapies.
Table (N=4,991; model C-statistic 0.79)
Multivariable Predictor Incidence (%) or Median
Odds Ratio 
(OR)
95% Confidence 
Intervals
Age 66.5 (56; 75.8) 1.070* 1.06 - 1.08
Tachycardia 17% 2.05† 1.55 - 2.69
AF or flutter 7% 1.43† 1.00 - 2.05
First degree AV Block 5.6% 0.50† 0.26 - 0.93
High degree AV Block (2nd 
or 3rd) 0.5% 2.71† 0.85 - 8.61
ST deviation 41% 1.78† 1.38 - 2.29
QRS duration 90 (82; 102) 1.011* 1.007 - 1.016
*OR per unit of increase; †OR for presence vs. absence of effect
Age (years) and QRS duration (milliseconds): median (25th; 75th percentile)
10:00 a.m.
1001-111 Prolonged Inflammatory Activity is Associated With 
Rapid Progression of Non-Culprit Complex Lesion in 
Non-ST-Segment Elevation Acute Coronary Syndromes
Tatsuya Nakachi, Masami Kosuge, Toshiaki Ebina, Kiyoshi Hibi, Kengo Tsukahara, 
Jun Okuda, Toshiyuki Ishikawa, Kazuaki Uchino, Satoshi Umemura, Kazuo Kimura, 
Yokohama City University Medical Center, Yokohama, Japan, Yokohama City University 
Graduate School of Medicine, Yokohama, Japan
Background: Although inflammatory activity in the acute phase of NSTE-ACS is 
associated with the vulnerability and progression of atheromatous plaque, its clinical 
significance at follow-up remains unclear.
Methods: We studied 83 patients with NSTE-ACS who had negative troponin T to exclude 
the effect of myocardial necrosis. All patients underwent diagnostic coronary angiography 
(CAG) after a mean of 3 days, percutaneous coronary intervention (PCI) after a mean 
of 7 days, and follow-up CAG after 6 months. Rapid progression was defined as >10% 
diameter reduction of a pre-existing stenosis >50% or >30% diameter reduction of a 
stenosis <50%. Restenosis was defined as diameter stenosis >50%. The difference (Δ) 
between high-sensitivity CRP levels before and 24-48 h after CAG or PCI was evaluated. 
Patients were divided into tertiles according to ΔCRP after follow-up CAG: the lower (G-L; 
mean ΔCRP, -0.059mg/dl) (n=28), middle (G-M; mean ΔCRP, 0.007mg/dl) (n=28), and 
upper tertile (G-H; mean ΔCRP, 0.186mg/dl) (n=27).
Results: There were no differences in age, sex, coronary risk factors, lipid profiles, PCI 
procedural variables, medication, or the rate of restenosis in the 3 groups. In G-L, G-
M, and G-H, CRP on initial admission were 0.170 + 0.193, 0.111 + 0.086, and 0.296 + 
0.563 mg/dl (p=0.14), ΔCRP after initial diagnostic CAG were -0.184 + 1.308, 0.136 + 
1.542, and 1.220 + 1.809 mg/dl (p=0.01), ΔCRP after PCI were 0.149 + 1.532, 0.843 + 
1.911, and 2.086 + 2.932 mg/dl (p=0.02), the rates of the presence of non-culprit complex 
lesion were 36%, 39%, and 67% (p=0.04). The rate of rapid progression of non-culprit 
complex lesion was highest in G-H (30%), followed by G-M (11%), and lowest in G-L (7%) 
(p<0.05), but that of non-culprit smooth lesion did not differ in the 3 groups. G-H had the 
highest risk of rapid progression of non-culprit complex lesion even after adjustment for 
other covariates (OR 1.56, p<0.05).
Conclusions: Active inflammatory response even to nonspecific stimuli lasts for 6 
months after acute presentation and is associated with rapid progression of non-culprit 
complex lesion in NSTE-ACS. Prolonged inflammatory activity may be involved in the 
pathogenesis of non-culprit complex plaque progression.
10:00 a.m.
1001-112 Correlation between Troponin Elevation and Vasoactive 
Medication Use in Patients with Septic Shock
Abdi Jama, Allan Jaffe, Luciano Babuin, Jose Rio, Ogie Gajic, Bekele Afessa, Mayo 
Clinic, Rochester, MN
Background: Multiple organs, including the heart become dysfunctional in response 
to septic shock. Cardiac troponin T, a biomarker of choice of myocardial injury often is 
elevated in patients with sepsis. Concomitant disease, underlying hypotension and/or its 
treatment with vasoactive medications may contribute to this injury and thus elevated 
cardiac troponin T. This retrospective study investigated the relationship between use of 
vasoactive medications and elevations of cardiac troponin T.
Methods: Medical charts of eighty-four patients with septic shock admitted to the medical 
intensive care unit at Mayo Clinic, Rochester, MN from July, 1 2005 through December 
31, 2005 were studied. The definition of septic shock was based on the American 
College of Chest Physicians/Society of Critical Care Medicine consensus criteria. 
Data on demographics, acute physiology score (APS), Acute Physiology and Chronic 
Health Evaluation (APACHE) III, use of invasive/non-invasive mechanical ventilation, 
comorbidities, source of sepsis, cardiac troponin T, ECG, transthoracic echocardiography 
and vasoactive medications were collected. A cardiac troponin T value > 0.01 ng/ml was 
considered elevated. P value <0.05 was considered statistically significant
Results: Of the 84 patients with septic shock; 65 (77%) had troponin levels drawn. Fifty-
six out of the sixty-five (86%) had elevated cardiac troponin. There were no statistically 
significant correlation between the dose of vasopressor medications or inotropes and 
elevations of cardiac troponin T. However, patients who were treated with dobutamine as 
compared to those treated with pressors had higher cardiac troponin T levels (p=0.008).
Conclusions: The majority of patients with septic shock develop elevated cardiac 
biomarkers. Those treated with dobutamine have more marked elevations. Thus, potent 
vasoactive therapies may be negatively synergistic with the underlying disease state in 
terms of myocardial damage in this group of patients.
10:00 a.m.
1001-113 The Effect of Sodium Bicarbonate on Short- and 
Long-Term Renal Outcomes in Patients Undergoing 
an Emergent Cardiac Catheterization: A Prospective 
Randomized Controlled Trial
Masaharu Masuda, Takahisa Yamada, Takanao Mine, Takashi Morita, Shunsuke 
Tamaki, Yasumasa Tsukamoto, Keiji Okuda, Yuusuke Iwasaki, Masatake Fukunami, 
Division of Cardiology, Osaka General Medical Center, Osaka, Japan
Background: Previous studies have shown sodium bicarbonate (SB) prevents contrast- 
induced nephropaty. However, the effect of SB on long-term renal outcomes is uncertain 
in pts undergoing an emergent cardiac catheterization.
Methods: We enrolled 59 pts who had renal dysfunction (serum creatinine > 1.1mg/
dl) and underwent an emergent coronary angiography or intervention. These pts were 
randomized to receive a 154mEq/L infusion of either sodium chloride (SC, n=29) or SB 
(n=30), as a bolus of 3ml/Kg/h for 1 hour before the administration of contrast, followed by 
an infusion of 1ml/Kg/h for 6 hours during and after the procedure. Serum creatinine levels 
were measured at baseline and 2 days and 90 days after the contrast administration.
Results: There were no significant group differences in age, sex, incidence of diabetes 
mellitus, contrast volume, left ventricular ejection fraction or baseline serum creatinine. In 
pts infused with SC, the serum creatinine significantly increased 2 days after the contrast 
administration and remained higher for 90 days. However, in pts with SB, it remained 
unchanged (Fig). For a follow-up period of 7.2±4.1 months, the incidence of death or 
induction of maintenance hemodialysis was tended to be higher in pts infused with SC 
than that with SB (10% vs. 0%, p=0.11).t
Conclusion: In pts undergoing an emergent cardiac catheterization, hydration with SB 
preserves not only short- but also long-term renal function and may reduce the risk of 
death or induction of maintenance hemodialysis.
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1001-114 Fragmented QRS on 12-lead ECG is a Sign of Recent 
Non-ST Elevation Myocardial Infarction in Patients With 
Acute Coronary Syndrome
Mark Alber Michael, Hussam Suradi, Hicham El Masry, Bilal Khan, Mithilesh K. Das, 
Krannert Institute of Cardiology, Indiana University, Indianapolis, IN
Background: ST elevation and Q-wave are highly specific signs of ST-elevation 
myocardial infarction (STEMI), but there is no specific ECG sign of non-Q wave or non-
ST-elevation MI (NSTEMI). Fragmented QRS (fQRS) represents myocardial conduction 
delays due to myocardial ischemia or scar in patients (pts) with coronary artery disease. 
We, therefore, postulate that fQRS on a 12-lead ECG represents NSTEMI.
Methods: ECGs of 927 pts with acute coronary syndrome (ACS) were studied. ECGs 
were obtained 8 hourly during the first 24 hours of MI and then daily till discharge. The 
fQRS on 12-lead ECG was defined by the presence of fragmented QRS, notched R or S 
wave, or RSR` pattern without bundle branch block (BBB), in at least 2 contiguous leads 
in one of the coronary artery territories (LAD: lead V1 to V6, LCx: lead I, aVL and V6, and 
RCA: lead II, III and aVF).
Results: 360 pts had NSTEMI, 84 had STEMI and 370 patients had ACS without MI 
(control group). 57 and 56 pts were excluded from the MI and control group, respectively 
due to BBB or paced rhythm. New fQRS developed within 48 hrs in 177 pts (within 24 hrs 
in 160 pts[44%]) with NSTEMI and only in 17 control pts (49 % and 5%, p<0.001). ROC 
curve showed that sensitivity and specificity of fQRS for a NSTEMI were 49% and 95%, 
respectively (p=0.019, area under the curve=0.723). Positive and negative predictive 
values were 91 and 66%, respectively.
Conclusions: fQRS on 12-lead ECG is a highly specific sign for a recent NSETMI. 44% 
of pts develop fQRS within 24 hours and 49% within 48 hours of NSTEMI. 
10:00 a.m.
1001-115 Von Willebrand Factor But Not Tissue Factor Or Soluble 
CD40 Ligand Are Associated With Increased Risk Of 
Recurrent Events After ACS In PROVE IT-TIMI 22
Kausik K. Ray, David A. Morrow, Christopher P. Cannon, Marc S. Sabatine, Wei 
Guo, Nader Rifai, Eugene Braunwald, Brigham and Women’s Hospital, Boston, MA, 
University of Cambridge, Cambridge, United Kingdom
Background: Thrombosis is central to the pathobiology of acute coronary syndromes 
(ACS). Thus markers of coagulation such as von Willebrand factor (vWF), tissue factor 
(TF) and platelet activation (CD40-ligand) have been proposed as attractive biomarkers 
of the risk of recurrent events after ACS. However the relationship between these markers 
and outcome remains incompletely characterized. 
Methods: We assessed the relationship between vWF (mass), TF and soluble CD40 
ligand (sCD40L) (7 days after ACS) and risk of death or MI among patients enrolled in the 
PROVE IT-TIMI 22 trial (follow up 2 years). The association with outcome was assessed 
in a cox proportional hazard model adjusting for risk factors and statin regimen. 
Results: vWF, TF and soluble CD 40 ligand were measured using an established ELISA 
technique (n= 3892). Compared to quartile 1, risk of death or death/MI was higher among 
patients with vWF levels ≥ median (figure). The adjusted hazard of death and death/MI 
for vWF levels ≥ median were 1.75 (CI 1.11-2.76) and 1.57 (CI 1.23-2.0) respectively. 
However, the risk of death or MI across quartiles of TF and sCD40L and did not differ 
significantly from the lowest quartile (TF: Q4 vs Q1, HR 0.96 CI 0.7-1.4; sCD40L: Q4 
vs Q1, HR 0.95, CI 0.7-1.3). These findings were similar across other individual and 
composite endpoints.
Conclusion Elevated vWF concentration 7 days after ACS was associated with a higher 
risk of death or death/ MI at 2 years. In contrast to earlier findings, sCD40L and TF were 
not associated with outcome. 
10:00 a.m.
1001-116 Coronary Revascularization Procedure in Patients > 80 
Years Presenting with Acute Myocardial Infarction
Nicolas Mansencal, Rémy Pillière, Thierry Joseph, Franck Digne, Pascal Lacombe, 
Olivier Dubourg, AP-HP, Hôpital universitaire Ambroise Paré, Boulogne, France
Background: Studies evaluating revascularization strategy of acute myocardial infarction 
(MI) in elderly patients are rare. The aim of this study was to describe characteristics and 
outcome of pts > 80 years referred to a cath-lab for acute MI.
Methods: Over an 10-year study period, we analyzed the data of 1687 pts referred to 
our cath-lab for acute MI. We compared data between group 1 (pts > 80 years of age 
(n=152)) and group 2 (pts < 80 years (n=1535)).
Results: Mean age was 83.9 ± 3.3 years and 59.5 ± 11.6 years, respectively in group 
1 and 2. Significant differences occurred between the 2 groups concerning the number 
of previous MI (29% in group 1 vs. 18% in group 2, p=0.0008), smoking (15% vs. 55%, 
p<0.0001), hypertension (57% vs. 36%, p<0.0001) and hypercholesterolemia (30% vs. 
49%, p=0.009). Anterior location of MI was more frequent in group 1 (50% vs. 41%, 
p=0.03). Concerning the baseline angiographic characteristics, no differences occurred 
between 2 groups for the initial TIMI flow, whereas the rate of 3 diseased vessel was more 
frequently observed in group 1 (27% vs. 15%, p<0.0001). Thrombolysis was performed in 
only 3% of pts in group 1 vs. 22% in group 2 (p<0.0001). Primary stenting was similar in 2 
groups (p=0.27). Procedural success was 76% in group 1 vs. 89% in group 2 (p<0.0001). 
Procedural success of patients without cardiogenic shock was 86% in group 1 vs. 92% 
in group 2 (p=0.31). Among pts presenting with cardiogenic shock (18 patients in group 
1 and 60 in group 2), the in-hospital mortality was 83% vs. 62% (p=0.07). In pts without 
cardiogenic shock, in-hospital mortality was 10% in group 1 vs. 3% in group 2 (p<0.0001). 
In group 1, procedural success and outcome was similar if revascularization procedure 
was performed <3 hours, between 4-6 hours and > 6 hours after the symptom onset 
(respectively p=0.64 and p=0.44).
Conclusions: Angiographic characteristics of pts >80 years are different from pts <80 
years. However, primary angioplasty in elderly pts presenting acute MI is safe and must 
be systematically proposed. Procedural success and in-hospital survival rate is high in 
this high-risk population. On the other hand, prognosis of elderly pts presenting with 
cardiogenic shock is poor, despite rescue angioplasty.
10:00 a.m.
1001-117 Statins decrease the risk of Acute Myocardial Infarction 
and Coronary Heart Disease Mortality in patients with 
renal failure. A Meta-analysis
Saravanan Balamuthusamy, Janos Molnar, Sasikanth Adigopula, Nandana Mapakshi, 
Rohit Bhuriya, Anant Satyadev, Rohit Arora, Rosalind Franklin University, North 
Chicago, IL, Mount Sinai Hospital, Chicago, IL
Background: Although the role of statins in improving cardiovascular outcomes is well 
established, their role in patients with renal insufficiency is uncertain. We performed a 
meta-analysis of randomized clinical trials to evaluate the role of statins in renal failure 
(CKD stage 2 and above) patients in primary prevention of myocardial infarction and 
coronary heart disease.
Methods: Randomized controlled trials that analyzed cardiovascular outcomes in patients 
with renal failure were included for the meta-analysis. A total of 15,373 patients from 
four trials were analyzed. Chi-square test was used to assess inter-study heterogeneity. 
Relative risk across all studies was determined by meta-analysis with Mantel-Haenszel 
random-effects model.
Results: Statins were associated with significant relative risk reduction in acute 
myocardial infarction(AMI) and coronary heart disease(CHD) mortality in patients with 
renal failure (p<0.001). The relative risk for AMI and CHD was 0.77 (9.69-0.855: 95% CI) 
in our meta-analysis.
Conclusions: Statins significantly reduce the risk for CHD and AMI in patients with renal 
failure. Though protienuria was not analyzed in our meta-analysis, this reduction in CHD 
mortality and AMI might be explained by the pleotropic effects of statins which include 
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reduction in systemic inflammation, improvement in renal blood flow and endothelial 
function and inhibiting protein uptake in the proximal tubules
10:00 a.m.
1001-132 Pro-inflammatory Responses After Intracoronary 
Injections of Autologous Mononuclear Bone Marrow 
Cells in Patients with Acute Myocardial Infarction
Svein Solheim, Ketil Lunde, Ingebjørg Seljeflot, Pål Aukrust, Arne Yndestad, Haakon 
Grøgaard, Svend Aakhus, Kolbjørn Forfang, Harald Arnesen, Ullevål University 
Hospital, Oslo, Norway, Rikshospitalet University Hospital, Oslo, Norway
Background: The effects of intracoronary injections of autologous mononuclear bone 
marrow cells (mBMC) on inflammatory responses are not clarified.The aim of this 
substudy of ASTAMI* was to investigate the influence of intracoronary injections of mBMC 
on circulating inflammatory mediators in patients with acute myocardial infarction (AMI).
Methods: 100 patients with AMI treated with percutaneous coronary intervention were 
randomized to intracoronary injections of mBMC or control group. Fasting blood samples 
were drawn the day before stem cell transplantation (Tx-1), and after 1 day (Tx+1), 3 days 
(Tx+3), 2-3 weeks and 3 months for determination of tumor necrosis factor alpha (TNFα), 
interleukin 6 (IL-6), C-reactive protein (CRP), interleukin 8, interleukin 10, monocyte 
chemoattractant protein 1 (MCP-1) and CD40 ligand.
Results: Median values are given. In the mBMC group the levels of IL-6 increased 
significantly from baseline to Tx+1 compared to a decrease in the control group; (6.6 to 
8.2 vs 8.0 to 4.9 pg/ml); (p<0.01 for between group differences). Although IL-6 decreased 
in the mBMC group from baseline to 2-3 weeks, the decrease was less pronounced than 
in the control group; (6.6 to 4.4 vs 8.0 to 2.9 pg/ml); (p=0.03). During follow-up CRP levels 
decreased in both groups, but to a lesser extent from baseline to Tx+1, Tx+3 and 2-3 
weeks in the mBMC group; (16.1 to 14.4 to 10.7 to 5.7 vs 18.2 to 14.2 to 7.8 to 5.0 mg/l); 
(p<0.05 for between group differences at all time points). From baseline to 3 months the 
levels of TNFα were increased in the control group compared to the mBMC group; (1.9 
to 2.1 vs 2.0 to 2.0 pg/ml), and the levels of MCP-1 increased to a greater extent in the 
control group; (234 to 285 vs 251 to 267 pg/ml); (p=0.01 for both).
Conclusions: Intracoronary injection of mBMC in patients with AMI may induce a 
short term pro-inflammatory response, but possibly a slightly reduced inflammatory 
response after 3 months. These data may have implications for the timing of stem cell 
transplantation in AMI.
* Ketil Lunde, Svein Solheim, Svend Aakhus et al. Intracoronary Injection of Mononuclear 
Bone Marrow Cells in Acute Myocardial Infarction. New Engl J Med. 2006, 355; 1199-209.
10:00 a.m.
1001-133 Is it Possible to Predict Which Patients Need Distal 
Protection during Primary Percutaneous Coronary 
Intervention?
Hisashi Umeda, Tomoko Gochi, Mitsunori Iwase, Hironobu Maekawa, Naoki Yoshida, 
Kosuke Watanabe, Taro Okada, Tomotitsu Tani, Toyoaki Matsushita, Shigeki Yokota, 
Shinjiro Miyata, Nobutake Kurebayashi, Jun Takamura, Shigeo Sugino, Yasushi 
Takeichi, Ryoji Ishiki, Haruo Inagaki, Hideo Izawa, Toyoaki Murohara, Toyota Memorial 
Hospital, Toyota, Japan, Aichi Prefectural Cardiovascular and Respiratory Center, 
Ichinomiya, Japan
Background: Although the benefit of a distal protection (DP) during primary percutaneous 
coronary intervention (PCI) remains questionable, this appears to be effective in some 
clinical situations. We sought to identify in patients with acute myocardial infarction (AMI) 
which clinical and angiographic characteristics might indicate the patient who will benefit 
from the use of DP.
Methods: A series of 103 consecutive patients with AMI undergoing primary PCI using 
DP were compared with 98 consecutive patients treated by primary PCI alone.
Results: The overall rates of achievement of optimal reperfusion (myocardial blush grade 
2 or 3, and ST-segment resolution >70%) were similar between the 2 groups. However, 
DP use was associated with higher rates of optimal reperfusion in patients with right 
coronary artery (RCA) lesions (OR 2.45; 95% CI, 1.07 to 5.59; P=0.034), thrombus score 
4 or 5 (OR 2.64; 95% CI, 1.07 to 6.50; P=0.034) or infarct-related artery (IRA) of >3.5mm 
(OR 4.09; 95% CI, 1.02 to 16.40; P=0.047). In this population, DP use reduced the risk of 
thromboembolic complications by 64%, 45%, and 54%, respectively, resulting in a smaller 
infarct size. Multivariate analysis indicated that DP use was an independent predictor of 
optimal reperfusion in these patients.
Conclusions: The use of a DP during primary PCI might lead to a reduction of 
thromboembolic complications, subsequent higher rates of optimal reperfusion and 
reduced infarct size in patients with RCA culprit lesions, a large thrombus, or large IRA. 
10:00 a.m.
1001-134 ST Resolution After Primary PCI for STEMI is a Strong 
Predictor of Outcome
Yuling Fu, Kenneth W. Mahaffey, Thomas G. Todaro, Frans J. Van de Werf, Harvey D. 
White, Arnoud WJ van ‘t Hof, Torsten Toftegaard Nielsen, Galen S. Wagner, Peter X. 
Adams, Cynthia M. Westerhout, Paul W. Armstrong, APEX AMI Investigators, University 
of Alberta, Edmonton, AB, Canada
Background: Prior STEMI studies highlight the prognostic value of ST-resolution after 
fibrinolysis. Its utility after primary PCI is unclear. The APEX AMI trial provided a unique 
opportunity to examine this issue.
Methods: APEX AMI evaluated pexelizumab in 5,745 STEMI pts undergoing PCI < 6 
hours of symptoms. ECGs acquired at baseline and post-PCI (i.e. median 31, IQR (22-52 
min)) were core lab assessed (Schroeder).
Results: Complete ST-resolution (≥70%) occurred in 49.5%, partial (30 to <70%) in 
34.4% and none (<30%) in 16.1% of pts. Complete ST-resolution occurred more often in 
inferior MIs than in non-inferior (66.7% (inferior) vs. 40.7% (non-inferior), p<0.001). The 
30-day composite of death/CHF/shock was 8.2% (3.2%, 3.9% and 3.0%, respectively). 
Complete ST-resolution pts had superior outcomes at 30 days (vs. none, p-logrank<0.001; 
vs. partial, p-logrank<0.001; Figure A). As ST-resolution increased in all MIs there was 
a significant trend to lower 30-day composite outcomes (inferior MI, p<0.001; other MI, 
p<0.001, Figure B). Similar results were observed in 30-day mortality.
Conclusion: Regardless of infarct location, ST-resolution acquired 30-min post-PCI 
provided striking risk gradation. These findings indicate that the prognostic value of 
ST resolution acquired in fibrinolytic-treated STEMI pts is equally applicable in a large 
primary PCI-treated STEMI population. Hence this metric should be strongly considered 
as part of risk stratification in all reperfused pts.
10:00 a.m.
1001-135 Intracoronary Stem Cell Therapy Improves Left 
Ventricular Function and Decreases Infarct Size 
following Acute Myocardial Infarction: A Meta-Analysis
Michael J. Lipinski, Antonio Abbate, Reena Khianey, George W. Vetrovec, Giuseppe 
G. Biondi-Zoccai, University of Virginia Medical Center, Charlottesville, VA, Virginia 
Commonwealth University Health System, Richmond, VA
Background: Intracoronary stem cell therapy (ICSCT), whether derived from bone marrow 
or peripheral blood, continues to be evaluated in the setting of AMI with variable impact 
on left ventricular ejection fraction (LVEF). We performed a meta-analysis of randomized 
controlled trials comparing ICSCT following percutaneous coronary intervention (PCI) vs 
PCI alone for patients with AMI.
Methods: CENTRAL, mRCT, and PubMed were searched for eligible studies. Inclusion 
criterion was randomization within 14 days and exclusion for cardiogenic shock or cancer. 
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Random-effect odds ratios were pooled for dichotomous clinical outcomes, with generic-
inverse-variance pooling for changes in LVEF as the primary end-point and changes in 
infarct size and LV dimensions as secondary endpoints.
Results: We combined data from 9 studies enrolling 719 patients (median follow-
up 6 months [range 3-18 months]). Patients randomized to ICSCT had a significant 
improvement in LVEF by 3.6% (see table). The infarct size was also significantly reduced 
by 7.4% following treatment with ICSCT (95% CI -11.7 to -3.0, p=0.0009). Patients treated 
with ICSCT had a significant reduction in LV end systolic volume (-6.6 ml, 95% CI -10.5 to 
-1.9, p=0.03) and LV end diastolic volume (-3.0 ml, 95% CI -5.7 to -0.3, p=0.03).
Conclusions: This meta-analysis of randomized controlled trials on ICSCT following PCI 
for AMI compared with PCI alone demonstrated that patients with ICSCT had significant 
improvement in LVEF, infarct size, and LV dimensions.
10:00 a.m.
1001-136 Towards Reduced Symptoms-to-balloon Times In 
Primary Pci: Effects Of Prehospital Triage And Off-site 
Pci
Victor A. Umans, Hans Peels, Raymond Hautvast, Hans de Swart, Medical Center 
Alkmaar, Alkmaar, The Netherlands
Background: Pre-hospital triage by paramedics and improved accessibility of primary PCI 
by increasing the number PCI centers may lead to expedite treatment.
Methods: A randomized trial compared off-site with on-site PCI in 199 MI pts was performed. 
The primary endpoint of this study is angiographic success without MACE was equal in both 
groups. After this trial an additional 335 primary PCIs were performed. Prehospital triage 
was performed in 71% of those.
Results: In the randomized trial, 199 pts presenting with an acute ST elevation MI were 
included. All had angiography; 84 were treated by off-site PCI and had 89 onsite PCI. In 
16 pts an medical treatment was given. 35% had an anterior infarct, mean CKmb was 190 
U/l. Stenting was performed in 93% and post-PCI TIMI-3 flow of 91% in both centers. The 
30 days mortality was 3.5%. The figure shows the cumulative frequency curves of door-to- 
balloon and symptoms-to-balloon times. The mean door-to-balloon time was 33 min less 
(p<0.01) in the off-site vs the on-site clinic. Prehospital ECG was performed 38 min before 
admission and door-to-balloon time was significantly less in pts with a pre-hospital ECG 
than in pts without pre-hosp ECG (91 vs 75 min;p=0.0004)
Conclusions: This randomized study shows the efficacy of an off-site primary PCI by 
significantly reducing door and symptoms to balloon time when primary PCI is performed 
in a regional infarction center. A further reduction in treatment delay can be achieved by 
performing pre-hospital triage 
10:00 a.m.
1001-137 Infarct Transmurality And Infarct Size Assessed By 
Delayed Enhancement Magnetic Resonance Imaging: 
Association With Time-to-treatment, St-segment 
Resolution, And Timi-flow Grades
Holger Thiele, Axel Linke, Enno Boudriot, Dietmar Kivelitz, Gerhard Schuler, University 
of Leipzig - Heart Center, Leipzig, Germany
Background: The TIMI flow, ST-segment resolution (STR) and time-to-reperfusion 
(TTR) are associated with mortality in ST-elevation myocardial infarction (STEMI) after 
either fibrinolysis or percutaneous coronary intervention (PCI). As a result of excellent 
spatial resolution delayed enhancement magnetic resonance imaging (DE-MRI) allows 
assessment of infarct transmurality (IT), which might allow to assess the so-called 
wavefront phenomenon.
Methods and Results: This study analyzed 134 STEMI patients randomized to 
prehospital fibrinolysis or prehospital initiated facilitated PCI. Reperfusion times, 90 min 
STR and TIMI-flow grades pre and post PCI (for facilitated PCI patients) were assessed. 
IS was determined as percentage of left ventricular mass (%LV) by DE-MRI and IT was 
analysed by a score ranging from 0-64.
According to tertiles of TTR, IS was significantly smaller in the lowest with 5.1%LV 
(interquartile range [IQR] 2.0; 11.5) versus 11.3%LV (IQR 5.0; 15.6) in the middle and 
14.4%LV (IQR 5.8; 15.6) in the upper tertile (p<0.001). Similarly, IT was significantly 
smaller in the lower (5.5; IQR 2.0; 10.0) in comparison to the middle (11.0; IQR 4.0; 18.0) 
and upper tertile (13.0; IQR 6.5; 17.5; p=0.001). STR also correlated significantly with IS 
and IT (p<0.001). In the groups with complete (>70%), intermediate (70-30%), and no 
(<30%) STR IS was 4.2%LV (IQR 1.6; 10.5), 13.6%LV (IQR 8.0; 16.4), and 12.4%LV (IQR 
7.7; 17.9; p<0.001). In facilitated PCI patients the preinterventional TIMI flow correlated 
with IS (TIMI flow 0-I 10.8%LV [IQR 7.6; 17.3] vs. TIMI II-III 3.9%LV [IQR 0.9; 9.6]; 
p=0.002) and IT (TIMI flow 0-I 11.5 [IQR 8.0; 16.5] vs. 5.0 [IQR 2.0; 9.5]; p=0.003). In a 
multivariate model TTR was the strongest predictor of IS and IT (p=0.001) followed by 
type of reperfusion and STR (p=0.002).
Conclusions: Early STR, TTR and TIMI flow before PCI correlate with IS and more 
importantly with IT, underlining the assumed pathophysiological link between early flow 
restoration and perfusion in the infarct related artery, which is well-known as the wave-front 
phenomenon. This may explain why these clinical, angiographic and electrocardiographic 
measures are associated with long-term survival.
10:00 a.m.
1001-138 Gender Differences in the Treatment and Hospital 
Resource Consumption of Medicare Beneficiaries 
Admitted with a Primary Diagnosis of Acute Myocardial 
Infarction.
Aaron D. Kugelmass, Phillip P. Brown, Lynn G. Tarkington, Steve D. Culler, April W. 
Simon, Henry Ford Healthcare System, Detroit, MI, Cardiac Data Solutions, Inc., 
Atlanta, GA
Background: Women who sustain acute myocardial infarction (AMI) have worse risk-
adjusted outcomes than men, however, the basis for this is poorly understood. This 
study investigates the relationship between procedural utilization, costs, and in hospital 
mortality for men and women admitted with a primary diagnosis of AMI.
Methods: A retrospective analysis was conducted using the Medicare Provider Analysis 
and Review (MedPar) Files for fiscal year 2004 (FY04). The study sample consists 
of 267,649 Medicare beneficiaries (MB) admitted with a primary diagnosis of AMI 
to one of 1,230 hospitals performing PCI during FY04. A logistic regression equation 
(controlling for age, gender, race and 19 co-morbidities) was estimated to predict the 
risk-adjusted probability of in hospital survival for each MB. Treatments received (PCI, 
CABG, Thrombolytics, and GPIIb/IIIa) were identified using ICD-9-CM procedure coding. 
Beneficiaries were divided into two groups (STEMI or NSTEMI).
Results: 53.2% of the patients were men and 38.7% of the AMIs were classified as 
STEMI. The table indicates that for both STEMI and NSTEMI men were more likely to 
survive, receive more of each treatment, have higher hospital costs, and be discharged 
home. Women had longer average length of stays. (All differences are statistically 
significant p<0.01, except for thrombolytic use p<0.05.)
Conclusion: This analysis indicates that women, regardless of the type of AMI, are 
treated less aggressively and this may explain the lower survival rate.
Gender Differences in Treatment and Risk Adjusted Mortality Rates by 
STEMI and NSTEMI
STEMI NSTEMI
Men Women Men Women
Volume 56,648 47,001 85,815 78,210
Predicted 
Survival 87.0% 84.5% 93.9% 92.9%
Any PCI Rate 54.1% 46.2% 34.4% 29.0%
Any CABG 
Rate 14.0% 8.6% 14.7% 9.3%
Any 
Thrombolytic 1.3% 1.1% 0.4% 0.26%
Any GPIIb/IIIa 22.7% 19.2% 15.0% 12.1%
Discharged 
Home 70.8% 58.8% 72.3% 63.6%
Total Cost $20,237±20,554 $18,061±20,359 $18,477±19,918 16,317±18,864
Length of Stay 6.1±6.8 6.3±7.0 6.6±6.9 6.8±6.9
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1001-153 Clinical Factors Associated With Thrombolysis Failure 
in Patients Transferred to an Interventional Cardiac Unit 
for Myocardial Infarction: Data From RICO Survey.
Emmanuel Vigreux, Gilles Dentan, Jean-Claude Beer, Yves Laurent, Isabelle L’Huillier, 
Michel Vincent-Martin, Marianne Zeller, Yves Cottin, Service de Cardiologie, CHU, 
Dijon, France, Université de Bourgogne, IFR 100, Dijon, France
Background: Randomised studies have shown the benefits of hospital transfer for patients 
with acute myocardial infarction (AMI) to an interventional center particularly in the event of 
thrombolysis failure. However, the characteristics of these patients and outcomes have never 
been clearly established.
Methods: Based on the non-selected AMI population from RICO survey, we set out to compare 
patients who, after receiving thrombolysis therapy following MI, were transferred to interventional 
centers between 1st January 2001 and 25th November 2003. The criteria for thrombolysis failure 
were those used in routine clinical practice (persistent >50% ST segment elevation on ECG).
Results: Three hundred and one patients were analysed :group 1: failed thrombolysis; group 
2: successful thrombolysis. Thrombolysis failed in 47% of cases. Angiographic data confirmed 
the absence of coronary reperfusion (TIMI flow 0 or 1 on IRA) in only 49% of cases in group 1. 
In contrast, 11% of patients in group 2 had TIMI 0 or 1, even though they had been considered 
as reperfused. Rescue PCI was performed in 77% of patients with failed thrombolysis, within 
534(419-810) min) after symptom onset, which resulted in a return to normal flow (TIMI 3) on IRA 
in 99% of cases. Thrombolysis failure was associated with more extensive necrosis, increased 
onset of cardiac events (recurrent MI, AF, cardiogenic shock), and hospital death (12% vs 4%, 
p=0.007). The independent predictors of thrombolysis failure were diabetes, anterior wall location, 
and the presence of cardiogenic shock on admission. In contrast, patients who presented chest 
pain within the days or weeks preceding MI were at a lower risk of thrombolysis failure.
Conclusions: Our work revealed a substantial incidence of failed thrombolysis in patients 
transferred to an interventional center after thrombolytic therapy, which is associated with a poor 
in-hospital prognosis. Our data also highlight the existence of subgroups of patients, including 
those with diabetes or with anterior location MI, at an increased risk of thrombolysis failure, and 
thus identify patients who require more aggressive therapy in the context of acute MI.
10:00 a.m.
1001-154 Women and Men Have Differences in Outcomes 
and Potentially Response to Antithrombin Therapy: 
Preliminary Results From Subgroup Analyses in 
SYNERGY
Sabrina J. Stone, Kenneth W. Mahaffey, Robert Clare, Karen S. Pieper, Elliott M. 
Antman, Jacques Col, James J. Ferguson, Robert M. Califf, Judith S. Hochman, Cindy 
L. Grines, Duke Clinical Research Institute, Durham, NC
Background: Fewer women than men undergo early invasive management for ACS 
and outcomes differ for unknown reasons.
Methods: In SYNERGY, 9978 high-risk non-ST-segment elevation ACS patients were 
randomized to enoxaparin or unfractionated heparin (UFH) and managed with early invasive 
strategy. Outcome was analyzed by sex and treatment using multivariable regression modeling.
Results: See tables.
Conclusions: Women had lower rates of 30-day death/MI and TIMI major bleeding but 
more transfusions. A statistical interaction of sex and treatment for 6-month outcomes 
(p=0.06) and 1-year mortality (p=0.02) was observed favoring UFH in women. Analyses 
are needed to explore these findings, which may be due to chance, difference in 
pathobiology, disease extent, or treatment variation not accounted for in our study. 
Male Female P value (unadjusted)
6597 
(66.1%)
3380 
(33.9%)
BASELINE CHARACTERISTICS
History of hypertension 4256 (64.5%)
2530 
(74.9%) <0.0001
History of diabetes 1855 (28.1%)
1069 
(31.6%) 0.0003
Prior or ongoing tobacco use 4467 (67.8%)
1427 
(42.3%) <0.0001
History of hypercholesterolemia 3827 (58.4%)
2008 
(59.7%) 0.1982
Prior myocardial infarction 2034 (30.9%)
760 
(22.6%) <0.0001
Body mass index 27.7 27.6 0.3172
INCLUSION CRITERIA <0.0001
Age > 60, ECG changes, no positive 
biomarkers
866 
(13.6%)
669 
(20.3%)
Age > 60, no significant ECG changes, 
positive biomarkers
1331 
(20.9%)
616 
(18.7%)
Age < 60, significant ECG changes, 
positive biomarkers
1425 
(22.4%)
436 
(13.2%)
Age > 60, significant ECG changes, 
positive biomarkers
2736 
(43.0%)
1577 
(47.8%)
IN-HOSPITAL PROCEDURES
Diagnostic catheterization 6106 (92.6%)
3082 
(91.2%) 0.0161
PCI 3217 (48.8%)
1470 
(43.5%) <0.0001
CABG 1381 (20.9%)
483 
(14.3%) <0.0001
Male Female Adjusted P 
value for sex 
P value for 
interaction 
of sex and 
treatment
Enox UFH Enox UFH
30-day death/MI 466(14.2%)
506
(15.4%)
229
(13.5%)
216
(12.9%) 0.0118 0.3626
6-month death/MI 572(17.4%)
618
(18.8%)
300
(17.8%)
266
(15.9%) 0.0323 0.0624
1-year death 236(7.2%)
256
(7.8%)
144
(8.6%)
103
(6.1%) 0.0108 0.0190
GUSTO severe 
bleeding
78
(2.4%)
50
(1.5%)
58
(3.4%)
59
(3.5%) 0.1295 0.0467
TIMI major 
bleeding
326
(9.9%)
258
(7.8%)
127
(7.5%)
121
(7.2%) 0.0002 0.3789
Transfusion 
(pRBC, whole 
blood, platelets)
607
(18.4%)
554
(16.8%)
335
(19.8%)
332
(19.7%) 0.0003 0.1545
10:00 a.m.
1001-155 Soluble Lectin-like Oxidized Low Density Lipoproten 
Receptor-1 (sLOX-1) Is a Prognostic Biomarker for Acute 
Coronary Syndrome to Predict Recurrence or Death.
Noriaki Kume, Hirokazu Mitsuoka, Kazutaka Hayashida, Masaru Tanaka, Toru Kita, 
Kyoto University, Kyoto, Japan, Osaka Red Cross Hospital, Osaka, Japan
Background: Lectin-like oxidized LDL receptor-1 (LOX-1) appears to play key roles in 
atherosclerotic plaque rupture by mediating oxidized LDL-induced vascular cell dysfunction. 
Cell-surface LOX-1 is shed and released as soluble LOX-1 (sLOX-1). We previously 
showed that sLOX-1 is a more specific and sensitive biomarker for diagnosis of acute 
coronary syndrome (ACS) than high-sensitivity C-reactive protein (hs-CRP), troponin T and 
heart-type fatty acid binding protein (H-FABP). In the present study, we have explored if 
sLOX-1 can also be a useful serum biomarker to predict prognosis after ACS.
Methods: Patients (94) with ACS who underwent emergent coronary intervention (PCI) 
and serum sLOX-1 measurement at the acute stage were enrolled and their clinical 
courses were followed for up to 7 years at the longest.
Results: Among 94 patients, 13 patients died or had recurrent ACS (re-ACS or death 
group). Neither age (64.5+12.1 vs. 64.9+12.6), gender (male: 76.9% vs. 71.6%), 
prevalence of diabetes (23.1% vs. 30.1%), serum total cholesterol (190.0+49.7 versus 
190.6+35.8 mg/dl), triglycerides (109.7+33.3 vs. 120.7+34.7 mg/dl), nor HDL cholesterol 
(45.3+16.1 vs. 41.3+12.3 mg/dl) levels were significantly different between the re-ACS or 
death group (13 patients) and the event-free group (81 patients). Numbers of diseased 
coronary vessels did not significantly differ between the two groups either. Serum sLOX-1 
levels at the acute stage were significantly higher (p<0.005) in the re-ACS or death group 
(median: 6.6 ng/ml) than the even-free group (median: 2.54 ng/ml). Kaplan-Meier survival 
curves showed that ACS patients whose serum sLOX-1 above 3 ng/ml (46 patients) at 
the acute stage had significantly more recurrence of ACS or death than those below 3 
ng/ml (48 patients); the event-free survival rates after 6 years were 76.1% and 95.8%, 
respectively (p<0.005 by Logrank test).
Conclusions: Serum sLOX-1 appears to be a useful prognostic biomarker after ACS to 
predict recurrence of ACS or death, in addition to its usefulness as an early diagnositic 
biomarker for ACS.
10:00 a.m.
1001-156 Is In-stent Late Loss Related With The Risk Of Drug-
eluting Stent Thrombosis? A Meta-regression From 21 
Randomized Trials.
Raul Moreno, Cristina Fernandez, Luis Calvo, Angel Sanchez-Recalde, Guillermo 
Galeote, Rosa Sanchez-Aquino, Fernando Rivero, Jose L. Lopez-Sendon, University 
Hospital La Paz, Madrid, Spain, Hospital Clinico San Carlos, Madrid, Spain
Background: The benefit of drug-eluting stents (DES) in reducing binary angiographic 
restenosis and the need for new revascularizations is due to a reduction of in-stent late 
loss (ISLL) in comparison with bare-metal stents. Some authors have hypothesized, 
however, that neointimal a very low ISLL could increase the risk of stent thrombosis (ST). 
The aim was to evaluate whether there is any relationship between ISLL and the risk of 
ST in patients treated with DES.
Methods: We selected 21 randomized trials comparing bare-metal stents and DES that 
provided a clinical and angiographic follow-up: RAVEL, SIRIUS, E-SIRIUS, C-SIRIUS, 
DIABETES, SCANDSTENT, SES-SMART, PRISON-II, the study by Pache et al (sirolimus DES), 
TAXUS-I, TAXUS-II, TAXUS-IV, TAXUS-V, TAXUS-VI (paclitaxel DES), JUPITER-I, JUPITER-
II (tacrolimus DES), FUTURE-I, FUTURE-II, SPIRIT-I (everolimus DES), ENDEAVOR-II 
(zotarolimus DES), and STEALTH (biolimus DES). The relationship between the mean value 
of ISLL and the incidence of ST in patients allocated to DES in each trial was evaluated, using 
meta-regression techniques, and weigthing the results for the number of patients in each trial.
Results: The results revealed an absence of relationship between the mean value of 
ISLL and the incidence of ST in each trial: Y = 0.65 + 0.24 (X), where “Y” is the risk of ST, 
and “X” the mean value of ISLL (P = 0.798). 
Conclusions: The risk of ST after DES implantation is not related with ISLL. A very low 
mean value of ISLL is not associated with a higher risk of ST.
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1001-157 Prognostic Value and Clinical and Biochemical 
Correlates of Elevated Neutrophil to Lymphocyte Ratio 
Prior to Coronary Stenting
Masud H. Khandaker, Ryan Lennon, Amir Lerman, Charanjit S. Rihal, Mayo Clinic, 
Rochester, MN
Background: Elevated neutrophil to lymphocyte (N/L) may be predictive of long-term mortality 
after percutaneous coronary intervention (PCI). Clinical and biochemical correlates of systemic 
N/L ratio are poorly understood.
Methods: The Mayo Clinic PCI registry was examined to determine if an elevated N/L ratio 
predicts survival. Patients who underwent successful coronary stenting from 1995-2005 and 
survived to hospital discharge were included.
Results: A total of 9183 patients with complete blood counts within 7 days prior to PCI were 
divided into three groups; low (N/L < 2.5; n=3450), intermediate (N/L 2.5 - 5.0; n=3253) and high 
(N/L > 5.0; n=2480). Most were male and there were modest differences in age between the 
low (64.7 ± 12.0 years), intermediate (66.9 ± 12.1) and high group (68.2 ± 12.5). High N/L ratio 
group was associated with procedural shock (11% vs. 2% vs. 1%; p <0.001); LVEF < 40% (14% 
vs. 11% vs. 9%; p<0.001); higher levels of CK-MB (13.3 vs. 3.5 vs. 2.7; p< 0.001) and troponin T 
(0.7 vs. 0.1 vs. 0.0; p<0.001); thrombus in any lesion (53% vs. 32% vs. 25%; p<0.001) and more 
type C lesions (55% vs. 46% vs. 40%; p<0.001). Over 1600 deaths occurred over a median of 5 
years. Elevated N/L ratio was independently associated with higher rates of follow-up death and 
death or MI, but not target lesion revascularization after multivariate adjustment (Figure 1).
Conclusions: Elevated N/L ratio prior to PCI correlates with elevated CK-MB and troponin, and 
is a strong predictor of subsequent morbidity and mortality.
10:00 a.m.
1001-158 Preoperative CRP and NT-proBNP Predicts 
Postoperative Cardiac Events in Patients Undergoing 
Noncardiac Surgery
Jin-Ho Choi, Jun Hyung Kim, Wang-Soo Lee, Ji Hyun Yang, Joo-Yong Hahn, 
Seunghyuk Choi, Hyeon-Cheol Gwon, Duk Kyung Kim, Sang Hoon Lee, Eun-Seok 
Jeon, Samsung Medical Center, Seoul, South Korea
Background: Perioperative cardiac complication is a major cause of morbidity after 
noncardiac surgery. We hypothesized that measurement of cardiovascular biomarkers 
may have an additional value in predicting perioperative cardiac complications.
Methods: A cohort of 1021 patients referred for cardiac consultation before elective 
noncardiac surgery was enrolled prospectively. The level of hsCRP and NT-proBNP 
were measured within 2 weeks before surgery. Perioperative cardiac event (POCE) was 
defined as acute myocardial infarction, congestive heart failure including acute pulmonary 
edema or primary cardiac death within 5 days after surgery.
Results: POCEs occurred in 97 (9.5%) of the 1021 patients. The optimal cut-off value of 
NT-proBNP (≥ 340 pg/ml, sensitivity=77.3%, specificity=75.9%) and hsCRP (≥ 0.495 mg/dl, 
sensitivity=61.2%, specificity=73.8%) for prediction of POCE was derived from receiver 
operating characteristic analysis. Multivariable logistic regression analyses revealed that both 
preoperative high NT-proBNP and hsCRP was an independent predictor of POCE. Next, we 
compared the performance of predicting POCEs by comparing the area under receiver operating 
characteristic (ROC) curves. When a high preoperative NT-proBNP (≥ 340 pg/ml) and hsCRP 
(≥ 0.495 mg/dl) was combined with the Revised Cardiac Risk Index, the prediction power has 
significantly strengthened (area under ROC curve; 0.772 versus 0.660, p = 0.0001).
Conclusions: A high preoperative NT-proBNP (≥ 340 pg/ml) and hsCRP (≥ 0.495 mg/
dl) is a strong and independent predictor of POCE. Measurement of cardiovascular 
biomarkers may have a role in preoperative cardiac risk index development.
10:00 a.m.
1001-159 Relationship Between Neutrophil Count on Admission, 
Microvascular Injury, and Long-Term Outcomes in 
Patients Treated With Primary Coronary Angioplasty for 
Acute Myocardial Infarction
Takefumi Takahashi, Yoshikazu Hiasa, Yoshikazu Ohara, Shin-ichiro Miyazaki, Riyo 
Ogura, Naoki Suzuki, Shinobu Hosokawa, Koichi Kishi, Ryuji Ohtani, Tokushima Red 
Cross Hospital, Komatsushima, Japan
Background: An elevated neutrophil count on admission is associated with infarct size, 
left ventricular function, and 30-day outcomes after acute myocardial infarction (AMI). We 
hypothesized that the neutrophil count on admission would be related to the degree of 
microvascular injury and long-term outcomes.
Methods: We studied 115 consecutive patients with a first anterior wall AMI who 
underwent primary coronary angioplasty. Patients were divided into 2 groups based on 
the initial neutrophil count: low (<10000/mm3, n=73) and high (≥10000, n=42). Using a 
Doppler guidewire, the degree of microvascular injury was evaluated by the presence of 
systolic flow reversal (SFR), diastolic deceleration time (DDT), and coronary flow reserve 
(CFR). Adverse cardiac events combining cardiac death, recurrent MI, and congestive 
heart failure were recorded during an average follow-up of 62 ± 32 months.
Results: In patients with a high netrophil count, SFR was more frequently observed, DDT was 
shorter, and CFR was lower. Kaplan-Meier survival analysis showed a higher incidence of 
adverse cardiac events in patients with a high netrophil count. In a multivariate model, final TIMI 
grade ≤2 (OR 7.2, P=0.004), ejection fraction ≤40% (OR 5.1, P=0.03), and a higher neutrophil 
count (OR 3.1, P=0.03) were independent predictors of long-term adverse cardiac events. 
Conclusion: A higher neutrophil count on admission is related to severe microvascular 
injury and predicts long-term adverse cardiac events after reperfused AMI.
10:00 a.m.
1001-174 Long-term Clinical Outcome After Coronary Balloon 
Angioplasty: A 25 Year Follow-up Study
Ron T. van Domburg, Joost Daemen, Peter P. de Jaegere, Patrick W. Serruys, Erasmus 
Medical Center, Rotterdam, The Netherlands
Objectives To investigate the clinical outcome, up to 25 years, of the first 856 consecutive 
patients (age 56 years; 80% male) between 1981 and 1985 treated by coronary balloon 
angioplasty and to assess the life expectancy (LE) in subgroups.
Methods Follow-up status was established by contacting the civil registry, hospital 
records and by mailing the patients who were still alive. LE was assessed by calculating 
the areas under the Kaplan-Meier curves, assuming similar LE as the matched normal 
population beyond 25 years of follow-up.
Results Median follow-up was 23 years (21-26 years). The cumulative 10-, 20- and 25-year 
survival rates were 78%, 50% and 37%, respectively. The cumulative MACE-free survival 
rates at 10-, 20- and 25-year were 31%, 15% and 9%, respectively. Impaired LVEF (HR 
2.9), diabetes (HR 2.3), multivessel disease (HR 1.7) and age (HR 1.03/year) emerged as 
independent predictors of mortality in Cox multivariable regression. Overall LE was 17.8 
years. The LE in patients with normal and impaired LVEF was 18.7 years versus 14.5 years 
respectively (p<0.0001). The LE in diabetic patients was 2.9 years shorter than in the non-
diabetics (15.1 versus 18.1 years; p<0.0001) and the LE in multivessel disease patients was 
3.6 years shorter than those with single vessel disease(15.5 versus 19.0 years;p<0.0001)
Conclusions This study investigated the clinical outcome beyond 25 years. Almost all 
patients (>90%) experienced a cardiac event after the index angioplasty. 
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1001-175 Trends In LDL And Treatments In The US Over The Last 
Decade
Benjamin A. Steinberg, Christie M. Ballantyne, Deepak L. Bhatt, Gilles Montalescot, 
Shamir Mehta, Philip O’Hagan, Philip A. Poole-Wilson, Christopher P. Cannon, Brigham 
and Women’s Hospital & Harvard Medical School, Boston, MA
Background: Clinical trials have demonstrated that for LDL, “lower is better” for 
cardiovascular prevention. Guidelines continue to be updated, but whether LDL goals 
are being met is unknown.
Methods: CardioMonitor is an annual survey of outpatients with at least one cardiovascular 
condition or risk factor, sampled at a single time point from a diverse group of 250-300 
physicians. Data on approximately 5,000 cardiovascular disease (CVD) patients were 
collected throughout the US annually from 1998 to 2005 (except 2002).
Results: Of 36,000 US patients, 46% were female and 90% over the age of 45 years, with 
the predominant qualifying diagnoses being hypertension, dyslipidemia, and ischemic 
heart disease. From 1998 to 2005, the proportion of CVD patients with LDL <130 mg/dL 
almost doubled from 38% to 64%. Treatments for dyslipidemia increased from 31% to 
nearly 60% (see Figure). Of patients with type 2 diabetes or impaired glucose tolerance, 
the fraction meeting the 2001 goal of 100 mg/dL nearly tripled from 15% in 1998 to 44% 
in 2005. In the subset of patients with a history of MI or unstable angina, achievement of 
the 100 mg/dL goal increased from 18% in 1998 to 47% 7 years later, while those meeting 
the newest therapeutic option of 70 mg/dL rose from 3% to 13%.
Conclusion: Over the past 7 years, there has been a steady improvement in rates of 
dyslipidemia treatment and achievement of goals. However, more than half are not at 
goal and only 13% are at the new therapeutic option (<70 mg/dL), indicating need for 
further improvement. 
10:00 a.m.
1001-176 Sex, Prescribing Practices and Guideline 
Recommended Treatment Goals at Baseline in the BARI 
2D Study
Jacqueline E. Tamis-Holland, Jiang Lu, Neuza Lopes, Vera Bittner, Alice K. Jacobs, 
Michelle F. Magee, The Bari 2D Investigators, St. Luke’s-Roosevelt Hospital Center, 
New York, NY, University of Pittsburg, Pittsburg, PA
Background: Control of glycemia, BP and lipids in patients with diabetes (DM) and 
established cardiovascular disease (CVD) is key to achieving optimal outcomes. Prior 
research on women (W) with CVD has shown less aggressive treatment when compared 
with men (M). We hypothesized that among patients with DM and established CVD, 
approach to drug management would be similar in W and M, yet W would be less likely 
to achieve guideline targets.
Methods: We evaluated baseline variables and drug treatment for patients enrolled in 
the BARI 2D study.
Results: Among 2321 patients enrolled, 686 (29.6%) were W and 1635 (70.4%) were M 
There were differences in the sex distribution of ethnicity, with a higher proportion of black 
non Hispanic W enrolled compared with men p<.001. W were more likely to have a history 
of hypertension (87. 2% vs 80.4%, p<.001) and longer duration of DM, (12.2 + 9.6 vs 9.7 
+ 8.1 years, p<.001). W less often had a history of prior MI (27.9% vs 33.6%, p=.0074); 
were less likely to have completed a higher level of education (p<.001); exercise regularly 
(20.4% vs 27.9%, p<.001); or have ever smoked (48.1% vs 74.6%, p<.001). BMI was 
higher in W than M (32.9 + 6.9 vs 31.3 + 5.4, p<.001). Fewer W were at goal with respect 
to CVD related targets-LDL<100: 49.6% vs 62.4%, p<.001; A1C<7: 32.1% vs 42.1%, 
p<.001; BP<130/80: 40.8% vs 44.2%, p=.125. Among patients on therapy at study entry, 
despite a similar number of DM and CVD drug classes being prescribed, fewer W were 
at goal, LDL<100: ( 55.2% vs 69.0%, p<.001); A1c <7: ( 29% vs 39.0%, p<.001;) and 
BP<130/80: (39.7% vs 44.1%, p=.05). Among patients not at target, a similar proportion of 
W and M were on drug therapy for each respective CVD risk factor. Even after adjustment 
for age, ethnicity, drug therapy, and DM duration, W were still less likely to achieve target 
goals for LDL: (OR=0.6, 95% CI 0.49, 0.72) and A1C (OR=0.73, 95% CI 0.59, 0.89).
Conclusions: Among a high risk group of patients enrolled in a clinical trial, W were 
as aggressively treated with drugs for DM and CVD as M. Despite this equivalence in 
prescribing practices, W less often met targets for LDL and A1C.
10:00 a.m.
1001-177 Vascular Complications Following Cardiac 
Catheterization and Coronary Intervention 1998-2005: 
Influence of Gender
Robert J. Applegate, Matthew T. Sacrinty, Michael A. Kutcher, Talal T. Baki, Sanjay 
K. Gandhi, Renato M. Santos, William C. Little, Wake Forest University School of 
Medicine, Winston-Salem, NC
Background: Women may experience more complications after cardiac catheterization 
(CATH) and percutaneous coronary interventions (PCI) than men, but data describing the 
effect of gender on vascular complications (VC) after these procedures is limited. Thus, 
we evaluated the adjusted risk of vascular complications after CATH and PCI by gender 
from 1998 to 2005 in a large contemporary cohort.
Methods: 31,035 consecutive CATH (n=18,467) and PCI (n=12,568) performed via 
femoral access at a single site (WFUBMC) between 1998 and 2005 were evaluated. 
The relative incidence of VC was evaluated by logistic regression models adjusted for 
baseline covariates.
Results: Overall, the unadjusted incidence of any VC was 2.0% for women and 1.0% for 
men, p<0.05. The adjusted odds ratio for any VC comparing women to men for the entire 
study period was 1.77 (1.39-2.26) for all procedures, 1.55 (1.09-2.22) for CATH, and 1.94 
(1.39-2.72) for PCI. The incidence of VC fell for both men and women during the study 
period with an incidence of any VC in 2005 in women of 1.0% and in men of 0.6%, p=NS.
Conclusions: In this large single-center, contemporary observational study, women 
experienced more vascular complications than men following cardiac catheterization and 
PCI procedures. However, the incidence of vascular complications decreased over the 
eight-year study period for both men and women, with a non-significant difference at the 
end of the study period.
10:00 a.m.
1001-178 Systemic Inflammation 12 months after Stent 
Implantation; Comparison Between Sirolimus- eluting 
Stent and Bare-metal Stent
Yuki Yoshimura, Hiroyuki Okura, Takahiro Kawamoto, Teruyoshi Kume, Nozomi 
Watanabe, Eiji Toyota, Yoji Neishi, Yuji Koyama, Noriko Okahashi, Ken Saito, Ryotaro 
Yamada, Shintaro Nezuo, Tomoko Maehama, Kiyoshi Yoshida, Kawasaki medical 
school, Kurashiki, Japan
Background:It has been reported that peri-stent inflammatory response may occur 
after implantation of drug eluting stent.The aim of this study was to investigate systemic 
inflammation after sirolimus- eluting stent (SES) implantation.
Methods: Our study population comprised 206 patients (149 male, 57 female, mean age 
66±11) with angina pectoris who received either bare-metal stent (BMS) (n=134) or SES 
(n=72).We excluded patients with acute myocardial infarction and infectious disease.Serum 
highsensitivity C-Reactive protein (hs-CRP),white blood cell (WBC),and eosinophil were 
measured before, immediately after 1, 6 ,and 12 months following stent implantation.
Results Change of hs-CRP,WBC,and eosinophil level were shown in figure. There were 
no significant differences in the hs-CRP level between BMS and SES groups.After stent 
implantation,hs-CRP showed a trend toward lower in SES group than in BMS group 
(P=0.18).At 1,6,and12 months after stenting,hs-CRP did not differ between the 2 groups(all 
P=NS).Similarly,WBC,and eosinophil did not differ between the 2 groups(all P=NS).
Conclusions:There was no evidence of exaggerated systemic inflammatory response 
12months after SES implantation compared with BMS.
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1001-179 Chronic Obstructive Pulmonary Disease was an 
Independent Predictor of Sudden Cardiac Death, 
Cardiac Death and All-cause Mortality after 
Percutaneous Coronary Intervention and Coronary 
Artery Bypass Grafting.
Kei Nishiyama, Satoshi Sizuta, Ryoji Taniguchi, Natsuhiko Ehara, Yoshizumi Haruna, 
Mitsuru Abe, Masanao Toma, Yutaka Furukawa, Satoshi Kaburagi, Osamu Doi, Hirofumi 
Kambara, Masafumi Nara, Katsuhiko Matsuda, Shuichi Hamasaki, Chuwa Tei, Hiroyuki 
Yamamoto, Ryuzo Sakata, Takeshi Morimoto, Yukiko Imai, Satoshi Teramukai, Masanori 
Fukushima, Toru Kita, Takeshi Kimura, CREDO-Kyoto Investigators, Department of 
Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan, 
Shizuoka General Hospital, Shizuoka, Japan
Background: Limited data are available on long-term mortality and morbidity of patients 
with chronic obstructive pulmonary disease (COPD) undergoing percutaneous coronary 
intervention (PCI) and coronary artery bypass grafting (CABG).
Methods: We analyzed 9873 consecutive patients who underwent first elective PCI (n=6876) 
and CABG (n=2997) in 2000-2002 at 30 institutions of CREDO-Kyoto registry. The primary 
end point was sudden cardiac death, cardiac death and all-cause mortality. Cox logistic 
regression models were used to determine whether COPD was an independent predictor of 
sudden cardiac death, cardiac death and all-cause mortality after PCI and CABG.
Results: A patient was considered to have COPD if it was listed as a co-morbid condition 
in our database. Baseline clinical characteristics showed that COPD was diagnosed in 
237 patients (2.4%), 425 (4.8%) had LV dysfunction (EF<0.35), 371 (3.8%) had end-
stage renal disease, 2496 (25.7%) had prior myocardial infarction, 3900 (39.5%) had 
multi-vessel disease, 3851 (39.1%) had diabetes mellitus, 104 (1.1%) had anemia (Hb < 
8.0), 229 (2.3%) had permanent atrial fibrillation and 2382 (24.4%) were old-old (age>75). 
COPD was associated with prolonged hospitalization after PCI and CABG (COPD: 22.6 
± 29.5 days v.s. non-COPD: 18.1 ± 21.8 days, P = 0.004). In-hospital mortality (1.7% 
v.s. 1.2%, P = ns) and in-hospital major adverse cardiac outcomes (3.3% v.s. 2.5%, P 
= ns) were not different between groups. During long-term follow-up (median follow-up 
period = 42.6 months), 877 patients (9.2%) died, in which 367 (3.8%) died of cardiac 
death and 132 (1.4%) died of sudden cardiac death. Multi-variate analyses (considering 
the baseline characteristics and the results of uni-variate analyses) indicated that 
COPD was an independent predictor of sudden cardiac death (relative risk 2.13, 95% 
confidence interval 1.53 to 2.83, P < 0.0001), cardiac death (relative risk 1.54, 95% 
confidence interval 1.19 to 1.93, P = 0.002) and long-term mortality (relative risk 1.48, 
95% confidence interval 1.26 to 1.73, P <0.0001) after PCI and CABG.
Conclusion: COPD was an independent predictor of sudden cardiac death, cardiac 
death and all-cause mortality after PCI and CABG.
10:00 a.m.
1001-180 Genetic Polymorphism C807T On Platelet Glycoprotein 
Ia, Affects Platelets Activation Only In The Presence Of 
High Von Willebrand Levels
Charalambos A. Antoniades, Dimitris Tousoulis, Carmen Vasiliadou, Kyriakoula Marinou, 
Nikolas Koumallos, Elli Stefanadi, Athanasios Trikas, Christos Pitsavos, Stella Brilli, 
George Latsios, Christodoulos Stefanadis, Athens University, A Cardiology Department, 
Athens, Greece
Background: Platelet glycoprotein Ia (GPIa) is a platelet receptor for collagen. Although 
genetic polymorphism C807T on GPIa gene affects the density of GPIa on platelet surface, 
its effect on platelet activation and the release of sCD40L is unknown. We examined the 
effect of this polymorphism on the release of sCD40L in healthy individuals and patients 
with stable coronary artery disease (CAD). We also examined whether the presence of 
endothelial injury as evaluated by von Willebrand factor levels (vWF) unmasks a possible 
effect of this polymorphism on platelet activation.
Methods. The study population consisted of 232 healthy individuals (48.51±0.76 years 
old) with no evidence of coronary atherosclerosis and 162 patients with CAD (49.1±0.22 
years old), at a stable clinical condition for at least 1 year. C807T polymorphism was 
evaluated by PCR, while vWF and sCD40L levels were determined by ELISA.
Results. The distribution of 807 CC/CT/TT was 47/80/35 in CAD and 84/127/21 in 
healthy individuals. The presence of 807T allele was associated with higher sCD40L in 
CAD patients but only in the presence of high vWF levels in healthy individuals (figure). 
Multivariate analysis showed that the presence of T allele was an independent predictor 
of sCD40L levels in patients with CAD (β=9.182(SE:1.024), p=0.0001).
Conclusions. The presence of 807T allele on GPIa gene affects platelet activation and 
the release of sCD40L in patients with CAD, as well as in healthy individuals with high 
von Willebrand factor levels.
10:00 a.m.
1001-195 Myocardial Ischemia and Open Coronary Arteries in 
Women: Etiological Mechanisms
Melissa Slivka, Saibal Kar, Bina Ahmed, Margo B. Minissian, Donna M. Polk, Maura 
Paul-Labrador, Leslee J. Shaw, Ryan Berg, Raj Makkar, Noel Bairey Merz, Cedars-Sinai 
Medical Center, Los Angeles, CA
Background: Recent study has shown that women with myocardial ischemia but open 
coronary arteries have an adverse prognosis comparable to obstructive coronary artery 
disease (CAD). Mechanisms for this ischemia are not well described.
Methods: Twelve women with clinical and stress testing evidence of myocardial 
ischemia, and no obstructive CAD were referred for coronary reactivity testing. Coronary 
reactivity testing included intra-coronary artery adenosine coronary flow reserve (CFR) 
(non-endothelial microvascular function), changes in coronary blood flow and vessel 
diameter follow three sequential doses of intra-coronary acetylcholine (endothelial 
dependent macro and microvascular function) and vasodilatation following intra-coronary 
nitroglycerine injection (non-endothelial dependent macrovascular function).
Results: Mean age was 56.4 ±2.8 years, 8% non-white, 0% diabetic, 75% dyslipidemic, 
50% hypertensive, 0% current smokers, 33% history of smoking, 33% on hormone 
replacement therapy, 25% had coronary vasospasm, and 25% had minor coronary 
luminal irregularities. 11 of 12 women demonstrated one or more abnormalities in coronary 
reactivity. The etiological mechanisms in this group of women are summarized in Figure 1.
Conclusions: This preliminary study shows that abnormal coronary reactivity is an 
important mechanism of ischemia in women with myocardial ischemia and no obstructive 
CAD. Results of these tests may help guide therapy. 
10:00 a.m.
1001-196 Comparison of effects of Sirolimus-Eluting Stent, Bare 
Metal Stent and Plain Only Balloon Angioplasty on 
Inflammatory Markers
Keiji Inoue, Naoto Inoue, Hiroshi Fujita, Tetsuya Tanaka, Akiko Matsuo, Yoshiharu Nishibori, 
Kenji Suzuki, Yumi Otuski, Naohiko Nakanishi, Yasutsugu Shiono, Kyoto Second Red Cross 
Hospital, Kyoto, Japan
Background: After percutaneous coronary intervention(PCI), inflammatory mechanisms 
play a crucial role in the pathologenesis of neointimal proliferation and restenosis. Few 
clinical data on influence of Sirolimus-eluting stent (SES) for inflammatory reaction after 
coronary stenting have been reported. We evaluated circulating plasma levels of C-reactive 
protein (CRP), white blood cell count (WBC) and fibrinogen after SES insertion compared to 
bare metal stents (BMS) implantation and plain only balloon angioplasty (POBA).
Methods: We included 818 patients (650 men, 168 women; 69.1 years of age; n=228 in 
the POBA group, n=350 in the BMS group, n=240 in the SES group) with stable angina 
and single vessel coronary artery disease, who underwent elective PCI. Blood samples 
were taken before PCI and 6 months later to evaluate CRP, WBC and fibrinogen.
Results: There were no significant baseline differences of CRP in comparison of 3 
groups (3.8±3.2 mg/L in POBA group, 3.7±9.9 mg/L in the BMS group, 3.8±3.9 mg/L in 
the SES group). WBC and fibrinogen showed no difference among 3 groups. CRP at 6 
months after coronary intervention decreased in all groups but those were significantly 
higher in the POBA than in the SES and BMS group. And CRP after angioplasty of SES 
group were the lowest among 3 groups (2.7±2.8 mg/L in POBA group, 2.4±2.3 mg/L 
in the BMS group, 1.6±1.8 mg/L in the SES group; p <0.01). At 6 months after PCI, 
WBC in SES and BMS group showed a decrease that was not noted in the POBA group 
(5714±1529 /mm3 in POBA group, 5444±1566 /mm3 in the BMS group, 5447±1487 /mm3 
in the SES group; at 6 months after PCI). In addition, the SES and BMS group showed 
a significant reduction in the fibrinogen compared to baseline values that was greater in 
SES group than BMS group (324±62 mg/dl in POBA group, 304±233 mg/dl in the BMS 
group, 292±66 mg/dl in the SES group; at 6 months after PCI).
Conclusions: Stent deployments were able to reduce CRP and fibrinogen more 
strongly compared with only balloon dilatation. And CRP and Fibrinogen after coronary 
intervention in SES group was remarkably lower compared with BMS group. This may 
reflect the possible benefits of Sirolimus on inflammatory reaction.
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1001-197 Delayed Time to Defibrillation and Mortality After In-
Hospital Ventricular Tachyarrhythmic Cardiac Arrest
Paul S. Chan, Harlan M. Krumholz, Noah Jones, Brahmajee K. Nallamothu, University 
of Michigan Medical Center, Ann Arbor, MI
Background: Although current guidelines recommend defibrillation within 2 minutes of 
an in-hospital cardiac arrest, clinical data to support this are limited.
Methods: We identified 6,744 patients with initial cardiac arrests from pulseless 
ventricular tachycardia or ventricular fibrillation at 369 hospitals in the National Registry of 
Cardiopulmonary Resuscitation. Using multivariable logistic regression models employing 
generalized estimating equations to adjust for clustering effects at the hospital level, we 
assessed whether a time to defibrillation >2 minutes was associated with higher mortality 
rates immediately post-resuscitation, within 24 hours, and for overall hospitalization. 
Factors associated with delays to defibrillation were also examined.
Results: A time to defibrillation >2 minutes (n=2000) was associated with a 30% higher 
risk of in-hospital mortality (adjusted relative risk [RR], 1.30; 95% CI, 1.26-1.34; p<.0001). 
This resulted in an absolute increase in mortality rate by 18.2% from 60.7% to 78.9% 
(95% CI: 15.8% to 20.6%). Other predictors of in-hospital mortality included: age; male 
sex; non-white race; ventricular fibrillation rhythm; arrest during afterhours; hospital bed 
location and size; non-cardiac admitting diagnosis; pre-existing congestive heart failure or 
diabetes mellitus; and central nervous system depression, sepsis, cancer, or respiratory, 
renal, or hepatic insufficiency at time of cardiac arrest. Delayed defibrillation was also 
associated with increased mortality risk immediately (RR, 1.48; 95% CI, 1.39-1.58; 
p<.0001) and within 24 hours post-resuscitation (RR, 1.37; 95% CI, 1.30-1.44; p<.0001). 
Hospital-level factors associated with delayed defibrillation included: small-sized (<250 
beds) hospitals; timing (after hours and weekends) and location (unmonitored hospital 
units) of cardiac arrest; and a non-cardiac diagnosis on admission.
Conclusion: Delayed defibrillation times exceeding 2 minutes for in-hospital cardiac arrests 
amenable to defibrillation are associated with sizable increases in mortality. These findings 
highlight potential hospital quality improvement areas for resuscitation response and treatment.
10:00 a.m.
1001-198 Clinical and Electrophysiological Data of Patients with 
a Rapid Atrial Fibrillation as the First Manifestation of 
Wolff-Parkinson-White Syndrome.
Béatrice Brembilla-Perrot, Charif Tatar, Olivier Yangni N’Da, Olivier Huttin, Frédéric 
Chometon, Olivier Marçon, Fabrice Duhoux, Marius Andronache, Etienne Aliot, Daniel 
Beurrier, Pierre Louis, Ning Zhang, Julien Bertrand, Cardiology, CHU of Brabois, 
Vandoeuvre Les Nancy, France
Background: The first manifestation of a Wolff-Parkinson-White syndrome (WPW) can be 
atrial fibrillation (AF) conducted at very high ventricular rates through the accessory pathway 
(AP). The incidence of malignant forms at electrophysiological study (EPS) is higher than the 
incidence of spontaneous events. The purpose of the study was to look for the clinical and 
electrophysiological predictors of adverse events in WPW as the first manifestation.
Methods: The data of 488 consecutive patients aged 6 to 81 years admitted for a WPW 
syndrome and EPS were reviewed; 38 of them (7.8 %), had a severe clinical event (group 
I): resuscitated sudden death (n =2) or documented rapid AF, cause of syncope and 
requiring cardioversion (n=6) or intravenous antiarrhythmic drug (n=30). In remaining 
452 patients (group II), EPS was indicated for unexplained syncope (n= 47), reentrant 
tachycardias (n=240) or patients were asymptomatic (n=165).
Results: In group I, the adverse event occurred in adrenergic situation; but during a 
sportive activity in only 4 patients. Group I age varied from 12 to 72 years (mean 36±19) 
and did not differ from group II (36±17). Sex male was more frequent in group I than in 
group II (69 % vs 59.5 %), but the differences were not significant. AP left lateral (LL) 
location was more frequent in group I (78 %) than in group II (41 %) (p< 0.001), and 
posteroseptal (PS) location was less frequent in group I than in group II (left PS AP 5 % of 
group I, 30 % in group II (p< 0.05), right PS AP 8 % of group I, 32 % of group II (p < 0.05). 
Malignant form at EPS (1/1 conduction through AP > 220 b/min in control state or > 310 
b/min after isoproterenol and AF induction was noted in 38 group I patients (100%) and 68 
group II patients (15 %) (p <0.001). Reentrant supraventricular tachycardia was induced 
in 11 group I patients (29%) and 257 group II patients ((57 %) (p <0.001).
Conclusions: Rapid atrial tachyarrhythmia conducted through the accessory pathway, 
responsible for sudden death or syncope, can be the first manifestation of a WPW at all ranges 
of life. Only the location of AP, frequently left lateral-sided and rarely posteroseptal-sided and 
the electrophysiological data differ in these patients from other patients with a WPW. 
10:00 a.m.
1001-199 Resuscitation with Liposome-Encapsulated Hemoglobin 
(TRM645) from Lethal Hemorrhage and Its Protective 
Effect on Myocardium During Hemorrhagic Shock
Bonpei Takase, Yashiro Nogami, Manabu Kinosita, Yoshitaka Ogata, Noriyuki Matsutani, 
Tadaaki Maehara, Masayuki I shihara, National Defense Medical College, Tokorozawa, Japan
Background: Liposome-encapsulated hemoglobin (Artificial Oxygen Carrier, TRM645) 
can serve as blood substitutes of oxygen-carrying capacity comparable to human blood. 
Since the cellular structure of TRM645 has the characteristics similar to natural red blood 
cells, the resuscitation effect of TRM645 in severe hemorrhage is expected.
Methods: Thus, we performed graded blood exchange experiment up to 85% blood loss 
in 19 rats. Under Sevofrane-anesthesia, 7 rats were gradually exchanged blood with 5% 
Albmin (Alb-group) while 5 rats exchanged with washed human erythrocyte (WHE-group) 
and 7 rats exchanged with TRM645 (TRM645-group). Complete-blood counts, blood 
pressure, heart rate, cardiac function (LV ejection fraction, LVEF) by 2D-echocardiography 
and serum heart-type fatty acid-binding protein (H-FABP) levels were measured.
Results: All rats died in Alb-group whereas all survived for following 24-hours in WHE-
group and TRM645-group (Fig 1 and 2) where hemoglobin levels were maintained. During 
hemorrhagic shock, LVEF decreased and H-FABP increased in Alb-group whereas these 
changes were suppressed in both WHE-group and TRM645-group (Fig 3 and 4).
Conclusions: TRM645 has a salutary anti-shock effect partly through protective effect on 
myocardium during lethal hemorrhage. 
10:00 a.m.
1001-200 1-Year Outcome after Coronary Revascularization 
among Patients with Left Anterior Descending Artery 
Disease and Diabetic Retinopathy: Sirolimus-Eluting 
Stent versus Coronary Bypass Surgery
Takayuki Ohno, Shinichi Takamoto, Noboru Motomura, Minoru Ono, Jiro Ando, Toshihiro 
Morita, Hideo Fujita, Yasunobu Hirata, Takashi Shigeeda, Akira Hirose, The University of 
Tokyo, Tokyo, Japan
Background: The choice of revascularization for patients with left anterior descending 
artery (LAD) disease and diabetic retinopathy is uncertain. The purpose of this study 
was to compare the 1-year outcome by revascularization strategy (sirolimus-eluting stent 
[SES] or CABG) for these patients with the different stage of retinopathy: no retinopathy 
(NDR), non-proliferative retinopathy (NPDR), and proliferative retinopathy (PDR).
Methods: Between April 2004 and September 2005, 220 consecutive patients with LAD 
disease underwent implantation of SES. Of these, 25 patients had NDR, 29 had NPDR, 
and 25 had PDR. For each retinopathy group, a comparison group undergoing CABG with 
the same stage of retinopathy and the same number of patients was created. Patients who 
selected for comparison groups were matched by age, HbA1c, creatinine, insulin, and EF.
Results: During 1 year after revascularization, there were 5 cardiac events (cardiac death, 
myocardial infarction, and repeat revascularization) in the NDR-SES patients, 2 in the NDR-
CABG patients, 17 in the NPDR-SES patients, 4 in the NPDR-CABG patients, 7 in the PDR-
SES patients, and 3 in the PDR-CABG patients. Most of events were repeat revascularizations. 
K-M estimates of the rate of events at 1 year were 21% (NDR-SES), 8% (NDR-CABG), 65% 
(NPDR-SES), 10% (NPDR-CABG), 22% (PDR-SES), and 12% (PDR-CABG), respectively. In 
the SES-patients, after adjustments for sex, age, and the potential confounding factors including 
the number of stents, the minimal stent diameter, and the extent of coronary disease, NPDR 
was the only predictor of cardiac events (HR, 3.9; P=0.015). K-M curves for cardiac events differ 
significantly between the SES patients and the CABG patients in the NPDR group (P<0.001). 
The total costs for the initial hospitalization and the 1-year follow-up period were significantly 
lower in the SES patients than the CABG patients in the NDR group (Japanese Yen; 3,632,356 
versus 4,765,4240; P=0.001), whereas those were significantly higher in the SES patients than 
the CABG patients in the NPDR group (7,407,886 versus 3,515,500; P<0.001).
Conclusions: CABG rather than SES is suitable for revascularization in patients with 
LAD disease and NPDR.
10:00 a.m.
1001-201 Risk-Adjusted Hospital Mortality is Similar Between 
Patients Undergoing Coronary Artery Bypass Grafting 
or Percutaneous Coronary Intervention for Residual 
Multi-Vessel Disease Following Primary Percutaneous 
Revascularization
Kurt G. Barringhaus, Robert J. Goldberg, Philippe Gabriel Steg, Gilles Montalescot, 
Frans Van de Werf, José López-Sendón, Rebecca Dedrick, Joel M. Gore, Center for 
Outcomes Research, University of Massachusetts Medical School, Worcester, MA, 
Hôpital Bichat-Claude Bernard, Paris, France
Background: The short- and long-term outcomes of acute coronary syndrome (ACS) 
patients with multi-vessel disease who are initially treated with primary percutaneous 
coronary intervention (PCI) and subsequently undergo surgical or percutaneous 
revascularization are currently unknown.
Methods: The study cohort consisted of patients enrolled in the Global Registry of 
Acute Coronary Events (GRACE) who presented with ST-segment elevation myocardial 
infarction (STEMI) and were initially treated with primary PCI, had TIMI flow <3 in 
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the index vessel, and had at least one additional vessel with stenosis ≥50% that was 
subsequently revascularized. Patients with left main stenosis ≥50%, prior coronary artery 
bypass grafting (CABG), and cardiogenic shock were excluded.
Results: Of the 219 patients meeting the study criteria, 36 underwent CABG and 183 
underwent PCI for non-culprit vessel revascularization following primary PCI. Patients 
undergoing CABG included a greater proportion with Killip class 3 (8.3% vs 1.1%), 
hyperlipidemia (58.3% vs 37.6%), and peripheral arterial disease (13.9% vs 4.9%) as 
compared with PCI patients. A greater proportion of patients had moderately or severely 
reduced ejection fractions in the CABG group vs the PCI group (70.0% vs 28.1%; 
P<0.05). Other baseline characteristics were similar between groups. The hospital death 
rate was higher in the CABG group as compared with the PCI group (8.3% vs 1.1%; 
P<0.05). However, mortality was not different between patients undergoing CABG or PCI 
after adjustment for a variety of potentially confounding prognostic factors. Reinfarction 
rates were similar between groups. Unplanned procedures within 6 months of discharge 
were lower in the CABG group (0.0% vs 10.4%; P<0.05).
Conclusions: Unadjusted hospital mortality among GRACE registry patients with multi-
vessel disease is higher in those undergoing CABG following primary PCI for STEMI. These 
findings are likely to be a result of a high-risk CABG population, as risk-adjusted mortality 
is similar between those undergoing CABG vs PCI. PCI patients are more likely to undergo 
unplanned procedures within 6 months of discharge as compared with CABG patients.
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1202-250 Transition to an Unstable Coronary Syndrome Is 
Marked by Hypercoagulability, Platelet Activation, 
Heightened Platelet Reactivity, and Inflammation: 
Results of the Thrombotic RIsk Progression (TRIP) 
Study.
Udaya S. Tantry, Kevin P. Bliden, Rolf P. Kreutz, Joseph DiChiara, Paul A. Gurbel, Sinai 
Center for Thrombosis research, Baltimore, MD
Background: It is well known from independent studies that inflammation, platelet 
reactivity, and hypercoagulability play important roles leading to the development of 
atherothrombotic events. However, to date, no single study prospectively evaluated all of 
these pathophysiologic processes together in patients with stable and unstable coronary 
artery disease (CAD).
Methods: Thrombin-induced platelet-fibrin clot strength (MA), time to thrombin generation 
(R), CRP, prothrombotic factors, platelet reactivity to ADP, and platelet activation (ADP-
stimulated and unstimulated GPIIb/IIIa receptor expression) were studied in patients 
with asymptomatic stable CAD (AS), and in patients undergoing PCI for stable (SA), 
unstable angina (UA), and myocardial infarction (MI). MA and R were measured by 
thrombelastography, GPIIb/IIIa expression by flow cytometry, and all other parameters by 
fluorokine multianalyte profiling (MAP) assays.
Results: Results and statistical significance are shown in the table. There was an incremental 
increase in all parameters from a clinically stable to an unstable disease state (Table)
Conclusion: A uniform and distinct pathophysiological state of heightened platelet 
reactivity to ADP, platelet activation, hypercoagulability, and inflammation marks the 
development of unstable cardiovascular disease from chronic stable disease. Further 
studies are required to investigate the mechanisms activating the prothrombotic state 
that destabilizes the disease. 
AS
(n=71)
SA
(n=84)
UA
(n=26)
MI
(n=7)
p value
(AS/SA)
p value 
(UA/SA)
CRP(ug/ml) 4+/-8 9+/-15 15+/-23 11+/-5 0.006 0.2
PA-I (ng/ml) 69+/-28 81+/-39 88+/-30 130+/-70 0.01 0.28
Fibrinogen(mg/ml) 3.7+/-0.8 4+/-2 4.8+/-3 3.7+/-0.8 0.15 0.22
VWF (ug/ml) 21+/-9 24+/-26 39+/-54 30+/-13 0.34 0.17
MA 65+/-5 67+/-10 70+/-6 69+/-6 0.002 0.053
R (min) 6.5+/-2 4.5+/-1.3 4.1+/-1.6 5.5+/-0.2 <0.0001 0.9
GPIIb/IIIa-
unstimulated
(MFI)
13+/-9 17+/-15 38+/-25 - 0.051 <0.0001
GPIIb/IIIa-stimulated
(MFI) 129+/-50 150+/-55 180+/-161 - 0.002 0.14
Noon
1202-251 Increased Mortality With Early Surgical 
Revascularization in Acute ST-Elevation Myocardial 
Infarction After Fibrinolysis: An Analysis of the GUSTO 
V Study
Saif Anwaruddin, Thomas H. Wang, Arman T. Askari, Matthew C. Backer, John M. Galla, 
Amy Hsu, A. Michael Lincoff, Eric J. Topol, Cleveland Clinic, Cleveland, OH, Case 
Western Reserve University, Cleveland, OH
Background: Importance of time to revascularization in acute ST segment elevation 
myocardial infarction (STEMI) has been demonstrated using fibrinolysis and percutaneous 
coronary intervention. Coronary artery bypass grafting (CABG) may often be necessary 
after STEMI but optimal timing for surgery remains poorly defined. 
Methods: In GUSTO-V, 16,588 patients with acute STEMI were randomized to standard-
dose reteplase or half-dose reteplase in conjunction with full-dose abciximab bolus 
and 12-hour infusion. We examined patients that underwent CABG within 7 days of 
randomization and then stratified based on time to CABG. Multivariable Cox regression 
analysis was used to assess the effect of timing of CABG on short (30 days) and long-
term (1 year) mortality.
Results: 549 (3.3%) patients underwent CABG within 7 days of STEMI (59 <= 24 hrs, 490 
> 24 hrs). Patients who underwent CABG within 7 days of randomization were more likely 
to have hypertension, hypercholesterolemia, diabetes, prior myocardial infarction, and 
prior revascularization while being less likely to have congestive heart failure than those 
who did not undergo CABG. In the cohort undergoing CABG following randomization, 
a shorter mean time to CABG was associated with higher 30-day and 1-year (p<0.01 
for both) mortality. Specifically, undergoing CABG within 24 hours of fibrinolysis was 
independently associated with a higher mortality rate at both 30 days (15.3% vs 2.9%, 
p<0.01) and at 1 year (22% vs 3.95%, p<0.01).
Conclusions: Early surgical revascularization (</=24hrs) following STEMI treated with 
pharmacologic reperfusion is associated with a higher 30-day and 1-year mortality. It 
may be prudent to adopt a more conservative approach to surgical revascularization 
immediately after fibrinolysis in STEMI.
Noon
1202-252 Safety and Tolerability of a Novel Tissue Factor/Factor 
VIIa Inhibitor rNAPc2 in Patients With Non-ST Elevation 
Acute Coronary Syndrome Managed Invasively: Results 
From the ANTHEM-TIMI 32 Trial
Richard G. Bach, Robert P. Giugliano, Daniel I. Simon, Marc J. Schweiger, Massoud A. 
Leesar, Stephen D. Wiviott, Michael A. Goulder, Steven R. Deitcher, Eugene Braunwald, 
Washington University Medical Center, St. Louis, MO, Brigham and Women’s Hospital, 
Boston, MA
Background: Activation of coagulation by tissue factor (TF) at a ruptured coronary plaque 
is a key event in NSTE-ACS. TF activity and thrombin generation, further increased by 
PCI, are not suppressed by current therapies. ANTHEM-TIMI 32 was a Phase 2 dose-
ranging study to assess safety and activity of rNAPc2, a novel TF/fVIIa inhibitor that 
blocks thrombin generation, when added to standard ACS therapy.
Methods: 203 pts <75y with NSTE-ACS managed invasively were randomized (4:1) to 
IV rNAPc2 (1.5-10 mcg/kg) or placebo q48h for dose-ranging; additional pts received 
open-label high dose rNAPc2 (10 mcg/kg) + half-dose (n=26) or no (n=26) heparin. The 
primary safety endpoint was adjudicated TIMI major/minor bleeding. RBC transfusion, 
prothrombin time (PT), plasma F1.2 (marker of thrombin generation), ischemia by 
continuous ECG, and anti-rNAPc2 antibody (Ab) were also measured. Thrombosis 
events were prospectively reported during heparin de-escalation.
Results: Despite prolongation of PT (trend p<.01), suppression of increased F1.2 
(p<.01), and reduced ischemia at high dose (p=.01), rates of major bleeding (1.9% vs. 
0%, p=.38), major/minor bleeding (3.7% vs. 2.5%, p=.70) and RBC transfusion (6.1% vs. 
2.5%, p=0.32) were not significantly increased by rNAPc2. In 40 pts on high dose rNAPc2 
+ full heparin, there were 3 (7.5%) major bleeds, but in 52 pts on high dose rNAPc2 + 
half or no heparin there was 1 major ( 1.9%) and no minor bleeds. All major/minor bleeds 
were procedure-related. Bleeding was associated with CABG but not anticoagulant type, 
use of clopidogrel, aspirin dose, or IIb/IIIa inhibitor use. No pt required recombinant fVIIa. 
Investigators reported 4 (15%) procedure-related thromboses in the no heparin group 
and none with half-dose heparin. Non-neutralizing Ab vs. rNAPc2 were detected at 42d in 
22 pts (12%) but not associated with clinical sequelae.
Conclusions: In NSTE-ACS pts managed invasively, TF targeted inhibition of thrombin 
generation by rNAPc2 reduced ischemia without a significant increase in bleeding. 
Adjunctive heparin at PCI may reduce the risk of procedural thrombosis. These data 
suggesting favorable safety of rNAPc2 require confirmation in larger scale clinical trials.
Noon
1202-253 Trends in the Treatment and Outcomes of Patients With 
Non-ST-Segment Elevation Acute Coronary Syndromes 
Managed Medically Without Cardiac Catheterization
Ezra A. Amsterdam, Eric D. Peterson, Fang-Shu Ou, L. Kristin Newby, Charles V. Pollack, 
Jr., W. Brian Gibler, E. Magnus Ohman, Matthew T. Roe, University of California, Davis, 
Medical Center, Sacramento, CA, Duke Clinical Research Institute, Durham, NC
Background: Despite emphasis on early invasive management for non-ST-segment 
elevation acute coronary syndromes (NSTE ACS), many patients receive medical 
management (MED) without cardiac catheterization as the sole treatment strategy.
Methods: We characterized temporal patterns of the use of MED in patients with NSTE 
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ACS (ischemic ECG changes and/or positive cardiac markers) from the CRUSADE 
initiative treated at 547 U.S. hospitals (1/02-12/05).
Results: Among 138,714 patients, 39,662 (28.6%) were in the MED group; 29,109 
(21.0%) received cardiac catheterization (CATH) without revascularization; 54,846 
(39.5%) underwent percutaneous coronary intervention (PCI); and 15,097 (10.9%) 
underwent bypass surgery. During the study interval, use of MED increased from 30.6% 
to 25.6%, use of PCI increased from 36.2% to 43.1%, and use of CATH and bypass 
surgery remained relatively constant. Temporal improvements in care were observed in 
patients in the MED group over 4 years (Table). Unadjusted in-hospital mortality rates in 
the MED group declined from 8.0% to 6.6% over the study interval.
Conclusions: Despite lower use of evidence-based medications for NSTE ACS patients 
managed medically, encouraging trends for improvements in care and lower mortality 
rates suggest that more widespread application of guidelines recommendations may 
further ameliorate adverse outcomes in this high-risk population. 
Use of Medications by Year in Medically Managed NSTE ACS Patients
2002
(n = 10,404)
2005
(n = 7,734)
Acute Medications (< 24 hrs)
Aspirin 87% 93%
Beta-blocker 72% 89%
Heparin 69% 79%
Clopidogrel 23% 43%
Discharge Medications
Aspirin 82% 90%
Beta-Blocker 78% 91%
Lipid-lowering agent 68% 81%
ACE Inhibitor or ARB 53% 67%
Clopidogrel 28% 53%
Noon
1202-254 Association of Primary Percutaneous Coronary 
Intervention Door-to-Balloon Time and Mortality in 
Patients Hospitalized With ST-Elevation Myocardial 
Infarction: Findings From the American College of 
Cardiology-National Cadiovascular Data Registry 
CathPCI Registry
Saif S. Rathore, Jeptha P. Curtis, Brahmajee K. Nallamothu, Yongfei Wang, Andrew 
J. Epstein, Harlan M. Krumholz, on behalf of the NCDR, Yale University School of 
Medicine, New Haven, CT
Background: Current ACC/AHA guidelines recommend ST-elevation MI (STEMI) patients 
receive primary PCI within 90 minutes of admission. Little is known about the continuous 
nature of this relationship, particularly among patients treated within guidelines-based 
recommendations.
Methods: The ACC National Cardiovascular Data Registry database was used to identify 
STEMI patients undergoing primary PCI in 2005. We restricted our analysis to patients 
who received primary PCI as their initial reperfusion strategy at centers performing >5 
primary PCIs, and had reported door-to-balloon times between 15 minutes and 6 hours 
(n=18,901). Logistic regression models utilizing fractional polynomials assessed the 
association between door-to-balloon time and in-hospital mortality adjusting for patient 
demographics, presentation, medical history, and hospital PCI volume
Results: Median door-to-balloon time was 88 minutes (interquartile range 65-116). Overall 
in-hospital mortality was 4.9%. Multivariable logistic regression models indicated any 
increase in door-to balloon time was associated with successive increases in patients’ 
adjusted risk of in-hospital mortality (Figure), including in those treated within 90 minutes
Conclusions: Our findings suggest that any delay in primary PCI is associated with 
higher in-hospital mortality in STEMI patients. Efforts should focus on reducing time to 
treatment as much as possible, even among those centers currently providing primary 
PCI within 90 minutes 
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1007-69 Circulating Endothelial Cells in patients with Impaired 
Glucose Tolerance following Acute Myocardial 
Infarction
Shahirose S. Jessani, Teri Millane, Gregory YH Lip, City Hospital, Birmingham, 
United Kingdom
Background: Impaired glucose tolerance (IGT) is common in non diabetic patients post 
acute myocardial infarction (AMI). We tested the hypothesis that significant endothelial 
damage was present in patients with IGT in the post AMI period as indicated by circulating 
endothelial cells (CECs).
Methods: Non diabetic patients post AMI underwent an oral glucose tolerance test 
predischarge.Fasting and 2-hour post-challenge plasma glucose and CEC levels in 
venous blood (quantified by CD146 immunobead method) were recorded.
Results: 79 patients [age 60(+/-12.8) yrs; 67 male] were studied. CECs were significantly 
higher in patients with IGT vs those with normal glucose tolerance (p < 0.001)( table 
1). There was a significant correlation between increase in CECs and increasing post 
challenge plasma glucose levels (Spearman, r = 0.37, p< 0.001).
Conclusion: IGT post AMI is associated with significant endothelial damage compared 
to those with normal glucose tolerance. IGT warrants early detection and lifestyle 
modification to prevent progression to frank diabetes.
Table 1 Circulating Endothelial Cell levels by glycemic status post acute myocardial infarction 
CECs cells/ml
Normal 
glucose 
tolerance 
(n = 33)
Impaired 
glucose 
tolerance 
(n = 34)
Newly detected 
diabetes mellitus
(n = 12)
Median (IQR) fasting CECs 5 (4 - 6) 9 (7 - 11)* 12 (9 -15)*
Median (IQR) CECs 2-hour 
post glucose challenge 7 (6 - 9)a 12 (9 - 16)*a 15 (13 - 18)*b
Between group analyses by Kruskal Wallis test with Dunn post hoc test. Pre and post 
glucose challenge CECs analysis by Wilcoxon signed ranks test.
* Significantly higher (p < 0.0001) compared to normal glucose tolerance.
a Significantly higher CECs at 2-hour post glucose challenge (p < 0.0001).
b Significant higher CECs at 2-hour post glucose challenge (p < 0.05).
2:30 p.m.
1007-71 Independent Role of Necrosis and Microvascular 
Obstruction in Early and Late Left Ventricular 
Remodeling After Reperfused Myocardial Infarction
Vicente Bodi, Juan Sanchis, Maria P. Lopez-Lereu, Julio Nunez, Luis Mainar, Roberto 
Sanz, Francisco J. Chorro, Angel Llacer, Hospital Clinico y Universitario, Valencia, 
Spain, ERESA, Valencia, Spain
Background: We aimed to define, using cardiovascular magnetic resonance imaging 
(CMR), the influence of transmural extent of necrosis (TEN) and of microvascular 
obstruction (MO) on left ventricular dilation after myocardial infarction (MI).
Methods: We analyzed 91 patients with a first ST-elevation MI, single-vessel disease 
and TIMI 3 flow; 72 patients were re-studied at 6 months. CMR was used to quantify end-
diastolic volume (EDV, ml/m2), Early Remodeling (EDV at 1 week >85 ml/m2) and Late 
Remodeling (EDV increase at 6 months >20%). TEN(>2 segments with late enhancement 
>50%) and MO (>2 segments without contrast uptake in the core of the infarcted area) 
were quantified in late enhancement imaging.
Results: TEN was detected in 57 patients (63%) and MO in 9 (10%). Early Remodeling 
took place in 21/91 patients (23%) and Late Remodeling in 11/72 (15%). Late 
Remodeling only took place in patients without Early Remodeling (19% vs. 0%, p=0.01). 
Early Remodeling was more frequent in patients with TEN (32% vs. 9%, p=0.01) but 
not in those with MO (22% vs. 23%, p=0.9); TEN (1.8[1.3-2.5] per segment, p=0.0005) 
was independently related to Early Remodeling. Late Remodeling was more frequent in 
patients with MO (57% vs. 11%, p=0.001) but not in those with TEN (18% vs. 11%, p=0.9). 
MO (1.8[1.1-2.8] per segment, p=0.01) was independently related to Late Remodeling. 
We divided patients in those without TEN (n=34), with TEN (n=48) and with TEN+MO 
(n=9). EDV-1 week was smaller in patients without TEN (65±14, 79±25, 77±14 ml/m2, 
p=0.02). Patients with TEN+MO showed bigger EDV-6 months (63±12, 73±28, 85±17 
ml/m2, p=0.04) and deltaVTD (-3±19, -3±20, 16±20%, p=0.05).
Conclusions: Early Remodeling relates to the extent of necrosis and Late Remodeling 
to the extent of microvascular obstruction. Patients with severe Early Remodeling do not 
show further dilation.
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1007-72 Increased Myocardial Prevalence of C-Reactive Protein 
in Human Coronary Heart Disease: Relation to Local 
Endothelial Injury and Microvessel Rarefaction
Angela C. Cook, Mandar Joshi, Hong Huang, Bing Han, Leona W. Ayers, John Anthony 
Bauer, Columbus Children’s Research Institute, Columbus, OH, The Ohio State 
University, Columbus, OH
Background: Increased plasma C-reactive protein (CRP) is a biomarker of coronary 
heart disease (CHD) but cellular sources during disease progression and potential roles 
as a participant of the disease process are not well defined. A key component of CHD 
and other forms of cardiovascular disease are endothelial injury and dysfunction. We 
have recently shown that human CRP is directly toxic to human endothelial cells in vitro, 
causing oxidant mediated apoptosis at clinically relevant concentrations (<5mcg/ml).
Methods: Here we tested the hypotheses that CRP expression is detectable in human 
cardiac specimens, that CRP is elevated in myocardium from patients with CHD, and 
that these changes are related to local endothelial stress and/or microvessel rarefaction. 
Cardiac specimens (LV anterior free wall) were collected at autopsy within 4 hrs of death 
and were classified as normal controls (CTL) or documented evidence of CHD without 
myocardial infarction (n=12 per group). Automated methods for immunohistochemistry 
and digital image analyses were used to investigate regional prevalence of CRP, in 
full thickness myocardial cross-sections to define discrete analyte distributions among 
myocyte, coronary artery (100+μm diameter), and microvessel regions (<40μm diameter). 
Prevalence of subendocardial microvessels was determined using an anti-CD31 antibody 
and an automated counting subroutine. CHD myocardium had increased interstitial 
fibrosis and hypertrophy.
Results: Myocyte regions in CTL had slight but detectable levels of CRP (confirmed 
by western blotting and antibody quenching), which was increased in the CHD group 
(p<0.05). In addition, microvessel prevalence was significantly reduced in CHD 
myocardium when compared to CTL, and this rarefaction was inversely correlated to 
adjacent myocardial CRP prevalence (correlation analysis, p<0.05).
Conclusions: These findings provide evidence supporting myocardial CRP as a locally 
produced inflammatory marker and as a potential participant of myocardial endothelial 
toxicity and microvascular rarefaction. These observations may also help to explain the 
strong predictive value of increased blood CRP to CHD progression in humans.
2:30 p.m.
1007-73 TNF-α Enhances the Engraftment of Mesenchymal Stem 
Cells onto Infarcted Myocardium via BMP-2
Yong Sook Kim, Youngkeun Ahn, Hye Jeong Park, Yong Hee Shin, Soo Yeon Joo, Sang 
Rok Lee, Kye Hun Kim, Hyung Wook Park, Young Joon Hong, Ju Han Kim, Myung 
Ho Jeong, Jeong Gwan Cho, Jong Chun Park, Chonnam National University Hopsital, 
Gwangju, South Korea
Background: Mesenchymal stem cells (MSCs) have therapeutic potential after myocardial 
infarction. We hypothesized that cytokines released from infarcted myocardium play an 
important role in recruit and potentiation of MSCs. We elucidated whether TNF-α, one of 
cytokine released from infarcted myocardium, modulate the behavior of rat bone marrow-
MSCs in vivo and in vitro system.
Methods: Allogeneic MSCs were isolated from the femoral bone of Sprague-Dawley rats, 
characterized, cultured, and labeled with DAPI, To examine the effect of TNF-α on MSC, 
MSCs were treated with TNF-α (10 ng/mL) for 24 hours before injected into infarcted 
myocardium of rats. Myocardial infarction was induced by left anterior descending 
coronary artery ligation for 30 minutes followed by release. Two weeks later, the number 
of DAPI-labelled MSCs on myocardium of rat was counted. To measure the adhesiveness 
of MSC, neonatal rat cardiomyocytes were co-cultured with DAPI-labeled MSC with or 
without TNF-α pretreatment. After 30 minutes, non-adhesive MSCs were removed, and 
remained MSCs on cardiomyocytes were counted under fluorescent microscope.
Results: The expression of BMP-2 was increased by TNF-α in mRNA (2.7-fold of 
control, p<0.05) and protein level (3.23±0.43 ng/mL in TNF-α-treated MSC, p<0.05). The 
expressions of monocyte chemoattractant protein (MCP)-1, interleukin (IL)-6, vascular 
endothelial growth factor (VEGF), and phosphorylated signal transducer and activator 
of transcription (STAT)-3 were also increased in TNF-a treated MSCs. The number of 
engrafted TNF-a-stimulated MSCs on rat myocardium was larger than non-treated MSCs 
(1.82-fold, p<0.05). Adhesion assay showed that the adhesiveness of TNF-α-stimulated 
MSCs on cardiomyocytes was 1.74-fold increased (p<0.05)
Conclusions: Our results demonstrated that TNF-α improved the engraftment of MSCs 
on infarcted myocardium through increase its adhesiveness and BMP-2 probably acted 
as a putative mediator.
2:30 p.m.
1007-74 Myocardial Infarction After Age Ninety: Outcomes in 
10,213 Nonagenarians
Nora M. Cosgrove, William J. Kostis, Yu-Hsuan Shao, Alan C. Wilson, Abel E. Moreyra, 
John B. Kostis, for the MIDAS Study Group, UMDNJ-Robert Wood Johnson Medical 
School, New Brunswick, NJ, UMDNJ-School of Public Health, Piscataway, NJ
Background. Most studies of acute myocardial infarction (MI) focus on patients up to age 85. 
However, the aging of the population has resulted in increasing numbers of nonagenarians.
Methods. Using the statewide Myocardial Infarction Data Acquisition system (MIDAS) including 
all admissions for acute MI in New Jersey, we examined the occurrence, characteristics and 
outcomes of first MI (n=10,213) among patients aged 90-99 between 1986-2002.
Results. The annual number of nonagenarians with acute MI nearly doubled from 858 
women and 426 men in 1986 to 1598 women and 840 men in 2002. This increase was 
primarily due to an increase in the age specific population while the annual rate of acute 
MI occurrence remained relatively stable (for women 1.4% 1986 and 1.5% in 2002, for 
men 1.8% and 1.9% respectively). The in-hospital mortality for both Q and non-Q MIs 
for both men and women remained stable between 1986-2002 and was higher for Q 
MI (approximately 35%) than non-Q MI (approximately 15%). One year mortality also 
remained stable and was higher for men and for those with Q-wave infarction (men Q 
70.6%, men non-Q58.5%; women Q 59.8%, women non-Q 50.5%). Overall, one year 
mortality post MI was 52.1% for men and 51.6% for women which is about three times the 
reported age and sex specific mortality in New Jersey. The temporal trends of decreasing 
MI mortality observed in younger populations were not observed in the oldest group. 
One year mortality risk was association by multiple logistic regression adjusting for 
demographics, co-morbidity, complications and hospital type Q-wave MI (OR 1.13, 1.00-
1.26), renal disease (OR 2.27, 1.85-2.79), anemia (OR 1.18, 1.03-1.35), cancer (OR 
1.79, 1.32-2.42), hypertension (OR 0.76, 0.68-0.85) and cerebrovascular disease (OR 
1.63, 1.34-1.98). Revascularization procedures (OR 0.34, 0.24-0.50) were associated 
with lower one year mortality.
Conclusion. More than half of nonagenarians who experience an MI die within one year. Those 
who have revascularization procedures have much lower mortality. Despite the increased risk of 
revascularization procedures in this aged population, they are effective in reducing mortality.
2:30 p.m.
1007-75 Increased Glucose Uptake by Amphiphysin SH3 
Reduces Hypoxia-induced Apoptosis in Cultured 
Neonatal Rat Cardiomyocytes
Yu-Kyung Kim, Tae-Keun Oh, Jin-Sook Kwon, Kyung-Kuk Hwang, Il-Ha Jeung, No-
Kwan Park, Jang-Whan Bae, Dong-Woon Kim, Myeong-Chan Cho, Chungbuk National 
University Hospital, Cheongju, South Korea
Background: Amphiphysin was known to play an important role in clathrin-mediated 
endocytosis. In the cardiomyocytes (CMCs), the role of Amphiphysin was not known. We 
investigated the effect of glucose-uptake by the mutated Amphiphysin SH3 domain gene 
expression, defective Amphiphysin, in cultured neonatal rat CMCs under the normoxic 
or hypoxic conditions.
Methods: We ligated Amphiphysin SH3 with lenti-GFP viral vector using multi-cloning 
sites, and produced lenti-virus for gene transfer using calcium phosphate method at 293T 
cell (human embryonic kidney cell). Neonatal rat CMCs (5×105 cells) were infected by lenti-
Amphiphysin SH3 virus (1.5×107 IU) for 48 hours. Transfected CMCs by lenti-Amphiphysin 
SH3 virus (CMCs/Amp-SH3) virus were evaluated by confocal laser microscope. We 
measured the glucose-uptake of CMCs/Amp-SH3 using glucose transport assay with 
control at normoxic condition. After hypoxic injury with the hypoxic chamber (1% O2) for 
48 hours, we measured the apoptosis of CMCs/Amp-SH3 by microscopic examination 
and evaluated the survival signals by Western blot analysis.
Results: 1) More than 90% of CMCs had GFP expression by confocal laser microscope. 
Glucose uptake was increased approximately 5-folds in CMCs/Amp-SH3 than control in 
normoxic condition. (1.399 vs 0.257 nmol/mg/min) 2) After hypoxic injury for 48 hours, the 
cell death and apoptosis of CMCs/Amp-SH3 were significantly decreased (approximately 
70-80%) by the microscopic examination. The expression of p-akt and survivin was 
increased at CMCs/Amp-SH3 by Western blot Analysis. Conclusion: Amphiphysin 
SH3 gene increased glucose-uptake in the neonatal rat CMCs at nomoxic condition, 
and attenuated CMCs’ apoptosis under hypoxic condition via enhanced expressions of 
Akt, survivin. Theses findings suggest the Amphiphysin SH3 is one of the candidates for 
ischemic protection of myocardium.
2:30 p.m.
1007-90 Mitochondrial Haplogroup N9b is Protective Against 
Myocardial Infarction in Japanese Males
Mitsutoshi Oguri, Kimihiko Kato, Kazuhiro Yajima, Takeshi Hibino, Kiyoshi Yokoi, Hitoshi 
Matsuo, Tomonori Segawa, Sachiro Watanabe, Yutaka Nishigaki, Noriyuki Fuku, 
Sachiyo Yamaguchi, Yoshinori Nozawa, Masashi Tanaka, Yoshiji Yamada, Department 
of Cardiovascular Medicine, Gifu Prefectural Tajimi Hospital, Tajimi, Japan
Background: Superoxide, which mitochondria mainly produce in vascular endothelial 
cells, plays an important role in the pathogenesis of atherosclerosis and coronary artery 
disease. Accordingly, mitochondrial functional differences are thought to be one of the 
most important factors for the risk of myocardial infarction among various individuals. In 
the present study, we surveyed mitochondrial haplogroups associated with myocardial 
infarction in Japanese subjects.
Methods: The study population comprised 2137 unrelated Japanese individuals, including 1181 
subjects with the disease (920 males, 261 females) and the control subjects (522 males, 434 
females). Twenty-nine mitochondrial single nucleotide polymorphisms of 12 major mitochondrial 
haplogroups (F, B, A, N9a, N9b, M7a, M7b, M7c, G1, G2, D4 and D5) were determined by use of 
28-plex PCR and fluorescent beads combined with sequence-specific oligonucleotide probes.
Results: Multivariate logistic regression analysis with adjustment for age, sex, body mass index, 
and prevalence of smoking, hypertension, hypercholesterolemia, and type 2 diabetes revealed that 
haplogroup N9b was significantly (P<0.004) lower in all subjects (odds ratio, 0.30), and in males 
(odds ratio, 0.20). Additionally, haplogroup M7c was related to resistance against the disease in all 
subjects (odds ratio, 0.47). In contrast, there were trends towards higher prevalence of disease in 
haplogroup G1 for males (odds ratio, 2.07). A stepwise forward selection procedure revealed that 
haplogroup N9b was a protective factor against the disease for all subjects (P=0.0018), and for 
males(P=0.0005). No significant haplogroup-related associations were detected for females.
Conclusions: Our data suggest that haplogroup N9b confers resistance against 
myocardial infarction in Japanese males. Determination of human mitochondrial DNA 
single-nucleotide polymorphisms may prove informative for predicting the genetic risk for 
coronary artery diseases such as myocardial infarction, and, therefore, may contribute to 
the primary prevention of this condition.
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1007-91 Variants in Genes Associated with Inflammation and 
Vascular Cell Function are Associated with Vulnerable 
Plaque
Camille G. Frazier, Svati Shah, Charlotte L. Nelson, David Seo, Elizabeth R. Hauser, 
David Crosslin, Simon Gregory, Pascal J. Goldschmidt-Clermont, Christopher B. 
Granger, L. Kristin Newby, Duke University Medical Center, Durham, NC
Background: Plaque rupture underlies acute coronary syndromes and often occurs 
at nonobstructive coronary lesions (CAD). We hypothesized that gene variants could 
identify subjects at high risk for plaque rupture.
Methods: From the Duke CATHGEN clinical and DNA sample registry, we identified 30 
cases with nonobstructive CAD at cardiac cath who had death, myocardial infarction or 
unstable angina within 6 months and 30 controls (same cath findings; no subsequent 
event) matched on age, sex and ethnicity. A customized Illumina SNP (single nucleotide 
polymorphism) array incorporated SNPs associated with atherosclerosis in our prior work 
(n=99) and the literature (n=29). Logistic regression models evaluated associations of 
SNPs with clinical events.
Results: Cases and controls were well-matched on sex (each 50% women), age (52 vs 51 
yrs) and ethnicity (63% Caucasian; 30% African American; 7% other). Cardiac risk factors 
and admission meds were similar, but discharge meds differed from cases to controls: 
statins, 73 vs 48%; nitrates, 43 vs 15%; calcium channel blockers, 40 vs 4%. In adjusted 
models, 6 genes were associated with 6-month outcomes (Table). Variants in FGFR2, 
mediating cell proliferation and proteoglycan activity, were most strongly associated.
Conclusion: Six genes were associated with 6-month clinical outcomes among patients 
with nonobstructive CAD. If confirmed, these findings may advance our knowledge of 
plaque rupture and our ability to discriminate low and high risk patients.
Genetic Associations with Plaque Rupture
Gene GenotypeOR
Genotype
P-value
CASR 0.28 0.03
GLB1 0.30 0.03
SLC15A2 0.44 0.05
IL7R 2.62 0.03
LHFLP2 2.61 0.04
FGFR2 22.08 <0.001
2:30 p.m.
1007-92 Low Rates of Adverse Outcome among Acute Coronary 
Syndrome Patients: Observations From The Australian 
Acute Coronary Syndromes Prospective Audit 
(ACACIA)
Derek P. Chew, John Amerena, David Brieger, Jamie Rankin, Steven Coverdale, 
Carolyn Astley, Victoria Elegant, Flinders Medical Centre, Adelaide, Australia, Concord 
Hospital, Sydney, Australia
Background: The optimal management of acute coronary syndromes (ACS) is now well 
described by clinical trial evidence. How well this evidence translates to reduced clinical 
outcomes outside trials is less certain. We examined the current patterns of care and 
outcomes for ACS patients in Australia.
Methods: The ACACIA study is a prospective Australian multi-centre registry of 
consecutive patients with ST elevation MI (STEMI), and high/intermediate risk non-ST 
elevation ACS (NSTEACS HR/IR) spanning metropolitan, regional and rural sites. Data 
collected included, clinical risk factors, in-hospital care and clinical events.
Results: A cohort of 3402 patients was enrolled; the median age was 65.5 years. Female 
and non-metropolitan patients comprised 35.5% and 23.9%, respectively. STEMI patients 
constituted 22.2%, NSTEACS- HR and NSTEACS-IR were 57.3% and 20.5% of patients, 
respectively. The use of evidence-based therapies was highest among STEMI patients, 
with a gradient of diminishing use in the other risk strata. (table) In-hospital mortality was 
low (STEMI 4.0%, NSTEACS-HR 1.8%, NSTEACS-IR 0%), as was recurrent MI (STEMI 
2.4%, NSTEACS-HR: 2.8%, NSTEACS-IR 1.1%) and stroke (STEMI 0.7%, NSTEACS-
HR: 0.4%, NSTEACS-IR 0%).
Conclusions: A nationwide study of ACS management demonstrates a low rate of in-hospital 
adverse outcomes with the modern era. These data suggests that the accrued evidence-base 
for ACS management is translating to improved clinical outcomes in the real world.
Therapies by group
STEMI
(n=756)
NSTEACS
High-risk (n=1948)
NSTEACS
Int-risk (n=698)
Aspirin (%) 90.4 88.3 84.7
Clopidogrel (%) 79.5 62.8 49.8
Beta-blocker (%) 77.1 69.9 65.0
GP IIb/IIIa inhibition (%) 37.7 9.2 1.4
ACE-I/ARB ( %) 79.6 70.5 64.3
Statin (n, %) 89.1 85.4 83.3
Angiography (%) 88.8 53.2 33.0
PCI (%) 68.3 22.0 7.4
2:30 p.m.
1007-94 Infarct Size, Viability, and Correlates in Patients 
Presenting With a Persistent Total Occlusion of the 
Infarct-Related Artery 3-28 Days Post Myocardial 
Infarction: An Occluded Artery Trial (OAT) Substudy
Camille A. Pearte, James E. Udelson, Mariusz Kruk, Harmony R. Reynolds, Witold 
Ruzyllo, Zygmunt Sadowski, Anna Teresinska, Bartosz Bychowiec, Thomas Höchtl, 
Jose Antonio Marin-Neto, Eric A. Cohen, Benita Busz-Papiez, Paulo Caramori, 
Christopher Adlbrecht, Carey Kimmelstiel, Christopher E. Buller, Sandra Forman, 
Gervasio A. Lamas, Judith S. Hochman, New York University School of Medicine, New 
York, NY, Tufts-New England Medical Center, Boston, MA
Background: Preserved viability is prognostically important post myocardial infarction 
(MI). Infarct size and viability in patients (pts) with persistent total occlusion (PTO) of the 
infarct-related artery (IRA) post MI and relation to angiographic collaterals or other clinical 
factors has not been well characterized.
Methods: Of the pts enrolled in OAT, 124 in the viability substudy underwent resting 
SPECT Tc-99m imaging prior to randomization. Infarct size was quantitated as % of the 
left ventricle (LV) with <60% peak uptake. Viability was classified as moderately retained 
for defects 40-60% of peak uptake, and severely reduced if <40%. Pts with no defects 
<60% were set to 61% for analysis. Baseline clinical and core lab evaluated angiographic 
characteristics were compared for associations with infarct size and viability.
Results: Among the 79 pts (66 men, 13 women) with complete data so far, mean infarct 
size was 26% of the LV (range 0-70%), mean viability was moderate (42% peak uptake, 
range 25-61%), and the majority (50/79) had moderately retained viability. PTO of the 
left anterior descending had the largest infarct size and lowest viability (p=0.0001), and 
women had smaller MIs than men (19% vs. 27%, p=0.004) despite having more LAD 
infarcts. With increasing angiographic collateral grade (0,1,2), infarct size decreased 
(33%, 26%, 15%, p=0.07) and retained viability increased (38%, 43%, 47%, p=0.03); 
however these associations became weaker with adjustment for IRA and gender. Of the 
clinical measures, with adjustment for IRA and gender, being on insulin was associated 
with larger infarct size (p=0.002), and history of CHF (p=0.04), higher serum glucose 
(p=0.01), and being on insulin (p=0.03) were associated with lower retained viability. No 
association was found between infarct size or retained viability with age, prior MI, or other 
traditional coronary risk factors.
Conclusions: In pts presenting with PTO of the IRA 3-28 days post MI, infarct size and 
preservation of viability are related to IRA, gender, and serum glucose; and despite PTO, 
there is often moderately retained viability demonstrable within the infarct zone, even 
when there are poorly or no visualized collaterals by angiography.
2:30 p.m.
1007-95 Does CRP Measured At Admission, Discharge, Or 
One Month Have Incremental Clinical Value To Predict 
Outcome In Acute Coronary Disease?
Peter Bogaty, Franz Dauwe, Luce Boyer, Serge Simard, Robert Dupuis, Benoit Verret, 
Thao Huynh, Rene Roux, Michel D’Astous, Fernand Bertrand, Gilles R. Dagenais, 
James M. Brophy, Quebec Heart Institute, Quebec, PQ, Canada, McGill University 
Health Center, Montreal, PQ, Canada
Background: It remains unclear if C-reactive protein (CRP) has incremental predictive 
value in the follow-up of patients (pts) with acute coronary syndromes.
Methods: We prospectively measured CRP at admission, discharge, and 1 month later 
in 1210 pts hospitalized in 8 hospitals with acute myocardial infarction (MI; 64%) or 
unstable angina (UA; 36%). Patients underwent extensive clinical characterization and 
were followed for 1 year.
Results: Mean age was 62 ± 12 years, 75% were men, 20% had diabetes, 28% previous 
MI, 30% vascular disease, 6% previous heart failure, and 28% previous revascularization. 
At 1 year, there were 58 deaths (4.8%), 79 nonfatal MI (6.5%) and 148 UA (12.2%; 26/148 
with ECG changes). The primary endpoint of death, MI, and UA with ECG changes 
occurred in 142 pts (11.7%) at 1 year. CRP values (mg/L; mean±SD) in relation to the 
primary end-point and odds ratios (OR) are shown in Table. 
Event at 
1 yr
(n=142)
No event at 
1 yr
(n=1068)
Unadjusted OR 
(95%CI)
Adjusted* OR 
(95%CI)
CRP 
admission 19.5 ± 44.2 13.6 ± 26.1 1.20 (1.06-1.36) 1.06 (0.92-1.22)
CRP discharge 18.8 ± 28.7 22.1 ± 33.4 0.98 (0.85-1.14) 0.93 (0.79-1.09)
CRP at 1 
month 5.5 ± 7.5 4.9 ± 10.1 1.23 (1.00-1.50) 1.03 (0.86-1.23)
*Multivariate adjustment included age, diabetes, history of heart failure, heart failure 
during admission,+ troponin, CK >1000 U/L, and creatinine clearance <50 ml/min.
CRP at admission and 1 month was significantly associated with the primary outcome in 
univariate but not multivariate analysis. There was no association of any of the 3 CRP 
measurements with MI alone in univariate analysis.
Conclusions: The modest predictive ability of CRP disappeared after adjusting for 
common clinical variables. This large prospective study does not support the clinical utility 
of measuring CRP in acute coronary syndromes.
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1007-96 Blood Rheology in Stable Angina and Acute Coronary 
Syndrome: a Logical Basis for the Transition?
Byoung Kwon Lee, Tamas Alexy, Rosalinda Wenby, Azhil Durairaj, Anilkumar Mehra, Herbert 
J. Meiselman, University of Southern California, Keck School of Medicine, Los Angeles, CA
Background: The transition from stable angina (SA) to acute coronary syndrome (ACS) 
primarily results from the rupture of vulnerable plaque due to fluid forces associated with 
local blood flow. Inasmuch as elevated blood rheological factors lead to increases of 
these forces, we tested the hypothesis that ACS blood would exhibit higher viscosity and 
greater RBC aggregation than SA blood.
Methods: Blood samples were obtained from 51 angina patients at the LAC-USC Medical 
Center just prior to diagnostic cardiac angiography. Subsequent patient classification 
indicated 16 SA and 35 ACS subjects; the latter group was sub-classified as 16 unstable 
angina (UA) and 19 acute myocardial infarction (AMI). Rheological measurements 
included whole blood viscosity, plasma viscosity, and RBC aggregation via erythrocyte 
sedimentation rate (ESR) and by aggregation indices at stasis (M) and low shear (M1) 
using an automated aggregometer; routine clinical laboratory data were also obtained.
Results: Compared to SA patients, ACS subjects had significantly worse rheological 
parameters: 1) Higher whole blood viscosity at low shear (17-36% increase, p<0.001), 
and elevated plasma viscosity (1.71±0.12 vs. 1.59±0.07 cP, p<0.001); 2) Enhanced RBC 
aggregation as judged by ESR (58.2±25.3 vs. 35.7±15.5 mm/hr, p<0.001), and by RBC 
aggregation indices at stasis (49% higher M, p<0.005) and at low shear (52% higher M1, 
p<0.005); 3) Elevated WBC (8.65±2.44 vs. 7.19±1.87 x 109/L, p<0.05) and hs-CRP (3.89±3.34 
vs. 1.17±1.44 mg/L, p<0.001). The rank order of rheological abnormalities was AMI>UA>SA. 
No significant differences were found for age, sex, BMI, and cholesterol profiles.
Conclusions: Our findings of significant hemorheological differences between SA 
and ACS patients suggest: 1) a progressive worsening of blood rheology promoting 
the development of ACS; 2) the possibility of an unstable equilibrium between plaque 
vulnerability and a critical level of rheological factors required for triggering plaque 
rupture. Prospective studies are required to test this hypothesis: if validated, therapy 
aimed at regulating blood rheology in SA patients may lead to improved patient care, 
clinical outcome and better prevention.
2:30 p.m.
1007-111 Growth-Differentiation Factor-15 for Early Risk 
Stratification in Patients with Acute Chest Pain
Kai M. Eggers, Tibor Kempf, Bertil Lindahl, Lars Wallentin, Kai C. Wollert, Department 
of Medical Sciences, Cardiology, Uppsala University Hospital, Uppsala, Sweden, 
Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany
Background: Growth-differentiation factor-15 (GDF-15) is a distant member of the 
transforming growth factor-β cytokine superfamily that is strongly induced in the heart in 
experimental models of myocardial ischemia and infarction. We have recently observed 
that circulating levels of GDF-15 are an independent prognosticator in patients with 
NSTE-ACS. We have now assessed the usefulness of GDF-15 for risk stratification in a 
more unselected population of 416 patients admitted to the CCU with chest pain and no 
ST-segment elevation.
Methods: GDF-15 was measured with an immunoradiometric assay. The prognostic 
value of GDF-15, NT-proBNP, CRP, and creatinine-clearance on admission, and serial 
troponin I testing within 24 hours was retrospectively evaluated by ROC-curve and 
multivariate analyses. The prognostic utility of GDF-15 cut-off values that were previously 
defined in patients with NSTE-ACS was also investigated (1,200 and 1,800 ng/L).
Results: An NSTE-ACS was diagnosed in 49.3% of the patients. GDF-15 levels below the 
upper limit of normal (1,200 ng/L) were found in 30.8% of the patients, 32.2% presented 
with levels between 1,200 and 1,800 ng/L, and 37.0% with levels >1,800 ng/L. Ten deaths 
and 19 myocardial (re)-infarctions occurred during 6 months of follow-up. Increasing levels 
of GDF-15 were associated with a poor prognosis, with mortality rates of 0.0, 1.5, and 5.2% 
(P=0.013 for trend), and rates of myocardial (re)-infarction of 0.0, 5.2, and 7.8% (P=0.007 
for trend) in the respective strata of GDF-15. The areas under the ROC curves for the 
combined endpoint of death and (re)-infarction were 0.80 for GDF-15, 0.78 for NT-proBNP, 
0.62 for CRP, 0.73 for creatinine-clearance and 0.73 for troponin I. By multivariate analysis, 
GDF-15 as continuous variable (OR 3.2; 1.5-7.0) and age by years (OR 1.1; 1.0-1.1) 
emerged as the only independent predictors for the combined endpoint.
Conclusions: GDF-15 is a new and powerful prognosticator in patients with acute chest 
pain that appears to provide prognostic information beyond traditional risk markers. GDF-
15 cut-off values of 1,200 and 1,800 ng/L were very useful for early risk stratification.
2:30 p.m.
1007-112 Does Progression of Coronary Artery Disease Differ in 
Patients With Stable and Acute Coronary Syndrome?
Tina L. Pinto Slottow, Daniel H. Steinberg, Probal Roy, Aamir Javaid, Ashesh Buch, 
Rebecca Torguson, Kimberly Smith, Zhenyi Xue, Natalie Gevorkian, Augusto D. 
Pichard, Lowell Satler, William O. Suddath, Kenneth Kent, Ron Waksman, Washington 
Hospital Center, Washington, DC
Background: Cardiac risk factor modification has slowed but not halted progression of coronary 
artery disease (CAD). This study examined differences in disease progression in patients who 
presented with acute coronary syndrome (ACS) and stable angina (SA) who underwent PCI.
Methods: Data on 2186 consecutive patients who underwent PCI for ACS and 1848 
who underwent PCI for SA were drawn from our prospective angioplasty database. CAD 
progression was defined as revascularization in non-target lesions and evaluated at 
6 months, 1, 2, 3, and 4 years from the index procedure. Demographics and clinical 
outcomes were examined, stratifying by presence of progression.
Results: SA and ACS patients who developed CAD progression were more likely to have 
a history of CAD, old MI, prior PCI, and in-stent restenosis (p<0.001) at index procedure. 
ACS patients who progressed had a higher number of diseased vessels during the index 
procedure (p=0.003). Standard medication (aspirin, statin) was similar in all groups. At 
1 year, CAD progression was similar in both groups. Long-term follow up at 2, 3, and 4 
years revealed a higher incidence of CAD progression in the SA group compared to the 
ACS group. (Table)
Conclusions: Patients presenting with ACS are less likely to develop significant 
progression of CAD during long-term follow up than patients who undergo PCI for SA. 
Patients with a history of CAD, prior PCI, or old MI were more likely to develop significant 
new lesions requiring revascularization and should be monitored carefully.
CAD Progression
% new disease (n) Stable angina Acute coronary syndromes p value
6 months 13.7 (254/1848) 12.5 (274/2186) 0.256
1 year 22.8 (280/1230) 21.5 (313/1454) 0.441
2 year 53.5 (286/535) 43.3 (321/742) 0.0003
3 year 71.9 (286/398) 58.6 (326/556) <0.0001
4 year 77.6 (288/371) 66.6 (329/494) 0.0004
2:30 p.m.
1007-113 Systolic Dysfunction is Frequent and has a Similar 
Prevalence in Patients with ST and Non-ST Elevation 
Myocardial Infarction
Michael C. Kontos, Thomas T. Noel, Michael Stevens, Joseph P. Ornato, Charlotte 
S. Roberts, James L. Tatum, Robert L. Jesse, Virginia Commonwealth University, 
Richmond, VA
Background: Ejection Fraction (EF) is a powerful predictor of mortality in patients (pts) 
after myocardial infarction (MI). However, most predictive data were derived from clinical 
trials mainly limited to ST elevation MI (STEMI) pts, and before the widespread use of 
troponin (TnI). In addition, because it was infrequently assessed, there is little data on the 
relative prevalence of low EF in STEMI and Non-STEMI pts.
Methods: Over 6 years, 1,648 consecutive pts admitted from the ED were diagnosed 
with MI, of whom 1,505 (91%) had EF measured. An elevated TnI was defined using 
ACC/ESC criteria, and an abnormal EF as <50%.
Results: Among the 1,505 consecutive pts diagnosed with MI who had EF assessed, 336 
(22%) had STEMI. One year mortality was 20%. Mortality was significantly higher for pts 
with non-STEMI compared to STEMI (22% vs 13%; p<0.001). Abnormal EF was found 
in 810 pts (54%)(57% of STEMI, 53% of non-STEMI), and 34% had an EF <40% (30% 
STEMI, 34% non-STEMI; p=ns). EF distribution was similar for STEMI and non-STEMI 
pts, and mortality increased sharply once EF was < 40% (Figure). Mortality in non-STEMI 
pts was similar or higher for all categories of EF compared to STEMI pts.
Conclusions: EF is a powerful predictor of mortality in pts with both STEMI and non-
STEMI. Because similar, high proportions of STEMI and non-STEMI pts have systolic 
dysfunction, EF should be assessed in all pts with MI. 
2:30 p.m.
1007-114 Renal Failure Independently Predicts Hospital Mortality 
In Consecutive Patients With NSTEMI In Clinical 
Practice: Results Of The ACOS-Registry
Anselm K. Gitt, Harm Wienbergen, Tobias Heer, Frank Towae, Martin G. Gottwik, 
Jochen Senges, Institut f. Herzinfarktforschung, Ludwigshafen, Germany
Background: Patients with renal failure have a high cardiovascular morbidity and 
mortality. Little is known about the impact of renal failure on the acute outcome of Non-
ST-elevation myocardial infarction (NSTEMI) in clinical practice.
Methods: Between 2000 and 2002 a total of 6358 consecutive patients with NSTEMI 
were enrolled into the multicenter ACOS-registry in Germany. We examined the impact of 
renal failure on hospital outcome of NSTEMI in clinical practice. Renal failure was defined 
as serum creatinine > 2.0 mg/dl.
Results: Out of 6358 patients with NSTEMI, 288 (4.5%) had renal failure. NSTEMI 
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patients with renal failure were older and significantly more often had prior myocardial 
infarctions and coronary interventions as well as a higher prevalence of concomitant 
diseases as compared to NSTEMI patients without renal failure. They less often did 
undergo PCI within 48h after admission. After adjustment for these differences by 
multivariate regression analysis, renal failure was associated with significant higher 
hospital mortality (OR 3.02, CI 2.13-4.29).
Conclusion: Renal failure in consecutive NSTEMI patients was an independent predictor 
of outcome with three-fold increased hospital mortality in clinical practice. 
Renal Failure
n=288
No Renal Failure
n=6070 p- value
Age (years) 74.1 68.5 < 0.001
Female Gender 32.6 % 34.2 % ns
Prior MI 35.8 % 24.3 % < 0.001
Prior PCI / CABG 23.6 % 18.0 % < 0.001
Hypertension 80.2 % 69.6 % < 0.001
Diabetes 56.3 % 29.4 % < 0.001
Hyperlipidemia 60.1 % 65.2 % ns
pAVD 28.8 % 8.5 % < 0.001
Smoking 14.2 % 25.9 % < 0.001
PCI < 48h after admission 11.5 % 33.1 % < 0.001
Hospital Mortality 18.1 % 4.4 % < 0.001
Hospital MACCE (Death / MI / Stroke) 21.9 % 9.0 % < 0.001
2:30 p.m.
1007-115 Erythrocyte Transfusions after Acute Myocardial 
Infarction in Diabetic and Non-diabetic Patients
Tina L. Pinto Slottow, Daniel H. Steinberg, Probal Roy, Aamir Javaid, Ashesh Buch, 
Rebecca Torguson, Kimberly Smith, Zhenyi Xue, Natalie Gevorkian, Augusto D. 
Pichard, Lowell Satler, Lowell Satler, William O. Suddath, Kenneth Kent, Ron Waksman, 
Washington Hospital Center, Washington, DC
Background: Insulin-treated diabetic patients have been associated with increased 
transfusion rate in the setting of coronary artery bypass surgery. This study investigated 
factors predicting use of erythrocyte transfusions after acute ST elevation myocardial 
infarction (STEMI).
Methods: Data was drawn from 1444 consecutive patients from our prospective 
angioplasty database who underwent primary or facilitated PCI between January 2000 
and August 2006. Rates of transfusion and incidence of bleeding was noted among 113 
insulin-treated diabetic (ID) patients, 289 non-insulin-treated diabetics (NID) and 1042 
nondiabetic (ND) patients. Major bleeding was defined as hematoma >4 cm, hematocrit 
drop >15%, or gastrointestinal bleed.
Results: The NID and ID groups contained more women and more patients with 
hypertension, hypercholesterolemia, and chronic renal insufficiency (p<0.001). Despite 
a similar incidence of major bleeding in the NID and ND groups, the NID group had a 
hematocrit nadir similar to the ID group. Both the NID and ID groups were more likely to 
receive erythrocyte transfusions than the ND group. (Table)
Conclusions: After STEMI, ID patients have a higher rate of bleeding compared to NID and 
ND patients. Nevertheless, ID and NID patients have the same hematocrit nadir and receive 
more transfusions compared to ND patients. This increase in transfusion rate in diabetic 
patients can contribute to worse prognosis after STEMI when compared to ND patients.
(%) Insulin-treated Non-insulin-treated Nondiabetic p value
Gastrointestinal bleed 6.4 2.8 2.2 0.037
Hematocrit drop >15% 9.5 2.7 5.2 0.029
Hematoma >4 cm 2.1 1.1 1.2 0.623
Major bleed 13.4 5.2 6.3 0.009
Transfusion 17.9 16.9 10.2 0.002
Baseline hematocrit 36.4 39.2 40.5 0.037
Hematocrit nadir 33.7 33.1 36.1 0.015
Discharge hematocrit 39.1 37.1 41.7 0.791
2:30 p.m.
1007-116 Effectivity And Safety Of Intracoronary Autologous 
Bone Marrow Stem Cell Transplantation In Large 
Anterior Myocardial Infarction - A Randomized Study
Jan Horak, Martin Penicka, Petr Kobylka, Michael Aschermann, Ales Linhart, H. Skalická, 
Petr Widimsky, On behalf of the Research grant IGA 8225 and Charles University 
Research Project MSM0021620817, Cardiocenter, 3rd Medical School Charles University 
and University Hospital Kralovske Vinohrady, Prague, Czech Republic
Background: To investigate safety and functional effects of intracoronary (i.c.) 
transplantation of autologous bone marrow-derived mononuclear cells (BMNCs) in 
patients with a large acute anterior myocardial infarction (AMI).
Methods: Twenty-six patients with large anterior AMI (age 59 ± 12 y, LVEF 38±6 %), 
treated with primary PCI with stent implantation > 4 hours after symptoms onset were 
randomly assigned either to i.c. BMNCs injection 4 to 11 days after PCI (n = 15, group 1) 
or standard medical therapy (n = 11, group 2). Coronary angiography was repeated at 4 
months. In 5 patients, 20% of BMNCs were radiolabeled with 99mTc-HMPAO and mixed 
with the rest of the BMNCs suspension. Nuclear imaging was performed at 2 and 20 
hours after i.c. injections to monitor the myocardial uptake of transplanted BMNCs.
Results: In two patients from the group 1, serious complications occurred before BMNCs 
transplantation: 1 patient had a ventricular septal rupture before planned BMNCs implantation 
and was urgently operated, 1 patient suffered a subacute stent thrombosis with reinfarction 
immediately after BMNCs harvest, leading ultimately to death. During the 4-month follow-
up, one patient from group 1 was hospitalized for worsening heart failure. Rate of significant 
in-stent restenosis was equal in both groups (18% vs. 18%, p = NS). LVEF increased in 
both groups (from 40±11% to 46±11 % in group 1 vs. from 39±6 % to 47±10 % in group 2, 
p = NS) . Likewise, end-diastolic and end-systolic volume decreased significantly to similar 
extent in both groups (ns). Mean radioactivity uptake by the heart ranged from 1.31% to 
5.10% at 2 hours and from 0% to 1.34% at 20 hours after transplantation.
Conclusions: Intracoronary transplantation of BMNCs did not improve cardiac function 
or LV remodeling in patients after large anterior AMI as compared to standard therapy. 
Moreover, BMNCs harvest early after large AMI may be associated with serious 
complications. As a result of these findings, the study was terminated prematurely.
2:30 p.m.
1007-117 A History of Stroke or Peripheral Arterial Disease is 
Common in Patients With Acute Myocardial Infarction 
and is Associated With Less Aggressive Therapy and 
Worse In-Hospital Outcome. Insights From the RICO 
Survey.
Marianne Zeller, Jack Ravisy, Michel Vincent-Martin, Isabelle L’Huillier, Yves Laurent, 
Hamib Makki, Maurice Giroud, Yves Cottin, Service de Cardiologie, CHU, Dijon, France, 
Université de Bourgogne, IFR 100, Dijon, France
Background: Extracardiac vascular disease (EVD) (stroke/transient ischemic attack and 
peripheral arterial disease) and acute myocardial infarction (AMI) share common risk 
factors and formation processes. However, patients with EVD are generally excluded 
from AMI trials. We aimed to analyse the impact of EVD on prognosis on population-
based AMI survey.
Methods: From the RICO survey database, we analysed all the consecutive patients 
hospitalised for AMI in the 6 cardiologic units from one region of eastern France between 
1st January 2001 and 31st August 2005.
Results: Prior EVD was reported in 479 (12%) of the 3925 patients, including 168 (4%) 
with stroke/TIA, 280 (7%) with peripheral arterial disease and 31(1%) with both. Patients 
with EVD were 7 years older than those without prior EVD (74(65-82) vs 67(54-77) y, 
p<0.0001). They were more likely to have diabetes, hypertension, prior MI, and renal 
insufficiency. However, the frequency of left ventricular dysfunction and anterior wall 
location were similar to patients without EVD. Necrosis size as assessed by peak plasma 
CK level was also similar among the groups. In the acute phase, patients with EVD were 
less frequently treated with β-blocker (64 vs 77%, p<0.001), GpIIbIIIa receptor blocker 
(26 vs 32%, p=0.018) and LMWH (39 vs 53%, p<0.001). In-hospital mortality (7 vs 4 %, 
p=0.005), stroke (3 vs 1%, p<0.001) and heart failure (46 vs 28%, p<0.001) rates were 
higher in EVD patients. Prior EVD was independently associated with a higher risk of 
death or heart failure during the hospital stay (OR(95% CI), 1.45(1.13-1.88), p=0.004). 
Conclusion: Patients with prior EVD constituted 12% of our non-selected AMI population 
and had high risk factors features, but similar clinical characteristics. Prior EVD was 
independently associated with worse in-hospital outcomes even after adjustment 
for potential confounders. Our data support the hypothesis that EVD shares common 
risk factors with acute MI yet undetermined and suggest that in such patients, more 
aggressive therapy is warranted.
2:30 p.m.
1007-132 Percutaneous Right Heart Catheterization with 
Ventricular Assist Device for Right Ventricular 
Infarction
DaLi Feng, Jane Leopold, Frederic Mouquet, Ronglih Liao, Joseph Loscalzo, Cardiology 
Division, Mayo Clinic, Rochester, MN, Cardiovascular Division, Department of Medicine, 
Brigham and Women’s Hospital, Boston, MA
Background: Inferior myocardial infarction (MI) with right ventricular MI (RVMI) is 
associated with poor prognosis. Therapies for RVMI with shock include intravenous 
fluids, inotropic agents, intra-aortic balloon counterpulsation, and revascularization. None 
of the therapies addresses the fundamental pathophysiology of RVMI, i.e., RV dilatation, 
pericardial constrictive effect, and underfilling of the left ventricle (LV). We evaluated the 
feasibility of a novel percutaneous right heart catheter system with a RV assist device 
(RVAD) in RVMI.
Methods: A pulmonary artery (PA) flotation catheter was inserted into the PA and a 
pigtail catheter placed in the LV in 8 pigs. The proximal port of a12 F assist catheter was 
percutaneously inserted into the right atrium (RA) via the right jugular vein and the distal 
port into the main PA via the right femoral vein and RV. The two ports of the assist catheter 
were connected externally to a centrifugal pump, which draws blood from RA, bypasses 
RV, and expels blood into the PA. A RVMI was induced by occlusion of the proximal right 
coronary artery. Hemodynamic indices were measured at different times with RVAD on/
off, and before and after intravenous infusion (IVF) of 500 cc of Ringer’s solution.
Results: The RVAD achieved maximal flow rate of 1.8 1/m and significantly improved 
hemodynamic as shown in the table.
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Conclusions: A percutaneous catheter-based RVAD for RVMI is feasible and effective in 
this pilot animal study. The system can unload right heart and improves LV filling.
Pressure(mmHg) Baseline RVAD 5 min RVAD 1 hour RVAD Off RVAD restart Before IVF After IVF P value
Mean RA Pressure 10±2 6±2 6±1 9±2 7±2 9±2 11±3 <0.001
PA Systolic Pressure 26±2 34±3 33±2 24±1 29±3 25±2 28±3 <0.001
PA Diastolic Pressure 16±2 23±4 22±3 13±2 20±3 16±2 18±1 <0.001
PA Wedge Pressure 12±1 19±4 19±5 10±2 18±3 13±3 15±2 =0.02
LV End Diastolic 
Pressure 7±1 9±2 10±2 8±1 10±2 7±1 10±2 =0.01
Systolic BP 73±9 82±9 85±11 77±11 89±12 86±8 83±2 =0.07
Diastolic BP 43±8 46±7 54±8 47±8 57±10 54±8 50±4 =0.32
2:30 p.m.
1007-133 A Phase II Randomized, Placebo-Controlled, Single-Blind, 
Multi-Center Dose-Escalation Study to Evaluate Tolerability, 
Safety, Pharmacokinetics, and Pharmacodynamics 
of a Single Intravenous Administration of INO-1001 in 
Subjects with ST-Elevation Myocardial Infarction (STEMI) 
Undergoing Primary Percutaneous Coronary Intervention: 
Results of the TIMI 37A Trial
David A. Morrow, Kenneth Baran, Ricardo Krakover, Harold Dauerman, Sabina A. 
Murphy, Sujatha Kumar, Carolyn H. McCabe, Chaim M. Brickman, Andrew L. Salzman, 
Brigham & Women’s Hospital, Boston, MA, Inotek Pharmaceuticals, Beverly, MA
Advances in pharmacologic and mechanical reperfusion therapy have improved 
outcomes in STEMI. However, reperfusion injury is a significant complication without 
treatment options. INO-1001 is a potent inhibitor of poly(ADP-ribose) polymerase (PARP), 
a mediator of oxidant-induced myocyte dysfunction/death during reperfusion.
Methods: We assessed the safety & pharmacokinetics of INO-1001 in a single-blind, dose-
escalating trial in STEMI pts (N=40) undergoing primary PCI within 24h of onset. An exploratory 
analysis of efficacy was based on biomarkers of inflammation and hemodynamic stress.
Results: INO-1001 was to be initiated IV x1 (200mg, 400mg or 800mg in 250ml D5W) 
prior to crossing the lesion in 30 pts and compared with 10 pts given D5W alone. INO-
1001 was well tolerated with no related serious adverse events. A trend toward more 
frequent asymptomatic transaminitis was observed with 800mg. Plasma from INO1001-
treated pts reduced ex-vivo PARP activity >90% at all doses. No deaths or heart failure 
occurred by 30d. Serial CRP & IL-6 levels showed a trend toward blunting of inflammation 
post-MI with INO-1001 (Fig), with no difference in B-type natriuretic peptide or CKMB. PK 
data will be presented.
Conclusions: In this first pilot trial of INO-1001 in STEMI, INO-1001 was associated 
with significant ex-vivo inhibition of PARP and a trend toward a reduced inflammatory 
response. The safety profile from this preliminary experience supports future study of 
INO-1001 as a novel therapy for reperfusion injury.
2:30 p.m.
1007-134 Preprocedureal N-Terminal Pro-B-Type Natriuretic 
Preptide Predicts Angiographic No-Reflow 
Phenomenon During Stent Implantaion in Patients with 
Acute Myocardial Infarction
Youngkeun Ahn, Seo Na Hong, Nam Sik Yoon, Sun Ho Hwang, Kye Hun Kim, Sang Rok 
Lee, Young Joon Hong, Ju Han Kim, Myung Ho Jeong, Jeong Gwan Cho, Jong Chun 
Park, Chonnam National University Hopsital, Gwangju, South Korea
Background: The no-reflow Phenomenon after primary percutaneous coronary 
intervention (PCI) is associated with greater infarct size, worse functional recovery, and 
higher incidence of complication in acute ST-elevation myocardial infarction (STEMI). The 
aim of this study was to assess the relation between preprocedural N-terminal pro-B-type 
natriuretic peptide (NT-proBNP) and angiographic no-reflow phenomenon.
Methods: We measured serum NT-proBNP level in 106 consecutive AMI patients 
(63.7±11.9 years, male 72%) on admission and before PCI. Angiographic no-reflow after 
PCI was defined as Thrombolysis in Myocardial Infarction (TIMI) flow grade <3.
Results: The baseline clinical characteristics including time from the chest pain onset 
between the groups with no-relow group (n=56) and normal reflow group (n=50, TIMI 
flow grade=3) are similar. The level of NT-proBNP was significantly higher in the no-
reflow group than that in the normal reflow group (2840.3±5335.6 vs. 377.5±600.7 pg/mL, 
p=0.001). Also, the level of high-sensitivity C-reactive protein (hs-CRP), monocyte, and 
troponin-T were significantly higher in the no-reflow group than those in the normal reflow 
group. There were no significant differences in the distribution of target vessel or number 
of receiving intravenous or intracoronary abciximab between the groups. In no-reflow 
group, NT-proBNP level was much higher in patients with TIMI flow grade I or II (n=18, 
1924.1±2311.32 p/Ml). The area under the receiver-operating characteristic (ROC) curve 
for NT-ProBNP level was 0.79, and the optimal cut-off value identified by ROC analysis 
was 500 pg/mL. At the standard cutpoint of > 500 pg/mL, elevated NT-proBNP level 
shows high probability of no-reflow phenomenon (odd ratio, 5.84; 95% CI, 2.43 to 14.06; 
p<0.001). In multivariate analysis, the NT-proBNP was an independent predictor for no-
reflow phenomenon along with troponin-T, whereas hs CRP and monocyte were not.
Conclusions: Preprocedural NT-proBNP is and strong predictor for the development of 
no-reflow phenomenon after PCI in patients with acute STEMI.
2:30 p.m.
1007-135 Initial Aspirin Dose for the Treatment of ST Elevation 
Myocardial Infarction
Jeffrey S. Berger, Amanda Stebbins, Christopher B. Granger, Paul W. Armstrong, Frans 
Van de Werf, Harvey D. White, R. John Simes, Karen Pieper, Robert A. Harrington, 
Robert M. Califf, Eric D. Peterson, Duke University Medical Center, Durham, NC
Background: ISIS-2 demonstrated that 162.5mg of immediate aspirin reduced morbidity 
and mortality in ST elevation myocardial infarction (STEMI). Thus, the ACC/AHA gave a 
class IA recommendation for immediate 162mg of aspirin. In contrast, 325mg of aspirin 
received a class IC recommendation. In clinical practice, however, STEMI patients often 
receive 325mg of immediate aspirin. We therefore compared outcomes associated with 
the use of 162 versus 325mg aspirin in STEMI.
Methods: Using data from the combined GUSTO I and GUSTO III trials (n=48,422 STEMI 
patients), we compared the relationship between immediate use of 162 vs. 325mg of 
aspirin and 24-hour mortality, 7-day mortality, and in-hospital moderate/severe bleeding. 
We used multivariable analysis with previously validated mortality and bleeding models 
from the GUSTO database to adjust for baseline imbalances between the groups.
Results: Aspirin 162 mg was used by 75.6% (n=36,594) of patients. There were 1,370 
(2.8%) deaths at 24 hours, 2.9% among the 325mg and 2.8% among the 162mg 
(P=0.894). At 7 days there were 2,393 (5.0%) deaths, 5.2% among the 325 mg and 
4.9% among the 162mg (P=0.118). After adjustment for baseline imbalances, there was 
no significant relationship between aspirin dose and 24-hour mortality (OR 0.99, 95% 
CI 0.79-1.22, P=0.896) or 7-day mortality (OR 1.00, 95% CI 0.86-1.17, P=0.978). In-
hospital moderate/severe bleeding occurred in 11.5% (5538 of 48422) of the cohort, 9.3% 
among the 325mg and 12.2% among 162mg (P<0.001). After adjustment for baseline 
imbalances, 325mg was associated with a significant increase in moderate/severe 
bleeding (OR 1.14, 95% CI 1.05-1.24, P=0.003).
Conclusion: In a large retrospective analysis, 325mg of first dose of aspirin was associated 
with a significant increase in the risk of moderate/severe bleeds compared with 162mg. 
Although these data are non-randomized, they suggest that for the first dose of aspirin, 162 
mg aspirin may be as effective as and safer than 325mg for the acute treatment of STEMI.
2:30 p.m.
1007-136 Enoxaparin vs Unfractionated Heparin in Women 
Undergoing Fibrinolysis for ST-Elevation Myocardial 
Infarction in ExTRACT-TIMI 25
Jessica L. Mega, David A. Morrow, Erika Ostor, Maria Dorobantu, Jie Qin, Elliott Antman, 
Eugene Braunwald, TIMI Study Group, Brigham & Women’s Hospital, Boston, MA
Background The manifestations and outcomes of CVD differ between women and men. 
The safety and efficacy of pharmacologic reperfusion in women with STEMI have been 
of particular interest. 
Methods We investigated the outcomes in women and men in ExTRACT-TIMI 25, 
which randomized STEMI patients with planned fibrinolysis to enoxaparin (ENOX) or 
unfractionated heparin (UFH). 
Results Compared to men (N=15,696), women (N=4,783, 23%) were older (68 vs 57 
yrs, P<0.001) and more likely to have HTN and DM (P<0.001 for each). They were also 
at higher risk as assessed by the TIMI Risk Score (TRS) > 3 (59 vs 29%, P<0.001). The 
unadjusted 30-day mortality rate for women was over two-fold greater than that for men 
(13.2 vs 5.4%). After adjusting for the TRS, women remained at higher 30-day risk of 
death (OR adj 1.32 , 95% CI 1.15 - 1.54, P<0.001) but similar risk of ICH (OR adj 0.81, 
95% CI 0.52 - 1.26, P=0.35). The rate of death or MI at 30 days was reduced by ENOX in 
women (15.4 vs 18.3%, P=0.007). Major bleeding was more frequent in women receiving 
ENOX vs UFH (2.3 vs 1.4%, P=0.022) but similar among women and men on ENOX (2.3 
vs 2.0%, P=0.39). In women and men, the rate of death, MI, or major bleeding (net clinical 
benefit) was significantly lower with ENOX (Figure). 
Conclusions In ExTRACT-TIMI 25, women presented with a profile of higher baseline 
risk with higher short-term mortality. Women had a similar relative but greater absolute 
risk reduction than men when treated with ENOX compared to UFH as adjunctive 
antithrombin therapy with fibrinolysis. 
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1007-138 The Efficacy Of Invasive Therapies In Myocardial 
Infarction Is Different In Elderly Or Younger Patients?
José C. Nicolau, Luciano M. Baracioli, Fábio B. Jatene, Luiz B. Puig, Luiz O. Dallan, 
Noedir Stolf, Eulógio Martinez, Pedro Lemos, Everton P. Gomes, José A. Ramires, 
Heart Institute (InCor) University of São Paulo Medical School, Brazil, São Paulo, Brazil
Background: In elderly patients with AMI, little is known about the role of invasive 
treatment (IT - CABG or PCI), especially in the long-term after hospital discharge.
Methods: We analyzed 1588 pts with AMI, included prospective and consecutively in a 
databank, followed for up to 7.5 y (mean survival time 5.65 y). From the patients, 548 were 
older than 69 y (elderly group-EG) and the remaining 1040 were <70y-o (younger group-
YG).The impact of IT used in comparison with conservative treatment (CT), was analyzed 
for the EG and YG groups, in non-adjusted and adjusted models, utilizing Kaplan-Meier 
curves, log-rank and Cox regression analyses.The adjusted models included 15 prognostic 
variables, (e.g., fibrinolytic use, ST- or non-ST elevation AMI, infarct location).
Results: (a) Global population: the survival rates for IT (N=1088) and CT (N=500) at 
the end of follow-up were, respectively, 71.9% ± 0.022 and 47.2% ± 0.047 (Hazard-
ratio=0.55; 95% confidence interval 0.45-0.67; P<0.001); the adjusted HR was 0.62 (95% 
CI=0.51-0.77; P<0.001). (b) YG: the survival rates for IT (N=754) and CT (N=286) were 
81.5% ± 0.021 and 66.6 ± 0.051 (HR=0.68; 95% CI=0.49-0.94; P=0.018); the adjusted 
HR was 0.74 (95% CI=0.53-1.03, P=0.073). (c) EG: the survival rates for IT (N=334) 
and CT (214) were 48.8% ± 0.055 and 20.3% ± 0.069 (HR=0.58; 95% CI=0.45-0.75; 
P<0.001); the adjusted HR was 0.64 (95% CI=0.49-0.83; P=0.001) - See table.
Conclusions: in the long-term after MI, IT utilized in-hospital are more efficacious in 
elderly patients.
Invasive therapies in AMI (see text)
Groups Non-adjusted HR p Adjusted HR p
Global 0.55 <0.001 0.62 <0.001
Younger 0.68 0.018 0.74 0.073
Elderly 0.58 0.001 0.64 0.001
2:30 p.m.
1007-153 Should Clinical Guidelines Emphasize Statistical 
Significance over Clinical Importance? A Reappraisal 
of the 2004 ACC/AHA Treatment Guidelines for STEMI
Sameer Amin, Shervin Eshaghian, Prediman K. Shah, George A. Diamond, Sanjay 
Kaul, Cedars Sinai Medical Center, Los Angeles, CA
Background: Treatment guidelines aid clinicians to relate their practice preferences 
objectively to the published evidence. However, the burden of proof is primarily determined 
by conventional tests (P value,CIs) that rely heavily on statistical significance but provide 
little guidance regarding clinical importance.
Objective: A reappraisal, with emphasis on both statistical & clinical significance, of the 
clinical trial evidence underlying the 2004 ACC/AHA treatment guidelines for STEMI.
Methods: Five Class I, Level A recommendations were analyzed. Posterior probabilities 
(Pr) that the relative difference in primary end-point is greater than the putative threshold 
value for clinical importance (δ>0% to 30%) and the “delta value” used for sample size 
estimation were derived from a Bayesian analysis using an uninformative prior and the 
empirical evidence summarized as a random-effects meta-analytic odds ratio (OR).
Results: Pr was >95% for δ>0% in all but two (BB<30d and Fl>6m); for δ>10% in 2 (Fl, 
PCI ). Pr of δ>20% was <50% in all except PCI. In only 2 cases was Pr of delta value 
>50% (Fl, PCI).
Conclusions: The probability of clinically important difference (typically 15-20% RRR) is 
far less than that implied by conventional statistical significance for 3 out of 5 categories. 
Bayesian analysis provides a useful tool in quantifying clinically meaningful difference, 
and should therefore, complement conventional tests of statistical significance in critically 
evaluating guideline-mandated therapies. 
Guideline
Primary
Endpoint
(# of trials)
Sample
Size
Summary OR 
(95% CI) P-value
Delta 
value
Pr 
δ>0%
Pr
δ>10%
Pr
δ>20%
Pr
δ>30%
Pr
(Delta
value)
Fibrinolysis (Fl) vs 
Placebo
< 6mo f/u
Death
(7) 43,976 0.78 (0.70-0.87) <0.01 18% 100% 99% 49% 0% 68%
Fibrinolysis (Fl) vs 
Placebo
> 6mo f/u
Death
(3) 7,533 0.81 (0.62-1.07) 0.14 35% 93% 71% 32% 5% 1%
PCI vs Fibrinolysis (Fl)
< 6mo f/u
Death, MI, or 
CVA (13) 6,124 0.53 (0.44-0.65) <0.01 43% 100% 100% 100% 99% 42%
PCI vs Fibrinolysis (Fl)
> 6mo f/u
Death, MI, or 
CVA (5) 635 0.26 (0.16-0.43) <0.01 52% 100% 100% 100% 100% 97%
BB vs Placebo 
< 30d Death (29) 73,188 0.95 (0.88-1.02) 0.16 35% 92% 6% 0% 0% 0%
BB vs Placebo
>1yr Death (26) 38,298 0.82 (0.73-0.92) <0.01 NA 100% 92% 20% 0% NA
ACEI vs Placebo
< 6mo f/u Death or CHF (4) 92,135 0.91 (0.86-0.97) <0.01 25% 100% 20% 0% 0% 0%
ACEI vs Placebo
> 6mo f/u
Death
(4) 12,056 0.83 (0.76-0.91) <0.01 23% 100% 75% 1% 0% 0%
Aldosterone 
Antagonists (AA) vs 
Placebo
Death
(1) 6,632 0.84 (0.74-0.96) 0.01 19% 100% 76% 8% 0% 15%
2:30 p.m.
1007-154 Mortality and Repeat Coronary Interventions 30 Years 
after Venous Coronary Bypass Surgery: A Follow-up 
Study of 1041 Patients
Ron T. van Domburg, F. Bartolozzi, AP Kappetein, Ad J. Bogers, Erasmus Medical 
Center, Rotterdam, The Netherlands
Objectives To investigate the long-term clinical outcome (up to 30 years) after 
coronary bypass surgery CABG and to assess the life expectancy (LE) among several 
subgroups.
Methods We analyzed the 30-year outcome of the first 1041 consecutive patients (age 
53 years, 88% male) who underwent venous CABG between 1971 and 1980.
Results Median follow-up was 29 years (26-36 years). At follow-up 196 patients were still 
alive. Only 10 patients (1%) reached the age of 90 years. The cumulative 10-, 20- and 
30-year survival rates were 77%, 40% and 15%, respectively. The cumulative 10-, 20- 
and 30 year freedom from death and coronary reintervention rates were 60%, 20% and 
6%, respectively. Age (HR 1.04/yr), extent of vessel disease (VD) (2VD HR 1.3; 3VD HR 
1.8), left main disease (HR 1.6) and impaired LVEF (HR 1.7) were independent predictors 
of mortality. We were able to assess the exact LE by calculating the area under the 
Kaplan-Meier curves. Overall LE was 17.6 years. LE in patients with 1-, 2- and 3-vessel 
disease was 21.4 years, 18.8 years and 15.4 years, respectively (p<0.0001). Patients 
with impaired LVEF had a significant shorter LE than patients with normal LVEF (13.9% 
vs 19.3%; p<0.0001)
Conclusions This is the last and ultimate follow-up study which comprises the whole life 
cycle of the first patients who underwent CABG. Overall median life expectancy was 17.6 
years. Since the majority needed a repeat intervention, CABG is a palliative treatment of 
a progressive disease. 
2:30 p.m.
1007-155 Clinical Utility of Serial Monitoring of Myeloperoxidase 
Levels in Patients Presenting for Evaluation of Chest Pain
Stephen J. Nicholls, Marie-Luise Brennan, Danielle Brennan, Shirley Mann, Tom Jackson, 
Stanley L. Hazen, Cleveland Clinic, Cleveland, OH, Prognostix Inc, Cleveland, OH
Background: Baseline levels of myeloperoxidase (MPO) predict clinical outcome in 
subjects with suspected acute coronary syndromes (ACS). The impact of serial MPO 
testing has not been investigated.
Methods: MPO levels were measured in plasma samples collected at baseline, as well 
as 4, 8 and 16 hours following presentation in 632 sequential subjects with complaint of 
chest pain (within 4h onset) of suspected cardiac origin. The ability of MPO levels at each 
time point to predict the clinical diagnosis and adverse cardiac outcomes at 30 days and 
6 months was determined.
Results: Patients (age 63+/-14 years, 58% male, 57% Caucasian, median MPO 1,636 
pmol/L at baseline) had a diagnosis of myocardial infarction (MI) and ACS during initial 
presentation in 23.6% and 40.5%, respectively. 30 day and 6 month rates of major 
adverse cardiac events (MACE) were 40.6% and 43.2%, respectively, with 30 day and 
6 month rates of revascularization being 30.4% and 31.2%, respectively. In addition 
to elevated baseline levels, elevated MPO levels at 4-16 hours following presentation 
continued to predict the likelihood of MI (adjusted odds ratios (ORs) 2.1-4.3, p<0.03) or 
ACS (adjusted ORs 2.8-4.7, p<0.001) on multivariate analysis in all subjects, as well as 
troponin T negative (<0.03 mg/dL) subjects. MPO elevation at 4-16 hours also continued 
to predict the likelihood of MACE (adjusted ORs 5.0-7.3 (30 day), p<0.001; and 3.8-7.3 
(6 month), p<0.002) and revascularization (adjusted ORs 5.1-7.4 (30 day), p<0.001; and 
4.8-8.3 (6 month), p<0.001) on multivariate analysis. Detection of an MPO level >650 
pmol/L at any time following presentation compared with only baseline presentation 
resulted in a lower percentage of MACE missed at both 30 days (3.3 v 12.9%) and 6 
months (4.0 v 12.3%) in both the entire cohort, as well as in patients with persistently 
negative troponin T levels.
Conclusion: Elevated systemic levels of MPO continue to predict clinical outcome 
when measured up to 16 hours following presentation for evaluation of chest pain. Serial 
determinations result in a reduction of clinical events that are not identified by baseline 
only sampling and conventional risk prediction algorithms.
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1007-156 Long-term Prognostic Value and Therapeutic 
Implications of Continuous ST-segment Monitoring in 
Acute Coronary Syndrome
Andrew T. Yan, Raymond T. Yan, Mary Tan, Aurora Mendelsohn, Sanjit Jolly, David 
H. Fitchett, Anatoly Langer, Shaun G. Goodman, St. Michael’s Hospital, Toronto, ON, 
Canada, Canadian Heart Research Centre, Toronto, ON, Canada
Background: Continuous ST-segment monitoring can detect recurrent silent ischemia 
in the setting of acute coronary syndrome (ACS). We sought to investigate: (1) the 
incremental long-term prognostic value of ST-segment monitoring beyond the validated 
Global Registry of Acute Coronary Event (GRACE) risk score in ACS; and (2) whether ST-
segment monitoring can identify patients who benefit from early revascularization.
Methods: We determined the GRACE risk score (a validated predictor of in-hospital 
death) in 681 non-ST elevation ACS patients enrolled in the Integrilin and Enoxaparin 
Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) trial. The 
GRACE risk score was calculated based on age, heart rate, systolic blood pressure, Killip 
class, creatinine, cardiac arrest, ST segment deviation, and cardiac biomarker status. All 
predictor variables were collected on presentation. Continuous ST-segment monitoring 
in the first 48 hours was analyzed by an automated algorithm and reviewed by a blinded 
cardiologist. Clinical outcomes were centrally adjudicated in a blinded fashion.
Results: The median GRACE risk score was 115 (interquartile range 97 to 137) and 
ST-segment shifts were present in 19.1% of 681 patients. After a median follow-up of 30 
months, patients with ST-segment shifts had a higher risk of death (17.7% vs 5.8%, log-
rank P<0.001) and death or myocardial infarction (MI) (24.6% vs 11.1%, log-rank P<0.001). 
In multivariable analysis adjusting for GRACE risk score, the presence of ST-segment shifts 
remained an independent predictor of death (adjusted hazard ratio [HR]=2.37, 95% CI 1.38-
4.09, P=0.002) and death/MI (adjusted HR=1.93, 95% CI 1.25-3.00, P=0.003). In-hospital 
revascularization was independently associated with a lower risk of death/MI among 
patients with ST-segment shifts but not among those without (P for interaction=0.02).
Conclusion: Continuous ST-segment monitoring provides incremental prognostic 
information beyond the validated GRACE risk score determined on presentation, and 
identifies high-risk patients who benefit from early revascularization. This simple and 
valuable clinical tool may be useful in the routine management of ACS.
2:30 p.m.
1007-157 Joint Effects Of Diabetes And Dialysis In Predicting 
Long Term Outcomes Following Percutaneous 
Coronary Interventions
Mamoru Toyofuku, Yasuhiko Hayashi, Yoshiko Masaoka, Hironori Ueda, Tadamichi 
Sakuma, Yuji Muraoka, Hidekazu Hirao, Takenori Okada, Toshiharu Oka, Takehito 
Tokuyama, Chikaaki Motoda, Tsuchiya General Hospital, Hiroshima, Japan
Background: Diabetes and dialysis are established risk factors for adverse outcomes 
following percutaneous coronary interventions (PCI) instead of a high procedural 
successful rate. We investigated the joint effects of these factors on three year outcomes 
of patients treated with PCI.
Methods: Consecutive 1142 patients (age<80yr) [124 dialysis patients (65 DM and 59 
non-DM) and 1018 non-dialysis patients (399 DM and 619 non-DM)] who underwent PCI 
between April 2000 and March 2003 were enrolled and followed for 3 years. The stents 
used in this study were all bare metal stents. End points were cardiac death, myocardial 
infarction, and revascularization related to target lesions (TLR).
Results: By the third year, cardiac death and myocardial infarction occurred in 31% of patients 
in DM & dialysis, 8.7 % in non-DM & dialysis, 4.8 % in DM and non-dialysis and 3.8 % in non-
DM and non-dialysis. The occurrences of restenosis were 49 % of patients in DM & dialysis, 30 
% in non-DM & dialysis, 34 % in DM and non-dialysis and 23 % in non-DM and non-dialysis.
Hazard ratios for the occurrence of composite end points of cardiac death, myocardial 
infarction and TLR according to diabetes and dialysis were 2.9 (P=0.0000) in DM & 
dialysis, 1.58 (P=0.0003) in DM and non-dialysis, and 1.32 (P=0.27) in non-DM and 
dialysis, respectively, compared with non-diabetic and non-dialysis patients.
Conclusions: Diabetes and dialysis jointly contribute to the poor outcome following PCI in 
the 2nd generation bare metal stent era. Further research is needed to confirm the effect of 
current drug-eluting stent on the outcome after PCI in such high risk subset of patients.
2:30 p.m.
1007-158 Prediction of Cardiac Events in Patients With Reduced 
Left Ventricular Ejection Fraction Using Dobutamine 
Cardiovascular Magnetic Resonance Assessment of 
Wall Motion Score Index
Erica Dall’Armellina, Timothy M. Morgan, Hollins Clark, Sangeeta Mandapaka, Paige 
Clark, J. Jeffrey Carr, William Ntim, Craig A. Hamilton, John Hoyle, Kerry M. Link, W. 
Gregory Hundley, Department of Internal Medicine/Cardiology Section,Wake Forest 
University School of Medicine, Winston Salem, NC
Introduction: Dobutamine cardiovascular magnetic resonance (DCMR) assessment of 
ischemia has a high clinical utility in predicting cardiac prognosis in patients with normal left 
ventricular ejection fraction (LVEF). The prognostic utility of DCMR rest and stress induced 
LV wall motion abnormalities in patients with a reduced LVEF at rest is unknown.
Methods: We identified 240 consecutive patients with a LVEF <55% poorly suited for 
stress echocardiography, who underwent DCMR and in which left ventricular (LV) wall 
motion score index (WMSI) was assessed at rest, low dose, and after peak intravenous 
infusion of dobutamine/atropine. WMSI was defined as the cumulative sum of individual 
segment score divided by the number of interpreted segments. All participants were 
contacted an average of 5+1 years after the DCMR by personnel unaware of the 
stress test results to ascertain the post DCMR occurrence of cardiac death, myocardial 
infarction (MI), and unstable angina or congestive heart failure resulting in hospitalization. 
All events were substantiated through review of the participants’ medical records.
Results: Resting and peak WMSI were both predictive of hard events (p<0.0001). The 
increase in WMSI from low to peak dose, compared to the change in WMSI from rest to low 
dose of dobutamine, was significantly higher (p<0.0012) in patients who experienced any 
cardiac event compared to participants with no events. Also, the stress induced increment 
in WMSI was associated with reduced free survival for any (p<0.005) and hard (p<0.03) 
events. The trend was similar for men (p= 0.007) and women (p=0.10). After performing 
multivariate analyses that included risk factors for coronary arteriosclerosis and MI, the 
increase in WMSI during dobutamine infusion independently predicted any cardiac event. 
Also, the stress induced change in WMSI added significant incremental benefit in predicting 
any cardiac event (p=0.003). Finally, the location of the myocardial segments responsible 
for the increase in WMSI was predictive of future cardiac events (p=0.012).
Conclusions: In patients with reduced LVEF, DCMR assessments of WMSI at rest and 
stress, identify those at risk for a future cardiac event.
2:30 p.m.
1007-159 2-Year Results from the TAXUS-V ISR Trial: A 
Randomized Trial of Paclitaxel-Eluting Coronary 
Stents versus Vascular Brachytherapy for Treatment of 
Restenosis in Bare Metal Stents
Stephen G. Ellis, Cleveland Clinic, Cleveland, OH
Background: The TAXUS V in-stent restenosis (ISR) trial evaluates the safety and efficacy 
of the TAXUS® Express2™ polymer-based, paclitaxel-eluting stent (PES) compared to 
vascular brachytherapy (VBT) for the treatment of ISR in bare metal stents. Previously 
reported 9-month results demonstrate that PES resulted in clinically and angiographically 
superior outcomes. The long-term safety profile and durability of the efficacy advantages 
of PES for ISR treatment will be evaluated with long term follow up.
Methods: TAXUS-V ISR is a prospective, 37-center, randomized, open-label trial powered 
for sequential non-inferiority and superiority testing of PES (N=195) vs. VBT (N=201) for 
the treatment of ISR. The primary endpoint is ischemia-driven TVR at 9 months.
Results: The 9 month superiority endpoint was met. PES compared to VBT resulted in 
a significant reduction of 40% in TVR (10.5% vs. 17.5%, p=0.046). 12-month outcomes 
are now available and shown in the table. 24-month outcomes will be available for 
presentation by March 2007. 
Intent-to-Treat, All Patients (N=396)
Table of Contents
•	 Efficacy and Safety Measures
Efficacy and Safety Measures
Brachytherapy
(N=201)
TAXUS
(N=195) p-Value
1-Year MACE 24.9% (47/189) 17.5% (33/189) 0.078
Cardiac Death 0.5% (1/189) 0.5% (1/189) 1.000
MI 5.8% (11/189) 3.7% (7/189) 0.334
TVR, Overall 22.2% (42/189) 15.9% (30/189) 0.116
TLR, Overall 16.9% (32/189) 9.0% (17/189) 0.022
Target Vessel or Stent Thrombosis
30 Days 0.5% (1/199) 0.5% (1/194) 1.00
31 - 180 Days 1.0% (2/199) 1.0% (2/194) 1.00
1 Year (Cumulative) 3.2% (6/187) 1.6% (3/188) 0.337
Conclusion: At both 9 and 12 months, the treatment of bare metal ISR with PES 
compared to VBT significantly reduces clinical restenosis (TLR) with acceptable safety 
rates (death, MI and stent thrombosis). Longer-term follow-up will help to evaluate the 
long-term risk/benefit profile of PES. The 2-year results will be presented and will address 
whether or not the TLR advantage of PES, as well as the adequate safety profile, is 
sustained in the long term.
2:30 p.m.
1007-174 C-Reactive Protein and B-type Natriuretic Peptide 
Independently Predict Hospitalization for Heart Failure 
after Acute Coronary Syndromes and Identify Patients 
who Benefit from Intensive Statin Therapy in the 
PROVE IT-TIMI 22 Trial
Benjamin M. Scirica, David A. Morrow, Christopher P. Cannon, Kausik K. Ray, Marc S. 
Sabatine, Nader Rifai, Petr Jarolim, Amy Shui, Carolyn H. McCabe, Eugene Braunwald, 
TIMI Study Group, Boston, MA, Brigham and Women’s Hospital, Boston, MA
Background- Heart failure (HF) is an important cause of morbidity in patients with ACS. 
Recent data suggest a direct role for CRP in exacerbating myocardial injury but data 
regarding the clinical relationship between hsCRP and risk of HF after ACS are few.
Methods- PROVE IT-TIMI 22 randomized pts stabilized after ACS, to either intensive 
(atorvastatin 80mg) or moderate (pravastatin 40mg) statin therapy. Hospitalization for HF 
was determined during a mean f/u period of 24 months. We evaluated hsCRP along with 
BNP, an established predictor of HF, 30 days after hospitalization.
Results- Pts who developed HF had higher 30 day levels of hsCRP (median 4.7 v. 1.9 
mg/L, p<0.001) and BNP (median 73 v. 22 ng/l, p<0.0001) compared to those without 
subsequent HF. A level of hsCRP>2mg/l was associated with an increased risk of HF 
regardless of levels of BNP (adjHR 2.7, p=0.01 for BNP<80pg/ml) and (adjHR 3.2, 
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p=0.018 for BNP>80 pg/ml), with the highest risk in pts with elevated levels of both 
markers (adj HR 11.4, p<0.001). (Figure) Intensive statin therapy reduced the risk of HF 
in pts with hsCRP>2mg/l, whether levels of BNP were >80 pg/ml (adj HR 0.29, p=0.015) 
or <80pg/ml (adj HR 0.39, p=0.037), while there was no effect in pts with hsCRP<2mg/l (p 
for interaction=0.039).Conclusion- Both 30 day levels of CRP and BNP are independently 
associated with the risk of HF after ACS and identify high-risk pts. Intensive statin therapy 
reduces the risk of heart failure, in particular among pts with elevated levels of hsCRP. 
2:30 p.m.
1007-175 Serum Cystatin C Reflects The Presence and Severity 
Of Coronary Artery Disease In Stable Angina Patients.
Yun-Hyeong Cho, Hyuck Moon Kwon, Bum-Kee Hong, Yonsei University, Seoul, South Korea
Background: Atherosclerosis is an inflammatory disease characterized by extensive 
remodeling of the extracellular matrix architecture of the arterial wall. Cysteine 
proteases cathepsins S and K abound in human atherosclerotic lesions. In contrast, 
reduced expression of cystatin C, their endogenous inhibitor, has been demonstrated 
in atherosclerotic lesions. Serum cystatin C has been recently considered a marker of 
renal ultrafiltration efficiency. This study has examined the associatiation between serum 
cystatin C and the presence and severity of coronary artery disease(CAD) in patients with 
stable angina(SA). To investigate this hypothesis, we measured plasma levels of cystatin 
C in patients undergoing coronary angiography.
Methods: This study enrolled 164 consecutive SA patients with significant(>50%) CAD, 
and 159 consecutive patients without significant CAD. The serum cystatin C has been 
investigated between two groups before coronary angiography. The association of serum 
cystatin C level and the severity of CAD has also been evaluated.
Results: Patients with significant CAD had significantly higher level of cystatin C 
compared to patients without significant CAD in univariate analysis(p<0.05). There was 
no significant difference in creatinine between two groups(p=0.268). Serum cystatin C 
showed significant positive correlations with age, diabetes, hypertension, creatinine. In 
multivariate analysis, serum cystatin C was not an independent risk factor for significant 
CAD. Patients with multiple CAD(≥2 vessel disease) had significantly higher level of 
cystatin C compared to patients without multiple CAD in univariate analysis (p<0.05). 
Creatinine showed no significant difference between two groups(p=0.218).
Conclusions: Cystatin C is increased in SA patients with significant CAD and multiple 
CAD. Serum cystatin C levels may reflect the presence and severity of CAD. Local 
variations of cystatin C synthesis in atherosclerosis are not likely to determine its serum 
concentration.
2:30 p.m.
1007-176 Effect of Amlodipine on the Clinical Outcome in 
Diabetic Patients with Coronary Artery Disease after 
Angioplasty : Results from the Cardiovascular Events 
Follow-up Trial in Kokura (CAVEFT-Kokura)
Hiroyoshi Yokoi, Yoshimitsu Soga, Shinichi Shirai, Kenji Ando, Koyu Sakai, Katsuhiro 
Kondo, Masashi Iwabuchi, Hitoshi Yasumoto, Hideyuki Nosaka, Masakiyo Nobuyoshi, 
Kokura Memorial Hospital, Kitakyushu, Japan
Background: CAMELOT Study showed that the administration of amlodipine to diabetic 
patients with coronary artery disease (CAD) resulted in reduced adverse cardiovascular 
events, especially repeat coronary revascularization.
Objective: To compare the effects of amlodipine versus placebo on restenosis and 
clinical outcome after percutaneous coronary intervention (PCI) for diabetic patients.
Methods:In a prospective, double-blind design, 540 patients with 659 denovo lesions 
were randomized to receive 5-10mg of amlodipine or placebo. Diabetic patients were 
enrolled in171 patients (32%).The primary angiographic endpoint was minimal lume 
diameter (MLD) at 6 month assessed by follow-up (FU) quantitative coronary angiography 
(QCA). Clinical end points were death, myocardial infarction, coronary bypass surgery 
and repeat any PCI at 12 months.
Results:Angioplasty was performed in all patients without complications ;461 patients 
(85%) had received coronary stent implantation.FU QCA was obtained in all patients. The 
MLD at FU was significantly larger in the amlodipine group (1.50±0.52mm in the amlodipine 
group versus 1.42±0.52mm in the placebo group: p=0.035). The loss index was tendency 
to be lower in the amlodipine group (0.54±0.66 in the amlodipine group versus 0.61±0.56 in 
the placebo group: p=0.076).The binary restenosis (defined as >50% diameter stenosis at 
FU) rate was 22.6% in the amlodipine group versus 28.5% in the placebo group (p=0.078).
The composite incidence of clinical events were occurred in 89 patients (32%) in the 
amlodipine group versus 102 patients (39%) in the placebo group (p=0.103).The composite 
incidence of clinical events in diabetic patients were occurred in 30 patients (37%) in the 
amlodipine group versus 51 patients (57%) in the placebo group (p=0.007).
Conclusion: Administration of amlodipine in diabetic patients resulted in reduced adverse 
cardio vascular events after PCI.
2:30 p.m.
1007-177 Assessment of Angiopoietin 1 and Angiopoietin 2 gene 
expression in Stable Coronary Artery Disease after 
Angiotensin Converting Enzyme Inhibitor Treatment
Mary E. Marketou, Joanna E. Kontaraki, Evangelos A. Zacharis, George E. Kochiadakis, 
Dimitris A. Arfanakis, Aikaterini N. Giaouzaki, Panagiotis E. Vardas, Heraklion University 
Hospital, Heraklion, Greece
Background: The renin-angiotensin system has been implicated in endothelial cell 
dysfunction, development and progression of atherosclerosis. Angiopoietins (Ang) are 
significant angiogenic and endothelial cell growth factors that have been implicated in the 
atherogenic process. We investigated the effect of perindopril - a long-acting angiotensin 
converting enzyme inhibitor (ACE-i) - on Ang1 and Ang2 gene expression in peripheral 
monocytes in patients with stable coronary artery disease (CAD).
Methods: Thirty patients (18 male, aged 64 ± 9 years) with stable angina lasting > 6 
months, without clinical evidence of heart failure or uncontrolled hypertension were 
randomly assigned to receive treatment with either 4 mg perindopril (n= 16) or placebo (n= 
14). Blood samples were taken before and 3 months after therapy initiation. Mononuclear 
cells were isolated using anti-CD14+ antibodies and mRNAs were estimated by real-time 
quantitative reverse transcription-PCR and expressed as fold induction.
Results: After treatment with perindopril, Ang1 gene expression was significantly 
downregulated (Folds in perindopril group: 0.58 ± 0.45 versus placebo: 1.71 ± 1.9, p= 
0.02). Ang2 gene expression did not show any significant difference between the two 
groups (Folds in perindopril group: 1.68 ± 2.45 versus placebo: 2.4 ± 2.9, p= NS).
Conclusion: Treatment with perindopril results in a significant attenuation in Ang1 
expression in patients with stable CAD. Our findings may provide new insights into the 
anti-atherogenic action of ACE-i.
2:30 p.m.
1007-178 Is Diabetes a Significant Risk Factor in Contemporary 
Percutaneous Coronary Intervention (PCI)?
Mohammed Andron, Mohanad Egred, Albert Alahmar, Roger Moore, Elved Roberts, 
Anthony D. Grayson, Nicholas D. Palmer, Raphael A. Perry, Cardiothoracic Centre, 
Liverpool, United Kingdom
Background: Historically, diabetic patients undergoing PCI have a less favorable outcome.
Aim: To assess the impact of diabetes on in-hospital major adverse cardiac and 
cerebrovascular events (MACCEs) and 1- year clinical outcome following coronary stent 
placement in the modern era of PCI.
Methods and Results: All patients who underwent successful stent placement between 
January 2000 and March 2004 were enrolled. A total of 4891 consecutive patients were 
enrolled, of whom there were 674 (13.8%) diabetics and 4217 (86.2%) non diabetics. 
To account for the differences in case-mix between diabetics and non-diabetics, a one 
to many propensity-matched and a multivariate analyses were performed. In hospital 
MACCE was similar between the two groups (diabetics 1.4% vs non-diabetics 1% 
p=0.44). One year event rates were also not different with regard to death (2.8% vs 3%, 
p=0.34) and target lesion revascularization (TLR) (6.5% vs 5.8%, p= 0.54). However, 
when TLR was stratified by the type of stent used [bare metal (BMS) vs drug eluting 
(DES)], the use of BMS showed that diabetic patients had a trend toward higher rate of 
TLR (7.5% vs 5.9% p=0.18), whereas for DES, diabetics had lower rate of TLR at one year 
than their non-diabetic counterparts (1.1% vs 5.7%, p=0.014). Furthermore, the logistic 
regression analysis showed that vessel size <2.5mm (OR 2.3, p<0.001), treating left main 
stem lesions (OR 2.9, p=0.009), and restenotic lesions (or 1.8, p=0.011) were positive 
predictors of TLR, while DES was a negative predictor of TLR (OR 0.48, p=0.005).
Conclusion: In this study, diabetes did not appear to have a significant impact on 
adverse outcome following PCI. Furthermore, the use of DES resulted in reduced TLR 
rates in diabetic patients.
2:30 p.m.
1007-179 Comparison Of Angiopoietin-1 And Angiopoietin-2 
Gene Expression Levels Among Patients Treated With 
Sirolimus-eluting Versus Bare Metal Stents
Mary E. Marketou, George E. Kochiadakis, Joanna E. Kontaraki, Dimitris A. Arfanakis, 
Aikaterini N. Giaouzaki, Emmanuel I. Skalidis, Michael Hamilos, Panagiotis E. Vardas, 
Heraklion University Hospital, Heraklion, Greece
Background: Angiopoietin-1 (Ang1) and angiopoietin-2 (Ang2) are significant endothelial 
and angiogenic growth factors, respectively, which play an essential role in vascular 
injury. We evaluated the expression of Ang1 and Ang2 mRNA in patients undergoing 
implantation of sirolimus-eluting stents (SES) compared to bare metal stents (BMS).
Methods: Thirty patients (18 male, aged 68 ± 14 years) with stable angina, who 
underwent elective single vessel percutaneous coronary intervention were randomized to 
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SES (n=15) or BMS (n=15) implantation. Blood samples were taken before and 3 weeks 
after PCI. Mononuclear cells were isolated using anti-CD14+ antibodies and mRNAs 
were estimated by real-time quantitative reverse transcription-PCR.
Results: All procedures were successful. There were no significant baseline differences 
in mononuclear Ang1 and Ang2 expression between the two groups (p=NS, for both). One 
month after stent implantation, Ang1 gene expression was downregulated by 32% in the 
SES group and upregulated by 90% in the BMS group (Folds in SES: 0.68 ± 0.42 versus 
BMS: 1.91 ± 1.84, p= 0.04). Ang2 gene expression did not show any significant difference 
between the two groups (Folds in SES: 0.78 ± 0.85 versus BMS: 1.67 ± 2.94, p= NS).
Conclusion: Patients with stable angina treated with SES showed a significant post- 
procedural attenuation in Ang1 expression. We assume that this attenuation may be 
implicated in the impaired re-endothelization observed after SES implantation and could 
potentially initiate thrombosis formation.
2:30 p.m.
1007-180 Angiotensin Converting Enzyme Inhibitors Beneficially 
Modify Vascular Endothelial Growth factor gene expression 
and protein levels in Stable Coronary Artery Disease
Mary E. Marketou, Dimitrios Panutsopulos, Evangelos A. Zacharis, George E. 
Kochiadakis, Dimitris A. Arfanakis, Demetrios A. Spandidos, Panagiotis E. Vardas, 
Heraklion University Hospital, Heraklion, Greece, Heraklion University, Heraklion, Greece
Background: The renin-angiotensin system has been implicated in the development 
and progression of atherosclerosis. Vascular endothelial growth factor (VEGF) is a key 
component in both inflammatory angiogenesis and atherosclerotic plaque progression. 
We investigated the effect of perindopril - a long-acting angiotensin converting enzyme 
inhibitor (ACE-i) - on VEGF gene expression and the circulating protein levels in patients 
with stable coronary artery disease (CAD).
Methods: Thirty patients (18 male, aged 64 ± 9 years) with stable angina lasting > 6 
months and without clinical evidence of heart failure or uncontrolled hypertension were 
randomly assigned to receive treatment with either 4 mg perindopril (n= 16) or placebo (n= 
14). Blood samples were taken before and 3 months after therapy initiation. Mononuclear 
cells were isolated using anti-CD14+ antibodies and mRNAs were estimated by real-time 
quantitative reverse transcription-PCR (TaqMan) and expressed as fold induction. VEGF 
serum levels were determined each time by ELISA.
Results: There were no significant baseline differences in mononuclear VEGF gene 
expression and serum protein levels between the two groups (p=NS, for both). After treatment 
with perindopril, VEGF gene expression was significantly downregulated (Folds in perindopril 
group: 0.64 ± 0.25 versus placebo: 1.21 ± 0.9, p= 0.03) and VEGF protein levels were 
decreased (from 376 ± 46 pg/mL to 282 ± 46 pg/mL, p=0.001). No significant difference was 
detected in the placebo group (from 342 ± 64 pg/mL to 358 ± 89 pg/mL, p=NS)
Conclusion: Treatment with perindopril results in a significant attenuation in VEGF gene 
expression and circulating protein levels in patients with stable CAD. Our findings may 
afford a better understanding of the anti-atherogenic effects of ACE-i.
2:30 p.m.
1007-195 Low Incidence of Significant Bradycardia During 
Therapy With an If Current Inhibitor Ivabradine: Heart 
Rate Reduction Depends on Baseline Heart Rate
John Camm, Irina Savelieva, Jeffrey S. Borer, St George’s University of London, 
London, United Kingdom, Weill Medical College, Cornell University, New York, NY
Background: Ivabradine is a novel heart rate (HR)-lowering agent that acts specifically 
on the sinus node by selectively inhibiting the If current. Ivabradine binding to f-channels is 
restricted to open channel state. Since the pacemaker potential is modulated by several 
ion channels, 100% block of the If current would cause only a 25-30% reduction in the 
sinus node rate.
Methods: Whether HR reduction by ivabradine correlates with baseline HR in the clinical 
setting, was studied in 1328 pts with documented stable coronary artery disease (CAD) 
treated with ivabradine 5, 7.5 or 10 mg bd. Resting ECGs were recorded at baseline and 
after 3 to 4 months of treatment and were read centrally.
Results: HR reduction by ivabradine clearly depended on HR at baseline. Inverse linear 
correlations between baseline HR and changes in HR on treatment were observed for 
all 3 doses of ivabradine (coefficients of correlation r = -0.54 to -0.57) [Figure]. Thus, 
HR-reducing effect with ivabradine was smaller in pts with the lowest baseline HR and 
more pronounced in pts with tachycardia. At 2 recommended treatment doses, there were 
no reports of severe bradycardia <40 bpm in pts treated with 5 mg bd; the incidence of 
bradycardia was 0.5% in pts treated with 7.5 mg bd.
Conclusions: Therapy with ivabradine is asssociated with a low incidence of severe 
bradycardia. A small proportion of patients who developed clinically significant bradycardia 
can be explained by plateau dose-response and HR dependent effects of ivabradine on 
HR reduction. 
2:30 p.m.
1007-196 Long-Term Adherence to the ACC/AHA Class I Post-
Discharge Medications and Recommendations 
Using Optimal Medical Therapy in 2,287 Patients with 
Established Coronary Heart Disease: Interim Data from 
the Clinical Outcomes Utilizing Revascularization and 
Aggressive Drug Evaluation (COURAGE) Trial.
Marcin Dada, Robert A. O’Rourke, Koon K. Teo, Pamela M. Hartigan, Merril Knudtson, 
William Kostuk, David J. Maron, Paul Casperson, William S. Weintraub, William E. 
Boden, Hartford Hospital, Hartford, CT
Background: Despite scientific evidence from multiple randomized controlled trials 
(RCT) that individual secondary prevention interventions reduce morbidity and mortality, 
few studies have evaluated long-term intervention with multiple ACC/AHA recommended 
therapies in patients with established coronary heart disease (CHD). We sought to 
compare adherence to comprehensive treatment guidelines at baseline and at 60-months 
of follow-up in patients with chronic CHD enrolled in the COURAGE trial.
Methods: COURAGE is a large multicenter North American RCT comparing 
percutaneous coronary intervention plus aggressive medical therapy versus aggressive 
medical therapy alone during a median 5 year follow-up. Medical therapy in both arms 
conforms with current ACC/AHA treatment guidelines and includes aspirin, clopidogrel, 
long-acting metoprolol and/or amlodipine, lisinopril, and simvastatin. Treatment targets 
include systolic (S) and diastolic (D) BP<130/85 mmHg, LDL-cholesterol 60-85 mg/dL, 
AHA step II diet, and exercise 5 times/week. Medical therapy and multiple risk factor 
intervention is protocol-driven and delivered by nurse case managers at each site.
Results: Compared to baseline rates of therapy, data at 60 months show improvement 
in the use of anti-platelet agents (91% vs 97%), beta blockers (73% vs 86%), 
antihypertensive agents (ACE inhibitors 49% vs 69%, calcium blockers 31% vs 49%, and 
angiotensin II receptor blockers 4% vs 12%), and statins (71% vs 97%). There was also 
substantial improvement in attaining pre-defined follow-up treatment targets for LDL (25% 
vs 70%), SBP (39% vs 65%), DBP (81% vs 94%), AHA step II diet (51% vs 76%), and 
exercise (23% vs 38%) when compared to baseline data.
Conclusions: Increased adherence to ACC/AHA class I post-discharge medications 
and recommendations in the COURAGE trial is associated with improved multiple risk 
factor goal attainment, and provides a real-world model for this approach in patients with 
established CHD.
2:30 p.m.
1007-197 New Insights in the Management of Cardiogenic Shock 
Complicating Myocardial Infarction. Role of Urgent 
Heart Transplantation
Dabit Arzamendi, Ricardo Kiamco, Ana García-Álvarez, Mónica Masotti, Eulalia 
Roig, Félix Pérez-Villa, Amadeu Betriu, Cardiology - Thorax Institute - Hospital Clínic, 
Barcelona, Spain
Background: Timely percutaneous coronary intervention (PCI) improves prognosis of 
patients with cardiogenic shock (CS) complicating acute myocardial infarction (AMI). 
However, lack of myocardial reperfusion despite successful PCI still encompasses high 
mortality rates. The impact of heart transplantation (HT) in this setting has not been 
analysed. We sought to assess the role of HT in the management of AMI patients(pts) 
complicated by refractory CS after PCI. The primary end-point of the study was mortality 
at one year follow up.
Methods: Between January of 2001 and December of 2005 a total of 39 pts qualified for 
the study, as they presented with refractory CS unsuitable for surgical revascularization 
and no contraindication for HT (age<65, no comorbidities). Compatible donors could 
be recruited for 10 pts and they underwent urgent HT. The remaining 29 pts served as 
controls. The two groups were well balanced in terms of age (46 vs. 52 years, HT vs. 
noHT), number of diseased vessels (1.9 vs. 1.6), pulmonary capillary wedge pressure (19 
vs. 18mmHg), cardiac index (2.2 vs. 2.3 L/min/m2) and left ventricular ejection fraction 
( 22% vs. 25%).
Results: Mortality rates were significantly lower in the HT group, both in hospital (10% vs. 
45% p<0.03) and at 1 year (10% vs. 48.3% p<0.03)
Conclusions: Urgent HT dramatically improves survival of AMI patients presenting with 
refractory CS despite early PCI. Therefore, this approach-when ever feasible- needs to 
be considered in the management on this particular subset of pts. 
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2:30 p.m.
1007-198 Cardiovascular Emergencies in Cruise Ship 
Passengers: Clinical Presentation and Outcomes
Gian M. Novaro, Craig R. Asher, Howard S. Bush, Kenneth R. Fromkin, Michael Y. 
Shen, Marcelo Helguera, Sergio L. Pinski, Cleveland Clinic Florida, Weston, FL
Background: More than 10 million people (many of them elderly and thus likely to 
harbor cardiovascular disease (CV)) embark on cruise ship travel worldwide every 
year. The clinical presentation and outcome of CV emergencies presenting during 
cruise ship travel remain largely unknown.
Methods: Our department provides contracted cardiology consultations to several large cruise 
lines. Initial consultation is established via teleconference with the requesting physician on the 
ship’s infirmary. We prospectively maintained a registry of all such consultations during a 2-
year period. Patient (pt) demographics, symptoms, initial diagnosis, recommended therapy and 
triage were recorded. Pts triaged to our institution were followed until hospital discharge.
Results: One hundred consecutive pts were identified (age 66 ± 14 years, range 18-90 years; 
76% male). The most common symptom was chest pain (50%). The most common diagnosis 
was acute coronary syndrome (ACS) (58%; ST elevation in 21% and non-ST elevation in 37%), 
followed by heart failure (16%) and atrial arrhythmias (15%). 16 pts received on-board fibrinolytic 
therapy, which was judged unsuccessful in 3. Fibrinolytic therapy was withheld in 5 pts due to 
relative contraindications. On-board mortality was 3%. Overall, 75% of pts required hospital 
triage: 50% to the nearest port-of-call and 25% to our institution. Among the 25 pts triaged to our 
institution, 18 (72%) underwent a revascularization procedure (12 PCI, 6 CABG). One pt died. 
10% of pts had cardiac symptoms in the days or weeks prior to boarding; all of them required 
hospital triage. Access to a baseline ECG would have been clinically useful in 23% of cases.
Conclusions: CV emergencies, such as ACS and heart failure, are not uncommon 
on cruise ships. They are often serious, requiring hospital triage and coronary 
revascularization. A pre-travel medical evaluation is recommended for passengers with 
a cardiac history (especially if with active symptoms) or a high-risk profile. Passengers 
should be encouraged to bring a copy of their ECG on board. Cruise lines should establish 
mechanisms for prompt consultation and triage.
2:30 p.m.
1007-199 Mortality Following Percutaneous Coronary 
Intervention for Cardiogenic Shock: Is It Fair to Publicly 
Report Outcomes?
Shafeeq Ahmed, Ravishankar V. kalaga, Hemal H. kadakia, Richard T. Ruffin, Jr., 
AravindRao Kokkirala, Francis J. Kiernan, Justin B. Lundbye, Marcin Dada, Deborah 
Murphy, Jeff Mather, Raymond G. McKay, Hartford Hospital, Hartford, CT
Background: In spite of aggressive revascularization with percutaneous coronary 
intervention (PCI), the in-hospital mortality rate for patients (pts) presenting with 
cardiogenic shock (CS) secondary to acute myocardial infarction remains high. Quality 
assurance agencies publicly reporting PCI outcomes often do not appropriately risk-
stratify this class of pts.
Methods: Retrospective analysis of 115 pts with CS treated with emergent PCI between 
1/03 and 6/06 at a high volume tertiary center was made to determine in-hospital and 9-
month clinical outcomes. The study group included 63.5% males with a mean age of 67±13 
years. ST-segment elevation myocardial infarction (STEMI) was present in 97 pts, while the 
remaining 16 had non-STEMI. Cardiac arrest prior to being treated with PCI occurred in 45 
pts (39.1%). Multivessel coronary artery disease (left main, 3 vessel and 2 vessel disease) 
was present in 68.7%. Mean left ventricular ejection fraction measured 35±16%. Treatment 
included coronary stenting in 85.2% with use of GP IIb/IIa agents in 74.8%.
Results: Angiographic success with TIMI 3 flow in the infarct vessel was achieved in 88.8% 
of pts. Emergent CABG and/or valve repair was performed in 3.5%. In-hospital mortality 
was 40.9% and 38.8% at 9 months. Initial hemodynamic improvement was noted in 55.3% 
of 47 pts who subsequently died. In-hospital CS death data as shown below:
Causes of Death:
A) Persistent shock with subsequent cardiac arrest 21/47 (44.7%)
B) Support withdrawn for anoxic brain damage 14/47 (29.8%)
C) Support withdrawn after prolonged hospitalization 12/47 (25.5%)
with multisystem failure
Conclusions: Although in-hospital mortality remains high for CS pts treated with PCI, 
many deaths are secondary to non-cardiac causes unrelated to and often in the presence 
of PCI success. Since outcomes in this class of pts comprise the largest percentage of 
publicly reported PCI mortality, reporting agencies need to develop better risk stratification 
methods to more accurately compare healthcare providers and institutions.
2:30 p.m.
1007-200 Coronary Artery Bypass Surgery Might Be Superior to 
Percutaneous Coronary Intervention With Drug-Eluting 
Stents for Unprotected Left Main Coronary Artery 
Disease
Gengo Sunagawa, Tastuhiko Komiya, Nobushige Tamura, Genichi Sakaguchi, Taira 
Kobayashi, Hiromasa Nakamura, Tomokuni Furukawa, Akihito Matsushita, Takashi 
Murashita, Shun Watanabe, Kurashiki Central Hospital, Kurashiki, Japan
Background: Improvements in results with percutaneous coronary intervention (PCI) 
with drug-eluting stents (DES) have been extending their use in patients with unprotected 
left main coronary artery (ULMCA) disease.
Methods:  From August 2004 to March 2006. when DES became available at our country, 73 
patients underwent CABG, and 97 patients underwent PCI with DES for ULMCA disease. In 
the CABG group, 57 patients had off-pump surgery. In the PCI group, all patients had sirolimus-
eluting stent implantation. Survival, major adverse cardiac cerebrovascular events(MACCE) 
and target lesion revascularization were analyzed by the Kaplan-Meier method.
Results: The preoperative Euroscore was 5.7±3.5 in the CABG group and 4.1±2.4 in 
the PCI group (p<0.01).There was no significant difference in other preoperative factors 
between the two group. The mean follow-up was 251±118 days in the CABG group and 
288±187 days in the PCI group. The survival at one year was 95.8% in the CABG group 
and 96.8% in the PCI group (p=0.99). The MACCE-free survival at one year was 94.0% 
in the CABG group and 81.9% in the PCI group (p=0.29). The freedom from target vessel 
revascularization was 97.8% in the CABG group and 87.6% in the PCI group(p=0.18).
Conclusions: Although the patients in the CABG group were sicker than that in the PCI 
group, there was no difference in the degree of the protection against death between 
CABG and PCI. CABG might be superior to PCI in terms of MACCE-free survival and the 
freedom from target lesion revascularization.
2:30 p.m.
1007-201 An Evaluation of the Safety of Aprotinin Use: 
The Retrospective Evaluation of Aprotinin in 
CardioThoracic Surgery (REACTS) Study
Craig I. Coleman, Vera T. Rigali, Jonathan Hammond, Jeffrey Kluger, William L. Baker, Jr., 
C. Michael White, Hartford Hospital, Hartford, CT, University of Connecticut, Storrs, CT
Background: Aprotinin is a drug used to reduce bleeding in patients undergoing cardiothoracic 
surgery (CTS) with cardiopulmonary bypass (CPB). A recent cohort evaluation found elevated 
risks of renal, cardiovascular, and cerebrovascular events when aprotinin was used.
Objectives: Determine the impact of aprotinin on safety variables among patients receiving 
CTS with cardiopulmonary bypass from a single United States hospital that employs aprotinin for 
complex surgeries and Jehovah’s Witnesses and only uses kaolin-based ACT determinations.
Methods: This was a single-center, retrospective cohort evaluation of all consecutive 
patients who underwent CTS with CPB between January 1, 2000 and December 31, 
2005. The main outcome measures assessed included the development of myocardial 
infarction, cerebrovascular events and renal dysfunction. Propensity score adjusted 
multivariate logistic regression was utilized to calculate adjusted odds ratios (AOR) with 
95% confidence intervals (CIs).
Results: A total of 3,348 patients were evaluated of which 362 (10.8%) received 
aprotinin and 2,986 (89.2%) did not. The study population was 66.9 ± 10.8 years of age, 
73.9% were male, 12.1% had previous CTS and 25.7% underwent valve surgery. Upon 
propensity score adjusted multivariate logistic regression, patients receiving aprotinin 
were less likely to experience a neurological complication compared to those not 
receiving aprotinin [AOR; 0.65 (95%CI 0.46-0.91)] and did not have an elevated odds of 
myocardial infarction [AOR; 1.04 (95%CI 0.53-2.04)] but were more likely to experience 
postoperative renal dysfunction [AOR; 2.03 (95%CI 1.37-3.01)].
Conclusions: When used prudently, aprotinin was not associated with negative 
myocardial or cerebrovascular outcomes but was associated with an increased risk of 
renal dysfunction. It is not known if the renal dysfunction reflects renal damage or a 
transient reduction in glomerular filtration.
ACC.ORAL CONTRIBUTIONS
802 
Contemporary Treatment of Patients with 
Acute Coronary Syndrome
Monday, March 26, 2007, 7:00 a.m.-8:30 a.m.
Room 208-209-210
7:00 a.m.
802-3 Use and Outcomes of Acute Clopidogrel Therapy in 
Non-ST-Segment Elevation Myocardial Infarction in 
Community Practice: Results From CRUSADE
Deepu Alexander, Fang-Shu Ou, Matthew T. Roe, Charles V. Pollack, Jr.,  
E. M. Ohman, Christopher P. Cannon, W. B. Gibler, Dan J. Fintel, Eric D. Peterson, 
David L. Brown, SUNY Stony Brook School of Medicine, Stony Brook, NY,  
Duke Clinical Research Institute, Durham, NC
Background: In 2002, the ACC/AHA guidelines recommended the early initiation of 
clopidogrel in patients with non-ST-segment elevation myocardial infarction (NSTEMI). 
However the degree to which acute clopidogrel has been incorporated into clinical 
practice and its effect on clinical outcomes remains unclear.
Methods: Using data from the CRUSADE National Quality Improvement Initiative, we studied 
trends in acute clopidogrel use within 24 hours of presentation among patients with NSTEMI 
treated at 545 US hospitals from Jan 2002 to Dec 2005. We limited our population to those not 
undergoing PCI within 24 hours, as well as those without contraindication to clopidogrel. Propensity 
modeling was used to identify factors associated with treatment; multivariable logistic regression 
was used to determine the association between acute clopidogrel and in-hospital outcomes.
Results: Among 93,362 NSTEMI patients not receiving acute PCI, 35,945 (38.5%) overall 
received clopidogrel within 24 hours of admission. However, use of acute clopidogrel rose 
significantly from ~30% in 2002 to ~50% in 2005, p <.0001 for trend. Relative to patients not 
treated acutely, those receiving acute clopidogrel were slightly younger (mean age 68.5 vs. 
69.2 yrs), more likely male (58.9% vs 57.1%) and more often had prior MI, PCI and CABG. 
Unadjusted in-hospital mortality was lower in the acute clopidogrel group (3.7% vs 5.7%, p 
<.0001); a difference that persisted after adjustment for baseline clinical risk factors, acute 
medications, catheterization <24h, and Year/Quarter (adjusted OR 0.65, 95% CI 0.58-
0.73). Major bleeding rates were similar among those treated vs not (9.5% vs. 9.5%, p = 
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.92) and did not change after risk adjustment (OR 0.97, 95% CI 0.87-1.09). Conclusion: 
While the acute use of clopidogrel has increased significantly, up to 50% of contemporary 
patients with NSTEMI in the U.S. are still not treated despite guideline recommendations. 
Among a community-based NSTEMI population, acute clopidogrel use is associated with 
reduced in-hospital mortality without significant increased risk for bleeding.
7:15 a.m.
802-4 Safety and Efficacy of Bivalirudin in High-Risk 
Patients with Acute Coronary Syndrome Admitted 
Through the Emergency Department: Implications 
for Upstream Management
Chadwick D. Miller, James W. Hoekstra, Charles V. Pollack, Steven V. Manoukian, 
Deborah B. Diercks, Andra L. Blomkalns, Francis W. Peacock, Gerard X. Brogan, Judd E. 
Hollander, Bernard Gersh, Gregg W. Stone, Wake Forest University, Winston-Salem, NC
Background: In the ACUITY trial, the use of bivalirudin monotherapy (BIV) resulted in 
superior net clinical outcome compared to unfractionated heparin or enoxaparin plus a 
GP IIb/IIIa inhibitor (Hep+ GPI) in patients with moderate and high risk NSTE ACS. The 
safety and efficacy of BIV versus BIV+GPI, or Hep+GPI in high-risk patients admitted 
through the emergency department (ED) has not been previously evaluated.
Methods: We analyzed high-risk patients (ischemic ST-segment changes and/or elevated 
cardiac biomarker) from ACUITY who were initially evaluated in the ED, excluding 
transfers and hospital direct admissions. Patients receiving Hep+GPI, BIV+GPI, and BIV 
were compared. Endpoints at 30 days included ischemic events (death, MI, unplanned 
intervention), major bleeding, and net clinical outcome (ischemic events + major bleeding).
Results: Of the 13,819 patients enrolled in ACUITY, 9463 (68.5%) met criteria for high 
risk. Of these, 6441 (68.1%) were initially evaluated in the ED. Outcomes are presented 
in the table below. Regression analysis to adjust for differences in baseline demographics 
between groups confirmed the findings. 
High Risk ED Patients Hep + GPIN=2147
BIV + GPI
N=2130
BIV
N=2164
Time from hospital admission to cardiac cath, 
median (h) 21.83 21.57 21.97
Time from randomization to cardiac cath, 
median (h) 6.5 6.6 6.5
PCI (%) 57.9% 59.2% 58.9%
CABG (%) 16.1% 14.1% 14.2%
Net clinical outcome (%) 14.2% 13.8% 12.3%
Ischemic Events (%) 8.9% 8.7% 9.3%
Major bleeding (%) 6.8% 6.8% 4.0%*
* p<0.0001 for BIV vs Hep + GPI
Conclusions: The use of BIV mono resulted in similar ischemic events and fewer 
major bleeding events compared with Hep + GPI in high-risk NSTE ACS patients 
initially evaluated in the ED. These findings were consistent with the overall ACUITY 
results and lend support for the use of a BIV strategy in ED patients destined for 
coronary intervention.
7:30 a.m.
802-5 Timing of Stent Thrombosis in the Real World: 
Comparison of Bare Metal Stents vs. Drug-Eluting Stents
Miranda C.A. Kramer, Rene J. van der Schaaf, Jose P.S. Henriques, Karel T. Koch, Jan 
Baan, Jr., Marije M. Vis, Jan G.P. Tijssen, Jan J. Piek, Robbert J. de Winter, Academic 
Medical Centre, Amsterdam, The Netherlands
Background: Stent thrombosis (ST) is a severe complication of stent implantation. There 
are concerns regarding the potential for late ST (30 days-6 months) and very late ST (> 
6 months) after DES implantation. We compared the timing of ST after BMS versus ST 
after DES in a large single centre consecutive cohort.
Methods and Results: DES were available from 2002. From a total of 10,732 patients 
treated with successful stent placement between January 1994 and March 2006, 9637 
were treated with BMS, 928 with DES and 173 with both BMS and DES. All patients 
treated with BMS received dual antiplatelet dual therapy during 1 month versus 6 months 
in patients treated with DES. We identified 140 patients with angiographic ST, 118 with ST 
after BMS and 22 with ST after DES. Time of ST after stent placement is shown in Table 
1. Early ST was significantly more frequent in BMS vs DES (85/118, 72% vs 11/22, 50%, 
p = 0.049). ST in DES between 30 days and 6 months after stent implantation occurred 
in just 1 patient ST in DES compared with 26 patients with ST in BMS. In this patient both 
antiplatelet drugs were discontinuated premature. Very late ST was significantly more 
frequent in DES (7/118, 5.9% vs 10/22, 45%, p < 0.0001). 
Conclusions: These data show that very late ST after DES occurred significantly more 
frequent in DES compared with BMS. In addition, there were no ST after 30 days in DES 
while the patient was on dual antiplatelet regime.
Table 1: timing of ST after BMS vs ST after DES. * ST < 6 months 
compared with ST> 6 months
BMS DES Total
Early ST (< 30 days), n 85 11 96 p = 0.049
Late ST (30 days - 6 months), n 26 1 27
Very late ST (> 6 months), n 7 10 17
118 22 140 p < 0.0001*
7:45 a.m.
802-6 Increased Bleeding Risk Among Asians With Non-ST-
Segment Elevation Acute Coronary Syndromes: Insights 
From the CRUSADE Quality Improvement Initiative
Tracy Y. Wang, Anita Y. Chen, Matthew T. Roe, Karen P. Alexander, L. Kristin Newby, 
Sidney C. Smith, Jr., Sripal Bangalore, W. Brian Gibler, E. Magnus Ohman, Eric D. 
Peterson, Duke Clinical Research Institute, Durham, NC, University of North Carolina 
School of Medicine, Chapel Hill, NC
Background: It has been suggested that Asians may respond differently to antithrombotic 
therapy, yet contemporary management and outcomes of non-ST-segment elevation acute 
coronary syndromes (NSTE ACS) in Asian patients (pts) have not been well characterized.
Methods: Using data from the CRUSADE initiative, we compared clinical characteristics, 
treatment patterns and in-hospital outcomes of 1071 Asian and 72,513 white pts 
hospitalized with NSTE ACS.
Results: Asian pts were more likely to have hypertension, diabetes and renal insufficiency 
compared to white pts. Body mass index (BMI) was lower in Asian pts (24.9 vs. 27.8 
kg/m2, p <.0001). The use of acute medical therapies, cardiac catheterization, and 
percutaneous or surgical revascularization did not significantly differ between the two 
groups after adjustment for pt and hospital characterstics. In-hospital mortality (5.0 vs. 
4.4%, adj. OR 1.24, 95% CI 0.88-1.73) and reinfarction rates (2.0 vs. 2.3%, adj. OR 0.94, 
95% CI 0.65-1.38) were also similar. In contrast, rates of major bleeding (13.4 vs. 9.4%, 
p <.0001) and transfusion (9.6 vs. 6.6%, p = .0005) were significantly higher in the Asian 
group and persisted after adjustment for bleeding risk factors and BMI (Table).
Conclusions: Despite similar treatment, Asian pts with NSTE ACS have significantly higher 
bleeding risk even after adjustment for bleeding risk factors and BMI. Further investigation 
is needed to explore the potential for ethnic variability in antithrombotic susceptibility. 
Risk of Major Bleeding Odds Ratio 95% CI P-value
Unadjusted 1.34 1.06-1.69 0.0130
Adjusted (bleeding risk factors) 1.35 1.10-1.65 0.0042
Adjusted (bleeding risk factors + BMI) 1.32 1.08-1.62 0.0069
8:00 a.m.
802-7 AZD6140 Suppresses Platelet Aggregation in 
Clopidogrel-Treated Patients Even in Those With High 
Aggregation Levels
Robert F. Storey, Robert A. Harrington, Steen Husted, Stanley Heptinstall, Robert G. 
Wilcox, Paul A. Gurbel, Peer Grande, Mark Wickens, Gary Peters, Håkan Emanuelsson, 
Christopher P. Cannon, University of Sheffield, Sheffield, United Kingdom, Duke 
University Medical Center, Durham, NC
Background: The DISPERSE2 study compared AZD6140, the first reversible oral P2Y12 
receptor antagonist, with clopidogrel in patients with non-ST elevation acute coronary 
syndromes (ACS). In a substudy, we assessed the effect of adding AZD6140 in patients 
already treated with clopidogrel and also examined the influence of platelet aggregation 
(PA) levels before AZD6140.
Methods: 44 patients received either a loading dose of AZD6140 90, 180, or 270 mg or 
clopidogrel 75 mg. All patients had previously been treated with clopidogrel plus aspirin. 
PA was measured using ADP 20 μM and optical aggregometry pre-dose and 2, 4, 8, and 
12 h post-dose. Data were analyzed according to AZD6140 dose and as tertiles of PA 
response before any dose of AZD6140.
Results: At 4 h after the initial dose there was no fall in PA in patients who continued 
clopidogrel, whereas all AZD6140 groups showed suppression of PA. PA was suppressed 
regardless of baseline levels (Table). The highest individual PA responses at 4 h were 
66% in the clopidogrel group and 19% in all AZD6140 groups combined.
Conclusions: AZD6140 rapidly induces additional suppression of PA in patients with 
ACS currently treated with clopidogrel, even for those patients continuing to show high 
levels of PA after treatment with clopidogrel.
Mean final percentage PA before and 4 h following first dose of AZD6140 
(90-270 mg) or clopidogrel.
Tertile* Group N Final Aggregation % Change % (SD)
Pre dose 4 hours post dose
Lower
AZD6140 10 19.3 2.2 -17.2 (7.6)
Clopidogrel 3 16.3 12.5 -3.8 (5.0)
Middle
AZD6140 9 40.2 2.6 -37.7 (6.0)
Clopidogrel 7 42.1 42.9 0.8 (8.4)
Upper
AZD6140 12 62.3 7.4 -54.9 (13.3)
Clopidogrel 2 56.0 47.8 -8.3 (3.2)
*Lower tertile, <35.5% final aggregation; upper tertile, >52.5% final aggregation.
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802-8 Invasive Treatment in Non-ST Elevation Acute Coronary 
Syndrome Promotes Long-Term Health-Related Quality 
of Life: Results From the FRISC II Trial
Magnus Janzon, Johan Lyth, Lars-Åke Levin, Eva Swahn, Department of Medicine and 
Care, Linköping, Sweden
Background: Treatment strategies, either invasive or non-invasive, for patients with Non ST-
Elevation Acute Coronary Syndrome (NSTE-ACS) vary. The strategies may have different short-
term and long-term effects as well as different impact on patient’s health related quality of life.
Methods: A total of 2457 patients with NSTE-ACS were randomized to either invasive or non-
invasive treatment. We prospectively recorded the patients’ health related quality of life using two 
questionnaires, the generic Medical Outcomes Study Short Form 36 (SF-36) and the Euro-Qol 
(EQ) 5 D, at randomization and after three and six months, one, two and five years of follow-up.
Results: There was a high response rate (92%) at randomization. The invasively treated 
group showed a significantly better quality of life in all eight domains and two component 
scores at the three- and six-month follow-ups (p<0.01) than the non-invasively treated 
group. These differences remained at the twelve-month follow-up, with significance in seven 
of the domains and in the physical component score. At five years follow-up there was a 
significant better quality of life in the general health domain. I all other seven domains there 
was a trend toward better quality of life as well as in both component scores, but it did not 
reach statistical significance. The EQ 5 D index was significantly higher for the invasively 
treated group during all measurements. At five years follow-up the EQ 5 D index was 0.79 
for the invasively treated group and 0.76 for non-invasively treated group, p=0.35.
Conclusions: Patients with NSTE-ACS receiving early invasive intervention after an 
unstable episode showed improvement in health related quality of life up to the five-year 
follow-up compared to non-invasively treated patients.
ACC.SYMPOSIUM / FEATURED ORAL ABSTRACT 
PRESENTATION
615 
Assessing Overall Risk and Assessing 
Treatable Risk in the Acute Coronary 
Syndrome Patient
Monday, March 26, 2007, 9:30 a.m.-10:30 a.m.
Room 217-218-219
9:30 a.m.
615-5 Major Bleeding in Acute Coronary Syndrome Patients 
is Associated with a Marked Pro-Inflammatory 
Response: Results from the ACUITY Inflammatory 
Biomarker Sub-Study
Joseph Jozic, Steven R. Steinhubl, Roxana Mehran, W. Craig Hooper, Gregg W. Stone, 
George Dangas, University of Kentucky, Lexington, KY, Columbia University Medical 
Center, New York, NY
Background Bleeding in ACS patients has been associated with an increased adverse 
cardiac events during follow up, although the mechanism is unknown. The impact of in 
hospital major bleeding on the inflammatory response has not previously been explored.
Methods 13,819 patients were enrolled in the ACUITY Trial, randomized to a heparin 
plus GPIIb/IIIa inhibition or bivalirudin. The primary study end point was a composite of 
death, myocardial infarction, unplanned revascularization, and major bleeding at 30 days. 
186 patients were enrolled in an inflammatory biomarker sub-study. hsCRP and other 
biomarkers were measured at baseline, discharge and at 30 days by a core laboratory.
Results The median hsCRP level of the 186 patients was 3.5 mg/L at baseline, and 
increased by 1.1 mg/L on average at discharge. 11.8% of sub-study patients experienced 
a composite ischemic endpoint, with no associated change between baseline and 
discharge hsCRP. However a striking increase in hsCRP (+ 17.3 mg/L IQ range 2-111) 
was seen in the 5.9% of patients (n=11) who had a major, non-CABG bleed (p=0.0007).
Conclusions Major bleeding events in patients experiencing an ACS is associated with 
striking increases in inflammation as measured by change in hsCRP from admission 
to discharge. The heightened inflammatory response with bleeding may help explain 
increases in long-term thrombotic events in this population. 
ACC.POSTER SESSION
1013 
Myocardial Ischemia and Infarction
Monday, March 26, 2007, 9:00 a.m.-12:30 p.m.
Hall H
10:00 a.m.
1013-69 Comparison of Five Different Cardiac Troponin Assays 
in Patients with End-Stage Renal Disease on Chronic 
Hemodialysis
Lene H. Madsen, Søren D. Ladefoged, Per R. Hildebrandt, Dan Atar, Frederiksberg 
University Hospital, Frederiksberg, Copenhagen, Denmark
Background: Several studies have documented the importance of cardiac troponin 
(cTn) elevation as a prognostic marker in end-stage renal disease (ESRD) with varying 
percentages of elevated troponin concentrations (0-82%) and both in- and decrease in levels 
during hemodialysis. The reason for the elevated concentrations is not clarified, but it seems 
established that it results from myocardial release. We do not know, however, whether the 
different assays recognize the same patients within ESRD populations. The aim of this study 
was (i) to compare concentrations of troponin measured by five different assays in a cohort 
of patients on chronic hemodialysis, (ii) to investigate whether hemodialysis affects troponin 
concentrations, and (iii) to determine the prognostic potential for the different assays.
Methods: One hundred and nine patients on chronic hemodialysis were included. Serum 
cardiac troponin T (cTnT) was measured pre- and post-dialysis using Elecsys 2010 and 
troponin I (cTnI) using Access AccuTnI, AxSYM, Dimension RxL and AIA-600II.
Results: Since all of the comparative measurements in our study are performed from the 
same blood samples, i.e., identical substrates, we can be sure that the frequency of elevated 
concentrations only depends on the assay used. The cTnT assay had the highest percentage 
of elevated concentrations for all chosen cut-offs with a significant decrease in levels during 
dialysis. A significant decrease in concentration of cTnI was also seen using Access AccuTnI, 
but not for other cTnI assays. All assays correlated with each other, p<0.001, except the 
Dimension. Three assays (Elecsys 2010, AxSYM and AIA-600II) demonstrated a significant 
increased mortality with raised concentrations of troponin, p<0.001.
Conclusion: In conclusion the results of our study confirm the need for standardization of 
commercially available cTn assays with improvement of assay precision. We demonstrate 
that the diverging results in previous studies most likely are based on substantial 
differences in the analytical performance of the assays. At present, the diagnostic value 
of cTnI appears superior to cTnT, while the prognostic value of cTnT exceeds the one of 
cTnI in patients with ESRD.
10:00 a.m.
1013-70 Nicotine Patches are Safe to Use in Patients with 
Coronary Artery Disease and Stress-Induced 
Myocardial Ischemia
Monika J. Leja, James Case, Timothy M. Bateman, Ami Iskandrian, Marvin W. 
Kronenberg, Su-Min Chang, Sherif S. Iskander, Joseph A. Matthias, Kenneth R. Strahs, 
Rajesh G. Mishra, Mitchell L. Kotler, Maria E. Frias, John J. Mahmarian, Craig M. Pratt, 
The Methodist DeBakey Heart Center, Houston, TX
Background: The safety of smoking cessation with the aid of nicotine patches in patients 
(pts) with coronary artery disease (CAD) is uncertain.
Methods: We performed the first prospective multicenter randomized placebo controlled 
trial in 55 smokers (mean age 59±7 yrs) comparing the effects of nicotine patches on 
stress-induced myocardial ischemia using single photon tomography (SPECT). All pts 
had a quantified >9% stress-induced myocardial perfusion defect by SPECT, and smoked 
>20 (means 29±10) cigarettes/day. Pts were randomized to receive either 21 mg nicotine 
patches or placebo while continuing to smoke with SPECT repeated after 1 week. Pts 
were then encouraged to stop smoking, while using patches with repeat SPECT at week 
4. Nicotine and exhaled carbon monoxide (CO) levels were measured prior to each 
SPECT. The primary endpoint was the change in total PDS from baseline to week 1, 
placebo vs active patches..
Results: Active patch users showed a CO reduction which paralleled their decreased 
cigarette use. However, despite a significant increase in nicotine levels in the active group 
no significant changes in total or ischemic PDS were observed in pts randomized to 
active versus placebo patch therapy. Table statistics are treatment comparisons from 
ANCOVA with baseline as covariate.
Conclusions: Nicotine patches do not increase stress-induced myocardial ischemia and 
therefore appear to be a safe method for aiding smoking cessation in pts with CAD and 
active ischemia.
Active Patches Placebo Week 1 Week 4
Baseline Week 1 Week 4 Baseline Week 1 Week 4 p Value p Value
Total PDS (% LV) 25±16 24±15 23±15 21±10 19±10 17±10 .09 .37
Ischemic PDS (% LV) 15±11 14±11 13±9 12±7 11±8 11±8 .78 .55
Nicotine (ng/ml) 233±102 365±156 372±198 286±99 226±105 199±124 .001 .001
CO (ppm) 22±12 15±9 12±14 23±11 22±13 19±16 .02 .05
Cigarettes smoked/
day 25±8 11±7 7±9 31±15 17±14 11±13 .37 .70
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1013-71 Disruption of the Smad3 Signaling Pathway Attenuates 
Post-infarction Remodeling
Marcin J. Bujak, Guofeng Ren, Khaled Chatila, Marcin Dobaczewski, Anilkumar Reddy, 
George Taffet, Xiao-Fan Wang, Nikolaos G. Frangogiannis, Baylor College Of Medicine, 
Houston, TX, Duke University School of Medicine, Durham, NC
Optimal infarct healing requires timely activation and resolution of inflammatory pathways 
and transition to fibrous tissue deposition. TGFb regulates leukocyte recruitment, 
suppresses pro-inflammatory cytokine synthesis and promotes fibrosis by modulating 
fibroblast gene expression; these effects are mediated through activation of Smad-
dependent or Smad-independent pathways. We examined the role of Smad3 signaling 
in regulating inflammatory and fibrotic responses following myocardial infarction using 
a mouse model of reperfused infarction and isolated fibroblasts from WT and Smad3 
-/- hearts. Histological, molecular and echocardiographic endpoints were examined and 
hemodynamic parameters were assessed using left heart catheterization. In the absence 
of injury Smad3 null hearts had comparable function and similar morphology with WT 
hearts. After 7 days of reperfusion, Smad3 -/- mice exhibited lower LVEDV, showed better 
preservation of fractional shortening and decreased E-peak velocity in comparison with 
WT animals, suggesting decreased remodeling and attenuated systolic and diastolic 
dysfunction. However, infarct size was comparable between groups. Smad3 null animals 
had comparable macrophage infiltration and decreased neutrophil recruitment in the 
infarcted myocardium and showed timely repression of inflammatory gene synthesis 
and resolution of the inflammatory infiltrate. Although myofibroblast density was higher 
in Smad3 null infarcts, expression of the matricellular protein osteopontin was markedly 
lower suggesting an altered matrix synthesis profile. TGFb markedly upregulated TIMP-1 
and TIMP-2 mRNA expression by WT, but not Smad3 null cardiac fibroblasts, suggesting 
that the effects of TGFb on their matrix-degrading properties is dependent on the 
Smad3 pathway. Smad3 gene disruption results in decreased adverse remodeling and 
attenuated systolic and diastolic dysfunction following reperfused myocardial infarction 
without affecting the size of the infarct. Smad3 signaling is not crucial for repression of 
inflammatory gene synthesis in healing infarcts, but critically regulates cardiac fibroblast 
behavior and extracellular matrix metabolism.
10:00 a.m.
1013-72 Amino Acid Supplementation Differentially Modulates 
STAT1 and STAT3 Activation in the Myocardium 
Exposed to Ischaemia/reperfusion Injury
John Abboud, Joshua Martindale, Allebban Zuhair, Zhaokan Yuan, Justin Di Rezze, 
Jeffrey Putt, Karuna Chilukuri, Deepak Koul, David Patel, Riccardo Raddino, Louis 
Saravolatz, Julius Gardin, Paul Townsend, Carol Chen-Scarabelli, Tiziano M. Scarabelli, 
St John Hospital/Wayne State University, Detroit, MI, University of Michigan, Ann Arbor, MI
Background and Aims of the study: We previously showed that the transcription factor 
STAT1 plays a critical role in promoting apoptotic cell death, whereas, the related STAT3 
family member may antagonize STAT1 and protect myocytes from ischemia/reperfusion (I/
R) injury. We also documented that mixed amino acids (AA) can enhance myocyte survival 
by preserving mitochondrial functional capacity during I/R injury. Here, we investigated 
whether short-term supplementation with the same AA mixture has any effects on STAT1 or 
STAT3 activation in the Langendorff perfused rat heart exposed to I/R injury.
Methods & Results: In Sprague-Dawley rats given a single oral dose of mixed L-AA 
(1g/Kg), and exposed, after 6 hours, to 35 mins of ischemia, followed by 120 mins of 
reperfusion, AA prolonged the phosphorylative status of STAT3, while STAT1 activation 
remained unchanged. Enhanced STAT3 phosphorylation paralleled a reduction in Fas 
expression, a known STAT1 target gene and pro-apoptotic marker, which is upregulated 
following I/R. Moreover, abrogation of STAT3 activation by means of the JAK inhibitor 
AG490, reduced, though not abolished, the cardioprotective effects of amino acid 
supplementation following I/R.
Conclusions: Modulation of the functional balance between STAT3 and STAT1, with 
preferential activation of pro-survival STAT3 to the detriment of pro-apoptotic STAT1, 
represents one mechanism by means of which short-term oral supplementation with 
mixed AA protects the heart from I/R injury.
10:00 a.m.
1013-73 Failure to Prescribe Beta-Blockers in Patients with 
Sustained Ventricular Tachycardia and Ventricular 
Fibrillation Following Acute Myocardial Infarction: 
Results from the International VALIANT Registry
Jonathan P. Piccini, Patrick M. Hranitzky, Rakhi Kilaru, Jean-Lucien Rouleau, Harvey D. 
White, Philip E. Aylward, Frans Van de Werf, Scott D. Solomon, Robert M. Califf, Eric J. 
Velazquez, Duke Clinical Research Institute, Duke University Medical Center, Durham, NC
Background. Beta-blockade has been shown to decrease the incidence of sustained 
ventricular tachycardiad (VT)/ventricular fibrillation (VF), and improve survival in patients 
with impaired left ventricular function after acute myocardial infarction (AMI). We report on 
the use of beta-blockers (BB) acutely and at discharge in patients with AMI complicated 
by sustained VT/VF and heart failure (HF).
Methods. The VALsartan In Acute myocardial iNfarcTion Trial (VALIANT) Registry enrolled 
consecutive AMI patients at 84 hospitals across 9 countries between November 1999 and 
June 2001. From this registry, we determined the incidence of sustained VT/VF according to 
Killip classification, BB use in the first 24 hours and at discharge, and in-hospital mortality.
Results. Among 5391 patients in the VALIANT registry, sustained VT/VF occurred in 
306 (5.7%). The in-hospital mortality rate for patients with sustained VT/VF was 20.5%. 
Adjusted multivariate logistic regression identified sustained VT/VF as a major predictor 
of in-hospital death (OR 5.97; 95% CI, 3.73-9.61). Among those with sustained VT/VF, 
55% were treated with BB in the first 24 hours. Acute BB therapy was associated with 
a significantly decreased in-hospital death (ARR 56.5%, NNT 1.7), regardless of Killip 
classification: (RR 0.18; 95%CI, 0.13-0.25) in Killip Class I, (RR 0.24; 95% CI, 0.14-0.41) 
in Killip Class II, and (RR 0.18; 95% CI, 0.09-0.38) in Killip Class III/IV (P<0.0001 for all 
Killip classes). BB use in the acute setting was not associated with worsening HF (P=0.33). 
Patients with sustained VT/VF were also less likely to be discharged on BB therapy (59.6 
vs. 71.6%) (RR 0.60; 95% CI, 0.46-0.74; P<0.001). There was a trend toward lower rates 
of BB use with increasing Killip class (P=0.066), while patients with AMI complicated by 
HF were less likely to be discharged on BB therapy (RR 0.7; 95% CI, 0.52-0.94; P=0.007).
Conclusion. Sustained VT/VF is common following AMI. Among patients with sustained 
VT/VF, BB therapy in the first 24 hours after MI is associated with significantly decreased 
early mortality. Unfortunately, BBs are underutilized in-hospital and at discharge in 
patients with sustained VT/VF, especially in patients with HF.
10:00 a.m.
1013-74 Slowly Release a Synthetic Small Molecule: PGI2 
agonist Up-regulate Endogenous Growth Factors 
Expression and Augment Collateral Growth in Swine 
Chronic Cardiac Ischemia Model
Hiroshi Iwata, Masataka Sata, Kazuto Nakamura, Makoto Sumi, Yoshiki Sakai, Shinichi 
Takamoto, Ryozo Nagai, Department of Cardiovascular Medicine, University of Tokyo, 
Tokyo, Japan
Background: Among recent-developing strategies as the treatment of ischemic heart disease, 
small synthetic molecules are attractive because they are not so complicated to use in clinical 
practice. We identified novel PGI2 agonist; ONO1301 with unique features; a potent inhibitory-
activity against thromboxane synthesis. Furthermore, we synthesized slow-releasing ONO1301 
by processing with PLGA-polymer(ONO1301-MS). The main purpose of this pre-clinical study 
is to examine the efficacy of ONO1301-MS against ischemic heart disease.
Methods: In co-cultured endothelial cells with fibloblasts, ONO1301 enhanced both HGF 
and VEGF secretion as well as vascular-like tubular formation. Its efficacy was abrogated 
by anti-HGF and -VEGF neutralizing-antibodies. Next, efficacy of ONO1301-MS in 
chronic-ischemia model was evaluated in swine-model. After inducing chronic-ischemia 
by implanting ameroid-constrictor, ONO1301-MS was 1) directly injected by open heart 
surgery 2) trans-catheter injected through NOGA-catheter. Electro-mechanical and 
hemodynamic parameters were examined every 2 weeks. After harvest at 10 weeks, 
histological analyses were performed.
Results: ONO1301-MS significantly augmented collateral formation (ONO1301: control, 
1.34:1 in direct injection and 1.8:1 in trans-catheter). In direct injection, ONO1301-
MS improved cardiac output (ONO1301: control; 4.23±0.23: 3.16±0.15 L/min/m2) and 
left ventricular (LV) wall motion in ischemic area (ONO1301: control; 2.82:1). In trans-
catheter injection, ONO1301 significantly suppressed LV remodeling (LVEDV ONO1301:
control; 40.5±2.0mL vs. 48.7±2.1mL). ONO1301-MS also increased the capillary density 
in the ischemic tissue.
Conclusion: ONO1301-MS augmented collateral formation and improved LV function 
in swine chronic ischemia model by up-regulating endogenous growth factors. Local 
delivery of synthetic molecules might be useful in therapeutic angiogenesis.
10:00 a.m.
1013-75 Coronary Intervention Rates Following Coronary 
Angiography Without Prior Stress Testing: Results 
From the Investigation of National Coronary Disease 
Identification (INCIDENT)
James Li, Nancy L. Reaven, Susan E. Funk, Vernon F. Schabert, Joseph E. Lovett, 
Anthony N. DeMaria, Strategic Health Resources, La Canada, CA
Background: ACC/AHA Guidelines indicate that coronary angiography may be 
performed without prior stress testing for certain patients with acute anginal symptoms. 
Yet, few data are available regarding this diagnostic strategy’s yield of patients in need 
of percutaneous (PCI) or surgical (CABG) coronary intervention. Using a very large 
database comprising 2% of the U.S. adult population, we measured rates of coronary 
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angiography and subsequent intervention in patients presenting with acute anginal 
symptoms who underwent the recommended Guideline-specified tests without stress 
prior to angiography.
Methods: Our study population of commercial and Medicare enrollees numbered 4,355,625. 
Entry criteria included age over 44 years; continuous enrollment from 2001-2003 excepting 
death; a cardiac test with a diagnosis of coronary disease, heart failure, or a related cardiac 
symptom in 2001; evaluation for acute anginal symptoms with an ECG followed by CXR or 
echo; and subsequent evaluation with a third test. Exclusions included any cardiac diagnostic 
test or intervention in the 6 months prior to the initial ECG. We calculated the proportion of 
patients who underwent diagnostic coronary angiography as well as PCI or CABG within 60 
days of angiography. We further stratified these results by patient characteristics.
Results: 4,062 patients met entry and exclusion criteria. 48% were male, 37% were over 
64 years of age, 31% had diabetes and 72% had hypertension. Of patients undergoing 
the recommended test sequence, 13% (95% confidence interval [CI] 12-14%) were next 
sent for coronary angiography without stress testing. Of this group, 40% (CI 36-44%) did 
not receive PCI or CABG within 60 days. Men were more likely than women to receive 
PCI or CABG (68% vs. 48%, risk ratio [RR] 1.38 CI for RR 1.20-1.59).
Conclusions: In this study group drawn from a retrospective database of over 4 million 
patients, nearly half of patients presenting with acute anginal symptoms who underwent 
coronary angiography without stress testing did not receive either CABG or PCI. Even in 
presumed high-risk populations, these findings suggest that coronary angiography may 
not be preferable to stress testing early in diagnostic evaluation.
10:00 a.m.
1013-90 Cardiac Release Of Urocortin Precedes The Occurrence 
Of Irreversible Myocardial Damage In The Rat Heart 
Exposed To Ischemia/reperfusion Injury
Carol Chen-Scarabelli, Joshua Martindale, John Abboud, Zhaokan Yuan, Zuhair 
Allebban, Justin Di Rezze, Riccardo Raddino, Louis Saravolatz, Julius Gardin, Paul 
Townsend, Tiziano M. Scarabelli, St John Hospital/Wayne State University, Detroit, MI, 
University of Michigan, Ann Arbor, MI
Background And Objectives: Urocortin is a cardioprotective peptide released from 
cultured myocytes following hypoxia/reoxygenation.This study was aimed at evaluating 
whether cardiac ischemia can induce systemic release of urocortin.
Methods: Sprague-Dawley rats were exposed ex vivo or in vivo to 5, 10, 20 or 
30 min ischemia, followed by 2 hour reperfusion. CPK release was measured 
spectrophotometrically. Myocyte urocortin expression and apoptosis were assessed 
by immunocytochemistry, while urocortin release into perfusate and plasma by 
radioimmunoassay.
Results: Perfusate and plasma urocortin levels, which were undetectable in all normoxic 
hearts, significantly rose after 5 min ischemia, peaked after 10 min ischemia, and 
progressively diminished after 20 and 30 min ischemia (e.g. 63±9, 116±13, 48±7 and 
25±3pg/ml respectively following ex vivo ischemia). Likewise, 5 and 10 min ex vivo 
ischemia induced urocortin overexpression in cardiac cells (35±3.8% and 52±6.2% 
positive cells vs 12±2.2% in controls), while myocyte apoptosis and necrosis were not 
observed. Conversely, following 20 and 30 min ex vivo ischemia, the occurrence of 
myocyte apoptosis (6.3±1.2% and 8.9±2.3% respectively) and necrosis (CPK release: 
683±54.2 and 1028±85.9 mU/mon/gww respectively) paralleled a progressive reduction 
in myocyte expression of urocortin (24±1.8% and 18±3.2%), suggesting that cardiac 
expression and release of urocortin is mainly sustained by myocytes metabolically 
challenged, though still viable.
Conclusions: In hearts undergoing ischemia/reperfusion, cardiac release of urocortin, 
unlike that of conventional biomarkers, appears to take place before the occurrence of 
cell death, being primarily achieved by viable myocytes in metabolic distress. Hence, 
urocortin may be clinically useful as a potential marker of sublethal myocardial ischemia.
10:00 a.m.
1013-91 ALOX5AP Genetic Variants are Associated with In-Stent 
Restenosis After Percutaneous Coronary Intervention
Svati H. Shah, Elizabeth R. Hauser, Charlotte Nelson, Simon Gregory, David Crosslin, 
Carol Haynes, Jessica Johnson, David Seo, William E. Kraus, Christopher B. Granger, 
Pascal Goldschmidt-Clermont, L. Kristin Newby, Duke University Medical Center, 
Durham, NC
Background: Routine use of drug-eluting stents (DES) during percutaneous coronary 
intervention (PCI) has virtually eliminated instent restenosis (ISR); however, DES are 
associated with late stent thrombosis. There is no accurate way to predict who will suffer from 
ISR, although clinical risk factors for atherosclerosis overlap those for development of ISR. 
We hypothesized that candidate genes for atherosclerosis would be associated with ISR.
Methods: From the Duke cardiac catheterization lab, we identified 50 consecutive cases 
that had undergone PCI with bare-metal stents in a non-urgent setting, who subsequently 
developed symptomatic ISR of the target lesion (≥75% luminal narrowing) within 6 months 
post-procedure. Fifty controls were identified that had also undergone PCI with bare-
metal stent, but who did not have ISR within 6 months, matched on race, sex and age. 
We genotyped a total of 128 single-nucleotide polymorphisms (SNPs) from 73 candidate 
genes identified from a study of atherosclerosis and 11 genes identified from the literature 
as associated with ISR. SNPs were genotyped using the Taqman assay. Logistic regression 
models adjusted for cardiovascular risk factors were used to test for association.
Results: Cases and controls were closely matched by race, sex and age. ISR cases had a 
higher prevalence of diabetes, and more often had atherosclerosis in other coronary vessels 
than controls, but other clinical factors were similar. Six SNPs were significantly associated 
(p<0.05) with ISR. Three SNPs in the ALOX5AP gene were the most strongly associated, two 
of which were associated with increased risk (OR 3.7, p-value 0.01; OR 3.46, p-value 0.02), 
and the third of which was protective against ISR (OR 0.07, p-value 0.004). The three other 
SNPs resided in the ROR2, IGSF11 and GLB1 genes (p-values 0.01-0.04).
Conclusions: ALOX5AP, a gene within the inflammatory leukotriene pathway which has 
been linked to and associated with coronary atherosclerosis, is also associated with ISR. 
Genotyping these variants may help identify those at risk for ISR who would benefit most 
from use of DES.
10:00 a.m.
1013-92 How Likely Are Therapeutic Interventions 
Recommended by the 2002 ACC/AHA Clinical 
Guidelines for Acute Coronary Syndromes to be 
Clinically Worthwhile?
Shervin Eshaghian, Sameer Amin, Prediman K. Shah, George A. Diamond, Sanjay 
Kaul, Cedars Sinai Medical Center, Los Angeles, CA
Background Clinical guidelines align treatment recommendations to the strength of published 
empirical evidence as determined by conventional tests (P values, CIs) that rely heavily on 
statistical significance but provide little guidance with respect to clinical importance.
Objective A reappraisal, in terms of both statistical & clinical significance, of clinical trial evidence 
underlying the 2002 ACC/AHA treatment guidelines for acute coronary syndromes (ACS).
Guideline
(# of trials)
Sample
size Summary OR (95% CI) P-value Delta value
Pr
δ>0%
Pr
δ>10%
Pr
δ>20%
Pr
δ>30%
Pr (Delta
value)
Aspirin vs Placebo
(4) 2,856 0.40 (0.30-0.52) <0.01 50% 100% 100% 100% 100% 89%
UFH +ASA
vs
Placebo + ASA (6)
1,353 0.72 (0.50-1.05) 0.09 50% 96% 86% 65% 34% 0%
LMWH+ASA
vs
Placebo + ASA (1)
1,498 0.36 (0.19-0.68) <0.01 50% 100% 100% 99% 98% 84%
LMWH+ASA
vs
UFH+ASA
(4)
10,506 0.89 (0.76-1.05) 0.16 40% 91% 50% 6% 0% 0%
Clopidogrel
+ASA vs ASA
(1)
12,562 0.81 (0.71-0.91) <0.01 17% 100% 95% 33% 0% 58%
GPI+ASA+ Hep vs 
ASA+Hep
(6)
28,745 0.91 (0.85-0.98) 0.01 35% 99% 22% 0% 0% 0%
Early Invasive vs 
Early Conservative
(6)
9,057 0.95 (0.73-1.24) 0.72 31% 64% 31% 7% 0% 0%
Methods Class I, Level A recommendations (best-case scenario) were analyzed. 
Posterior probabilities (Pr) that the relative risk difference in death or MI is greater than the 
putative threshold value for clinical importance (δ>0% to 30%) and the “delta value” used 
for sample size estimation were derived from a Bayesian analysis using an uninformative 
prior and the empirical evidence summarized as a random-effects meta-analytic odds 
ratio (OR) of the clinical trial data.
Results Pr was >97.5% for δ>0% (equivalent to P<0.05) for 4 (ASA, LMWH, Clopidogrel, 
GPI); and for δ>10% to >30% for 2 (ASA, LMWH). Pr of delta value exceeded 50% in only 
3 (ASA, UFH, LMWH) and was 0% for GPI despite a significant P value.
Conclusions Probability of a clinically important difference is far less than that implied 
by conventional statistical significance for 5 of 7 guideline recommendations. Bayesian 
analysis helps make judgments about the clinical importance of medical interventions and 
should thereby complement the latter in development of practice guidelines. 
10:00 a.m.
1013-93 Left Ventricular End Diastolic Pressure is a Predictor 
of Suboptimal Myocardial Reperfusion in Patients 
Undergoing Percutaneous Coronary Intervention for 
ST-Elevation Myocardial Infarction
Scott J. Haugen, Gregg W. Stone, Roxana Mehran, Alexandra J. Lansky, Mitchell W. 
Krucoff, John Webb, David A. Cox, Bruce R. Brodie, John D. Carroll, JoAnn Lindenfeld, 
University of Colorado Health Sciences Center, Denver, CO
Background: Microvascular perfusion after PCI is an important predictor of outcomes in 
AMI. By reducing coronary flow, elevated LV end diastolic pressure (LVEDP) may contribute 
to suboptimal microvascular reperfusion; this hypothesis has never been examined.
Methods: EMERALD was a prospective, randomized, trial of distal protection during 
primary PCI in AMI. LVEDP was measured in 428 pts prior to PCI. Myocardial blush and 
ST segment resolution (STR) were assessed by independent core labs as markers of 
myocardial perfusion, and infarct size (ISz) was measured by tc-99m-sestamibi at 5-14 
days. Results were stratified by LVEDP tertiles.
Results: Median pre PCI LVEDP was 14 (11-16), 20 (19-22), and 27 (25-32) mmHg in 
the low, mid and high tertiles respectively. As seen in the Table, there was no relationship 
212A    ABSTRACTS - Myocardial Ischemia and Infarction  JACC  March 6, 2007 
M
yo
ca
rd
ia
l I
sc
he
m
ia
 a
nd
 I
nf
ar
ct
io
n
between baseline LVEDP and restoration of TIMI-3 flow or corrected TIMI frame counts 
(cTFC). Absent post-PCI myocardial perfusion (blush 0/1), however, and incomplete STR 
(<70%) at 30 mins strongly correlated with LVEDP. ISz was also significantly larger in pts 
with elevated pre-PCI LVEDP, and a strong trend was present for increased mortality.
Conclusion: There is a strong association between baseline LVEDP, suboptimal 
microvascular reperfusion, and ISz after primary PCI, independent of epicardial coronary 
flow. These data warrant studies of agents which reduce LVEDP to enhance myocardial 
salvage and clinical outcomes after primary PCI in AMI. 
Low LVEDP Mid LVEDP High LVEDP P
TIMI-3 91.9% 90.8% 91.0% 0.94
cTFC (median) 19 (14-26) 20 (14-25) 20 (15, 30) 0.26
Blush 0/1 12.1% 12.7% 25.0% 0.007
STR% <70% at 30 mins 29.9% 33.6% 43.9% 0.04
Infarct size (median) 7 (0-16) 10 (0-20) 15.5 (3-34) 0.0004
Death at 6 months 1.4% 1.6% 6.0% 0.06
10:00 a.m.
1013-94 A Risk Score to Predict Sudden Cardiac Death in 
Patients with ST-Elevation Myocardial Infarction
Jessica L. Mega, Sabina Murphy, David A. Morrow, Carolyn H. McCabe, Elliott M. 
Antman, Eugene Braunwald, C. Michael Gibson, TIMI Study Group, Boston, MA
Background: A risk score to predict sudden cardiac death (SCD) after fibrinolytic therapy 
for STEMI could assist with the management of patients who survive the initial 48 hours.
Methods: 45,369 patients in TIMI STEMI trials were used to derive & validate the TIMI 
SCD risk score.
Results: SCD occurred in 246 patients at a median of 9 days after the index MI (IQR 
5-15 days). Of 20 variables, 10 remained associated with SCD in a multivariable model 
from which a risk score for SCD was created: age 65-74 (OR 2.30, p<0.001), age ≥75 
(OR 3.90, p<0.001), creatinine >2 mg/dL (OR 2.96, 0.001), heart rate >100 beats per 
minute (OR 2.37, p<0.001), non-Caucasian race (OR 2.19, p<0.001), Killip class II-IV 
(OR 2.03, p<0.001), anterior MI (OR 1.65, p<0.001), prior diabetes (OR 1.39, p=0.04), 
prior hypertension (OR 1.36, p=0.03), and prior angina (OR 1.32, p=0.05). Applying the 
risk score, there was a significant 40-fold risk gradient from the lowest to highest score 
(p<0.0001, Figure). The SCD risk score demonstrated a good predictive capacity in the 
derivation cohort (c statistic 0.75). Using a bootstrap analysis, in which the cohort was re-
sampled 1,000 times with replacement, the mean c statistic was 0.75 +/- 0.016.
Conclusion: After the initial 48 hour period post-STEMI, a risk score based on clinical 
variables can be used to estimate the risk of SCD. The use of this risk score may be 
helpful in guiding medical and device-based therapies.
10:00 a.m.
1013-95 Impact Of A Guidelines Based Protocol To Improve 
Timeliness Of Reperfusion Therapy And In-hospital 
Outcomes
Henry H. Ting, Luis H. Haro, Bernard J. Gersh, Christine M. Bjerke, Choon-Chern Lim, 
Ryan J. Lennon, John F. Bresnahan, Allan S. Jaffe, David R. Holmes, Malcolm R. Bell, 
Charanjit S. Rihal, Mayo Clinic, Rochester, MN
Background: Patients with ST-elevation myocardial infarction (STEMI) experience 
delays in timeliness of reperfusion therapy. In 2003 at Mayo Clinic Rochester, Minnesota, 
median door-to-balloon (DTB) time was 98 minutes and 202 minutes, respectively for 
patients presenting to the emergency department (ED) or to regional hospitals (RH) 
without onsite percutaneous coronary intervention (PCI).
Methods: We implemented a guidelines based Fast Track protocol and treated 417 
consecutive patients from 2004 to 2006. Key system improvements included: ED or 
RH physician activation of catheterization lab and transport with a single call, standard 
protocol for reperfusion therapy, and prospective data collection and review. Patients 
presenting to ED were treated with primary PCI (ED PCI). Patients presenting to one 
of 25 RH located within 120 nautical miles from Rochester were treated with fibrinolysis 
(LYTIC) if symptom duration was < 3hours (RH LYTIC) and with primary PCI if symptom 
duration was > 3hours (RH PCI).
Results: Mean age was 62.8 + 14.1 (range 18-90) and 75% were male. DTB, door-to-
needle (DTN), and in-hospital outcomes for each subgroup are shown in the Table. 
ED PCI
n=195
RH PCI
n=99
RH LYTIC
n=123 P
DTB, median (minutes) 67 117 --
DTB <90 minutes 82% 13% --
DTN, median (minutes) -- -- 28
DTN <30 minutes -- -- 63%
Death 8 (4.1%) 6 (6.1%) 2 (1.6%) 0.22
Death or myocardial infarction (MI) 11 (5.6%) 8 (8.1%) 10 (8.1%) 0.61
Death, MI, or stroke 11 (5.6%) 9 (9.1%) 12 (9.8%) 0.34
Conclusions: Implementing a guidelines based protocol for STEMI improved DTB and 
DTN for patients presenting to ED with on-site PCI or to RH without on-site PCI. RH patients 
with symptom duration <3 hours treated with fibrinolysis have low in-hospital mortality 
(1.6%) and may not benefit from immediate transfer for primary or facilitated PCI.
10:00 a.m.
1013-96 Incidence and Clinical Relevance of Right Bundle-
Branch Block in Patients with ST and Non-ST Elevation 
Myocardial Infarction
Thomas Kleemann, Claus Juenger, Anselm K. Gitt, Rudolf Schiele, Steffen Schneider, 
Jochen Senges, Karlheinz Seidl, Herzzentrum, Ludwigshafen, Germany
Background: Left bundle branch block has been associated with poor outcome in 
patients with myocardial infarction. However, the prognostic role of right bundle branch 
block (RBBB) in acute ST elevation (STEMI) and Non-ST elevation myocardial infarction 
(NSTEMI) is not well known. Aim of the study was to evaluate the incidence and clinical 
relevance of RBBB in patients with acute STEMI and NSTEMI.
Methods: From the German prospective multicenter registries “Maximal Individual Therapy of 
Acute Myocardial Infarction” (MITRA PLUS) 20,233 consecutive patients with STEMI and 6,403 
patients with NSTEMI were analyzed. Patients with left bundle branch block were excluded.
Results: 894 (4%) patients with STEMI and 455 (7%) patients with NSTEMI 
presented with RBBB. 
Baseline characteristics, acute inhospital treatment and 1-year mortality (*p<0.05)
STEMI: RBBB
N= 894
STEMI:
No BBB
N= 9339
NSTEMI: RBBB
N= 455
NSTEMI
No BBB
N= 5948
Age (years) 71 66* 73 69*
Female 28% 32%* 23% 35%*
Diabetes 28% 23%* 36% 30%*
Prior MI 21% 15%* 29% 25%*
Cardiogenic shock 16% 6.6%* 8% 4%*
Acute reperfusion 57% 70%* 21% 33%*
Beta Blocker 71% 80%* 78% 85%*
Statins 51% 59%* 69% 75%*
1-year mortality 19% 9.2%* 13.6% 10.9% (ns)
Conclusions: 1. 4% of patients presenting with STEMI and 7% with NSTEMI have a 
RBBB. 2. Patients with RBBB are older, have increased comorbidities and less often 
receive optimal acute inhospital treatment. 3. In STEMI, patients with RBBB have a 
doubled 1-year mortality rate whereas in NSTEMI there is no difference in outcome for 
patients with RBBB compared to those without RBBB.
10:00 a.m.
1013-111 Severity of Coronary Artery Disease in Obese Patients 
Undergoing Coronary Angiography and Intervention; 
“Obesity Paradox” revisited
Ashutosh Niraj, Jyotiranjan Pradhan, Vikas Veeranna, Hisham Fakhry, Luis C. Afonso, 
Wayne State University/Detroit Medical Center, Detroit, MI
Background: Recent studies conducted overseas have emphasized the existence of an 
‘obesity paradox’ in patients undergoing coronary angiography, i.e. obese patients have less 
severe coronary artery disease (CAD) and better outcomes compared to lean patients. We 
sought to explore the association of body mass index (BMI) and CAD burden in US patients.
Methods: We analyzed data from 770 consecutive patients (61 % males, 55.6 % African 
Americans, 27.5 % Caucasians) referred for coronary angiography or intervention to 
Harper University Hospital, a tertiary referral center in Detroit, MI. Duke myocardial 
jeopardy (DMJ) score, a validated prognostication tool (predictive of 1-year mortality 
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in patients treated medically or with percutaneous intervention), was assigned to 
angiographic data (based on disease burden). The frequency of high-risk coronary 
anatomy (HRCA) defined as ≥ 50 % stenosis of the left main coronary artery and/or 
significant 3-vessel (≥70 % narrowing) was also assessed. BMI was calculated as weight 
(kgs) divided by the square of height (meters) 
Results: Mean BMI of the study cohort was 30.1 ± 6.1 kg/m2, and ranged from 18.8 to 54.8 
kg/m2. Obese patients (BMI ≥30.0 kg/m2, WHO criteria) referred for coronary procedures 
tended to be younger (58.8 ± 11.5 vs. 62.2 ± 12.1 yrs respectively, p < 0.001), were more 
likely to have diabetes (41.1 % vs. 28.6%, p< 0.001) and had a lower prevalence of HRCA 
(17.7 % vs. 23.1 %, p<0.05) compared to their non obese comparators (BMI < 30 kg/m2). 
A negative correlation was observed between BMI and age (r = - 0.15, P<0.001) as well as 
between BMI and DMJ score (r = - 0.07, p<0.05) indicating that patients with higher BMI’s had 
a lower CAD burden and were being referred for coronary angiography at a younger age.
Conclusions: In our study cohort, BMI appeared to be inversely related to CAD burden, 
based on DMJ scores. Obese patients also had a lower prevalence of HRCA. DMJ 
scores provide independent prognostic information in patients with CAD undergoing 
conservative management or percutaneous intervention. Although we did not assess 
survival patterns in this study, our observations lend further credence to the existence of 
an “obesity paradox” in our society.
10:00 a.m.
1013-112 Left Ventricular Apical Ballooning Syndrome in an 
European Population : Results of a Multicenter Italian 
Registry.
Alessandra Repetto, Mario Previtali, Luigi Ascione, Elisa Baldini, Giorgio Baralis, 
Francesco Della Rovere, Francesco Di Pede, Marco Ferlini, Stefania Panigada, Luigi 
Piatti, Jorge A. Salerno, Paolo Sganzerla, Luigi Vignali, Rita Camporotondo, Luigi 
Tavazzi, Multicenter Italian Registry on Apical BallooningSyndrome, Department of 
Cardiology, IRCCS Policlinico San Matteo-University of Pavia, Pavia, Italy
Background: Left Ventricular Apical Ballooning Syndrome (LVABS) is an acute cardiac 
syndrome whose pathogenesis and prognosis is not well defined. To assess the 
characteristics and the prognosis of LVABS in an European population, we performed 
a multicenter observational study.
Methods: 55 pts who fulfilled the diagnostic criteria for LVABS were studied. All pts 
underwent coronary angiography and LV angiogram within 48 hours from symptoms; 
36/55 pts were followed-up for a median time of 11.5 months.
Results: All pts were women aged 69±9 years; chest pain was the presenting symptom 
in 94%. An emotional or physical trigger was identified in 24 pts (44%) . Admission ECG 
showed anterior ST-elevation in 28 patients (51%), negative T-waves in 25 (45%), ST-T 
abnormalities in 2 (4%). Peak CK-MB and Troponin I were 28±14 mU/ml and 1.9±1.5 
ng/ml. At LV angiography 45 pts (82%) showed apical and 10 (18%) mid-ventricular 
ballooning. A dynamic LV gradient (range 20-95 mmHg) was recorded in 5 pts (9%). LV 
ejection fraction was 44±9% in the acute phase and improved to 55±10% at discharge. 
An abnormal (>27 frames) TIMI frame count (TFC) in left anterior descending (LAD), 
circumflex (CX) and right coronary artery (RCA) was present in 63, 58 and 39% of pts; 
mean TFC was 31±17 in LAD, 31±12 in CX and 27±13 in RCA. Major complications 
occurred in 6 pts (11%) including cardiogenic shock in 1 and LV failure in 5. Ergonovine 
Echo performed in 12 pts was negative in all cases. Dobutamine Echo induced a dynamic 
LV obstruction in 4/22 pts (18%). During follow-up non-cardiac death occurred in 1 pt, 
recurrences in 3, heart failure in 1, and stroke in 1.
Conclusions: 1) In an European population LVABS affects post-menopausal women, and is 
triggered by a physical or emotional stress in 45% of pts ; 18% of pts show a variant form with 
mid-ventricular ballooning. 2) Major complications related to LV failure occur in 10% of pts, but 
the short and medium-term prognosis is good with no cardiac death and rare recurrences; 3) 
Increased TFC suggests that a microvascular coronary dysfunction can play a pathogenetic 
role; 4) Negative ergonovine test suggests that coronary spasm is unlikely to be involved, 
while dynamic LV obstruction may play a role in a small subset of pts.
10:00 a.m.
1013-113 Early and Late Improvement of Left Ventricular Function 
after Drug Eluting Stent Implantation for Chronic Total 
Occlusions
Sharon W. Kirschbaum, Timo Baks, Robert-Jan M. van Geuns, Gabriel P. Krestin, Patrick 
W. Serruys, Pim J. de Feyter, Erasmus Medical Center, Rotterdam, The Netherlands
Background: The long-term effect of recanalisation of a chronic total coronary occlusion 
(CTO) on left ventricular function and volumes is currently unknown. Therefore, we 
studied the effect of drug-eluting stent implantation for CTO on left ventricular function 
and volumes at 5 months and 3 years follow-up.
Methods: MRI was performed in 20 patients before successful drug-eluting stent 
implantation for CTO and at 5 months and 3 years after recanalisation. Segmental wall 
thickening and left ventricular volumes and function were quantified on cine-images, and 
the transmural extent of the infarction (TEI) was scored on delayed enhancement images.
Results: A significant decrease in mean end-diastolic volume index (87±14 ml/m2 to 80±14 
ml/m2; p=0.03) and mean end-systolic volume index (36±12 ml/m2 to 31±13ml/m2; p=0.03) 
was observed three years after drug-eluting stent implantation. Mean ejection fraction 
tended to improve (60±8% to 61±10%; p=0.11). At 5 months, segmental wall thickening was 
improved significantly in segments with < 25% TEI (20±21% to 49±31%; p=0.003), tended to 
improve in segments with 25%-75% TEI (17±20% to 26± 21%; p=0.06) whereas segments 
with > 75% TEI did not improve (14±21% to -2±23%; p=0.30). Interestingly, at 3 years follow-
up a further increase in segmental wall thickening was observed in segments with < 25% TEI 
(to 71±51%; p=0.008) and in segments with 25%-75% TEI (to 50±46%; p=0.005) whereas 
segments with > 75% TEI remained severely dysfunctional (13±49%; p=0.94).
Conclusions: Left ventricular function improves after drug eluting stent implantation for CTO. 
Improvement in left ventricular function is seen in up to three years after recanalisation.
10:00 a.m.
1013-114 Non-ST-Segment Elevation Acute Coronary Syndrome 
Patients on Chronic Warfarin Anticoagulation: Care and 
Outcomes
Tracy Y. Wang, Anita Y. Chen, Eric D. Peterson, Richard C. Becker, E. Magnus Ohman, 
W. Brian Gibler, Matthew T. Roe, Duke Clinical Research Institute, Durham, NC
Background: Clinical trials of antithrombotic and invasive therapies in non-ST-segment 
elevation acute coronary syndromes (NSTE ACS) have generally excluded patient (pts) 
on chronic warfarin anticoagulation.
Methods: We examined pts with NSTE ACS in the CRUSADE initiative during 2003-
2006. Logistic generalized estimating equations (GEE) method was used to evaluate the 
association between chronic warfarin use and outcomes.
Results: Among 101,078 pts with NSTE ACS, 7201 (7%) were on chronic warfarin therapy 
at admission. Pts on warfarin were older with more comorbidities (hypertension, diabetes, 
renal disease, prior MI or stroke). They were less likely to receive acute antithrombotic 
medications or undergo invasive cardiac procedures (Table) and had longer waiting 
times to procedures (median time to cath 50 vs. 24 hrs, p <.0001). In-hospital mortality 
(5.9 vs. 4.1%, p <.001) was higher among pts treated with chronic warfarin vs. not; but 
this difference was not significant after adjustment (OR 0.90 [0.90-1.02]). However, non-
CABG-related transfusion rates were higher among pts on chronic warfarin (13.2 vs. 
9.0%, OR 1.09 [1.00-1.19]).
Table. Use of acute (<24 hours) medications and  
invasive cardiac procedures
Warfarin (%) No Warfarin (%) Adjusted OR [95% CI]
Aspirin 90.6 95.9 0.52 (0.46-0.57)
Heparin (LMW or 
unfractionated) 74.9 88.3 0.46 (0.42-0.50)
Clopidogrel 37.7 55.6 0.53 (0.50-0.56)
Glycoprotein IIb/IIIa inhibitors 25.5 47.6 0.57 (0.53-0.61)
Beta-blockers 88.3 89.6 0.92 (0.85-1.00)
Catheterization (within 48 hrs) 37.8 65.2 0.45 (0.41-0.48)
PCI (within 48 hrs) 20.4 42.1 0.56 (0.51-0.61)
CABG 7.3 12.5 0.68 (0.60-0.77)
LMW = low-molecular weight; PCI = percutaneous coronary intervention; CABG = 
coronary artery bypass grafting
Conclusions: Pts on chronic warfarin represent a challenging high-risk NSTE ACS 
population for whom there are limited trial data to base management strategies. Despite 
less aggressive antithrombotic and invasive management, transfusion risks remain 
elevated. Further studies are needed to determine an optimal treatment strategy that 
minimizes bleeding risk. 
10:00 a.m.
1013-115 Effects of Metabolic Syndrome on Pattern of Acute 
Coronary Syndromes
Isabella Tritto, Erberto Carluccio, Paolo Biagioli, Maurizio Bentivoglio, Ketty Savino, 
Gianfranco Alunni, Elena Settimi, Giuseppe Ambrosio, Division of Cardiology, University 
of Perugia School of Medicine, Perugia, Italy
Background: Metabolic syndrome (MS) is a cluster of metabolic risk factors (abdominal 
obesity, hypertension, atherogenic dyslipidemia, and insulin resistance), the concomitant 
presence of which increases by several folds the risk of cardiovascular disease. These 
patients are also at increased risk of developing acute coronary syndromes (ACSs). 
However, recent studies have challenged this notion, as they show that, among patients 
with ACSs, obese and overweight subjects have a reduced incidence of death and 
reinfarction in comparison with normal subjects, thereby questioning the true prognostic 
value of obesity and MS in this setting. ACSs encompass two patterns: ST-elevation 
myocardial infarction (STEMI), typically characterized by complete coronary occlusion by 
blood clot, and non-ST elevation myocardial infarction/unstable angina (NSTEMI/UA), in 
which acute ischemia is typically induced by platelet-rich thrombi. These two conditions 
require different therapeutic strategies and may also entail different prognosis. Since MS 
is accompanied by a pro-thrombotic state, we hypothesized that this may alter thrombus 
generation/composition, and thus shift towards one type of ACS over the other.
Methods: From 1995 to 2002 a total of 1,311 consecutive patients were admitted to our 
Cardiology Division with a diagnosis of ACS; of these, 396 patients (30.2%) fulfilled the 
diagnostic criteria for MS.
Results: Patients with MS showed an increased frequence of NSTEMI/UA (56.6% 
vs 48.6%; p<0.01), and concomitant reduced incidence of STEMI ((43.4% vs 51.4%; 
p<0.01). They also showed reduced incidence of in-hospital complications (32.4% vs 
39.5%; p<0.01) and in-hospital mortality (2.3% vs 4.7%; p<0.05). At multivariate analysis, 
MS was an independent predictors of NSTEMI/UA, together with history of myocardial 
infarction, and pre-admission therapy with statins or aspirin.
Conclusions: In patients with ACS, presence of Metabolic Syndrome may favor NSTEMI/
UA over STEMI. This observation is consistent with the reduced incidence of in-hospital 
complications and mortality, and may contribute to explain the controversial data about 
the prognostic value of obesity and MS.
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1013-116 Cost and Effectiveness Comparison of Very Early 
Treatment With Primary Percutaneous Coronary 
Intervention Facilitated With Abciximab or Thrombolytic 
Therapy for Acute ST-Elevation Myocardial Infarction.
Magnus Janzon, Mikael Aasa, Johan Lyth, Leif Svensson, Johan Herlitz, Lars Grip, 
Lars-Åke Levin, Department of Medicine and Care, Linköping, Sweden
Background: Prospective randomized trials comparing reperfusion by primary 
percutaneous coronary intervention (PCI) with thrombolytic therapy have documented 
superior clinical outcomes with PCI. On the other hand primary PCI is more costly than 
thrombolytic therapy. Modern adjunctive antithrombotic treatment may improve the 
outcome, compared with what was achieved in previous studies, but will also increase 
the costs. There are no published randomized clinical trials comparing the costs and 
effectiveness of the different early treatment strategies.
Methods: Patients with ST-elevation myocardial infarction were randomized to enoxaparin 
followed by abciximab prehospital if possible and immediate transfer for optional PCI (n 
= 101) or to receive enoxaparin followed by reteplase (n = 104). Health care resources 
(hospitalizations, investigations, interventions, outpatient visits and pharmaceuticals) 
were collected for 1 year as well as utility weight by the EuroQol 5 D at randomization, at 
1 month and 12 months.
Results: At one year follow-up the mortality was 5.0 % in the PCI group and 7.7 % in the 
thrombolytic group, n.s. The cost for interventions was significantly higher in the PCI group 
5 919 € versus 4 043 €, p < 0.001. The cost for hospitalizations was significantly lower in 
the PCI group 6 428 € versus 8 210 €, p = 0.03 as well as the cost for pharmaceuticals 
1 016 € versus 1 308 €, p < 0.001. There were no significant differences in costs of 
investigations or outpatient care. The total health care cost for the PCI group was 16 507 
€ and 16 569 € for the thrombolytic group, n.s.
The average QALY during first year was 0,757 in the PCI group and 0,730 in the 
thrombolytic group. The difference was not statistically significant.
Conclusions: Despite very high immediate costs in the primary PCI group the difference 
completely disappeared during the one year follow-up. There was a tendency toward a 
gain in QALY in the primary PCI group. The long-term cost-effectiveness needs to be 
assessed in an analytical decision framework.
10:00 a.m.
1013-117 Assessment of Efficacy with Allogenic Mesenchymal 
Precursor Cells: A Targeted Translational Model of 
Acute MI.
Marlos R. Fernandes, Guilherme V. Silva, Edie M. Oliveira, Ricardo Sanz-Ruiz, Pilar 
Jimenez-Quevedo, Franca S. Angeli, Yi Zheng, Fred A. Baimbridge, John Canales, 
Cristiano O. Cardoso, Silviu Itescu, James T. Willerson, Emerson C. Perin, Texas Heart 
Institute, Houston, TX
Background: Early reperfusion remains the primary objective in the treatment of acute 
MI. However, myocardial salvage cannot always be achieved. We sought to evaluate 
the effect of transendocardial injections of mesenchymal precursor cells (MPC) 
following acute MI.
Methods: Balloon occlusion of the distal left anterior descending (LAD) coronary artery for 
90 min was performed in 14 sheep, followed by passive reperfusion. Five days after MI, 
15.8±0.9 transendocardial NOGA guided injections of 225 x106 MPC vs cell carrier were 
performed in the viable myocardium at the border of the MI. Immunosuppressant therapy 
was not administered. Left ventricular ejection fraction (LVEF) was assessed before 
MI, at cell injection and at 8 weeks follow-up (f/u) after cell therapy, by left ventricular 
angiography. Histopathological analysis was performed to evaluate inflammation at the 
injection sites. Comparison between groups was performed by two tailed unpaired t test.
Results: A total of 5 treated and 4 control animals survived MI. Both groups had similar 
LVEFs at 5 days after MI (51.4±6.1% vs 53.3±4.6%, respectively - p=0.19). At f/u, control 
animals had significant deterioration of LVEF when compared with the treated animals 
(fig). There was no inflammation present at the injected sites.
Conclusions: These preliminary data suggest that transendocardial injection of allogenic 
MPC 5 days after MI is safe. MPC injections precluded LVEF deterioration after MI. 
Further efficacy evaluation is warranted. 
10:00 a.m.
1013-132 Influence of Recurrent Myocardial Infarction on 
Mortality Risk in Patients on Contemporary Therapy 
Following a Myocardial Infarction: The VALIANT Trial
Jens J. Thune, James E. Signorovitch, Larsr Kober, Robert M. Califf, John J.V. 
McMurray, Eric J. Velazquez, Aldo P. Maggioni, Marc A. Pfeffer, Scott D. Solomon, 
Brigham and Women’s Hospital, Boston, MA, Duke Clinical Research Institute, Duke 
University Medical Center, Durham, NC
Background. We aimed to quantify the impact of a non-fatal recurrent myocardial 
infarction (reMI) on the risk of death in patients with left ventricular dysfunction, heart 
failure, or both following an acute MI.
Methods. VALIANT enrolled 14,703 patients with acute high-risk MI; follow-up continued 
for 3 years. Endpoints were reviewed by an independent committee according to 
predefined criteria. Using Cox regression, we assessed the hazard of cardiovascular 
(CV) death after the first non-fatal reMI in 13,611 patients who were alive and free of a 
reMI 30 days after index MI.
Results. Patients who had a reMI (n=1407; 9.6%) were older, more often female, and had 
more CV risk factors. Of reMIs, 1031 (73%) were considered non-fatal. The rate of first 
non-fatal reMI was highest in the weeks to months following index-MI, and declined over 
time (median time to first non-fatal reMI, 145 days [interquartile range 47-378 days]). The 
1-year CV mortality following a non-fatal reMI was 19% (95% CI, 16%-22%) compared 
with 4.9% (4.5%-5.3%) for patients free of reMI 145 days after index MI. Risk of CV death, 
relative to patients without reMI, was highest early after the reMI and declined over time 
(Figure). Even patients who survive 1 year after a reMI are at a more than 2-fold risk of 
CV death compared with patients without a reMI.
Conclusion. Non-fatal reMI remains a significant and persistent predictor of short- and 
long-term CV death in patients on contemporary post-MI therapy. 
10:00 a.m.
1013-133 Direct Transport Of Patients With Acute Myocardial 
Infarction To Interventional Cardiology Centre 
Following ECG Transmission From Home Shortens 
Delay To Primary PCI
Maciej Karcz, Pawel Bekta, Maciej Brasse, Pawel Tyczynski, Miroslaw Skwarek, Maciej 
Dabrowski, Jacek Kadziela, Krzysztof Kukula, Andrzej Kosik, Witold Ruzyllo, Institute of 
Cardiology, Warsaw, Poland
Background: Since 2001 our tertiary interventional cardiology centre (ICC) has been 
performing round-the-clock primary percutaneous coronary interventions (pPCI) in acute 
myocardial infarction (MI) with yearly volume of ca. 700 pPCI’s, with 80% of patients (pts) 
transferred via community hospitals (CH) and with most MI pts entering the medical system 
by calling an ambulance. We investigated whether direct transport of pts from home (H) to 
ICC can shorten the time to arrival at ICC.
Methods: In 05/05 we launched a regional pilot system in which 12-lead ECG can be taken 
at H using Lifepak 12 defibrillator (Medtronic) and transmitted to ICC. If MI is confirmed pt is 
transported directly to ICC by-passing CH. Control group consists of pts transported to ICC 
by the same ambulances but via CH (for ECG and diagnosis). Study endpoint is the time: 
arrival of an ambulance at H - arrival at ICC.
Results: The system comprises 36 ambulances in 18 stations 3-120 kms away from ICC 
and serving a population of 1.7 million. Out of 770 pts whose ECG’s were transmitted, 158 
pts (median age 64 years, 70% male, 86% STEMI) were transported directly to ICC with no 
deaths during transport. Median time H - ICC was 82 mins and was significantly shorter (by 
33 mins) than in the control group of 185 pts (H - CH - ICC, 115 mins). The difference was 
driven entirely by significant shortening (by 43 mins) of the time interval from arrival of an 
ambulance at H to the moment pt eventually starts his journey towards ICC either from H or 
from CH (median time 30 mins with direct transport vs. 73 mins in the control group). When 
the whole region was divided into 4 concentric zones based on distance from the ICC, 
significant gain in time H - ICC was seen with direct transport for pts coming from each zone 
(zone 0 gain of 54 mins (44 vs. 98 mins), zone 1 gain of 40 mins (60 vs. 100 mins), zone 2 
gain of 37 mins (75 vs. 112 mins), and zone 3 gain of 38 mins (105 vs. 143 mins)).
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Conclusion: Direct transport of pts with acute MI to interventional cardiology centre 
following ECG transmission from home significantly shortens delay to arrival at ICC as 
compared to conventional transport via community hospital. This gain may augment 
myocardial salvage and further improve clinical outcome after pPCI.
10:00 a.m.
1013-134 Inhibition of δ-Protein Kinase C to Ameliorate 
Reperfusion Injury During Primary Percutaneous 
Coronary Intervention for Acute ST-Elevation 
Myocardial Infarction - Preliminary Results from the 
DELTA MI Trial
Matthew T. Roe, Kevin Grimes, Eric Bates, Neal Kleiman, Christoph Bode, Kurt Huber, 
Christopher B. Granger, Marco Costa, C. Michael Gibson, Scott D. Solomon, Petr 
Widimsky, Zygmunt Sadowski, Daria Mochly-Rosen, Robert A. Harrington, Duke Clinical 
Research Institute, Durham, NC
Background: KAI-9803, a δ-Protein Kinase C inhibitor, has been shown to reduce infarct 
size, limit myocyte and endothelial cellular damage, and enhance regional contractile 
function when administered prior to reperfusion in animal models of acute MI.
Methods: We performed a dose-escalation, first-in-human study to evaluate the safety 
and efficacy of KAI-9803 in 154 patients with anterior acute ST-elevation MI (STEMI). 
Patients with an occluded LAD infarct artery on angiography were randomized 2:1 to 
KAI-9803 or placebo into one of 4 dose cohorts (0.05, 0.5, 1.25 and 5.0 mg of KAI-9803). 
KAI-9803 was administered first to the distal infarct bed during initial balloon inflation and 
second via the guide catheter after restoration of antegrade flow in the LAD. Multiple safety 
parameters were assessed and efficacy was evaluated with a variety of biomarkers of 
myocardial viability and tissue perfusion (post-PCI angiography, ST-segment resolution, 
cardiac marker release patterns, infarct size with nuclear scintigraphy, and regional wall 
motion with echocardiography) as well as 6-month clinical outcomes.
Results: Final study results are expected by March, 2007 for abstract presentation. 
Clinical characteristics by dosing cohort are listed in the table.
Conclusions: Inhibition of δ-Protein Kinase C has the potential to ameliorate multiple 
aspects of reperfusion injury for patients with STEMI. The impact of KAI-9803 for STEMI 
will be comprehensively assessed with the final results of the DELTA MI trial.
Baseline Clinical Characteristics
Cohort 1 
(0.05 
mg)(n= 37 )
Cohort 2
(0.5 mg)(n 
= 38 )
Cohort 3
(1.25 mg)(n 
=38 )
Cohort 4
(5.0 mg)(n 
=41 )
Median Age (yrs) 61 59.5 59.0 59.0
Male Gender(%) 73.0 71.1 73.7 85.4
Diabetes Mellitus (%) 10.8 21.1 21.1 14.6
Prior Heart Failure (%) 0 2.6 2.6 2.4
Current Smoking (%) 29.7 44.7 44.7 36.6
Killip Class II-III (%) 5.4 18.4 2.6 9.8
Median Symptom onset to 
presentation (hrs) 1.3 1.6 2.5 2.9
Median Presentation to first 
balloon inflation (hrs) 1.8 1.5 1.3 1.3
10:00 a.m.
1013-135 Implementation of an Emergency Department, 
Interventional Cardiology Therapeutic Team Reduces 
Door to Balloon Times for ST Segment Elevation 
Myocardial Infarction Patients Presenting to the 
Emergency Department
Peter G. Paige, Peter Whittaker, Mark I. Furman, Gideon Bosker, Gregory A. Volturo, 
University of Massachusetts Medical School, Worcester, MA
Background: For acute management of ST-segment elevation myocardial infarction 
(STEMI), the American College of Cardiology recommends catheter-based revascularization 
of infarct-related arteries within 90 minutes of hospital arrival (door-to-balloon time; 
DBT). We hypothesized that the development of a collaborative Emergency Department 
/ Interventional Cardiology Therapeutic Team (EDICT) and the initiation of specific time 
saving protocols would significantly reduce DBT in a large academic medical center.
Methods: DBT was determined in 47 consecutive STEMI patients presenting to 
the emergency department (ED) during a 10-month period from November 2004 
to September 2005 prior to initiation of EDICT. After initiation of EDICT, a series of 
interventions was implemented over eight months; a total of 61 consecutive patients 
assessed from October 2005 to September 2006. Specifically, the interventions included; 
real time interdepartmental case reviews, ED attending activation of the cath lab (CL), 
definition of an EDICT STEMI team, diminished number of IV drip medications initiated 
in the ED prior to CL, designation of an ED STEMI room, CL compatible equipment in 
the ED, STEMI pre-hospital alert protocol, ED/ CL direct phone access, ED parking for 
CL team, pre-hospital provider education, patient outcome feedback to the ED, defined 
course of travel from ED to CL.
Results: The implementation of our EDICT protocols significantly reduced the DBT from 
94.8 ± 5.2 mins to 79.7 ± 4.4 mins (P=0.03). In addition, the proportion of patients meeting 
the 90-minute DBT target time was significantly increased from 40% to 67% (P=0.007). 
The introduction of our protocols took several months; however, after full implementation 
in the most recent patient group (n=13), the DBT was further reduced to 67.9 ± 6.4 mins 
and compliance with the 90-minute guideline further increased to 92%.
Conclusions: Implementation of our EDICT protocols not only improved collaboration 
between the ED and CL, but also accelerated passage of STEMI patients through the 
ED. The result was a significant reduction in door-to-balloon time and an increase in the 
proportion of patients receiving revascularization within the 90-minute target.
10:00 a.m.
1013-136 Effects of Nicorandil on Left-Ventricular Remodeling 
after Direct Percutaneous Coronary Interventions in 
Patients with ST-Elevation Myocardial Infarction
Nobuhiko Atsuchi, Hiroyoshi Yokoi, Daisuke Kamoi, Kiyoshi Hayashida, Hitoshi 
Nakashima, Manabu Setoguchi, Kazuhito Hirata, Kenji Horiuchi, Saiseikai Kumamoto 
Hospital, Kumamoto, Japan
Background: Nicorandil is an antianginal agent with a dual mechanism of action: nitric 
oxide donor and ATP-sensitive potassium channel opener. Nicorandil has been reported 
to significantly improve outcome by reducing major adverse cardiac events (MACE) in 
patients with stable angina. Furthermore, nicorandil improves no-reflow phenomenon during 
percutaneous coronary interventions (PCI). However, it is unclear if nicorandil is also effective 
in patients with ST-elevation myocardial infarction (STEMI) who underwent direct PCI.
Methods: To examine the effects of nicorandil in STEMI treated by PCI, a prospective, 
randomized, multicenter trial was conducted at 5 medical centers located in Kyushu, 
Japan from June 2004 to February 2006. Eighty-two patients with initial STEMI were 
randomized to treatment with intravenous and/or intracoronary administration of nicorandil 
(Group N, n=41) or without (Group C, n=41). In Group N, nicorandil was administered 
prior to direct PCI by intravenous (4 mg) and/or intracoronary (2 mg) injections followed 
by continuous intravenous drip for 24 hours (6 mg/hr) after the initial injection. All patients 
underwent follow up coronary angiogram and left-ventriculogram at 6 months after PCI.
Results: Although baseline characteristics and procedural details were the same in both 
groups, TIMI-3 flow was achieved more frequently in group N (97.6% vs. 82.9%, p<0.05) 
after direct PCI. No MACE was observed in both groups during the follow up period. 
Left ventricular ejection fraction was same in both groups, however, end diastolic and 
systolic volume indexes (EDVI and ESVI, ml/m2) were smaller in group N (68.9±21.0 
vs. 86.7±37.6, EDVI, p=0.03; 27.9±11.3 vs. 38.7±26.4, ESVI, p=0.046) as compared to 
group C. Nonsiginificant trend in favor of nicorandil use was observed for serum brain 
natriuretic peptide (BNP) levels (pg/ml) measured at 6 months (80.4 vs. 93.3).
Conclusions: Nicorandil administration prior and post direct PCI for 24 hours in STEMI 
patients prevents left ventricular remodeling at 6 months after the index event.
10:00 a.m.
1013-137 Percutaneous Coronary Intervention After Early 
Prehospital Thrombolysis: Reasonable, Useless or 
Dangerous?
Hans-Richard Arntz, Dirk Mueller, Uwe Zeymer, Benjamin Franklin Med. Ctr., Charité, 
Berlin, Germany, Klinikum Ludwigshafen, Ludwigshafen, Germany
Background: According to recent reports, PCI alone is superior to the combination of 
PCI shortly after thrombolysis (TL). It is unclear whether these results are also true for pts 
with very early initiation of TL.
Methods: We analysed data from the prospective PREMIR registry on prehospital 
treatment of STEMI pts in the physician manned EMS in Germany.
Results: A total of 2187 pts were included into the study of whom 984 were treated with 
primary PCI (PPCI), 502 had prehospital thrombolysis (PHL)and 434 no reperfusion Tx. 
Of the PHL pts 216(43%)were treated with PHL alone (PHL-), 286 (57%) had additional 
PCI (PHL+) performed in 64% within 2hrs,in 15% within 2 to 6 hrs and in 21% >6hrs after 
hospital admission. No differences between the PHL+ and PHL- groups existed regarding 
sex (77% males), history of STEMI (16%), PCI (8%), CABG (3%), hypertension (57%), 
and diabetes (18%). PHL+ pts had a shorter mean symptom duration to start of PHL 
(91Min) and were younger (mean 62 years) compared to PHL- pts (106 Min and 64 years 
respectively, p<0.01). Frequency of anterior infarction was slightly higher in PHL+ (45%) 
compared to PHL- pts (42%, p=ns). Total mortality to discharge was 6.9% for all pts, 4.3% 
for pts treated by PPCI and 5.8% for pts treated by PHL (difference between PHL and 
PPCI=ns) but was 14.5% for pts without reperfusion Tx (p<0.001 compared to the active 
treatment groups). Outcome for the PHL+ and the PHL- groups was similar with respect 
to mortality, cardiogenic shock, heart failure, and stroke (5.6%, 11.7%, 8.5%, and 0.7% for 
PHL+ pts vs 6.1%, 7.5%, 11.7%, and 2.8% for PHL- pts, p=ns). Re-infarction, however, 
was more frequent in PCI+ pts (7.1%) vs 2.8% in PCI-pts, p<0.04). With respect to time 
delay to PCI there were less major adverse cardiac events in pts with a delay <2hrs 
compared to those with a longer delay ( MACE rate 28% vs 46%, p=0.02), which may in 
part caused by selection bias.
Conclusions: As shown in randomised trials, TL initiated early (within 2-3hrs after symptom 
onset) may be an adaequate stand-alone strategy for STEMI and - in contrast to recent 
studies may be also safely combined with early PCI. It must, however, be defined in future 
studies which pts may profit from the combination of early TL rapidly followed by PCI
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1013-138 Troponin Is As Accurate As CK And CKMB For 
Estimation Of Infarct Size
Dan Tzivoni, Daniel Koukoui, Victor Guetta, Lena Novak, Graham Cowing, CASTEMI 
Study Investigators, Shaare Zedek Medical Center, Jerusalem, Israel
Background: Many studies assessed the correlation of infarct size with both peak 
level and area under the curve (AUC) level of CK and CKMB, however, no large scale 
studies have correlated the level of troponin T with infarct size. Troponin is currently used 
predominantly for detection of myocardial damage while CK is used for estimation of its 
extent. The purpose of this abstract is to compare the accuracy of troponin T to that of 
CK in assessing infarct size.
Troponin T CK SPECT(n=267)
Peak AUC Peak AUC InfarctDay 7
EF
Day 7
Troponin
Peak
(n=261)
AUC
(n=259)
0.706
0.722
-0.573
-0.604
CK
Peak
(n=261)
AUC
(n=256)
0.888
0.832
0.859
0.858
0.722
0.726
-0.596
-0.615
CKMB
Peak
(n=261)
AUC
(n=257)
0.884
0.856
0.878
0.887
0.920
0.899
0.898
0.924
0.721
0.739
-0.571
-0.618
Methods: CASTEMI was a multicenter, double blind, randomized, placebo controlled study 
investigating two caldaret (MCC-135) doses in 387 patients with large MI all underwent primary 
coronary intervention. All patients had repeated measurements of CK, CKMB and troponin T. 
SPECT infarct size was performed on day 7 and ejection fraction (EF) was calculated. The 
current study included 267 patients in whom enzyme and SPECT data was available.
Results: Good correlation (p<0.001, Spearman) was found between peak level and 
AUC of troponin T and CK and CKMB (see table). Troponin T, CK and CKMB correlated 
similarly with infarct size and EF (p<0.001, Spearman).
Conclusions: Troponin can be used reliably not only for detection of myocardial damage 
but also for assessment of infarct size. 
10:00 a.m.
1013-153 Temporal Evolution in Management of Elderly Patients 
Admitted for ST Segment Elevation Myocardial 
Infarction and Impact on Mortality in the Franche-
Comte Region of France
Francois Schiele, Jean-Pierre L. Bassand, Investigators of the “Réseau Franc-Comtois 
de Cardiologie”, University Hospital Jean Minjoz, Besancon, France
Background: 1 month mortality in elderly patients (pts) (>75 years) admitted for acute 
myocardial infarction (MI), mortality is twice as high as among younger pts. Despite this 
higher risk, elderly pts often receive fewer effective therapies. Changes over time in the 
management of elderly pts and impact on 1 month mortality are poorly documented.
Methods: A prospective multicenter registry was designed, including all (10) cardiology 
centers of the Franche-Comte region of France (1.2 million inhabitants). Demographic and 
clinical characteristics at admission were recorded. In-hospital treatment was compared 
between two periods (2001 vs 2005), including reperfusion therapy, antiplatelets, ACE 
inhibitors, betablockers & statins. All-cause mortality was assessed at 1 month.
Results: Elderly pts represented 43% of the population admitted for ST elevation MI (n= 
276: 148 patients in 2001; 128 in 2005). Elderly pts admitted in 2001 and 2005 had similar 
clinical characteristics. Compared with 2001, there was a significant increase in the use 
of aspirin, clopidogrel, reperfusion therapy (more patients eligible and more actually 
reperfused), ACE inhibitors and statins in 2005. Conversely, the use of betablockers 
remained stable. At 1 month, we observed a huge and significant reduction in mortality 
(18.2 in 2001 versus 7.8% in 2005, p=0.0012).
Conclusions: In 2005, elderly pts with STEMI received more guidelines-recommended 
treatments compared with 2001. A significant reduction in mortality was observed.
N(%)
Elderly (>75 years) STEMI 2001 (n=148) STEMI 2005 (n=315) P
Aspirin 128 (86) 124 (97) 0.002
Clopidogrel 23 (16) 99 (77) 0.001
Any oral antiplatelet 131 (89) 126 (98) 0.001
Eligible reperfusion 96 (65) 93 (73) 0.16
Actually reperfused 44 (30) 71 (56) 0.001
Actual/eligible 44/96 (46) 71/96 (76) 0.001
ACE inhibitors 71 (48) 91 (71) 0.001
Statins 47 (32) 113 (88) 0.001
1 month mortality 27/148 (18.2) 10/128 (7.8) 0.0012
10:00 a.m.
1013-154 Marriage and 1-Year Post Myocardial Infarction 
Mortality: Better for Men Than Women
Homaa Ahmad, Rasha N. Bazari, Kimberly J. Reid, Judith H. Lichtman, Viola Vaccarino, 
Donna M. Buchanan, John A. Spertus, Mid America Heart Institute of Saint Luke’s 
Hospital, Kansas City, MO
Background: Being married is associated with a better prognosis for men recovering 
from an acute myocardial infarction (AMI). It is unclear whether women derive the same 
benefits from marriage as men. We examined the effect of marital status by gender on 
one year mortality post AMI.
Methods: Between January 2003 and June 2004, 2,411 AMI patients were prospectively 
screened and enrolled from the PREMIER study across 17 U.S. centers. Survival was 
modeled using a multivariable proportional hazards regression. Married individuals 
included common law marriages. Single status included divorced, separated, widowed 
or never married. Covariates in the multivariable models included extensive demographic 
and clinical factors along with a marital status-by-gender interaction term.
Results: Overall, 60.2% of the population were married at baseline (68.5% of men 
and 43.5% of women, p<0.001). Marriage conferred a survival benefit to married men 
compared to single men (hazard ratio [HR] 0.59, 95% confidence interval [CI]: 0.38, 0.92, 
p=0.02). The same benefit, however, was not seen in women (HR 1.32, 95% CI: 0.77, 
2.24, p=0.31; Figure). In the fully-adjusted model, a significant interaction of the effect of 
marriage by gender was observed (p=0.0214).
Conclusions: Marriage appears to have a protective mortality effect for men, but not for 
women. Further research to elucidate the mediating factors for these associations may 
identify opportunities to eradicate this observed disparity in outcome. 
10:00 a.m.
1013-155 Mid-regional Pro-atrial Natriuretic Peptide (MR-proANP) 
Predicts Risk Of Death Or Heart Failure In Patients 
With Acute Myocardial Infarction. Leicester Acute 
Myocardial Infarction Peptide (LAMP) Study 
Sohail Q. Khan, Onkar Dhillon, Russell O’Brien, J. Struck, N. Morgenthaler, I. Squire, 
Joan E. Davies, A. Bergmann, Leong L. Ng, University of Leicester, Leicester, United 
Kingdom, BRAHMS AG, Hennigsdorf/Berlin, Germany
Background: Natriuretic peptides including atrial natriuretic peptide (ANP) predict 
survival in post AMI patients. Clinical use has been limited due to its relative instability. 
Its precursor mid-regional proANP (MR-proANP) is more stable in circulation and ex 
vivo. We sought to investigate the cardiovascular prognostic value of MR-proANP and 
compared it to N terminal B type natriuretic peptide (NT-BNP), a marker of death and 
heart failure Methods: We studied 982 consecutive post AMI patients (720 men, mean 
65.1 ± 12.2 years). Plasma measurements were made 3-5 days after chest pain onset. 
Plasma concentration of NT-BNP was determined using an in-house non-competitive 
chemiluminescent immunoassay and MR-proANP was detected using a novel commercial 
assay (BRAHMS AG). Patients were followed-up for the combined endpoint of death or 
heart failure (HF).
Results: Median follow up was 343 days (range 0-764). There were 101 deaths and 49 
readmissions with HF. MR-proANP was raised in patients with death or HF compared to 
survivors (median [range] pmol/L, 274[31-1150] vs. 105[4.9-1210], p<0.0001). Using a 
multivariate binary logistic model, log MR-proANP (OR 4.36), log NT-BNP (OR 2.8), log 
creatinine (OR 8.77), age (OR 1.03), male gender (OR 0.62) and past history of MI (OR 
2.53), were significant independent predictors of death or heart failure. The receiver-
operating curve for MR-proANP yielded an area under the curve (AUC) of 0.79(95% 
CI: 0.75-0.84, p<0.001) for NT-BNP the AUC was 0.80 (95% CI: 0.75-0.84, p<0.001); 
the logistic model combining the 2 markers yielded an AUC of 0.84 (95% CI: 0.81-0.88, 
p<0.001). The Cox proportional hazards model for predicting death or heart failure revealed 
the same variables (including log MR-proANP (HR 3.21), log NT-BNP (HR 2.44)). Kaplan-
Meier analysis confirmed significantly better clinical outcome in patients with MR-proANP 
below the median in patients stratified by NT-BNP (below median, P=0.0001, above median 
P<0.0001). Similar findings were obtained with death and HF as individual endpoints.
Conclusion: After an AMI, MR-proANP is a powerful predictor of death and HF 
independently of well established prognosticators including NT-BNP.
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1013-156 Fate of Small-sized Side Branches After Coronary Stent 
Implantation
Jin Bae Lee, Young-Su Lee, Jae Kern Ryu, Ji Yong Choi, Kee-Sik Kim, Sung Gug 
Chang, Daegu Catholic University Medical Center, Daegu, South Korea
Background: Few data are available about the acut and late patency of small side 
branch. Our purpose was to identify angiographic and procedural predictors for acute 
and late side branch occlusion after coronary stent implantation.
Methods: We evaluated 196 side branches (41 patients with 49 lesions) with a reference 
diameter of ≤2mm; the lesions were covered by 50 stents. Angiographic follow-up was 
completed in all patients with 196 side branches 6 ± 3 months after stent implantation. 
Side branch occlusion (SBO) was defined as a Thrombolysis In Myocardial Infarction 
(TIMI) flow ≤1. The TIMI flow of before PCI, after stent implantation, and at follow-up 
were evaluated. Clinical and the following angiographic parameters were recorded: 
reference diameter, minimal lumen diameter, diameter stenosis, AHA/ACC lesion type, 
TIMI flow, lesion length, number of side branches, stent size. Side branches were also 
characterized by ostial and reference diameter, ostial stenosis, TIMI flow, and ostial side 
branch angle related to the main vessel.
Results: Acute SBO affected 50 side branches in 196 side branches(39.2%). By multiple logistic 
regression, independent predictors for acute SBO were (1) the side branch TIMI flow ≤1 at 
baseline (OR [odds ratio] 0.2109, 95% CI 1.126-3.950, P = .020); (2) an ostial side branch angle 
less than 60 degree(OR 2.809, 95% CI 1.136-7.350, P = .026); (3)AHA/ACC lesion type B2/C 
(OR 0.392, 95% CI 0.162-0.949, P = .038). Among the initially occluded side branches, 84.0% 
were spontaneously reperfused at follow-up. Late SBO involved 4.1% of the side branches. 
By multiple logistic regression, independent predictors for late SBO was the ostial side branch 
stenosis(>50%) before stenting (OR 0.565, 95% CI 0.038-0.839, P = .005).
Conclusions: Acute SBO after stenting occurred in 39.2% of cases. Most acutely 
occluded side branches underwent late spontaneous reperfusion. The predictors for 
acute SBO were the side branch TIMI flow at baseline, the ostial side branch angle less 
than 60 degree, and AHA/ACC lesion type B2/C. The predictor for late SBO was the ostial 
side branch stenosis (>50%) before stenting.
10:00 a.m.
1013-157 Do Myocardial Perfusion Abnormalities Predict Survival 
in Patients who Develop Myocardial Infarction late After 
Stress Testing?
Abdou A. Elhendy, Jeroen Bax, Don Poldermans, Ron van Domburg, Marshfield Clinic, 
Marshfield, WI, Thoraxcenter, Rotterdam, The Netherlands
Background: Acute myocardial infarction (AMI) can occur in patients (pts) with previously 
normal stress myocardial perfusion imaging (MPI). It is not known whether the prognosis 
of these pts differ from those with abnormal MPI. Aim of this study is to assess the 
predictors of mortality after AMI among pts who previously underwent stress MPI.
Methods: We studied 1,386 pts who underwent exercise or dobutamine stress 99m 
technetium tetrofosmin MPI. Among them, 109 pts (age 62 ± 11 year, 73 men) developed 
AMI 2.1 ± 2.7 years after the stress test and represented the study population. Pts were 
subsequently followed for the occurrence of death during or after the acute event.
Results: Myocardial perfusion was normal in 31 pts and abnormal in 87 (45 had reversible 
defects). During a mean follow up of 3.1 ± 2.4 years after AMI, death occurred in 35 (32%) 
pts. Death rate was 16% in pts with previously normal vs 33% in pts with abnormal perfusion 
(figure). In a Cox model, independent predictors of death were age (risk ratio (RR) 1.06, 95% 
CI 1.02-1.1), heart failure (RR 2.7, CI 1.3-5.5), and abnormal MPI (RR 2.5, CI 1.3-4.5).
Conclusions: Pts with a previously normal stress MPI are less likely to die after AMI than 
pts with an abnormal MPI. These findings suggest that AMI after a normal MPI occur in 
pts with lower atherosclerotic burden. 
10:00 a.m.
1013-158 Short-term Daily Administration of L-arginine 
Improves Endothelial Function and Arterial Stiffness 
in Healthy Smokers
Gerasimos Siasos, Dimitris Tousoulis, Charalambos Vlachopoulos, Nikos Ioakeimidis, 
Kostas Zisimos, Charalambos Antoniades, A. Papavasiliou, Christodoulos Stefanadis, 
Athens University, A Cardiology Department, Athens, Greece
Objective: L-arginine is essential for normal endothelial function. Endothelial 
dysfunction is accompanied by increased arterial stiffness. Aim of the present study 
was to investigate in healthy smokers the effect of a short-term daily L-arginine 
administration on vascular function.
Methods: We studied the effect of a 3-day oral administration of L-arginine in 12 healthy 
smokers (aged 24±3yrs) on 3 occasions (day0: baseline measurements, day1 and day3). 
The study was carried out on two separate arms, one with L-arginine (7gr tid) and one 
with placebo according to a randomized, placebo-controlled, double-blind, cross-over 
design. All measurements were performed one hour after L-arginine or placebo intake. 
Endothelial function was evaluated with flow-mediated dilatation (FMD) of the brachial 
artery. Carotid-femoral pulse wave velocity (PWV) was measured as an index of aortic 
stiffness and augmentation index (AIx) as a measure of arterial wave reflections. Plasma 
levels of interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α) and soluble intercellular 
adhesion molecule (sICAM-1) were measured with ELISA.
Results: Compared to placebo, L-arginine led to a progressive increase of FMD (by 
1.74%, p=NS at day 1 and by 1.96%, p<0.05 at day 3), indicating a favorable effect on 
endothelial function. Moreover, L-arginine intake led to a progressive decrease of PWV 
(by 0.32 m/s at day1 and by 0.36 m/s at day 3, both p<0.01) and of AIx (by 5.1%, p<0.01 
at day 1 and by 9.3%, p<0.001 at day3), indicating a decrease in aortic stiffness and wave 
reflections. Finally, 3-day oral administration of L-arginine decreased the level of sICAM 
(p<0.05), whereas, there was no effect on IL-6 and TNF-α.
Conclusion: Short-term daily administration of L-arginine, a precursor of nitric oxide 
synthesis in vascular endothelium, improves arterial performance in healthy smokers. 
These findings provide further insights into the cardiovascular profile of this molecule.
10:00 a.m.
1013-159 Culprit Coronary Lesions Requiring PCI Following Vascular 
Surgery Often Arise From Non-Obstructive Disease
Sara T.N. Murray, Heba S. Wassif, Thomas E. Moritz, Lizy Thottapurathu, Gordon 
Pierpont, Steve Goldman, Greg C. Larsen, Herbert B. Ward, Edward O. McFalls, VA 
Medical Center, Minneapolis, MN, University of Minnesota, Minneapolis, MN
Background: The natural history of coronary artery disease following a major vascular 
operation is not well understood. The aim of this study was to determine the proportion of 
culprit coronary artery lesions requiring revascularization following vascular surgery that 
had no significant stenosis at the same site preoperatively.
Methods: The Coronary Artery Revascularization Prophylaxis (CARP) Trial was 
a multicenter study that tested the long-term survival benefit of coronary artery 
revascularization prior to elective vascular surgery. Among the randomized patients who 
subsequently required a percutaneous coronary intervention (PCI) following the vascular 
operation, the stenosis of the culprit lesions from the follow-up angiogram was compared 
to the stenosis at the same site on the preoperative baseline angiogram.
Results: Thirty patients underwent PCI in a total of 34 coronary arteries at a median of 15 
months following vascular surgery. As shown in the figure, 19 of 34 culprit lesions (55.8%) 
had non-obstructive disease prior to vascular surgery, and 11 of those 19 (57.9%) were a 
result of restenosis at the site of previous deployment of a bare metal stent.
Conclusions: Culprit coronary artery lesions requiring PCI following an elective vascular 
operation often arise from non-obstructive coronary artery disease. Therapies that 
stabilize existing plaques and prevent restenosis have the greatest promise for improving 
postoperative outcomes in patients undergoing vascular surgery.
10:00 a.m.
1013-174 Cystatin C is a Independent Predictor of recurrent 
spontaneous Myocardial Infarction or Death in High 
Risk nSTE-ACS patients
Alexander Hirsch, Fons Windhausen, Jan P. van Straalen, Gerard T. Sanders, Johan 
Fischer, Jan G.P. Tijssen, Robbert J. de Winter, on behalf of the ICTUS investigators, 
Academic Medical Center, Amsterdam, The Netherlands
Background: Rrenal dysfunction has been recognized as an important risk factor for 
cardiovascular complications after myocardial infarction. Cystatin C is a serum marker of 
renal function which has a relationship beween plasma levels and glomerular filtration rate, 
independent of age, gender, race and bodysurface area. The prognostic value of Cystatin C in 
patients with a non ST elevation acute coronary syndrome with an elevated cardiac troponin T 
(cTnT) is unknown. Therefore we assessed whether Cystatin C is an independent predictor of 
mortality and myocardial infarction in nSTE-ACS patients with an elevated cTnT.
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Methods: Baseline samples for Cystatin C measurements were available in 1128 nSTE-
ACS patients with an elevated cTNT randomized to an early or a selective invasive strategy. 
Follow-up was available up to 3 year for the endpoint death or spontaneous MI and up to 4 
year for mortality alone. Patients were divided into quartiles of Cystatin C level at baseline.
Results: Mortality by 4 year was 3.7%, 4.1%, 6.9%, and 16.8% respectivelyin the four 
quartiles of Cystatin C (p<0.0001). Kaplan-Meier estimates of the cumulative rate of 
death or spontaneous MI by 3 year are shown in figure. In a Cox regression analysis, 
Cystatin C was a independent predictor of death or spontaneous MI within 3 year follow-
up (Q4 vs. Q1-3; HR 1.8 (95% CI 1.2 - 2.6; p=0.003).
Conclusion We showed that Cystatin C is a strong independent predictor of death or 
spontaneous MI within 3 year follow-up in nSTE-ACS patients with an elevated cTnT. 
10:00 a.m.
1013-175 Clinical Predictors of Presence of Left Main Coronary 
Artery Disease on Angiography in a Large Cohort
Svati H. Shah, Charlotte Nelson, Judith A. Stafford, Christopher B. Granger, William E. 
Kraus, Elizabeth R. Hauser, Duke University Medical Center, Durham, NC
Background: CAD in the left main (LM) occurs in 5-7% of patients undergoing 
angiography, and untreated, has a 50% 3-year mortality. LM is the most heritable location 
for CAD, suggesting a genetic component. We sought to identify clinical factors predictive 
of LM CAD in a large cohort undergoing cardiac catheterization. Known and suspected 
predictors were evaluated in patients without known CAD (for potential diagnostic use), 
as well as in patients with known CAD (to identify factors unique to LM disease).
Methods: We identified all subjects undergoing first cardiac catheterization at Duke University 
from 1986-2005. Subjects with a history (HX) of revascularization, transplant or congenital 
heart disease, or with missing data, were excluded, leaving N=41,244 in the overall cohort. Of 
these, 24,304 had significant CAD on angiography. Multivariable logistic regression models 
for the presence of LM CAD (≥50% stenosis) were constructed with 21 covariates.
Results: For the overall cohort, (in order of importance) age, male sex, presence of 
carotid bruits, HX of MI, chest pain, white race, HX of PVD, diabetes, dyslipidemia, 
smoking, family HX of CAD, and lower BMI were highly significant independent predictors 
of LM CAD (p<0.0001); less significant predictors were increased systolic blood pressure, 
year-of-procedure, HX of CHF, renal disease, MI at time of procedure, COPD, and HX 
of cerebrovascular disease (p<0.05). For the subgroup with CAD, increased age, carotid 
bruits, male sex, HX of CHF, PVD and white race were highly significant predictors of LM 
CAD (p<0.0001); lower BMI, year-of-procedure, HX of dyslipidemia, chest pain, smoking, 
and renal disease were predictive, but less significant than in the overall cohort (p<0.05). 
C index for the overall model was 0.74, and 0.66 for the CAD cohort model.
Conclusions: We have constructed a model with clinical factors predictive of 
presence of LM CAD in a large cohort. Variables in the overall cohort recapitulate 
factors associated with CAD in general. However, few of these variables are predictive 
of presence of LM disease among subjects with known CAD. This suggests there may 
be factors specific to LM CAD, such as genetic variants, that are yet unidentified.
10:00 a.m.
1013-176 Experience Of 1,000 Acetylcholine(ACh) Spasm 
Provocation Tests: What Have We Learned?
Shozo Sueda, Akira Ohshita, Hiroaki Kohno, Yousuke Izoe, Hiroshi Fukuda, Saiseikai 
Saijo Hospital, Saijo, Japan
Background: The purpose of this study was to clarify the frequency of provoked spasms 
and the complications during spasm provocation test of ACh, retrospectively.
Methods: From 1991 to 2004, we performed 1,000 consecutive spasm provocation 
tests of ACh to evaluate coronary vasospasm. ACh was injected in incremental doses of 
20/50/80 microgram into the RCA and of 20/50/100 microgram into the LCA. Subjects were 
excluded if patients had left main narrowing (>50%), triple-vessel disease and two-vessel 
disease with both occluded. When coronary spasm was induced and did not resolve 
spontaneously within 3 minutes after completion of ACh injection, or when hemodynamic 
instability due to coronary spasm occurred, 2.5-5.0 mg of ISDN was administered into the 
responsible vessel. Coronary spasm was defined as transient >99% narrowing.
Results: (1)Coronary spasm was provoked in 39% of patients. The frequency of provoked 
spasms in patients with IHD was significantly higher than that in those with non-IHD (54% vs. 
13%, p<0.01). (2)There was no difference in provoked spasms between patients with and 
without fixed stenosis (39% vs. 39%, ns). Multiple spasms were observed in 46% (177/387). 
(3)There was a significant difference in sex, history of smoking and hyperlipidemia between 
patients with and without spasms. (4)Severe complications were observed in 17 patients 
(1.7%), However, no death and no serious irreversible complications were determined. (5)13 
patients developed VT (DC: 2 pts, thump version: 6 pts). (6)There were 3 patients (0.3%) 
who developed shock, like the spasm of left main trunks. (7)Surgical drainage was performed 
in one patient who complicated with cardiac tamponade (0.1%) by inserting the temporary 
pace maker. (8)Paf occurred in 164 patients (17%) out of 960 patients who had SR before 
the provocation test. Intravenous administration of anti-arrhythmic agents was necessary to 
recover SR in 52 patients, while 112 patients were recovered to SR within a few minutes.
Conclusions: Although ACh spasm provocation test was safe and reliable method, we 
should be take care of performing it in spite of selective procedure.
10:00 a.m.
1013-177 Logistic Regression Models to Identify Negative 
Predictors of Agreement of Findings of 64-Slice 
Computed Tomography and Conventional Coronary 
Angiogram for Evaluation of Patency of Drug Eluting 
Stents and Bare Metal Stents in Coronary Arteries
Koki Nakamura, Nobusada Funabashi, Masae Uehara, Kenji Okubo, Kazushi Suzuki, 
Makoto Terao, Yuzuru Mita, Fumiaki Maeda, Yoko Mikami, Issei Komuro, Chiba 
University Graduate School of Medicine, Chiba, Japan, Awa Medical Association 
Hospital, Tateyama, Japan
Background: To identify negative predictors of agreement of findings of 64-multislice 
computed tomography (MSCT) and conventional coronary angiogram (CAG) for 
evaluating patency of drug-eluting stents (DES) and bare metal stents (BMS) in 
coronary arteries, using logistic regression models.
Methods: 48 consecutive subjects, with 75 stents (16 DES, 59 BMS; 31 LAD, 13 LCx, 
and 31 RCA) underwent enhanced ECG-gated MSCT (Light Speed VCT). Stents were 
classified into 3 categories based on implantation site: (1) RCA (2) LAD (3) LCx. Logistic 
models were made in each category to predict agreement of findings of CT and CAG for 
evaluation of patency of stents using sex, age, heart rate, body mass index (BMI) (kg/m2), 
diabetes mellitus [DM], hypertension [HT], stent size (mm), and stent type (DES or BMS).
Results: In CAG, patency was confirmed in 15 DES and 54 BMS. Significant stenosis >50% 
was observed in 1 DES and 5 BMS and total occlusion was observed in 1 BMS. In CT, 
patency was confirmed in 69% DES (83, 75 and 50% with 3.5, 3, and 2.5 mm diameters, 
respectively), and in 78% BMS (80, 78, 81, 100 and 57% with 4, 3.5, 3, 2.75 and 2.5 mm 
diameters, respectively). 8% BMS revealed a low CT area inside the stents (1 with 4, 1with 
3.5, and 3 with 3mm diameter) with significant stenosis. 3% BMS revealed total occlusion (1 
each with 3.5 and 2.5mm diameter). Patency of 31% DES and 22% BMS was unconfirmed. 
Complete agreement of findings of CT and CAG were observed in 69% DES and 80% BMS. 
In logistic models, significant negative predictors of agreement of findings were, by category: 
(1) BMI (relative risks, 0.7727, 95% Confidence Intervals (CI): 0.6153-0.9702); (2) site of 
stent in LAD only (positive predictor) and BMI (relative risks, 4.5877 and 0.7690, 95% CI: 
1.0199-20.6370 and 0.6074-0.9736 respectively); (3) BMI (relative risks, 0.7731, 95% CI: 
0.6170-0.9689). Type of stent was not a significant predictor in any category.
Conclusions: 64-slice-MSCT is a non-invasive diagnostic-modality with potential for 
evaluating patency of DES with a low incidence of restenosis. However, when BMI is 
high, or site of stent implantation is not in LAD, it remains difficult to perform accurate 
evaluation of patency of stents irrespective of type of stent.
10:00 a.m.
1013-178 Sirolimus-eluting Stent Implantation For The Percutaneous 
Treatment Of Unprotected Left Main Coronary Artery 
Disease: A Clinical Analysis Based On J-cypher Registry
Mamoru Toyofuku, Yasuhiko Hayashi, Kazuaki Mitsudo, Takeshi Morimoto, Takeshi Kimura, 
on behalf of j-CYPHER Investigators, Tsuchiya General Hospital, Hiroshima, Japan
Background: The role of stenting in the treatment of unprotected left main coronary 
artery (LMCA) disease remains controversial in the drug-eluting stent era.
Methods: Design of this registry was multi-center prospective enrollment of consecutive 
patients from 40 centers in Japan. From Aug 2004 to Jun 2006, 288 patients received 
sirolimus-eluting stent (SES) for the elective treatment of unprotected LMCA and followed 
for 30 days, and 204 patients achieved 6 month follow-up. Patients were divided into 
two groups of single-stent approach [stenting only in main branch; group S; 214 patients 
(74%)] and two-stents approach [stenting both in main and side branch; group T; 74 
patients (26%)]. Two strategies were selected according to the operators’ discretion. We 
compared 30 days and 6 months outcomes of both strategies.
30 days and 6 months outcomes following elective LMCA 
stenting with SES
30 days Whole (N=288)
Single-stent 
(N=214)
Two-stent 
(N=74) P
Cardiac death (%) 3 (1.0) 1 (0.5) 2 (2.7) 0.16
Sudden cardiac death (%) 3 (1.0) 1 (0.5) 2 (2.7) 0.16
Stent thrombosis (%) 3 (1.0) 1 (0.5) 2 (2.7) 0.16
Target lesion 
revascularization (%) 1 (0.4) 0 (0.0) 1 (1.3)
6 months Whole (N=248)
Single-stent 
(N=180)
Two-stent 
(N=68) P
Cardiac death (%) 10 (4.0) 5 (2.3) 5 (7.4) 0.35
Sudden cardiac death (%) 6 (2.4) 2 (1.1) 4 (5.9) 0.06
Stent thrombosis (%) 3 (1.5) 1 (0.7) 2 (3.6) 0.18
Target lesion 
revascularization (%) 9 (4.4) 5 (3.4) 4 (7.1) 0.26
JACC  March 6, 2007    ABSTRACTS - Myocardial Ischemia and Infarction    219A 
M
yocardial Ischem
ia and Infarction
Results: Procedural successes were achieved in all patients. In group T, distal LMCA 
diseases were more commonly observed (96% vs. 67%, P<.0001). Mean LVEF was 
comparable between the two groups (54% vs 56%, NS). The outcomes according to the 
strategies are shown in table.
Conclusions: In our population, SES implantation for unprotected LMCA disease was 
safe with regard to immediate and mid-term mortality rate. In two-stents approach, the 
occurrence of suden death appeared relatively high than that in single-stent approach. 
Because our study is an ongoing situation, further long term follow-up is required.
10:00 a.m.
1013-179 Accuracy of Three Dimensional Quantititive Coronary 
Analysis by Comparison with Intravascular Ultrasound 
and Two Dimensional Quantitive Coronary Analysis
Jin Bae Lee, Young-Su Lee, Jae Kern Ryu, Ji Yong Choi, Kee-Sik Kim, Sung Gug 
Chang, Daegu Catholic University Medical Center, Daegu, South Korea
Background: Traditional angiography of vasculature is limited by its 2-dementional(2-D) 
projection of complex 3-dementional(3-D) structure. Rotational angiography provides a 
dynamic multiple-angle perspective of the coronary tree during a single contrast injection. 
The 3D model of a vessel segment of interest can predict the appropriate gantry angle for 
subsequent interventional guidance. The goal of the study was analyze the accuracy of 
this new 3D quantitative coronary analysis(QCA) system by comparison with intravascular 
ultrasound(IVUS) and 2D QCA.
Methods: 3D QCA, 2D QCA, and IVUS were performed in 27 segments(12 patients with 
15 vessels). The obtained values of branch to branch length and vessel diameter were 
analyzed by T test and Pearson correlation analysis.
Results: The branch to branch length measured by 3D QCA was more correlated with 
that of IVUS results(mean ± SE, SD: 0.77 ± 0.26, 1.34) than that of 2D QCA (mean ± SE, 
SD: -1.42 ± 0.51, 2.7) by T test. Vessel length measured by 3D QCA was more correlated 
with IVUS result than that of 2D QCA(Pearson correlation : 3D QCA and IVUS:0.966, 
2D QCA and IVUS: 0.962) by Peason correlation. Vessel diameter measured by 3D 
QCA were more correlated with IVUS than 2D QCA(Pearson correlation : 3D QCA and 
IVUS:0.836, 2D QCA and IVUS: 0.588).
Conclusions: 3-D QCA permits an accurate, reproducible and sensitive comprehensive 
three-dimensional geometric analysis of the coronaries and is superior to 2-D QCA with 
respect to extended length and diameter evaluation. 
10:00 a.m.
1013-180 Relationship of Mild Renal Insufficiency to C-reactive 
Protein and Coronary Plaque Morphology as Determined 
by Intravascular Ultrasound-Virtual Histology
Yoshiki Matsuo, Takashi Kubo, Satoshi Ueno, Akio Kuroi, Takashi Tanimoto, Takashi 
Yamano, Takashi Masho, Hironori Kitabata, Shigeho Takarada, Toshio Imanishi, Yoshiaki 
Tomobuchi, Takashi Akasaka, Wakayama medical university, Wakayama, Japan
Background: It has been reported that chronic kidney disease (CKD) increases 
cardiovascular event risk and is associated with a systemic proinflammatory state. However, 
little is known about the relationship between morphology of coronary plaques and plasma 
C-reactive protein (CRP) in patients with mild renal insufficiency (MRI). The objectives of 
the present study was to assess plaque composition using spectral analysis of Intravascular 
ultrasound (IVUS) radio frequency data and CRP levels in patients with MRI.
Methods: The study population included 71 patients with stable angina pectoris whose 
serum creatinine level was less than 2.0 mg/dl. Patients underwent IVUS examination before 
percutaneous coronary intervention and blood sampling for serum creatinine and CRP levels. 
Plaque composition of de novo native coronary artery stenosis was investigated and spectral 
analysis of IVUS radiofrequency data was performed with IVUS-Virtual Histology software. The 
glomerular filtration rate (GFR) was estimated by Cockcroft-Gault equation.
Results: Thirty-six patients had MRI defined as GFR < 60 ml/min/1.73m2, and 35 had normal 
renal function (NRF) defined as GFR >/= 60 ml/min/1.73m2. Compared with patients with NRF, 
dense calcium percentage (8.4 ± 7.1% vs 4.1 ± 2.9%, P<0.01) and necrotic core percentage 
(12.9 ± 7.9% vs 9.1 ± 6.0%, P<0.05) in the culprit lesion were greater in MRI. Moreover, of these 
MRI patients, diabetic subjects (n=11) were more likely to have greater dense calcium (14.7 
± 8.7% vs 7.7 ± 6.7%, P<0.05) and necrotic core percentage (21.8 ± 7.4% vs 11.5 ± 6.8%, 
P<0.05) than those in patients without diabetes (n=25). The level of CRP in patients with MRI 
was significantly higher than those with NRF (0.35 ±0.24 mg/dl vs 0.23 ± 0.17 mg/dl, P<0.05). 
There was a significant positive correlation between plasma log-CRP levels and the amount of 
necrotic core (r=0.27, p<0.05).
Conclusions: The coronary plaque morphology in patients with MRI had greater percentage of 
calcium and necrotic core and was significantly related to plasma CRP levels, which is thought to 
contribute to the high cardiovascular event rate in CKD patients.
10:00 a.m.
1013-195 Effect of Increasing Metabolic Syndrome Score on 
Atherosclerotic Plaque Burden in Coronary Artery Disease: 
Volumetric Assessment by Intravascular Ultrasound
So-Yeon Choi, Seung-Jea Tahk, Byoung-Joo Choi, Myeong-Ho Yoon, Hong-Seok Lim, Soo-Jin 
Kang, Joon-Han Shin, Ajou University School of Medicine, Suwon, South Korea
Background: The metabolic syndrome (MS) has been known as one of potential risk factor of 
coronary artery disease (CAD). We studied the relation between the MS score -the number of 
markers including elevated blood pressure, triglycerides (TG), low HDL cholesterol, hyperglycemia 
and abdominal obesity- and the extent of atherosclerotic plaque in patient with CAD.
Methods: Patients with CAD revealed more than 50% stenosis on coronary angiogram were 
sequentially enrolled and underwent the IVUS analysis at a constant speed of 0.5 mm/sec. The 
lumen area (LA), the vessel area (VA), and the plaque area (PA) were measured at 0.5-mm 
intervals within lesion and the plaque burden (PB), the area stenosis (AS) were assessed at the 
most narrowest point. The estimating volume was measured by echoPlaque 2 software. Clinical 
data for MS scoring were completely obtained.
Results: 283 patients with symptoms of CAD (208 men, mean age: 57±11) were divided into 
6 groups based on their MS scores (score: patients; 0: 45, 1: 86, 2: 67, 3: 61, 4: 16, 5: 8). A low 
HDL cholesterol level (47%) was the most frequently observed marker, followed by increased 
blood pressure (45%), TG (42%), waist circumference (30%), and fasting glucose (20%). An 
increasing MS score was significantly related to higher frequency of acute coronary syndrome. In 
307 lesions, there was no relationship between the MS score and angiographic and IVUS severity 
of stenosis (LA and %AS) at the most narrowest point. However, the MS score was significantly 
correlated with VA (p=0.015), PA (p=0.041) and the plaque eccentricity index (p=0.001) at the 
most narrowest point. For volumetric analysis, mean analysis slices was 36.2±8.6 and atheroma 
volume averaged 312.4±94.9 mm3 for each lesions. The atheroma volume were larger in subjects 
with higher scoring group (p=0.0031).
Conclusions: Although stenosis severity was not different among MS score subgroups, 
volumetric measurements of IVUS for disease burden were worse in subjects with higher 
MS scoring. Therefore, the MS score provides a clinically useful index of the extent of 
atherosclerotic disease.
10:00 a.m.
1013-196 “Cool It”: Therapeutic Hypothermia for Anoxic 
Encephalopathy in a High-Risk Transfer Population of 
Cardiac Arrest Patients_Initial Results
Kalie Edelstein, William M. Parham, Jon Hokanson, Barbara T. Unger, David I. Page, Pam S. 
Rush, Charlene R. Boisjolie, Timothy D. Henry, Michael R. Mooney, Minneapolis Heart Institute 
Foundation at Abbott North, Minneapolis, MN
Background: Therapeutic hypothermia (TH) is emerging as the treatment of choice 
for anoxic encephalopathy following cardiac arrest and is currently recommended by 
ACC and ILCOR guidelines.
Methods: In this consecutive series, “Cool It” protocol results were analyzed for cardiac arrest 
patients who met inclusion criteria of unresponsiveness after a return of spontaneous circulation 
(ROSC): initial Rankin score 4. Pts were cooled to a target core temp of 33ºC for 24 hrs.
Results: From 2/06 to 8/06, 18 pts, mean age 58.2, were cooled. 15/18 pts presented at 
referring emergency departments (ED) and were transferred an average of 68 miles to Abbott 
Northwestern (ANW) hospital. 11 pts were part of the Level 1 (L1) Heart Attack Program for 
emergent percutaneous coronary intervention (PCI) treatment of their ST-elevation myocardial 
infarction (MI). 7 pts were non-L1 (NL1). For L1 pts, from arrival at ANW average time to onset 
of cooling was 153 mins. Mean time between ROSC and cooling was 193 mins, and the 
subsequent mean time to 33ºC was 173 mins. Average time in transfer from presenting ED 
to ANW was 31 mins. The mean time in the cath lab was 81 mins, and the mean time from 
initial balloon deployment to cooling was 142 mins. Mean ejection fraction (EF) prior to PCI was 
15%, and pre-discharge mean EF was 35%. 7/11 L1 pts were in cardiogenic shock. 6/11(54%) 
L1 pts survived with favorable neurological outcomes, and 5/6 had a Rankin score of 1: return 
to independent living at home. All 5 previous L1 workers returned to work. NL1 survival was 
2/7(28%). Overall survival was 8/18(44%). Initial rhythm VT/VF survival was 8/12(67%), and 
PEA/asystole survival was 0/6(0%).
Conclusions: TH can be extended to a broader range of pts than previously studied. Favorable 
results were found in this high-risk group of L1 transfer patients. Further, a TH protocol may serve 
as a constructive neuroprotective adjunct to an established acute MI program.
10:00 a.m.
1013-197 Acute Coronary Angiographic Findings in Survivors of 
Out-of-Hospital Cardiac Arrest
Zacharias Alexandros Anyfantakis, Gabriel Baron, Pierre Aubry, Dominique Himbert, 
Laurent J. Feldman, Didier Tchetche, Jean-michel Juliard, Dennis V. Cokkinos, Philippe 
Gabriel Steg, Hopital Bichat - Claude Bernard, Paris, France
Background: The diagnosis and treatment of acute coronary artery disease in survivors 
of out of hospital cardiac arrest (OHCA)is very difficult. The role of emergency coronary 
angiography and percutaneous intervention (PCI) in this setting is debated. We assessed 
the prevalence of coronary lesions on emergency angiography in these patients, the 
frequency of indications for PCI and the impact of PCI on survival.
Methods: 72 consecutive OHCA survivors underwent systematic routine emergency 
coronary angiography upon hospital admission. Pts with critical stenoses or occlusion 
underwent ad hoc PCI
Results: 63.9% had at least one coronary stenosis > 50%, with single vessel disease 
in 23.6% and multivessel disease in 40.3%. Total occlusion was present in 16.7%, and 
irregular lesions (suggestive of ruptured plaque)or thrombus were present in 25%. A final 
clinical diagnosis of acute myocardial infarction was assigned in 37.5% of the patients. 
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PCI was attempted and successful in 24 patients. Hospital survival was 48.6%. By 
multivariate analysis, use of PCI was not an independent predictor of survival
Conclusions: The majority of OHCA survivors have angiographic coronary artery 
disease, but only a minority have angiographic or clinical evidence of acute coronary 
syndrome. PCI was warranted in one third of the patients, but was not an independent 
predictor of survival. There is a dire need for improved methods to identify patients with 
acute myocardial infarction among survivors of OHCA.
10:00 a.m.
1013-198 Are There Any Differences in the Clinical And 
Angiographic Correlates of Short- And Long-term 
Mortality In Patients Undergoing Coronary Artery 
Bypass Surgery?
Rajendra H. Mehta, Emily Honeycutt, Linda K. Shaw, Carmelo A. Milano, Michael H. Sketch, 
Jr., Duke Clinical Research Institute and Duke University Medical Center, Durham, NC
Background: Differences in the clinical and angiographic factors associated with short- and long-
term mortality after CABG are currently less known.
Methods: Accordingly, we analyzed 8229 patients undergoing CABG enrolled in the Duke 
Cardiovascular Disease Database (1986 to 2003).
Results: At a median follow-up of 6 years, 22% undergoing isolated CABG died. Independent 
correlate of 30-day and long-term (beyond 30-day) death as determined from multivariable 
models are shown in Table in descending order of their Chi-square values (c-index 0.76 and 0.79, 
respectively). Age, ejection fraction, BMI, cerebrovascular disease, IMA use, and increase cholesterol 
were associated with both events. While hemodynamic status (preoperative myocardial infarction, 
NYHA Class, cardiogenic shock), female gender and non-Caucasian race were associated with 
30-day death; comorbid conditions (serum creatinine, COPD, diabetes, CHF, peripheral vascular 
disease and left main disease) were more likely to be associated with death beyond 30 days. 
30-day and Long-term Correlates of Mortality in Patients Undergoing CABG
Variables- 30-day 
death
Wald 
Chi-
square
Odds 
Ratio
95% 
CI
Variables-long-term beyond 
30-day death
Wald Chi-
square
Hazard 
Ratio
95% 
CI
Age, per 10-year 
increase 33.1 1.58
1.35-
1.84 Age, per 10-year increase 411.2 1.62
1.54-
1.69
NYHA Class 15.9 1.33 1.16-1.52 Serum Creatinine, mg/dl 227.0 1.23
1.19-
1.26
Non-Caucasian race 13.5 1.75 1.30-2.35 LV ejection fraction 153.5 0.98
0.98-
0.98
Cardiogenic shock 12.8 3.31 1.72-6.39 COPD 76.7 1.29
1.22-
1.36
Cerebrovascular 
disease 11.7 1.86
1.30-
2.65 Diabetes 52.1 1.40
1.28-
1.53
Female gender 9.5 1.60 1.19-2.16 Prior heart failure 49.1 1.46
1.32-
1.63
BMI <28 kg/m2 8.9 0.92 0.87-0.97 Peripheral vascular disease 34.7 1.38
1.24-
1.54
Hypercholesterolemia 8.4 0.64 0.47-0.87 Cerebrovascular disease 29.1 1.38
1.23-
1.55
LV ejection fraction 7.8 0.98 0.97-0.99 BMI >28 kg/m2 23.4 1.03
1.02-
1.04
BMI >28 kg/m2 6.5 1.05 1.01-1.08 Hypercholesterolemia 22.7 0.81
0.74-
0.88
Preoperative MI 5.9 1.45 1.07-1.95 BMI <28 kg/m2 20.3 0.96
0.94-
0.98
Internal mammary 
artery use 4.2 0.62
0.39-
0.98 Left main disease 12.2 1.20
1.08-
1.32
Internal mammary 
artery use Internal mammary artery use 7.4 0.81
0.69-
0.94
Conclusions: Our study suggests that correlates of acute and long-term death are different 
among patients undergoing CABG. These differences should be kept in context when 
counseling patients undergoing CABG and may help facilitate improved clinician-patient 
discussions regarding the individual’s short- and long-term mortality risks after CABG.
10:00 a.m.
1013-200 Broad Spectrum Adenoviral CC-Chemokine Blockade 
Attenuates Long Term Vein Graft Accelerated 
Atherosclerosis in ApoE-Knockout Mice
ZIAD A. ALI, Asim M. Akhtar, Christina A. Bursill, Robin P. Choudhury, David R. 
Greaves, Keith M. Channon, University of Oxford, Oxford, United Kingdom
Background: Accelerated atherosclerosis, a major cause of late vein graft (VG) failure 
after bypass surgery, is characterized by inflammation. The CC-chemokines (CKs) are 
critical in the mediation of accelerated atherosclerosis through monocyte recruitment.
Methods: To investigate the role of monocyte recruitment in VG atherosclerosis, we 
administered a soluble CC-CK binding protein (‘35K’) using in vivo gene transfer to ApoE-KO 
mice that underwent interposition bypass grafting. Two days prior to operation a recombinant 
adenovirus encoding a broad spectrum CC-CK inhibitor (Ad35K) or green fluorescent protein 
(AdGFP, control) was administered.
Results: Gene transfer was confirmed by the detection of 35K protein in plasma and green 
fluorescent cells in hepatocytes of control animals at 2 and 4 weeks following surgery. 
Grafts were harvested 12 weeks post surgery. Ad35K gene transfer significantly reduced 
late VG atherosclerosis lesion area by 33 % (*P <0.05) compared to AdGFP control. 
Immunohistochemistry revealed gene transfer reduced macrophage content by 85% (# 
P<0.01). Interestingly, a 35KD protein was detected in the plasma of Ad35K treated animals 12 
weeks postoperatively, indicating CC-CK blockade was able to prolong adenoviral half-life.
Conclusions: A single intravenous injection of the CC-CK inhibitor 35K significantly 
reduced VG atherosclerosis, highlighting the importance of the CC-CK class in VG 
disease and their potential as a target for improving VG patency.
10:00 a.m.
1013-201 Platelet Activity And Aspirin Efficacy After Off-Pump 
Compared To On-Pump Coronary Artery Bypass 
Surgery
Frantisek Bednar, Pavel Osmancik, Tomas Vanek, Heidi Mocikova, Martin Jares, 
Zbynek Straka, Jan Hlavicka, Petr Widimsky, Cardiocenter, Kralovske Vinohrady 
University Hospital, Clinic of Cardiac Surgery, Prague, Czech Republic, 3rd Medical 
School of Charles University, Prague, Czech Republic
Background: Changes in hemostasis and aspirin efficacy after coronary artery bypass 
grafting (CABG) surgery and their influence on graft failure is currently still discussed. 
There is lack of information about platelet activity and aspirin efficacy after off-pump 
compared to on-pump CABG surgery in early postoperative period.
Methods: 60 patients undergoing CABG were enrolled in prospective randomized study 
(30 off-pump vs. 30 on-pump). Platelet activity was determined by membrane expression 
of platelet antigen CD 62P (P-selectin) by flow cytometry as % of positive cells. Aspirin 
efficacy was assessed by platelet aggregometry after arachdonic acid (ARA) stimulation. 
Blood samples were collected before surgery, immediately postoperatively, on days 1,2, 
5 and day 30 after surgery.
Results: Baseline characteristics and intraoperative variables were comparable in both 
groups, except for grafts count. In off-pump group, membrane expression of CD62P 
was increased in early postoperative period compared to preoperative values with 
maximum diffference observed on day 2 (2,5+1,2 vs.1,6+0,8; p<0.05). In the on-pump 
group, postoperative expression of CD62P was similar to preoperative values during 
whole period studied with only non-significant tendency to decreased expression on 
day 5 (1,4±0,5 vs. 1,7±0,9; p=N.S.). The difference in CD62P expression was significant 
between both groups on day 5 (2,1±0,7 vs. 1,4±0,5; p<0.05). No changes to preoperative 
values were evident in both groups on day 30. Platelet ARA-aggregation was significantly 
decreased immediately after operation and on day 1 in both groups (-70%;p< 0,05) and 
the decrease was sustained until day 30. However, there was an unexpected increase 
of ARA agregation on day 2 compared to day 1 and day 5, in off-pump patients even 
significantly higher than in on-pump (41±15 vs. 30±17; p<0.05).
Conclusions: The platelet activity is higher in early postoperative period in off-pump 
compared to on-pump CABG surgery. The present anti-platelet treatment with aspirin seems 
to be insufficient in early postoperative period, irrespective of surgical technique used.
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1019-69 Can C Reactive Protein Levels Be a Predictor of 
Intravascular Ultrasound Intimal Hyperplasia Obstruction 
after Zotarolimus-Eluting Stent implantation?
Julio Maia, Andrea S. Abizaid, Alexandre Abizaid, Leandro I. Lasave, Dimytri Siqueira, 
Fausto Feres, Luiz A. Mattos, Rodolfo Staico, Luiz F. Tanajura, Amanda G M R Sousa, 
J. Eduardo Sousa, Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil
Background: Levels of C-reactive protein (CRP) have been associated with increased 
risk for cardiovascular events. However, its possible role in predicting restenosis after 
drug-eluting stents (DES) has not been well established.
Objective: To evaluate whether elevated levels of CRP correlates with higher in-stent 
intimal hyperplasia (IH) volume by intravascular ultrasound (IVUS) at 4-month follow up 
(FU) after DES implantation.
Methods: Thirty-seven patients (P) were successfully treated with the implantation of 
1 zotarolimus-eluting stent (ZoMaxx™) for de novo single lesions in native coronary 
arteries. We measured CRP in all P post-procedure. IVUS was performed after the 
procedure and at 4-month FU. P were divided in four quartile-groups (QUA) according to 
the post-procedure levels of high-sensitive CRP and analyzed by ANOVA.
Results: Baseline characteristics were similar among the groups. In-stent IH was 
evaluated and compared to the CRP level (table). There was significant increase of in-
stent IH in the forth QUA compared to the first (10.11±7.41 versus 3.20±3.89; p=0.03). 
By multivariate regression analysis including all clinical and angiographic data, CRP was 
correlated to in-stent IH volume (r 0.61; p=0.0001 IC95% 0.3-0.7).
Conclusions: Four-month IVUS volumetric analysis showed higher in-stent IH in P with 
elevated CRP. Although these findings might associate DES restenosis to the elevation 
of this biomarker, further studies are necessary to assess its relevance on clinical 
outcome.
QUA 1 QUA 2 QUA 3 QUA 4
Number of Patients 8 9 10 10
CRP Levels (mg/L) 0.10 - 1.00 1.01 - 3.06 3.07- 8.60 8.61 - 52.6
I H Volume (mm3) 3.20 ± 3.89 2.53 ± 2.50 4.12 ± 3.60 10.11 ± 7.41
2:30 p.m.
1019-70 Sildenafil Exerts Direct Cardioprotective Effects On 
Hl-1 Cells Inducing Nitric Oxide-mediated Opening Of 
MitoKATP Channels
Joshua Martindale, Zuhair Allebban, Zhaokan Yuan, John Abboud, Justin Di Rezze, 
Ravindra Kakarla, Louis Saravolatz, Julius Gardin, Paul Townsend, Carol Chen-
Scarabelli, Tiziano M. Scarabelli, St John Hospital/Wayne State University, Detroit, 
University of Michigan, Ann Arbor
Background & Objectives: Sildenafil (S) is believed to exert cardioprotection inducing 
relaxation of vascular smooth muscle cells. S can also protect myocytes directly, by inducing 
the expression of cytoprotective proteins, such as nitric oxide (NO) synthase. Here, we aimed 
at testing whether a) S can directly protect HL-1 cells against hypoxia(H)/reoxygenation(R); 
b) whether S-induced cardioprotection is mediated by activation of mitoKATP channels 
(mKATP); and, if so, c) whether this activation is direct or mediated by NO.
Methods: HL-1 cells were incubated for 1 h with S (10 ug/ml) and exposed to 3 h H 
and 6 hours R. Apoptosis was assessed by DNA fragmentation, TUNEL, or caspase 
immunoblotting. NO synthase protein or mRNA expression was measured by 
immunoblotting or real-time RT-PCR, respectively.
Results: HL-1 cells exposed to H/R displayed 1.5±0.4% TUNEL+ cells, whereas cells 
pretreated with S showed only 0.6±0.2% TUNEL+ cells, similar to control cells. DNA 
fragmentation in H/R-treated cells was 1.9±0.5 fold greater than control cells (1.0±0.2 
fold); S-pretreated cells exhibited only 1.4±0.1 fold DNA fragmentation relative to control. 
In addition, H/R-treated cells displayed a 4.6±2.1 fold increase in active fragments of 
caspase-3 compared to control, whereas S-pretreated cells exhibited a decrease to 
2.8±0.6 fold over control. To determine if NO synthase is involved in S-induced protective 
effects, inducible NO synthase (iNOS) protein expression levels were assessed. S induced 
iNOS protein expression by 1 hour, and reached even higher levels by 2 and 4 hours. 
Real-time RT-PCR also showed that S induced iNOS mRNA by 2.6±1.8 fold, compared 
to controls. The NO scavenger PTIO, as well as the specific inhibitor of mKATP channels 
5-hydroxydecanoate (5HD) abolished S-mediated cardioprotection, suggesting that S-
induced opening of mKATP channels is not direct, but mediated by NO production.
Conclusions: Here, we show, for the first time, that S directly protects HL-1 cardiac 
cells from H/R-induced apoptosis. Furthermore, we demonstrate, again for the first time, 
that S provides cardioprotection by inducing indirect opening of mKATP channels, via 
modulation of NO production.
2:30 p.m.
1019-71 Cardiac Overexpression of Sarcoplasmic Reticulum 
Ca2+-ATPase with Resistance to Oxidative and 
Acidotic Stress Protects against ex vivo and in vivo 
Postischemic Myocardial Injury
M.A. Hassan Talukder, Anuradha Kalyanasundaram, Xue Zhao, Poornima Bhupathy, 
Gopal J. Babu, Arturo J. Cardounel, Muthu Periasamy, Jay L. Zweier, Davis Heart and 
Lung Research Institute, The Ohio State University, Columbus, OH
Background: Myocardial ischemia/reperfusion (I/R) injury is associated with contractile 
dysfunction and myocyte death. Sarcoplasmic Reticulum Ca2+-ATPase (SERCA) plays 
a central role in cardiac contraction and relaxation by maintaining intracellular Ca2+ 
homeostasis. Reactive oxygen species (ROS) and peroxynitrite are formed during 
postischemic reperfusion and damage SERCA, contributing to cellular Ca2+ overload and 
injury. During myocardial ischemia and early reperfusion, marked acidosis occurs and 
can greatly decrease SERCA activity. While SERCA2a is the cardiac isoform, SERCA1a 
has been shown to substitute SERCA2a with faster Ca2+ transport kinetics and resistance 
to oxidative and acidotic stress. Recently, we have proposed that cardiac-specific 
expression of SERCA1a not only substitute for SERCA2a but can improve postischemic 
contractile recovery and myocardial salvage.
Methods: In vitro I/R studies were performed in Langendorff hearts from SERCA1a 
transgenic (TG) and non-transgenic (NT) mice for Ca2+ uptake activity, ROS and 
peroxynitrite measurements, and electron microscopy (EM). In vivo regional myocardial 
I/R studies were performed for myocardial infarction.
Results: Baseline coronary flow, LV developed pressure and Ca2+ uptake was markedly 
higher in isolated TG hearts. While, both NT and TG hearts generated comparable extents of 
postischemic ROS and peroxynitrite, TG hearts exhibited accelerated and markedly improved 
(~2-fold) recovery of postischemic myocardial contractile function with reduced (~2-fold) 
infarction. Concordantly, Ca2+ uptake activity was decreased by only 10% in postischemic 
TG hearts compared to 25% decrease in NT hearts. EM showed better-preserved myofibrillar 
and mitochondrial ultrastructure in TG hearts. The cardioprotective effect of SERCA1a was 
also observed during in vivo regional I/R with markedly reduced myocardial infarct size.
Conclusions: Our findings that TG hearts were markedly protected against I/R 
injury, suggest that a SERCA isoform of faster kinetics with resistance to oxidative 
and metabolic stress provides potent myocardial protection with preservation of Ca2+ 
uptake, myocardial function and cell viability.
2:30 p.m.
1019-72 Time Course Of Microvascular Obstruction After Acute 
Myocardial Infarction: Rapid Expansion Of Anatomic 
No-reflow During Reperfusion In The Pig
Eleftheria Tsagalou, Charalampos Pierrakos, Nikolaos Lazaris, Efstratios Charitos, 
Paraskevi Savvari, Sotiris Marinakis, Hercules Pozios, john Venetsanakos, George 
Maroulidis, stavros Stavrakis, Maria Anastasiou-Nana, University of Athens, Athens, Greece
Background: Microvascular obstruction within an area of myocardial infarction indicates worse 
functional recovery and a higher risk of post-infarction complications. Because the time course 
of microvascular obstruction after infarction/reperfusion has not been completely studied, we 
examined whether microvascular obstruction reaches its full extent very early after reperfusion.
Methods: In a swine ischemia-reperfusion model with descending coronary artery (LAD) 
occlusion and reperfusion, the anatomic no-reflow was determined at 0, 15 and 120 min of 
reperfusion, by injection of thioflavin S, through a catheter cannulating the LAD at the end of 60 
min of ischemia and through the left atrium at the end of 15 and 120 minutes of reperfusion.
Results: At the end of ischemia and before any reperfusion, the area of no-reflow was 
27.6±14% of the risk area. Fifteen minutes after reperfusion the no-reflow was 47.1±8% of 
the risk area (p=0.043 versus time 0) and 45±20% after 120 min of reperfusion (p=0.043 vs 
time 0 min and p=ns versus time 15min). This rapid expansion of the no-reflow predominantly 
occurred during the first 15 min of reperfusion.
Conclusions: Reperfusion injury appears to be responsible for a nearly twofold increase 
of anatomic no-reflow within the first 2h of reperfusion. This expansion of the no-reflow 
phenomenon predominantly occurs early, during the first 15min of reperfusion.
2:30 p.m.
1019-73 The Heart-Kidney Connection: Myocardial Infarction 
Accelerates Glomerular Dysfunction, Hypertrophy and 
Proteinuria in Experimental Mild Renal Insufficiency
Fernando L. Martin, Brenda K. Huntley, Alessandro Cataliotti, Gerald Harders, Margaret 
M. Redfield, Horng Chen, John C. Burnett, Jr., Mayo Clinic, Rochester, MN
Background: Decreased renal function is associated with increased cardiovascular 
morbidity in acute myocardial infarction (MI). We sought to confirm and extend previous 
work testing the hypothesis that MI without heart failure (HF) would of accelerate 
worsening of renal structure and function in a model of mild renal insufficiency (RI) 
produced by unilateral nephrectomy (NX).
Methods: Rats were assigned to 3 groups: Sham (n=10), NX (n=9) and NX+MI (n=10). 
Day 1 rats underwent NX and 1 wk later MI produced by coronary artery ligation. At 4 wk 
we assessed cardiorenal structure and function.
Results: Three wk following MI in the presence of NX, GFR was decreased compared 
to Sham (S) and NX groups (S: 7.3±0.8, NX: 5.2±0.6, NX+MI: 2.1±0.3 ml/min, p<0.01). 
Glomerular hypertrophy was present in the NX group compared to S and increased further 
in the MI+NX group compared to the NX group (S: 1±0.04, NX: 1.63±0.1, NX+MI: 2.13±0.1 
u3x106, p<0.01). Proteinuria had a strong trend to increase after MI+NX compared to S and 
NX. Plasma BNP was elevated in NX+MI compared to S and NX (p<0.05) as was plasma 
cGMP (p<0.01); however UcGMPV and UVBNP were not different among groups. GeneChip 
Rat Genome 230 2.0 Array (Affymetrix) revealed that gene expression of eNOS was 
downregulated in the NX+MI groups in the kidney compared to S and NX. EF was decreased 
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in NX+MI as compared to other groups (p<0.05) with no evidence of overt HF as SBP, UNaV 
and RAAS were not different among groups. 
Conclusion: We conclude that MI without overt HF accelerates renal structural and functional 
dysfunction in a model of mild RI. The downregulation of eNOS in the kidney and the failure of 
UcGMPV and UVBNP to increase despite elevations of plasma levels suggest an intrarenal 
derangement of the natriuretic peptide and/or NO pathways contributing to this important 
heart-kidney connection in MI.
2:30 p.m.
1019-74 Ethnic Differences in Plasma Adiponectin Levels 
among Hypertensive Adults
Allison A. Ellington, George G. Klee, Kent R. Bailey, Stephen T. Turner, Thomas H. 
Mosley, Jr., Iftikhar J. Kullo, Mayo Clinic, Rochester, MN, University of Mississippi 
Medical Center, Jackson, MS
Background: Low plasma adiponectin levels are associated with increased vascular risk. 
We investigated whether plasma adiponectin concentrations differ between hypertensive 
African Americans (AA) and non-Hispanic White (NWH) subjects.
Methods: Subjects included 819 AA from Jackson, MS (mean age 63.8 years; 72.6% 
women), and 782 NHW from Rochester, MN (mean age 60.5 years; 57.5% women) 
belonging to hypertensive sibships. Plasma adiponectin was measured by RIA and 
analyses were stratified by sex. We assessed whether ethnicity was a significant predictor 
of adiponectin levels after adjustment for the following risk factors: conventional (age, 
sex, BMI, total cholesterol, LDL-C, HDL-C, diabetes, smoking and systolic BP), ‘novel’ 
(homocysteine, CRP and fibrinogen), ‘metabolic’ (waist circumference, insulin, glucose and 
TG), ‘lifestyle’ (alcohol use, physical activity and education), and medications (statin and 
hypertension medications, and estrogen (in women)). Multiple regression analyses were 
performed using generalized estimating equations to account for intrafamilial correlations.
Results: Plasma adiponectin levels were significantly lower in AA men than in NHW men (10.4 
μg/mL vs. 8.7 μg/mL, P < 0.0001). AA ethnicity remained an independent predictor of lower 
adiponectin levels in men after adjustment for the covariates listed above. Additional independent 
predictors of lower adiponectin levels in men were higher insulin and TG, and lower HDL-C, 
systolic BP, homocysteine and smoking history. Plasma adiponectin levels also were significantly 
lower in AA women than in NHW women (10.9 μg/mL vs.14.0 μg/mL, P < 0.0001). As in men, AA 
ethnicity remained an independent predictor of lower adiponectin levels after adjustment for risk 
factors. Additional independent predictors of lower adiponectin levels in women were higher waist 
circumference, insulin and TG; lower HDL-C, BMI and homocysteine; and smoking history. 
Conclusion: Plasma adiponectin levels are markedly lower in hypertensive AA men and women 
than their NHW counterparts. Further work is needed to establish whether lower adiponectin 
levels contribute to the greater cardiovascular risk in hypertensive AA adults.
2:30 p.m.
1019-75 Excess Endothelin-1 Results in Fatal Calcium Overload in 
Porcine Myocardial Infarction and Isolated Rabbit Myocytes
Sophie Tamareille, Hela Achour, James Amirian, Patricia Felli, Roger J. Bick, Brian 
Poindexter, Yong-Jian Geng, Robert E. Lasky, Fenghua Li, William H. Barry, Richard W. 
Smalling, The University of Texas Health Science Center at Houston, Houston, TX
Background: The mechanisms by which left ventricular (LV) unloading limits infarct size 
in acute myocardial infarction are unknown. We tested the hypothesis that endothelin-1 
(ET-1) causes myocyte calcium (Ca2+) overload which results in myocardial reperfusion 
injury and can be inhibited by LV unloading immediately prior to reperfusion. 
Methods: 12 anesthetized pigs were subjected to 1 hour of left anterior descending coronary 
artery (LAD) occlusion followed by 4 hours of reperfusion. A trans-valvular LV assist device 
(LVAD) was initiated 15 min prior to reperfusion and maintained during the entire period of 
reperfusion (LVAD group, n=6). A control group (n=6) was subjected to reperfusion alone. 
In parallel, isolated rabbit myocytes were subjected to simulated ischemia/reperfusion with 
and without endothelin-1 and intracellular Ca++ was assessed with flow cytometry.
Results: Just prior to reperfusion, LV unloading significantly decreased the LV pressures. 
Infarct size (IS), expressed as a percentage of zone at risk, was also significantly reduced 
in the LVAD group compared to controls (24.10±6.45% vs 51.59±6.64%, P=0.014). LVAD 
support significantly reduced ET-1 release from the heart at 15 min (3.51±3.15 pg/100μL 
vs 8.86±1.76 pg/100μL, P=0.024), and 1 hour of reperfusion (-2.26±3.38 pg/100μL vs 
13.99±4.15 pg/100μL, P=0.002). LV unloading caused a significant reduction of Ca2+ 
overload (expressed as ischemic to non-ischemic intracellular Ca2+ ratio) at reperfusion 
(1.18±0.28 vs 4.86±1.20, P=0.016) and a similar reduction in the % of apoptotic cells 
(15.15±6.4% vs 56.69±5.17%, P=0.014) in the ischemic region. In isolated ventricular 
myocytes subjected to simulated ischemia/reperfusion, ET-1 at physiologic levels also 
increased Ca2+ uptake and decreased myocyte viability.
Conclusions: LV unloading, prior to reperfusion, reduces ET-1 release which results 
in decreased Ca2+ overload and reduced apoptosis in the ischemic region, leading to a 
54% reduction of IS in a porcine ischemia-reperfusion model. This suggests that ET-1 
release by ischemic myocardium at the time of reperfusion results in fatal myocardial Ca2+ 
overload and is likely an important mediator of reperfusion injury.
2:30 p.m.
1019-90 Acute Metformin Therapy Protects Against Myocardial 
Ischemia-Reperfusion Injury
John W. Calvert, Susheel Gundewar, Konstantinos P. Koulogiannis, Dvorah Holtzman, 
David N. Bartov, Saurabh Jha, Sandeep Patel, David J. Lefer, Albert Einstein College of 
Medicine, Bronx, NY
Background: Retrospective clinical studies have reported that the widely used 
anti-hyperglycemic drug, metformin, may protect against cardiovascular disease in 
patients with diabetes and metabolic syndrome. We sought to investigate the potential 
cardioprotective effects of acute low-dose metformin in a non-diabetic murine model of 
myocardial ischemia-reperfusion (I/R) injury.
Methods: Non-diabetic mice (n=10 per group) were subjected to 30 min of left coronary 
artery occlusion and 4 or 24 hr of R. Metformin, 125 μg/kg or vehicle was administered 
i.v. at the time of R. Mice were exsanguinated at 4hrs of R to measure serum cardiac 
enzymes using ELISA. In additional studies at 24 hr of R, hearts were excised and 
evaluated for infarct (INF) size using 2,3,5-triphenyltetrazolium chloride (TTC) staining.
Results: Mice receiving metformin exhibited a 50 and 56 % reduction in serum CK-
MB and troponin-T respectively. Additionally, metformin treated mice exhibited a 51% 
reduction in infarct size per area-at-risk (INF/AAR) and a 52% reduction in infarct size per 
left ventricle (INF/LV). No change in serum glucose level was observed in either group.
Conclusions: These dramatic results indicate that administration of low dose metformin 
confers cardioprotection by attenuating the extent of myocardial injury following I/R, 
independent of its anti-hyperglycemic effects. 
2:30 p.m.
1019-91 Stem Cell-Mediated Natural Intraventricular Tissue 
Engineering
Helge Möllmann, Holger M. Nef, Christian Troidl, Sandra Voss, Melanie Klement, 
Christian W. Hamm, Michael Weber, Sawa Kostin, Albrecht Elsässer, Kerckhoff Heart 
Center, Bad Nauheim, Germany, Max-Planck-Institute for Heart and Lung Research, 
Bad Nauheim, Germany
Background: We could recently demonstrate a fully differentiated tissue formation 
including vascular structures inside a ventricular septum defect occluder in man. However, 
the extent and the mechanism of this tissue formation are yet not fully understood
Methods: In order to further investigate the potential tissue formation we developed a 
pig model with minimal invasive placement of a polyurethane scaffold in the left ventricle 
and in the infrarenal aorta serving as control. The polyurethane scaffolds had no direct 
contact to ventricular or aortic structures. These foreign bodies were analyzed using 
immunohistochemistry and quantitative real-time PCR (RT-PCR).
Results: The tissue formation on the foreign bodies could be confirmed in both, the 
intraventricular and aortal scaffold. The newly formed tissue was mainly defined by smooth 
muscle cells. Numerous fibroblasts, myofibroblasts and vascular structures including 
vascular endothelial cells could be identified by immunohistochemistry. We found strong 
evidence, that the tissue formation is promoted by homing stem cells given the high 
degree of CD34, c-kit and sca-1 positive cells as evidenced by immunohistochemistry 
and RT-PCR. Interestingly, early cardiomyocyte markers (GATA-4, islet-1, Nkx2.5) were 
found in the intraventricular foreign body, whereas in the scaffold placed in the infrarenal 
aorta no cardiomyocyte formation could be demonstrated.
Conclusion: Since the foreign bodies had no direct contact to ventricular or vascular 
structures, it has to be assumed that the differentiated cells had not migrated per 
continuitatem but rather had been derived from the circulating blood. The fact that a 
cardiomyocyte-like transdifferentiation occurred only in the intraventricular but not in the 
aortal foreign body suggests that the intraventricular milieu and potential paracrine action 
play a crucial role.
2:30 p.m.
1019-92 Hydrogen Sulfide Donor Confers Protection Against 
Acute Myocardial Ischemia-Reperfusion Injury
Susheel Gundewar, John W. Calvert, Dvorah Holtzman, Konstantinos P. Koulogiannis, 
David Bartov, Saurabh Jha, Sandeep Patel, John W. Elrod, David J. Lefer, Albert 
Einstein College of Medicine, Bronx, NY
Background: Hydrogen sulfide (H2S) is an endogenously produced gaseous signaling 
molecule that has been reported to modulate a number of physiological actions including: 
vasodilation and inhibition of oxidative stress, leukocyte chemotaxis and apoptosis. We 
hypothesized that H2S would limit myocardial injury and improve ventricular function in an 
in vivo murine model of myocardial ischemia-reperfusion (I-R) injury.
Methods: Mice (n=8 per group) were subjected to 45 min of left coronary artery occlusion 
and 72 hr of R. The H2S donor, sodium hydrosulfide hydrate (NaHS, 50 μg/kg) or vehicle 
was administered i.v. at the time of R. At 72 hr of R, hearts were excised and evaluated 
for infarct size using 2,3,5-triphenyltetrazolium chloride (TTC) staining. High-resolution 
echocardiography was performed 1 week before ischemia (BASE) and 72 hr following 
reperfusion (POST) in each group.
Results: Mice receiving NaHS exhibited a 51% reduction in infarct size per area-at-risk 
(INF/AAR). NaHS treated mice also exhibited a 40% improvement in fractional shortening 
at 72 hr following R.
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Conclusions: These results indicate that administration of an H2S donor at the time of R 
may prove to be a promising treatment in attenuating the extent of myocardial injury and 
improving LV function following myocardial infarction. 
2:30 p.m.
1019-93 The False Paradox of Higher Case-Fatality of Acute 
Myocardial Infarction Among Young Women Compared 
to Men
Yu-Hsuan Shao, Abel E. Moreyra, Alan C. Wilson, William J. Kostis, Nora M. Cosgrove, 
John B. Kostis, UMDNJ-School of Public Health, Piscataway, NJ, UMDNJ-Robert Wood 
Johnson Medical School, New Brunswick, NJ
BACKGROUND. Young women hospitalized with acute myocardial infarction (MI) have 
higher in-hospital mortality than young men. However, the reasons for this difference 
have not been well characterized.
METHODS. We analyzed data on 260,131 patients who were discharged with the 
diagnosis of MI from non-federal hospitals in New Jersey and 148,474 out-of-hospital 
sudden cardiac deaths (SCD) between 1986 and 2002 in four age strata, 35-54, 55-64, 
65-74 and 75 years and above.
RESULTS. Young (35-54 years) women had higher in-hospital mortality than young men 
(3.6% vs. 2.2%, p<0.0001). When SCD was included in the analysis, young men had 
a higher death rate than women (18.6% vs. 17.2%, p=0.0007). Among NJ residents, 
young men were five time more likely to suffer SCD than women (36.2 vs. 7.1), four times 
as likely (178 vs. 43) to be hospitalized for MI and only twice (3.8 vs. 1.6) (all rate per 
100,000) more likely to die from MI in the hospital. Women had higher adjusted OR for 
in-hospital mortality (Panel A) and lower OR for SCD than men (Panel B) (among patients 
who had survived an MI for at least 3 years).
CONCLUSION. The higher mortality rate of young women hospitalized for MI compared 
to young men could be explained in part by the fact that young men with MI are more 
likely to die before admission.
2:30 p.m.
1019-94 Favorable Effect of Statins on Local Inflammatory 
Activation in Non-culprit Lesions of Patients With 
Multivessel Coronary Artery Disease.
Konstantinos Toutouzas, Maria Drakopoulou, Virginia Markou, John Karabelas, Manolis 
Vavuranakis, Eleftherios Tsiamis, Aris Androulakis, Dimitrios Tousoulis, Christodoulos 
Stefanadis, First Department of Cardiology, University of Athens, Hippokration hospital, 
Athens, Greece
Background: Marked thermal heterogeneity has been demonstrated in culprit lesions. 
Moreover, statin treatment reduces thermal heterogeneity in culprit atherosclerotic 
plaques. The impact however of statins in non-culprit (NCL) plaque temperature has not 
been extensively investigated. The aim of the present study was to investigate whether 
statin administration is associated with reduced local inflammatory activation in non-
culprit lesions.
Methods: We included 80 patients (pts) with acute coronary syndromes (ACS) or stable 
angina (SA) undergoing percutaneous coronary intervention in culprit lesions, having an 
intermediate non-culprit lesion. The NCL had to be clearly identified from the culprit lesion 
by the combination of precrisis and intercrisis ECG findings, left ventricular wall motion 
abnormalities, scintigraphic defects, and angiographic lesion morphology. Forty-eight 
pts were treated with statin≥ months and 32 pts were not treated. Local inflammatory 
activation was estimated by measuring the temperature difference of NCL (ΔT), assigned 
as the difference between the proximal vessel wall temperature from the maximal 
temperature at the atherosclerotic plaque.
Results: Mean ΔT was 0.08±0.07oC. Pts with ACS had higher ΔT compared to pts 
with SA (ACS: 0.10±0.07oC vs SA: 0.05±0.05, p<0.01). ΔT was less in pts treated with 
statin in both groups (ACS: 0.07±0.04°C vs 0.13±0.08°C p=0.009; SA: 0.04±0.04°C vs 
0.09±0.07°C, p=0.01). Pts with DM had increased thermal heterogeneity compared to 
non-diabetic patients (ΔT: 0.06±0.05ºC vs 0.11±0.9ºC, p<0.01). Pts with DM and ACS 
had increased thermal heterogeneity compared to non-diabetic patients with ACS 
(0.14±0.09ºC vs 0.08±0.04ºC, p<0.01). Furthermore, patients with DM and SA had also 
increased thermal heterogeneity compared to non-diabetics (mean ΔT: 0.09±0.08ºC vs 
0.04±0.04ºC, p=0.02).
Conclusions: Patients under statin treatment have less thermal heterogeneity in non-
culprit lesions than those not treated. Thus, statins seem to have a beneficial effect on 
non-culprit lesion heat production. Additionally, DM enhances inflammatory activation in 
non-culprit lesions.
2:30 p.m.
1019-95 ST2, a Novel Biomarker of Myocyte Mechanical 
Overload, Predicts Adverse ECG, Angiographic, 
and Clinical Outcomes in STEMI: Results from the 
CLARITY-TIMI 28 Biomarker Study
Marc S. Sabatine, Robert E. Gerszten, Luke J. Higgins, David A. Morrow, Catherine 
MacGillivray, Wei Guo, Christophe Bode, Christopher P. Cannon, Eugene Braunwald, 
Richard T. Lee, TIMI Study Group, Brigham and Women’s Hospital, Boston, MA
Background: Mechanically overloaded myocytes upregulate and secrete ST2, a receptor 
for the myocardial protective cytokine IL-33.
Methods: We correlated ST2 levels measured at baseline in 1239 STEMI pts undergoing 
lysis in CLARITY-TIMI 28 with ST resolution at 90 mins, angiographic findings at 2-8 d, 
and clinical outcomes through 30 d. Multivariable logistic regression was used to adjust 
for demographics, comorbidities, infarct location, Killip class, time to and type of lytic, 
and peak CK.
Results: Patients with higher levels of ST2 were more likely to have diabetes, present 
later after sx onset, have an anterior MI, be Killip Class II-IV, be treated with a non-fibrin-
specific lytic, and have a higher peak CK. Patients with higher levels of ST2 were less 
likely to achieve complete ST resolution at 90 mins (P=0.001), more likely to have an 
occluded infarct-related artery (P=0.0009), and more likely to have impaired myocardial 
perfusion (P=0.001) (Table). ST2 was a highly significant predictor of CV death (OR 3.95 
for 4th vs. 1st quartile, P=0.0001), CHF (OR 3.26, P=0.003), and the composite (OR 3.72, 
P<0.0001). After multivariable adjustment, patients in the top quartile of ST2 remained at 
an increased risk of CV death or CHF (adj OR 3.10, P=0.001).
Conclusion: Circulating levels of ST2 at presentation were a significant predictor 
of impaired reperfusion and CV death and CHF in patients with STEMI. By offering 
biochemical insight into myocyte overload, ST2 may serve as a new useful biomarker 
in STEMI. 
Outcome
ST2 P value for 
trendQuartile 
1
Quartile 
2
Quartile 
3
Quartile 
4
Complete ST Res at 90 mins 47.5% 42.1% 41.7% 34.8% 0.0001
TIMI Flow Grade 0/1 11.5% 10.7% 14.8% 20.3% 0.0009
TIMI Myocardial Perfusion 
Grade 0-2 43.0% 47.0% 52.7% 54.8% 0.0012
CV Death 2.5% 3.2% 3.2% 9.0% 0.0114
CHF 2.2% 1.2% 2.6% 6.8% 0.0962
CV Death or CHF 4.4% 4.4% 5.8% 14.5% <0.0001
2:30 p.m.
1019-96 Reperfusion “BURST” Arrhythmias as a Biomarker of 
Myocellular Damage Despite TIMI 3 Epicardial Flow
Mohamed Majidi, Andrzej S. Kosinski, Sana M. Al-Khatib, Miguel Lemmert, Ricardo G. 
Baeza, Suzanne W. Crater, Hein J. Wellens, Anton P. Gorgels, Mitchell W. Krucoff, Duke 
Clinical Research Institute, Durham
Background: Myocellular response to successful epicardial recanalization with primary 
PCI resulting in TIMI 3 flow is not always favorable. Sudden onset of ventricular arrhythmia 
with reperfusion may reflect reperfusion quality at a cellular level. Using simultaneous 
12-lead ECG continuous ST recovery, angiography and Holter recordings, we sought 
to correlate BURSTS of ventricular ectopy (VPC) associated with reperfusion with final 
infarct size in anterior STEMI pts treated with primary PCI.
Methods: All 142 pts with reperfused anterior STEMI had continuous digital 12-lead ECG 
and Holter monitoring, each analyzed separately in blinded core labs. BURST arrhythmia 
was defined by a sudden increase in VPCs, associated with > 50% ST recovery and TIMI 
3 flow by simultaneous angiography, based on a statistical outlier detection methodology 
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that accounts for baseline patient-specific VPC patterns. The presence or absence of 
BURST was correlated with day 7 infarct size by SPECT MIBI imaging, also analyzed in 
a blinded core lab.
Results: BURST was seen in 94 of 142 pts (66 %) with anterior MI and TIMI 3 flow after 
PCI. Correlation between BURST, predictive descriptors and infarct size is shown in table.
Conclusions: In anterior STEMI pts after successful PCI, BURSTS of ventricular 
arrhythmia associated with reperfusion predict larger infarct size. Well-defined reperfusion 
arrhythmias may be a useful real-time marker of myocellular response to epicardial 
recanalization in anterior MI.
BURST Arrhythmia
Variable Yes (n=94) No (n=48) P-value
Age, years [mean, (SD)] 57.4 (12.6) 58.0 (13.1) 0.59
Male, (%) 81 (86) 38 (79) 0.34
Pain to first balloon, min [median, 
(range)]
140.0 (105-
210)
176.5 (119-
236) 0.041
History of chronic angina, (%) 7 (7.5) 6 (12.5) 0.36
History of intermittent angina, (%) 36 (38.3) 17 (35.4) 0.85
BURST Arrhythmia
Study Outcome Yes (n=94) No (n=48) P-value
Infarct size at day 7, (%) [median, 
(range)] 26 (12-37) 14 (5-27)
0.0024 (adjusted: 
0.0007)
2:30 p.m.
1019-111 Baseline Hemoglobin and White Blood Cell Composite 
CBC Index Improves Risk Stratification in STEMI 
Patients
Roberto R. Giraldez, Mark S. Sabatine, David A. Morrow, Amy Shui, Carolyn H. 
McCabe, Elliott M. Antman, Eugene Braunwald, Brigham and Women’s Hospital, 
Boston, MA
Background: Hemoglobin (Hgb) and white blood cell (WBC) count are readily available 
predictors of cardiovascular events in acute coronary syndromes. The TIMI risk index 
(TRI = [HR*(age/10)^2 / SBP]) is an effective tool for predicting death in STEMI. We 
sought to develop a composite CBC index (CBCI) to predict mortality in STEMI and 
determine the additional risk stratification offered by adding CBCI to TRI.
Methods: We analyzed the association between baseline Hgb and WBC values and 30-d 
mortality in 18,682 pts undergoing lysis in ExTRACT-TIMI 25. Inspection of β coefficients, 
c-statistic, and r2 values in logistic regression models were used to determine the optimal, 
weighted combination of Hgb & WBC into a single CBCI as well as the combination of 
CBCI & TRI.
Results: Hgb levels <16.0 g/dL were associated with increased risk of death (OR 1.33, 
95% CI 1.28-1.38 for each 1 g/dL decrease). Elevations in WBC count >10x103/mm3 
also were associated with increased mortality (OR 1.07; 95% CI 1.05-1.08 for each 103/
mm3 rise). Regression modeling indicated the best CBCI to predict death was 4x(16-
Hgb)+(WBC-10). When categorized into quartiles CBCI revealed a 3-fold increase in 
death across groups (P<0.001). The CBCI was able to further stratify the risk of death 
across all TRI subgroups (Figure) in which both the CBCI (P=0.003) and TRI (P<0.001) 
were independent predictors of 30-d mortality.
Conclusions: CBCI is a powerful tool to further predict mortality in pts with STEMI either 
separately or in combination with TRI. 
2:30 p.m.
1019-112 Statin Therapy Prior to ST-elevation Myocardial 
Infarction is not Associated with Increased 
Spontaneous Reperfusion at the Time of Emergency 
Angioplasty
Ryan D. Christofferson, Hitinder S. Gurm, Russell E. Raymond, Sorin J. Brener, Arman 
T. Askari, Cleveland Clinic, Cleveland, OH
Background: There have been reports of increased spontaneous reperfusion of the 
infarct related artery (IRA) in ST-elevation myocardial infarction (STEMI) among patients 
on statin therapy. We sought to determine if statin therapy prior to STEMI results in an 
increase in spontaneous reperfusion as reflected by the initial Thrombolysis in Myocardial 
Infarction (TIMI) flow grade.
Methods: Retrospective review of the Cleveland Clinic interventional registry identified 
359 patients with confirmed STEMI who underwent emergency angioplasty from 1/02 
to 5/05. The diagnosis of STEMI was based on a diagnostic EKG and ongoing chest 
pain with symptom onset < 24 hours prior to catheterization. Statin use prior to ACS was 
recorded as ‘yes’ or ‘no’ by the operator, independent of duration of use. Spontaneous 
reperfusion was defined as TIMI grade 3 flow in the IRA.
Results: In 359 patients with STEMI, no association was found between spontaneous 
reperfusion and pre-STEMI statin use (see table below, Chi-square = .997, P = 0.36). This 
was true when grouping TIMI grade 0-2 compared to grade 3, and when looking at each 
TIMI grade individually. Additionally, no association was found between pre-STEMI statin 
use and level of creatine kinase-myocardial band elevation, procedural death, clinical 
shock, use of intraaortic balloon pump, or follow-up death.
Conclusions: Our retrospective review indicates no association between prior statin use 
and initial TIMI flow grade in STEMI.
TIMI grade according to prior statin use
No Statin Statin
TIMI grade 0-2 73.8% 26.2%
TIMI grade 3 79.5% 20.5%
2:30 p.m.
1019-113 Incidence and Characteristics of Coronary Spasm and 
Myocardial Bridge in Patients with Acute Myocardial 
Infarction
Seung-Woon Rha, Cheol Ung Choi, Soon Yong Suh, Jin Won Kim, Eung Ju Kim, Chang 
Gyu Park, Hong Seog Seo, Dong Joo Oh, Cardiovascular Center, Korea University 
Guro Hospital, Seoul, South Korea
Background: Acute myocardial infarction (AMI) in patients (pts) with normal or insignificant 
coronary artery has been recognized. We hypothesized that the coronary spasm with or 
without myocardial bridge (MB) may play an important role in the pathogenesis of AMI. 
We investigated the incidence and clinical characteristics of spasm documented in a 
series of Asian pts who presented with AMI.
Methods: A total 163 consecutive pts presented with AMI either ST elevation MI (STEMI) 
or Non-ST elevation MI (NSTEMI) between Oct 2004 and July 2006 were entered for 
analysis. Out of these 163 pts, 144 pts (88.3%) underwent PCI and 19 pts were not. Pts 
with documented MI with normal coronary artery was evaluated with acetylcholine (Ach) 
provocation test within two weeks of onset time.
Results: A total 7 pts (7/163, 4.3%) with AMI (3 STEMI and 4 NSTEMI) with normal 
coronary artery were identified among the study population. Hypertension (5/7, 71.4%) 
was dominant among classic coronary risk factors. Female was common (5/7, 71.4%) 
and showed relatively younger age (45.8±13.4 years). Mean ejection fraction was 
42.7%±10.6, showing mild left ventricular dysfunction and hypokinesis was the most 
frequent wall motion abnormality. Anterior wall (LAD territory) was the predilection 
location. Mean peak CK-MB was 73.9±99.7 ng/ml, Troponin-T 2.67±3.3 ng/ml, and BNP 
1840±2059 pg/ml. There was only one definite myocardial bridge in mid LAD (1/7, 14.3%) 
and three minimal fixed lesions (3/7, 42.9%) were observed. Incremental Ach provocation 
test showed significant vasospasm in 6 pts (6/7, 85.7%) and diffuse severe spasm (6/7, 
85.7%) rather than focal spasm (1/7, 14.3%). Their clinical course was benign with 
antianginal medication and the incidence of hemodynamic complications and ischemic 
recurrences were not common up to 6 months.
Conclusion: The incidence of AMI due to documented coronary vasospasm was 
4.3% (7/163). Female, younger age and hypertension were prevalent. Ach provocation 
test confirmed the role of spasm and/or MB in the pathogenesis of AMI with normal 
coronary artery. LAD territory was the predilection site and mostly showed diffuse severe 
vasospasm. Clinical follow up up to 6 months showed favorable prognosis.
2:30 p.m.
1019-114 Type Of GP IIb/IIIa Inhibitor And In-hospital Outcome In 
STEMI Patients Treated With Primary PCI: Results From 
The Nationwide French FAST-MI Registry
Loic Belle, Nicolas Danchin, Michael Angeoi, Philippe Asseman, Bernard Ritz, Jean-
Pierre Monassier, Hakim Benamer, Philippe Gabriel Steg, Jean Pierre Cambou, Hopital 
Europeen Georges Pompidou, Paris, France
Background: Most randomized trials of GP IIb/IIIa inhibitors (GPI) in STEMI patients 
treated with primary PCI have assessed the effects of abciximab. The aim is to compare in-
hospital mortality in patients with primary PCI for STEMI according to type of GPI used.
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Methods: FAST-MI is a nationwide French registry carried out over a one-month period 
in the fall 2005 which included consecutive patients with AMI admitted to CCUs <48 hours 
from symptom onset at the 223 participating centers.
Results: of the 1711 patients with STEMI, 563 had primary PCI, among whom 46% received 
GPI. Of those, 232 had abciximab, 69 tirofiban and 75 eptifibatide.
Baseline characteristics were similar in patients with abciximab, tirofiban or eptifibatide (Table). 
No GPI Abciximab Tirofiban Eptifibatide 
Age (years) 65+/-14 60+/-14 62+/-13 61+/-14
Women (%) 30 25 26 20
HTN (%) 50 44 52 44
Diabetes (%) 19 15 27 21
Current smokers (%) 44 44 44 41
Prior MI (%) 13 19 17 11
Prior CHF (%) 7 4 6 7
Killip >1 (%) 19 15 13 23
Anterior MI (%) 37 41 39 41
In-hospital mortality was 7.0% in patients without GPI. Among patients with GPI, mortality 
was 4.7% in those with abciximab, 4.3% for those with tirofiban and 2.7% for those 
with eptifibatide. Type of GPI was not associated with mortality in multivariate logistic 
regression analysis. Similarly, major bleeding was not different among the 3 agents (1.7% 
vs 2.9% vs 1.3%).
Conclusion: In this real world registry, the use of GPI in patients undergoing primary PCI 
for STEMI was associated with improved survival. There was no indication of a differential 
effect of the type of GPI used with respect to hospital mortality.
2:30 p.m.
1019-115 Paclitaxel Eluting Stents Compared to Bare Metal 
Stents in an Underserved Hispanic Population 
Presenting with Acute ST Segment Myocardial 
Infarction
Atman P. Shah, David M. Shavelle, William J. French, Harbor-UCLA Medical Center, Torrance, CA
Background: Drug-eluting coronary artery stents (DES) have been shown to reduce 
restenosis rates and target lesion revascularization rates (TLR). However, the 
effectiveness of DES in Hispanic patients who present with acute myocardial infarction 
with ST segment elevation (STEMI) has not been well established.
Methods: A non-randomized, retrospective analysis was performed on 213 Hispanic 
patients who presented with STEMI between August 2002 and August 2006 at a single 
academic tertiary care hospital that serves a primarly indigent population. Primary PCI 
was performed in 179 patients and rescue PCI for failed thrombolysis in 34. 136 patients 
received a paclitaxel-eluting stent (PES) and 77 received an uncoated stent (BMS). The 
incidence of death from cardiac causes, recurrent myocardial infarction (MI), target-lesion 
revascularization (TLR), and subacute thrombosis (SAT) was assessed at 1 year.
Results: Baseline clinical and angiographic characteristics in both groups revealed no 
statistically significant differences. All patients had clinical follow up at one year. There 
were statistically significant reductions in MI [2.2% (n=3 PES) vs. 10.3% (n=8 BMS), 
p=0.038] and TLR [5.9% (8) vs. 18.2% (14), p=0.04]. There was no difference in death 
[0.7% (1) vs. 1.2% (1), p=0.99]. There was an increased incidence of SAT in the PES group 
(5.1%, n=7) compared to the BMS group (1.2%, n=1, p=0.03). Premature clopidogrel 
discontinuation (less than 6 months) was the etiology of SAT in 6 of the 7 patients.
Conclusions: Use of DES is associated with lower rates of MI and TLR in Hispanics 
presenting with STEMI. However, there is an increased incidence of SAT in this population 
primarily due to premature clopidogrel discontinuation. The role of socioeconomic factors 
in premature antiplatelet discontinuation and its effects on SAT need further evaluation.
2:30 p.m.
1019-116 Effects of Balloon Angioplasty on the Tissue 
Composition of Acute Coronary Lesions. In Vivo 
Spectral Analysis of Intravascular Ultrasound 
Radiofrequency Data
Francois Schiele, Hu Wei, Vincent Descotes-Genon, Pierre Legalery, Nicolas 
Meneveau, Marie-France Seronde, Fiona Ecarnot, Jerome Varini, Jean-Pierre L. 
Bassand, University Hospital Jean Minjoz, Besancon, France
Background: Angioplasty in the setting of acute coronary syndrome sometimes leads 
to unexpected complications like distal embolization or no reflow phenomenon, even 
when effective antithrombotic dugs are used. This suggests that the mechanism of 
balloon angioplasty (BA) in unstable atherosclerotic stenoses remains incompletely 
documented. We aimed to assess the mechanism of BA using intravascular ultrasound 
(IVUS) gray scale (GS) and spectral radio frequency (RF) analysis.
Methods: In 20 patients, IVUS GS and RF were performed before and after BA. The zone 
of interest was 40 mm long: 10 mm in the proximal and distal reference segments and 
the 20 mm long segment covered by the balloon. At each mm, lumen and plaque cross 
sectional areas (CSA) were assessed by IVUS GS and plaque composition (fibrous, fibro 
fatty, dense calcium and necrotic core) by IVUS-RF. Quantitative and qualitative changes 
were determined by comparison between pre and post BA images.
Results: At baseline, the plaque of the zone of interest was composed, in 61%, of fibrotic; in 
15%, fibro-fatty, in 15% necrotic tissue and in 7% from dense calcium. BA was uncomplicated 
in all patients and resulted, at lesion site, in an 80% increase in Lumen CSA. At balloon 
segment, 35% of the lumen enlargement was due to an increase in total vessel CSA and 
65% to a significant decrease in plaque CSA. This reduction in plaque CSA resulted from a 
longitudinal redistribution of the tissue towards the reference segments. IVUS-RF analysis 
showed that the fibrous and fibro-fatty tissue were able to move longitudinally, whereas the 
calcium remained at the same level. Lastly, 1/3 of the necrotic tissue (a significant 15mm3 
volume) was lost after BA, suggesting the hypothesis of tissue embolization.
Conclusions: Acute atheromatous coronary plaques were composed of 60% fibrosis, 
16% fibro fatty and 15% necrotic tissue. BA induces lumen enlargement by vessel 
stretching (35%) and plaque volume decrease (65%). The decrease in plaque volume 
was the result of a longitudinal redistribution of fibrotic and fibro fatty tissue and the 
disappearance of 1/3 of the necrotic tissue present at baseline.
2:30 p.m.
1019-117 Fibrinolysis With Planned Early PCI Versus Primary PCI 
Alone: One-year Follow-up Results From The ASSENT-4 
PCI Study
Peter R. Sinnaeve, Kris Bogaerts, Paul W. Armstong, Christopher B. Granger, Allan M. 
Ross, Frans J. Van de Werf, University Hospital Gasthuisberg, Leuven, Belgium
Background: ASSENT-4 PCI examined whether full-dose TNK followed by PCI could mitigate 
the negative effects of delays associated with primary PCI. The trial was stopped prematurely 
because of an excess in-hospital mortality in the tenecteplase+PCI arm. At 90 days, mortality 
was 6.7% vs 4.9% for PCI alone. We examined the effect of both treatment strategies on one-
year mortality and whether outcomes in the elderly conformed with the overall population.
Methods & Results: 1667 patients were randomized to either TNK followed by PCI or 
to primary PCI alone. Vital status at 1 year was available for 96% of patients (n=1597). 
At 1 year, mortality remained lower in patients randomized to PCI alone, although not 
statistically significant (6.0% vs 7.8% TNK+PCI, P=0.125, RR 0.76, 95%CI 0.51-1.12). 
Survival curves show that excess mortality with combination treatment occurs early, 
with both curves remaining parallel after the first two months (Figure 1). In patients 
randomized in PCI centers, mortality rates were higher with TNK+ PCI than with PCI 
alone, consistent with the 90-day results (9.7% vs 6.5%, P=0.108). One-year mortality 
rates in elderly patients (>75y) were very high, but did not differ between both treatments 
(22% vs 21% respectively).
Conclusions: After 1-year follow-up, mortality remains non-significantly higher in STEMI 
patients treated with TNK+PCI versus those treated with PCI alone. There remains significant 
opportunities to enhance long-term outcomes after STEMI especially in elderly patients. 
2:30 p.m.
1019-132 A Meta-Analysis of Drug Eluting Stents for the 
Treatment of Acute Myocardial Infarction
Sen Devadathan, Douglas G. Fraser, Sanjay Sastry, Jonas Eichhofer, Timothy Gray, 
Manchester Heart Centre, MRI, Manchester, United Kingdom
Background: The role of Drug Eluting Stents (DES) in Acute Myocardial Infarction (AMI) 
is unclear due to concerns over stent thrombosis and uncertainties about the risk of target 
lesion revascularisation (TLR) in this setting.
Methods: We performed a meta-analysis of all trials with 6-12 month data that compared 
TLR, death/MI and stent thrombosis for DES and bare metal stents (BMS) in AMI. 
Outcomes at 6-12 months with separate analyses for all studies, and for randomised 
trials were performed.
Results: 4 randomised trials and 4 registries were identified. Pooled data from all studies 
showed significant reductions in TLR (3.6% vs. 9.5%, p<0.001) and death/MI (5.6% vs. 
9.6%, p= 0.008) for the use of DES with no difference in stent thrombosis ( 1.5% vs. 2.1, 
p=0.277). Selective analysis of the randomised trials confirmed a reduction in TLR with 
the use of DES (4.8% vs. 11.4%; p = 0.003, figure 1) without significant reductions in 
death/MI (4.7% vs. 5.9%, p =0.26 ) or stent thrombosis (2.2% vs. 2.6%, p= 0.62).
Conclusions: TLR rates of approximately 10% with BMS were significantly reduced 
using DES in AMI without compromising safety. An additional reduction in death/MI was 
not confirmed in the randomised data. 
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1019-133 Does NT-proBNP Predict And Explain Poor Outcomes In 
STEMI Patients? Insights From ASSENT-4 PCI
Peter R. Sinnaeve, Justin A. Ezekowitz, Kris Bogaerts, Christopher B. Granger, Paul 
W. Armstrong, Allan M. Ross, Frans J. Van de Werf, University Hospital Gasthuisberg, 
Leuven, Belgium
Background: NT-proBNP predicts clinical outcomes in STEMI patients treated with 
either fibrinolysis or primary PCI. However, its role in the setting of facilitated PCI has not 
yet been assessed, and it may be a tool to evaluate the lower event rates with primary 
PCI in ASSENT-4 PCI.
Methods: In ASSENT-4 PCI, 1667 patients were randomized to either TNK followed by 
PCI or to primary PCI alone. Primary endpoint was the composite endpoint of death, 
congestive heart failure and cardiogenic shock at 90 d. Baseline, discharge or day 7 
whichever comes first, and 90-day NT-proBNP levels were available for 1008, 971 and 
813 patients, respectively.
Results: Median baseline NT-proBNP was 152 pg/dL (interquartile range 56-514). 
Increasing quartiles of baseline NT-proBNP levels were associated with a higher risk 
of the combined endpoint at 90 days and mortality at 1 year (P<0.001). Adverse events 
tended to be more common with TNK+PCI, regardless of baseline NT-proBNP (with 
no significant interaction between baseline NT-proBNP and treatment effect at day 90 
(P=0.499) or one-year (P=0.390)).
Table: Baseline NT-proBNP levels: 90d outcome and 1y mortality
Primary 90d 
endpoint (%)
Q1 (0-56 
pg/mL)
Q2 (56-152 
pg/mL)
Q3 (152-514 
pg/dL)
Q4 (>514 
pg/dL) P value
TNK+PCI 8.62 13.53 18.94 32.09 P<0.001
PCI alone 6.57 5.17 13.93 27.97 P<0.001
One-year 
mortality (%)
TNK+PCI 0.88 7.14 8.40 13.53 P<0.001
PCI alone 1.54 2.59 5.17 14.66 P<0.001
NT-proBNP levels at discharge or day 7, or at 90 days were not significantly different 
between the two treatment arms.
Conclusions: Baseline NT-proBNP predicts death, cardiogenic shock and congestive 
heart failure at 90 days and one-year mortality in patients undergoing PCI with or without 
facilitation with tenecteplase. Baseline and subsequent NT-proBNP does not explain the 
lower mortality rate with PCI alone seen in this trial.
2:30 p.m.
1019-134 Remote Periconditioning Reduces Myocardial No-reflow 
by Decreasing Rho-Kinase Activity
Jing-lin Zhao, yuejin Yang, Run-lin Gao, Fu-wai heart hospital, Beijing, People’s 
Republic of China
Background: Remote periconditioning is induced by brief cycles of ischemia and 
reperfusion of a remote organ applied during sustained myocardial ischemia. It remains 
unknown whether the remote periconditioning can reduce myocardial no-reflow for which 
activation of Rho-kinase during ischemia/reperfusion may be one mechanism. Therefore, 
this study was sought to assess the effect of remote periconditioning on myocardial no-
reflow and explore the possible mechanism.
Methods: Coronary ligation area and the area of no-reflow were determined with both 
myocardial contrast echocardiography (MCE) in vivo and pathological means (Path) 
in thirty-five mini-swines randomized into 4 study groups: 8 in control, 9 in remote 
periconditioning induced by brief cycles of hindlimb ischemia, 10 in fasudil (a specific 
Rho-kinase inhibitor)-pretreated and 8 in sham-operated. Acute ischemia and reperfusion 
model was created with three-hour occlusion of the left anterior descending coronary 
artery followed by one-hour reperfusion. The Rho-kinase activity was quantified.
Results: Compared with the control group, remote periconditioning significantly improved 
ventricular function, increased coronary blood volume (P<0.05), decreased area of 
no-reflow (MCE: from 78.5±4.5% to 41.4±4.9%, Path: from 82.3±1.9% to 45.5±5.7% 
of ligation area, P<0.01) and reduced necrosis size (from 98.5±1.3% to 74.7±6.3% of 
ligation area, P<0.05). Remote periconditioning also decreased the Rho-kinase activity 
in the reflow and no-reflow myocardium (P<0.05-0.01). The specific Rho-kinase inhibitor 
Fasudil had the same effect on above parameters as remote periconditioning.
Conclusions: Remote periconditioning can reduce myocardial no-reflow after ischemia 
and reperfusion. This beneficial effect is partly through decreasing Rho-Kinase activity.
2:30 p.m.
1019-135 A Rapid Response Trauma Approach Drops 
Reperfusion Time in ST Elevation Myocardial Infarction
B. Hadley Wilson, J. Lee Garvey, Kevin M. Collier, Patricia M. Pye, Ann Lail, Angela D. 
Humphrey, Thomas Blackwell, Carolinas Medical Center, Charlotte, NC
Background: Few institutions meet the ACC/AHA guidelines for primary percutaneous 
coronary intervention (PCI) within 90 minutes of first medical contact. In patients with 
ST elevation myocardial infarction (STEMI) we have a new process, Code STEMI, 
paralleling a system-wide rapid response trauma model that simultaneously activates 
an interdisciplinary team. Our urban tertiary hospital aggressively revised the 90 minute 
goal from door-to-balloon (D2B) to 60 minutes and improved the 90 minute goal from 
paramedic arrival in the field.
Overall D2B Time Improvements
N Range Mean(minutes)
Median
(minutes)
% < 90 
minutes
% < 60 
minutes
Before Code 
STEMI 59 27-289 88.9 76.0 33/59=56% 18/59=31%
After Code 
STEMI 153 10-172 58.4 54.0 134/153=88% 92/153=60%
Statistical Test Anova Kruskal-Wallis Fisher's Exact Fisher's Exact
p-value <0.0001 <0.0001 <0.0001 0.0001
Methods: Eligible patients presented with a STEMI by prehospital ECG or first emergency 
department ECG. Consecutive primary PCI patients from 1/04-9/04 were compared to 
patients treated after the initiation of Code STEMI (10/04-6/06).
Results: Additionally, the percent of paramedic arrivals with D2B < 90 minutes increased 
from 70% to 93% (p=0.002) and D2B < 60 minutes increased from 46% to 71% (p=0.01). 
There was also dramatic improvement in the percent of non-paramedic arrivals reperfused 
< 90 minutes (32% before vs 80% after, p<0.0001) and < 60 minutes (5% before vs 46% 
after, p=0.0003). The mean time from paramedic arrival to reperfusion improved from 108 
minutes to 80 minutes (p<0.0001).
Conclusions: Implementation of a system-wide rapid response to STEMI patients 
significantly lowered D2B times. Therefore, activation of a Code STEMI process 
effectively surpasses the ACC/AHA guidelines for D2B times and allows expansion of the 
goal to first medical contact in the field.
2:30 p.m.
1019-136 Myocardial Protection By Intravenous 5-lipoxygenase 
Inhibitor Quercetin Administration Before Primary 
Angioplasty In Patients With Acute Myocardial 
Infarction: Short-term Results An Open Blind 
Randomized Trial 
Sergey Kozhukhov, Alexander Parkhomenko, Institute of Cardiology, Kiev, Ukraine
Background: Coronary revascularization in acute myocardial infarction (AMI) may 
reduce infarct size but also lead to additional reperfusion damage. Experimental studies of 
myocardial ischemia/reperfusion have demonstrated the limits of infarct size by metabolic 
agent quercetin (Q) and have suggested that Q has NO modulating, lipoxygenase 
blocking and antioxidant properties without any direct hemodynamic effects.
Methods: 47 pts with ST-elevation AMI hospitalized within 4 h of the onset of symptoms 
were randomized into gr. received Q i.v. during 5 days (n=26), starting about 40 min 
before primary PCI or into control gr. (n=21). The baseline clinical characteristics of both 
gr. were similar and did not differ with respect to single or multivessel PCI (p>0.05). All pts 
underwent dynamic echocardiography within 10 days of AMI. Infarct size was measured 
enzymatically based on serial MB-fraction CK measurements.
Results: CK-MB normalization time was achieved after 33.1±2.0 h in Q gr., versus 
47.5±2.4 h in control gr., p<0.01. Infarct size index was greater in control gr. (68.8±5.1 
g/equivalent vs 47.8±3.4 in Q gr., p<0.05). Increase in LV ejection fraction (EF) was 
registered in Q treated pts rather than in control gr. (10.8% vs 3.8%, p<0.05). Dynamics 
of development and extent of necrosis presented on fig.1. 
Conclusions: Our data suggest that Q probably reduces reperfusion damage and/or 
infarct size in pts with AMI subjected to PCI and increase EF. These findings require 
further extensive trials.
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1019-137 Safety and Efficacy of the Use of Endothelial Progenitor 
Cell Capture Stent (Genous® Bio-Engineered R Stent) 
in the Setting of Acute Myocardial Infarction: A Clinico-
Angiographic Follow-up
Melissa C. Co, Edgar Tay, Ing Han Lim, Jimmy Lim, Chi Hang Lee, Adrian Low, Huay 
Cheem Tan, Yean Teng Lim, National University Hospital, Singapore, Singapore, Tan 
Tock Seng Hospital, Singapore, Singapore
Background: The Genous® bioengineered R stent, coated with murine monoclonal anti-
human CD34 antibodies, is designed to attract circulating endothelial progenitor cells 
(EPCs) to rapidly establish a functional endothelial layer and promote healing. We assessed 
the use of this stent in primary percutaneous intervention (PCI) in ST-elevation myocardial 
infarction (STEMI) which in itself is associated with high thrombogenicity and EPC levels.
Methods: A total of 119 patients who presented with STEMI without cardiogenic shock 
and received primary PCI with Genous® stent implantation were prospectively enrolled 
in this study. All patients received dual anti-platelet therapy for a month; and immediate 
statin therapy after the procedure. The study endpoints were major adverse cardiac 
events (MACE) at 30 days and 6 months; and angiographic follow-up at 6 months.
Results: One hundred thirty one Genous® stents were implanted with 99% procedural 
success. The mean age of the study cohort was 54±11 years, among whom were 79% 
males and 28.5% diabetics. The mean lesion length was 17.5±7.2mm and mean reference 
vessel diameter 3.16±0.66 mm. Platelet glycoprotein IIb/IIIa inhibitor was used in 12% of pts 
and 55% had thrombosuction prior to stent implantation. The mean size of stent implanted 
was 3.04±0.33 mm, with 94% pts achieving TIMI 3 flow at the end of the procedure. One 
patient had acute closure due to an untreated proximal lesion while another patient had 
subacute stent thrombosis 10 days later. There were 2 (1.7%) deaths from cardiac failure at 
one month and 1(0.8%) death from sudden cardiac arrest at 6 months.
Conclusions: Genous® stent is safe for use in primary PCI for STEMI. The complete 6-
month clinical and angiographic follow-up results will be reported at the meeting.
2:30 p.m.
1019-138 Utilization of Emergency Medical Services for Hospital 
Transport in Patients with ST-Elevation Myocardial 
Infarction Results in a Shorter Door to Balloon Time
Nowwar G. Mustafa, Vinay Hosmane, Angela Disabatino, Lynne Bittner, Robert O’ 
Connor, Charles Reese, James Hopkins, William Weintraub, Ehsanur Rahman, 
Christiana Care Health System, Newark, DE
Background: Outcomes for ST-elevation myocardial infarction (STEMI) patients depend on 
how quickly flow is restored in the infarct related artery. National estimates show that only 
50-60% of patients with acute coronary syndrome symptoms utilize emergency medical 
services (EMS) for transport to hospital. We examined the impact of mode of transportation 
to the emergency department (ED) on door to balloon time (DTBT) in patients with STEMI.
Methods: This is a single center, retrospective study of consecutive patients who 
presented to the ED between January 2002 and August 2006 with STEMI and received 
primary percutaneous coronary intervention (PCI). The following time intervals were 
assessed: door to balloon (DTBT), door to PCI decision and PCI decision to balloon. 
Chi-square and independent t-test were used for statistical analysis.
Results: The study included 861 patients. The mean age was 61 years and 69% were 
males. EMS transported 637 patients (74%) to the ED and 224 patients (26%) used 
private transportation. Patients transported by EMS had significantly shorter mean 
DTBT (79.7 vs. 99.9 minutes p<0.001), mean door to PCI decision time (21.5 vs. 40.1 
minutes; p<0.001), and were more likely to have DTBT < 90 minutes (75% vs. 47%; 
p <0.001) when compared to those who used private transportation. There was no 
significant difference between the two groups in PCI decision to balloon time (57.0 vs. 
59.1 minutes; p=0.135).
Conclusion: Patients with STEMI who used private transportation to ED had significantly 
longer DTBT. Longer door to PCI decision time (but not PCI decision to balloon time) 
accounted for the delay in DTBT in those patients. Efforts should be made to shorten the 
initial assessment time of chest pain patients who arrive to ED by private transportation. 
The public should also be educated to utilize EMS transportation to ED when experiencing 
acute coronary syndrome symptoms.
2:30 p.m.
1019-153 Tenecteplase-pretreated STEMI Patients With TIMI 0-2 
Flow Before PCI Are Less Likely To Have TIMI 3 Flow 
After PCI
Walter Desmet, Allan Ross, Christopher Granger, Paul Armstrong, Frans Van de Werf, 
for the ASSENT-4 PCI investigators, University Hospital Gasthuisberg, Leuven, Belgium
Background: A strategy of full-dose tenecteplase preceding PCI by 1-3 hours was 
associated with more major adverse events than PCI alone in STEMI patients participating 
in the ASSENT-4 PCI trial.
Methods: In ASSENT-4 PCI patients with STEMI of less than 6 hours duration were 
randomised to standard primary PCI (n = 838) or PCI preceded by full-dose tenecteplase 
(TNK) (n = 829). Angiographic Core Laboratory readings of TIMI-flow before and after PCI 
are available for 954 patients.
Results: Before PCI, the incidence of TIMI 3 flow was higher in the TNK-pretreated 
patients than in the PCI alone group (57.9 vs 23.9 %, p<0.001).
However, of the patients in the TNK-pretreated group who presented with TIMI 0-2 flow, 
only 70.2 % showed TIMI 3 flow after PCI, as compared to 86.6 % in the PCI alone group 
: odds ratio for achieving TIMI 3 flow after PCI, adjusted for TIMI flow before PCI, for TNK-
pre-treated pts as compared to PCI alone pts 0.384 (0.258 - 0.570; p < 0.0001).
Data on interactions with concomitant antithrombotic therapies will be available.
Conclusion: Patients with TIMI 0-2 flow before PCI in the facilitated PCI group were 
less likely to have TIMI 3 flow after the procedure than patients who underwent PCI 
alone. The prothrombotic environment early after lytic therapy together with suboptimal 
antithrombotic co-therapy may explain these findings. 
2:30 p.m.
1019-154 Comparison Of Drug-Eluting Versus Bare Metal Stents: 
Timing Of Subacute Thrombosis Up To 2 Years
Robert J. Applegate, Matthew T. Sacrinty, Michael A. Kutcher, Talal T. Baki, Sanjay 
K. Gandhi, Renato M. Santos, William C. Little, Wake Forest University School of 
Medicine, Winston-Salem, NC
Background: Recent data suggest that drug-eluting stents (DES) may be associated 
with more late (>1 year) adverse events, especially subacute thrombosis (SAT). However, 
little late data are available from “real world” practice.
Methods: BMS were placed in 1,164 consecutive patients in the year prior to introduction 
of DES. DES were subsequently placed in 1,285 comparable patients at Wake Forest 
Baptist Medical Center. Early and late clinical events up to 2 years were evaluated.
Results: Patient and procedural characteristics of the two groups were similar, with an 
overall incidence of acute coronary syndromes of 72% (p=NS). The timing of SAT’s is 
shown. SAT’s occurred after BMS up to 6 months, but none thereafter. SAT’s occurred after 
DES from PCI up to 2 years of follow-up. The average time of SAT was 87±57 days for 
BMS, and 213±251 days for DES, p=0.172. Analysis of the incidence of SAT is ongoing.
Conclusions: Subacute thrombosis was not observed with BMS after 6 months, but 
continued to occur after 1 year with DES. These data have important implications for 
continued use of antiplatelet therapy after DES use.
2:30 p.m.
1019-155 Association between Recurrent Ischemia on 
Continuous ECG (Holter) Monitoring and Short and 
Long Term Mortality in Patients with non-ST-Elevation 
ACS in the MERLIN - TIMI 36 Trial
Benjamin M. Scirica, David A. Morrow, Ewa Karwatowska-Prokopczuk, Richard Cairns, 
Julian Aroesty, Carolyn H. McCabe, Eugene Braunwald, TIMI Study Group, Boston, MA, 
Brigham and Women’s Hospital, Boston, MA
Background: Recurrent ischemia after admission for non-STE ACS is common, though its 
relationship to short and long term cardiovascular outcomes in contemporary practice is not well 
defined. Continuous ECG (CECG) monitoring is a sensitive marker of recurrent ischemia.
Methods: Between Oct 2004 and May 2006, 6560 pts admitted with NSTEACS were 
randomized to the novel anti-ischemic agent ranolazine or placebo in the MERLIN-TIMI 36 
trial. At randomization, 3-lead CECG monitoring was initiated (duration 6.9 days). Recurrent 
ischemia was defined as ST dep >1mm from baseline lasting >1 min. At the time of submission, 
preliminaray data for 3479 pts were available. Median follow-up was 436 days.
Results: Recurrent ischemia was detected in 581/3479 pts (16.7%) with 289 pts (8.3%) 
experiencing >2 episodes. Compared to patients with no ischemia, patients with ST 
depression had higher rates of death/MI (25.7% v. 16% v. 8.6% for pts with >2, 1-2, and 
no episodes, respectively, p<0.0001) and death alone (Figure) with a similar pattern when 
excluding patients with an event in the first 7 days after randomization (p<0.0001). Elderly pts 
(>75yrs) were more likely to have ischemia on CECG (24.7 v. 15.3%, p<0.05) but there was 
no difference in the rates according to index diagnosis (18.1% for NSTEMI v. 15.5% for UA).
Conclusion: In this largest study of continuous ischemic monitoring in pts with NSTEACS, 
ischemia was strongly associated with short and long-term mortality and MI. CECG is a 
major clinical endpoint in MERLIN-TIMI 36.
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1019-156 Outcome of Patients After Successful Cardiopulmonary 
Resuscitation and Suspected Acute Coronary 
Syndrome Treated with an Early Invasive Strategy
Helge Möllmann, Holger M. Nef, Michael Weber, Matthias Rau, Christian W. Hamm, 
Albrecht Elsässer, Kerckhoff Heart Center, Bad Nauheim, Germany
Background: In recent years an early invasive strategy for patients with acute coronary 
syndromes (ACS) has been established. However, little data are available on the clinical 
outcome of patients admitted after successful cardiopulmonary resuscitation (CPR) 
who are treated with an early invasive therapy. Therefore, the aim of the study was to 
investigate clinical characteristics and the long-term prognosis of resuscitated patients.
Methods: We included 1254 consecutive patients (379 females, age 64±12 years) from 
April 2003 till March 2005 who were referred for primary PCI (STEMI) or early invasive 
diagnostic (NSTE-ACS) within 48 hours after the index event. Follow up data after 6 months 
were available for 1178 patients (94%).
Results: 63 patients (5.0%) of the study population were admitted after successful CPR. 
Resuscitated patients were 61.9±10.3 years old (p=n.s. versus entire study population). 
The final diagnosis was NSTEMI in 15 patients patients, STEMI in 38 patients, and other 
in 10 patients. In 8 patients (12.7%) coronary artery disease (CAD) could be excluded. 
22 patients (34.9%) had 1-vessel CAD, and 33 patients (52.4%) multi-vessel CAD. The 
extent of CAD did not differ from the entire population (p=0.76). Likewise, there was no 
difference in the frequency of prior myocardial infarction, PCI, and CABG, respectively. 
The time from onset of symptoms, either angina or cardiac arrest to admission was 
2.1 hours (IQR 1.5-4.8) in comparison to 5.8 hours (IQR 2.7-13.2) for non-resuscitated 
patients (p<0.01). At admission the cardiac biomarkers troponin T, CK-MB, myoglobin 
and BNP were significantly higher in resuscitated patients than in the entire population 
despite the shorter time until admission. The all-cause mortality after six months was 
29.2% in resuscitated patients compared to 3.9% in the entire population (p<0.01). The 
ejection fraction at follow-up after six months was significantly lower in patients after 
resuscitation (46.9±12.2% vs. 52.9±10.0%, p<0.01).
Conclusions: Our results indicate that patients after successful CPR benefit from an 
early invasive strategy. The long-term mortality rate in these patients was remarkably 
lower than in previously published studies.
2:30 p.m.
1019-157 Cystatin C is lower in Acute Coronary Syndrome than 
in Stable Angina and Non-ischemic Chest Pain: an 
apparent paradox?
Roberta Della Bona, Luigi M. Biasucci, Valentina Loria, Dato Ilaria, Micaela Conte, 
Domenico D’Amario, Giampaolo Niccoli, Giovanna Liuzzo, Filippo Crea, Catholic 
University, Rome, Italy
Background: Cystatin C is an accurate marker of renal function. Recent studies have 
shown that serum Cystatin C levels predict the risk of future cardiovascular events. To 
characterize the mechanism linking Cystatin C levels to risk of cardiovascular events, we 
measured serum levels of Cystatin C in patients with Acute Coronary Syndromes (ACS) 
and Stable Angina (SA) or Non-ischemic Chest Pain (NICP).
Methods: We studied 80 patients with ACS, 20 with SA, 47 with NICP. In all pts serum 
levels of Cystatin C were determined by high sensitive immunonephelometry. Furthermore 
in 69 patients (51 ACS and 18 SA ) who underwent coronary angiography, severity, extent 
and morphology of atherosclerosis lesions were assessed by two expert angiographers.
Results: Median level were significantly lower in ACS patients than in the remaining pts 
(0,94 mg/l; range 0.45-1.78 vs 1.17 mg/l; range 0.05-3.95; p<0.001). Cystatin C levels 
were similar between SA and NICP (1,005 mg/l; range 0.05-3.87 vs 1,20 mg/l; range 0.84-
3.95; p=0.1). At univariate analysis Cystatin C was significantly associated with stenosis 
score (p=0.05), extent score (p=0.03) and number of smooth lesions (p=0.001).
Conclusions: Our study demonstrates that, although Cystatin C is a marker of 
atherosclerotic burden, yet, paradoxically, during coronary instability, Cystatin C levels are 
lower than in stable patients. As Cystatin C has the potential to inhibit proteases, the low 
levels of Cystatin C observed in ACS might contribute to coronary instability. Therefore 
our findings may shed new light on the patho-physiological role and clinical meaning of 
this new marker of cardiovascular risk, which probably contains more information than 
those related to the mere renal function.
2:30 p.m.
1019-158 Creatinine Kinase-MB Enzyme Elevation in the 
Presence of Normal Troponin is a Powerful Predictor 
of Cardiovascular Complications in Non-ST Segment 
Elevation Acute Coronary Syndrome
Nicholas Kalayeh, Francisco J. Gonzalez, Akil Loli, Frank Cardello, Richard Gerkin, Robert 
E. Halligan, Jr., Kenneth B. Desser, Carl T. Hayden VA Medical Center, Phoenix, AZ
Background: Many patients present with an acute coronary syndrome (ACS) that is 
troponin (cTn) - but creatinine kinase-MB (CK-MB) +. There are, however, contradictory 
data concerning the prognostic importance of CK-MB+ and cTn- non-ST segment 
elevation ACS. The value of measuring CK-MB in patients with an ACS when cTn 
measurements are available is in question. The purpose of this study was to evaluate the 
significance of the CK-MB assay in this population.
Methods: 8654 patients who presented with non-ST segment elevation ACS had both 
CK-MB and cTn measured initially and every 8hrs. We examined 4 combinations of 
marker assay, CK-MB+/ cTn+, CK-MB+/cTn-, CK-MB-/cTn +, and CK-MB-/cTn-. Total 
CK-MB+ patients totaled 3647 (42%). Patients who presented with ACS were followed 
for the development of cardiovascular complications for 36 months. Such complications 
included myocardial infarction, cerebrovascular accident, peripheral vascular disease, 
and atrial fibrillation.
Results: Of 8654 patients, 3647 had elevated CK-MB in any 3 sets of cardiac enzymes 
during their initial hospitalization day. Positive cTn and CK-MB biomarkers were found 
in 9.35% of the patients and CK-MB+/cTn- biomarkers were present in 32.8%. After 
correction for cTn positivity and adjustment for coronary risk factors, results for all-cause 
mortality were not significant in the CK-MB+ /cTn- group. The CK-MB isoenzyme was 
found, however, to be an independent predictor for other cardiovascular complications. 
In this group, cerebrovascular events developed in 6%, with an odds ratio (OR) of 1.301 
(95% confidence interval (CI) 1.09 to 1.56). Peripheral vascular disease developed in 9% 
with an OR of 1.58, (95% CI 1.35 to 1.85) and 11% developed atrial fibrillation with an OR 
of 2.39, (95%CI 2.08 to 2.74).
Conclusions: Based on the above results, patients with a + CK-MB at any point during 
hospitalization with non-ST segment elevation ACS have a greater chance of developing 
cardiovascular complications, regardless of cTn measurements. Elevated CK-MB does 
not predict all-cause mortality in this patient population.
2:30 p.m.
1019-159 Chromogranin A is an Independent Prognostic 
Indicator across the Spectrum of Acute Coronary 
Syndromes
Torbjørn Omland, Anna M. Jansson, Helge Røsjø, Anita Persson, Thomas Karlsson, 
Johan Herlitz, Allan Flyvbjerg, Marianne Hartford, Kenneth Caidahl, Sahlgrenska 
University Hospital, Göteborg, Sweden, Aarhus University Hospital, Aarhus, Denmark
Background: Chromogranin A (CgA) is widely distributed throughout the neurendocrine 
system and may, due to its long in vivo and in vitro half-life, be an attractive candidate for 
assessment of overall neuroendocrine activity. Recently, increased plasma levels of CgA 
have been associated with adverse outcome in chronic and postinfarction heart failure. 
We hypothesized that CgA levels are related to long-term prognosis across the spectrum 
of acute coronary syndromes (ACS).
Methods: We assessed the association between circulating CgA levels obtained within 24 
hrs following admission and time to death in 1306 patients (median age 67 yrs, 30% female) 
admitted to a Scandinavian teaching hospital with a diagnosis of unstable angina, non-ST-
elevation myocardial infarction (NSTEMI) or ST-elevation myocardial infarction (STEMI).
Results: During a median follow-up time of 81 months, 360 patients died. After adjustment 
for age, gender, previous MI, angina, chronic heart failure, diabetes, hypertension, current 
smoking, index diagnosis, heart rate, peak CK-MB, troponin T, estimated creatinine 
clearance, and Killip class in a multivariable Cox proportional hazards regression model, 
logarithmically transformed CgA levels remained a strong independent indicator of 
long-term mortality (hazard ratio 1.30 (95% CI 1.17 - 1.46 per 1 SD increase in CgA; 
p<0.0001). After further adjustment for C-reactive protein (CRP), B-type natriuretic 
peptide (BNP) and left ventricular ejection fraction (LVEF) in the subset of patients in 
whom these measures were available (n=619), CgA still provided significant additional 
prognostic information (hazard ratio 1.18 (95% CI 1.00 - 1.38; p=0.046).
Conclusions: In patients with ACS, CgA levels obtained within 24 hrs of admission were 
associated with long-term mortality. This relationship was independent of index diagnosis 
and conventional risk factor, including LVEF, CRP and BNP.
2:30 p.m.
1019-174 Cardiac Magnetic Resonance Imaging During 
Dobutamine Stress Test to Detect Myocardial Perfusion 
Defects in Cardiac Syndrome X
Alfonso Sestito, Antonino Buffon, Gregory A. Sgueglia, Luigi Natale, Luca Mariani, 
Antonio Centola, Fabio Infusino, Filippo Crea, Gaetano A. Lanza, Università Cattolica 
del Sacro Cuore, Rome, Italy
Background: Conventional investigations failed to consistently show evidence of 
myocardial ischemia in patients with cardiac syndrome X (CSX). A recent cardiac magnetic 
resonance imaging (MRI) study, however, documented in these patients subendocardial 
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hypoperfusion during the intravenous administration of adenosine, which likely acts 
through a “blood steal phenomenon”. In the present study we aimed at assessing whether 
cardiac MRI during dobutamine stress test (DST), which acts by increasing myocardial 
oxygen demand, can be helpful in revealing perfusion defects in CSX patients.
Methods: We studied 18 patients with CSX (58±7 years, 7 men). All had effort angina, 
positive exercise stress test and normal coronary arteries at angiography. As a control 
group we enrolled 8 subjects (53±7 years, 3 men) without any evidence of heart disease 
according to clinical history, physical examination and non-invasive investigations. All 
participants underwent contrast-enhanced first-pass MRI myocardial perfusion study, 
both at rest and at peak of a pharmacological stress protocol with increasing intravenous 
doses of dobutamine (up to 40 μg/Kg/min). Standard 12-lead electrocardiogram and 
blood pressure were monitored throughout DST.
Results: At peak DST, CSX patient and controls showed similar heart rate (127±16 vs. 
138±9 bpm, respectively, p=0.43) and systolic blood pressure (171±18 vs. 155±29 mmHg 
respectively; p=0.16). Subendocardial perfusion defects at peak DST, absent at rest, 
were detected in 10 patients with CSX (56%) but in none of healthy subjects (p=0.01).
Conclusions: Our study shows that contrast-enhanced first-pass cardiac MRI during 
DST is able to detect subendocardial perfusion defects in about two thirds of patients with 
CSX, further supporting the microvascular ischemic origin of the syndrome. Accordingly, 
our data also suggest that cardiac MRI during DST can be particularly helpful in the 
clinical characterization of the more general population of patients with angina and 
normal coronary arteries.
2:30 p.m.
1019-175 Relationship of Inflammation With Endothelial 
Dysfunction and Coronary Flow Reserve in Patients 
With Cardiac Syndrome X
Alfonso Sestito, Angelo Santoliquido, Angela Di Giorgio, Gregory A. Sgueglia, Leonarda 
Galiuto, Roberto Flore, Fabio Infusino, Priscilla Lamendola, Paolo Tondi, Filippo Crea, 
Gaetano A. Lanza, Università Cattolica del Sacro Cuore, Rome, Italy
Background: Endothelial dysfunction (ED) and reduced coronary flow reserve (CFR) 
are detectable in patients with cardiac syndrome X (CSX). Recent data have shown 
increased markers of inflammation in these patients. No study, however, assessed 
whether inflammation correlates with ED and CFR in CSX patients.
Methods: We studied 24 CSX patients (59.4±7 years, 15 women) and 14 healthy 
subjects (54.5±9 years, 14 women). Systemic ED was assessed by measuring the 
percent changes of the right brachial artery diameter during reactive hyperemia (flow-
mediated dilation, FMD) after 5-minute forearm cuff inflation (250 mmHg), using high-
resolution ultrasound imaging. CFR was assessed in the left anterior descending (LAD) 
coronary artery using transthoracic Doppler echocardiography and calculated as the ratio 
of coronary blood flow velocity in the LAD coronary artery measured at rest and at peak 
of intravenous adenosine administration (140 μg/Kg/min in 90 sec). Serum C-reactive 
protein (CRP) was measured at rest, by a high-sensitivity nephelometric method before 
tests were performed.
Results: FMD of the brachial artery and CFR were both significantly lower in CSX 
patients than in controls (5±5% vs. 15±5%, p<0.0001; and 1.86±0.5 vs. 2.96±1.0, 
p<0.001; respectively). No significant correlation was found, however, between CFR 
and peripheral FMD in CSX patients (r=0.11, p=0.65). Serum CRP levels were higher in 
CSX patients than in controls (3.5±3 vs.1.3±0.9 mg/L, p=0.002), and showed a significant 
inverse correlation with FMD (r=-0.59, p=0.006), but not with LAD-CFR (r=-0.12, p=0.62), 
in CSX patients.
Conclusions: An increased low-grade inflammatory state is present in CSX patients 
and is associated with impaired endothelium-dependent vasodilator function. In contrast, 
inflammation is not associated with impaired coronary microvascular vasodilator 
response to adenosine in these patients. Accordingly, no significant association could 
be found between systemic FMD and impaired CFR in our CSX patients, suggesting 
that multiple pathophysiologic mechanisms contribute to the abnormalities in vascular 
function detectable in patients with this angina clinical syndrome.
2:30 p.m.
1019-176 Comparison of Percutaneous Coronary Intervention 
and Bypass Surgery Among Patients With a Chronic 
Total Occlusion and Multi-Vessel Coronary Artery 
Disease in the Bare Metal Stent Era.
Satoshi Shizuta, Ryoji Taniguchi, Natsuhiko Ehara, Takahiro Doi, Kei Nishiyama, Yutaka 
Furukawa, Ryozo Tatami, Teruaki Ushijima, Ryuichi Hattori, Manabu Shirotani, Noboru 
Nishiwaki, Masaru Tanaka, Kazuaki Minami, Yuki Sato, Saori Tezuka, Takeshi Morimoto, 
Yukiko Imai, Satoshi Teramukai, Masanori Fukushima, Toru Kita, Takeshi Kimura, 
CREDO-Kyoto Investigators, Department of Cardiovascular Medicine, Kyoto University, 
Kyoto, Japan
Background: Percutaneous coronary intervention (PCI) of a chronic total occlusion 
(CTO) has been reported to be associated with low primary success rate and high 
incidence of reocclusion. The safety and efficacy of PCI in patients (pts) with a CTO and 
multi-vessel coronary artery disease (MVD) compared with coronary artery bypass graft 
surgery (CABG) has not been well clarified.
Methods: CREDO-Kyoto is a multi-center registry of Japanese pts undergoing 
first PCI or CABG between Jan. 2000 and Dec. 2002. Data of 9,873 pts from 30 
institutions were available. The population of this study consisted of 1,165 pts with 
MVD and a CTO (PCI:623, CABG:542).
Results: The baseline characteristics were as follows; Age: 65 vs 66 (years); Male: 76 vs 
76 (%); Previous MI: 48 vs 48 (%); NYHA3/4: 6.6 vs 5.2 (%); Hypertension: 85 vs 78* (%); 
Diabetes: 45 vs 46 (%); Creatinine > 1.2 (mg/dl): 10 vs 12 (%); Hyperlipidemia: 53 vs 57 
(%); Smoker: 30 vs 30 (%); EF: 56 vs 56 (%); Three-vessel disease: 43 vs 83* (%); Proximal 
LAD involvement: 45 vs 62* (%) (PCI vs CABG, *p<0.05). Recanalization of a CTO was 
attempted in 444 pts (71%) in PCI group, with a success rate of 76%. Bypass grafting to 
the distal of a CTO was attempted in 485 pts (89%) in CABG group, with a patency rate of 
94% in coronary angiography (CAG) before hospital discharge. Follow up CAG at 6-month 
was performed in 289 pts (85%) in PCI group, and the successfully recanalized vessel 
was reoccluded in 28 (9.7%). During the follow-up period of 3.4±1.3 years, there were 
100 deaths, including 66 cardiovascular (CV) deaths. The 3-year overall and CV survival 
was 91.1% and 94.2% in PCI group, corresponding to 94.1% and 95.5% in CABG group 
(p=NS). The 3-year event free survival from death, MI, or cerebrovascular accident (MACE) 
was 86.2% and 87.0%, respectively (p=NS). The cumulative risk of any revascularization at 
3-year was 50.6% and 8.6%, respectively (p<0.0001). In the multivariate analyses, mode of 
revascularization neither affected long-term mortality nor MACE rate.
Conclusions: PCI with bare metal stent is an alternative to CABG as an initial strategy 
for pts with MVD and a CTO in terms of similar long-term mortality and MACE rate, though 
associated with a greater need for repeat revascularization.
2:30 p.m.
1019-177 Comparison of Percutaneous Coronary Intervention 
and Bypass Surgery in Patients With Multi-Vessel 
Coronary Artery Disease and Reduced Left Ventricular 
Function in the Bare Metal Stent Era.
Satoshi Shizuta, Natsuhiko Ehara, Ryoji Taniguchi, Yoshisumi Haruna, Yutaka Furukawa, 
Hirokazu Mitsuoka, Takahiro Doi, Naritatsu Saito, Akira Miura, Hajime Kotoura, Masaki 
Aota, Hiroshi Eizawa, Hiroshi Kato, Izumi Miki, Takeshi Morimoto, Yukiko Imai, Satoshi 
Teramukai, Masanori Fukushima, Toru Kita, Takeshi Kimura, CREDO-Kyoto Investigators, 
Kyoto University Graduate School of Medicine, Kyoto, Japan
Background: Recent randomized controlled trials (RCTs) have shown that PCI confers 
equivalent long-term survival to CABG in patients with multi-vessel coronary artery disease 
(MVD). However, those with reduced left ventricular (LV) function were largely excluded from 
the RCTs, and few data are available regarding the safety and efficacy of PCI compared 
with CABG in the high-risk subset of patients with MVD and poor LV function.
Methods: CREDO-Kyoto is a multi-center registry of Japanese patients undergoing 
first PCI or CABG between Jan. 2000 and Dec. 2002. Data of 9,873 patients from 30 
institutions were available. The population of this study consisted of 364 patients with 
MVD and LV ejection fraction (EF) ≤ 40% (PCI: 196 patients, CABG: 168 patients).
Results: The baseline characteristics were as follows; Age: 67 vs 66 (years); Male: 72 
vs 79 (%); Previous MI: 64 vs 72 (%); NYHA III/IV: 25 vs 15* (%); Hypertension: 82 vs 76 
(%); Diabetes: 51 vs 51 (%); Creatinine > 1.2 (mg/dl): 17 vs 18 (%); Hyperlipidemia: 45 
vs 47 (%); Smoker: 34 vs 28 (%); EF: 33 vs 33 (%); Three-vessel disease: 49 vs 84* (%); 
Proximal LAD involvement: 38 vs 60* (%) (PCI vs CABG, *p<0.05). No drug-eluting but 
bare metal stents were used in PCI group. Off-pump surgery was performed in 29% of 
CABG group. Three in PCI group and 2 in CABG group died during the hospitalization. 
During the follow up period of 3.3±1.5 years, there were 52 deaths, including 34 
cardiovascular deaths. The actuarial survival at 1-, 3-, and 5-year was 92.1%, 84.5%, and 
73.9% in PCI group, corresponding to 95.7%, 91.0%, and 85.3% in CABG group (p=0.05). 
The cumulative risk of any revascularization at 3-year was 42.9% and 9.2%, respectively 
(p<0.0001). After adjustment for baseline differences by the Cox regression model, PCI 
appeared to be an independent predictor of overall death (HR=2.8, 95%CI;1.3-5.7) and 
cardiovascular death (HR=3.4, 95%CI;1.4-8.7).
Conclusions: PCI with bare metal stent was associated with higher overall and cardiovascular 
mortality compared with CABG in patients with MVD and reduced LV function.
2:30 p.m.
1019-178 Less is Better, None is Best: Angina and Health Related 
Quality of Life
Karen P. Alexander, Patricia A. Cowper, Barbara L. Lytle, Judith A. Kempf, Eric D. 
Peterson, Duke Clinical Research Institute, Durham, NC
Background: Persistent angina occurs in one in five patients treated for significant 
coronary disease. The effect of persistent angina on physical function and health related 
quality of life (HRQOL) overall and across subgroups is unknown.
Methods: Patients catheterized at Duke Medical Center from 8/98- 4/01 with significant 
CAD and baseline angina were followed at 6 and 12 mo for symptoms with Seattle 
Angina Questionnaire (SAQ). Of survivors who completed 6 and 12 mo surveys, 204 
had persistent angina (PA) at 6 and 12 months, and another 618 were angina free. All 
patients were assessed by SF-36 mental component (MCS), physical component (PCS), 
and physical functioning (PF) scales at baseline and 12 months. We compared 12 month 
scores in those with PA to those who were angina free. Using linear regression analysis 
and adjusting for baseline scores, we determined significant predictors of 12 month 
HRQOL in this combined group.
Results: At 12 months, compared with pts who were angina free, those with PA had 
lower MCS (45.7 v 53.2), PCS (34.1 v 44.6), and PF (33.9 v 43.4) scores. Of patients with 
PA, 48% (98) experienced monthly angina, 41% (83) weekly angina, and 11% (23) daily 
angina. The strongest and most universal predictor of lower MCS, PCS, and PF scores 
at 12 months was the frequency of persisting angina (daily > weekly > monthly v. none). 
The effect of angina frequency on HRQOL was constant across gender, diabetes, and 
age (no significant interactions). Other independent contributors to lower HRQOL scores 
include COPD, arthritis, CHF, DM, BMI, no revascularization, fewer years of education, 
and female gender.
Conclusions: Persistent angina is associated with worse physical functioning and 
HRQOL at 12 months; an effect which is strongly associated with its frequency. This 
widespread effect also occurs without regard to age, gender or diabetes. As the majority 
of patients with PA experience weekly or daily angina, reducing the frequency of angina 
as well as its elimination are worthy therapeutic goals.
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1019-179 Effects of Diabetes on the Prevalence of Aspirin 
Resistance During Low Dose Aspirin Therapy
Paul A. Gurbel, Kevin P. Bliden, Srivasavi Chaganti, Joseph DiChiara, Udaya S. Tantry, 
Sinai Center for Thrombosis Research, Baltimore, MD
Background: Controversy exists regarding the relation of diabetes and other demographic 
variables on the prevalence of aspirin resistance (AR).
Methods: AR was measured after 81 mg aspirin for four weeks in 120 patients (diabetes 
= 23) with coronary artery disease by COX-1 specific assays (arachidonic acid (AA)-
induced light transmittance aggregation (AGG), AA-induced AGG by thrombelastography 
(TEG), VerifyNow, urinary thromboxane levels) and COX-1 nonspecific assays (ADP-and 
collagen-induced AGG and PFA-100).
Results: In the total group a low prevalence of AR (<5%) indicated by low platelet AGG 
(mean AA-induced AGG<10% and TEG mean AGG<15%) were measured during 81mg 
aspirin treatment. However, diabetes was associated with significantly increased ADP- 
(p=0.05) and collagen- induced AGG (p=0.002), and a nonsignificant increase in closure 
time (PFA-100). Similarly, AR was higher in diabetic patients as measured by ADP- (40% 
vs.17%, p=0.09) and collagen- induced AGG (17% vs. 10%, p=0.3), VerifyNow (22% vs. 
8%, p=0.04) and urinary thromboxane levels (30% vs. 8%, p=0.003), TEG (8% vs. 0%, 
p=0.009) and AA-AGG (4% vs. 0%, p=0.06). Overall, there were no significant effects of 
gender or hypertension on aspirin responsiveness or the prevalence of AR.
Conclusions: Diabetic patients with coronary artery disease during therapy with 81 
mg exhibit a higher prevalence of aspirin resistance than non-diabetics that is also 
associated with heightened levels of ADP-, and collagen- induced aggregation. These 
findings indicate an overall high platelet reactivity phenotype and provide a mechanistic 
explanation for the higher risk of thrombosis in diabetic patients during therapy with 
81mg aspirin. Future studies of higher aspirin doses in the diabetic patient should be 
considered
2:30 p.m.
1019-180 Angiographic Based Prevalence of Cardiovascular 
Disease in Pre-renal Transplant Patients
Ijaz Ahmad, Sanford Leff, Jonathan Marmur, Interfaith Medical Center, Brooklyn, NY
Background: Cardiovascular disease (CVD) is a leading cause of morbidity and mortality 
in dialysis patients. Previous ESRD databases, which estimate CVD prevalence to be 40 
to 60%, are based on clinical data, often lacking invasive confirmation of CVD. We present 
the analysis of CVD in an ESRD pre-transplant population using cardiac catheterization 
and cardiac non-invasive stress perfusion imaging to confirm the CVD diagnosis.
Methods: We report a retrospective analysis of 296 consecutively referred patients 
who underwent cardiac evaluation in anticipation of renal transplantation surgery. All 
patients received history, physical examination, 12 lead EKG, echocardiogram and stress 
myocardial perfusion imaging. Patients were referred for cardiac catheterization when 
the initial cardiac evaluation suggested structural heart disease which merited invasive 
diagnostic study.
Results: A total of 296 patients were studied; 98% were African-American; mean age 
54 years; mean duration of dialysis 3 years. Hypertension was predominant etiology 
of ESRD (86%), diabetes 51.7%, SLE 4%. The non-invasive evaluation showed 
hypertension uncontrolled in 54% of patients; left ventricular hypertrophy 64%; left 
ventricular systolic dysfunction 20%; exercise tolerance reduced in 83%. Patient with 
a history of CHF usually had a fluid overload etiology with normal LV systolic function. 
Based on non-invasive evaluation, 107 patients (36.2%) were recommended for cath; 
71 patients (24%) underwent catheterization. Among the catheterized patients 56% had 
CAD (one vessel disease 51% , two vessel disease 39%, three vessel disease 10%), left 
ventricular diastolic function was abnormal in 90% of patients
Conclusion: 1- The cath-based prevalence of CAD in ESRD pre-transplant patients 
appears to be lower than predicted by clinical/non-invasive evaluation. Single Vessel 
CAD was surprisingly prevalent. 2- In a predominantly hypertensive ESRD population 
LV diastolic dysfunction is very common (90%), systolic dysfunction relatively uncommon 
(20%).3- Echocardiographic features of the ESRD population include LVH, mild to 
moderate degenerative aortic and mitral changes, and LV diastolic dysfunction.
2:30 p.m.
1019-195 Electrically Induced Chest Constrictions During 
Ventricular Fibrillation Produce Blood Flow
Byron L. Gilman, James M. Berry, Kai Kroll, Thomas Nelson, Mark W. Kroll, Galvani, 
Ltd., 5933 Grimes Ave. S., Ste # 101, MN
Purpose: An Electrical Cardio-Pulmonary Resuscitation method (E-CPR®) has been 
developed to deliver shocks of greater magnitude than external pacing but of significantly 
lesser magnitude than external defibrillation, thereby producing Chest Constrictions 
(CC) similar to those produced by “cough CPR.” It is known that defibrillation success 
may be improved when Manual Chest Compressions (MCC) are applied to a patient in 
ventricular fibrillation (VF) prior to a defibrillation shock. It was hypothesized that E-CPR 
would produce blood flow equivalent to that produced by MCC.
Methods: A total of 87 E-CPR interventions were delivered to 3 pigs weighing 33.7±0.6 kg., 
while anesthetized and maintained on a ventilator. Blood velocity in the ascending aorta was 
measured using an intracardiac echo flow probe and the Time-Velocity-Integrals (TVI) were 
calculated. For each fibrillation episode, E-CPR was started following 10 seconds of VF and 
evaluated for 15-20 seconds. E-CPR stimuli comprise a 50-200 ms pulse train with a series of 
3-13 electrical pulses ranging from 0.15-7.5 ms wide at a pulse train rate of 30-150 per minute.
Results: E-CPR produced skeletal contractions and aortic flow TVI of 0.071 ± 0.044 
cm (n=87), similarly, MCC produced TVI of 0.05 ± 0.014 cm (n=3) and normal sinus 
rhythm produced TVI of 0.135 ± 0.085 cm (n=4)as shown in the table below. Flow 
produced by E-CPR ranged from TVI of 0.01-0.19 cm. The difference between E-CPR 
and MCC was not significant (p=.41)
Conclusion: E-CPR produced blood flow equal to and in some cases greater than that 
produced by MCC. Additional work is needed to determine patient-appropriate E-CPR 
stimulation protocols and to evaluate the performance of E-CPR following prolonged VF.
2:30 p.m.
1019-196 An Integrated Approach to the Treatment of Sudden 
Cardiac Death Improves Survival in an Urban Setting
Aamer Abbas, Brian E. Gulbis, Andrea C. Hall, Wing Yi Liu, Carmen W. Landrau, 
Manuel M. Reyes, Coung T. Pham, Husnu E. Kaynak, James J. McCarthy, David E. 
Persse, Stefano Sdringola, H. Vernon Anderson, Richard W. Smalling, Ali E. Denktas, 
The University of Texas Health Science Center, Houston, TX, Memorial Hermann Heart 
and Vascular Institute, Houston, TX
Background: Sudden cardiac death (SCD) is a major cause of mortality in the U.S. 
Our hospital is a level one Cardiovascular Center in a major metropolitan area and 
receives the majority of SCD patients in the region. Between the years 2001 to 2004 the 
city emergency medical services (EMS) demonstrated a survival in SCD of 36% in our 
hospital compared to 22% in other area hospitals which was still lower than desirable. 
The purpose of this study was to evaluate the effect of implementing an integrated system 
with the EMS for expedited SCD care (in conjunction with a pre hospital facilitated PCI 
trial for STEMI patients) on the outcomes in SCD patients.
Methods: We evaluated 92 SCD patients admitted to the CCU from 2004-2006, mean 
age 59±16, males 64%, myocardial infarction 60%, VT/VF, 66%. For comparison, city’s 
EMS data on survival from previous years were used. Spearman’s rank order correlations 
were done to identify the determinants of survival.
Results: There was a significant increase in survival after the integrated care approach 
was implemented (78/217 (36%) vs. 45/92 (49%) p=0.03). Survival significantly and 
inversely correlated with age ( dead vs alive, mean: 62.6 ± 15.5 vs 55.3 ± 15.6, p = 0.01), 
admission creatinine (2.0 ± 0.94 vs 1.54 ± 0.37, p = 0.007), admission glucose (281.6 ± 
105.2 vs 249.1 ± 110.5, p = 0.02) peak CK-MB (178.4 ± 269.8 vs 83.2 ± 120.9 p=0.03), 
number of vasopressors (1.9 vs 1.2 p=0.0003) and CPR down time (27 ± 18.9 vs 15 ± 
12.4, p = 0.02), Initial rhythm of VT/VF(55.3 % vs 77.8%, p = 0.005), witnessed arrest 
(74.5% vs 93.3%, p = 0.01) and performance of cardiac catheterization (23.4% vs 60%, p 
= 0.0002) during hospitalization were identified as having significant and direct correlation 
with survival in our group. Hypothermia, which is routinely done in our hospital, had no 
effect on overall mortality.
Conclusions: We identified age, witnessed arrest, number of vasopressors, peak CK-
MB, down time, initial rhythm, cardiac catheterization, admission glucose and creatinine 
as important predictors of outcome. Having an integrated system for acute cardiac care 
including SCD explains the survival improvement seen in our hospital compared to others 
which treat SCD in an ad hoc manner.
2:30 p.m.
1019-197 Gender Specific Effect of Previous Percutaneous 
Coronary Intervention on Early Mortality after Coronary 
Artery Bypass Surgery
Friederike Kendel, Vera Regitz-Zagrosek, Elke Lehmkuhl, Christoph Knosalla, Roland 
Hetzer, German Heart Institute Berlin, Berlin, Germany, Institute for Medical Psychology, 
Berlin, Germany
Background: Recent studies have shown that in patients with a history of multiple 
percutaneous coronary interventions (PCIs) in-hospital mortality after coronary artery 
bypass grafting (CABG) is increased. It is known that PCI is applied differently to both sexes 
and entails more complications in women. Moreover, significant age-dependent differences 
exist between men and women in early mortality after CABG. Therefore, we investigated 
whether the effect of previous PCIs on outcome after CABG was related to sex and age.
Methods: In-hospital mortality was analyzed in 9368 consecutive patients (24.2% 
women) operated on between 2001 and 2005 in the German Heart Institute Berlin. Risk 
factors, history of previous cardiac interventions, peri- and postoperative variables were 
obtained from the quality control (QC) database. To assess the effect of PCI on outcome 
after CABG in different sex and age groups, univariate and multivariate risk adjusted 
logistic regression analyses were performed. Therein, the cut-off for age was calculated 
by using the area under the receiver operator command curve (ROC). 
Results: Overall, women had a 1.8-fold (p<0.001) higher early mortality after CABG than 
men, with a cut-off for the effect of age on early mortality of 69.5 years. Mortality was 2.0-
fold higher in younger women (<69.5 years) than in age matched men and 1.3-fold higher 
above 69.5 years (p<0.012). A percentage of 28.7% of the younger men and 27.9% of 
the younger women had previous PCI (single or multiple) compared to 22.3% of the 
older men and 20.7 % of the older women. Common risk factors differed according to 
age and sex. Only in younger men, PCI was an independent predictor for higher early 
mortality (odds ratio (OR), 1.83; 95% confidence interval (CI), 1.23 to 2.73, p<0.003) after 
controlling for common risk factors. PCI was neither a predictor of risk in older men (OR, 
1.02) nor in younger (OR, 0.81) or older women (OR, 0.97).
Conclusions: PCI seems to be associated with in-hospital mortality in younger men. 
Vascular remodelling leading to an interaction of the effects of PCI and subsequent CABG 
might be more active in younger than in older patients and greater in men than in women.
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1019-198 The Comparison of Coronary Artery Bypass Surgery 
with Drug-Eluting Stent Implantation for the Treatment 
of Multivessel Coronary Artery Disease
Jun Hyung Kim, Hyeon-Cheol Gwon, Jeong Hoon Yang, Soo Jin Cho, Young Bin Song, 
Myung Joon Park, Joo Yong Hahn, Jin Ho Choi, Seung Hyuk Choi, Sang Hoon Lee, 
Kyung Pyo Hong, Jung Euy Park, Samsung medical center, Seoul, South Korea
Background: Recently, coronary artery bypass graft (CABG) has been ,to some degree, 
replaced with drug-eluting stent (DES) to treat the patients with multivessel disease. To 
compare the efficacy of DES with CABG, we investigated the clinical outcomes of the 
DES versus CABG in series of patients with multivessel coronary artery disease.
Methods: This is a single center registry study. Nine hundred eighty-five patients with 
multivessel disease who underwent percutaneous coronary intervention (PCI) with DES 
(n=529) and CABG (n=456), from March 2003 to March 2005 were included. The primary 
objective of this study was defined as the absence of major adverse cardiac and cerebral 
events at 12 month, including death from any cause, cerebrovascular accident (CVA), 
acute myocardial infarction (AMI), and repeat revascularization by PCI or CABG. The 
secondary objectives were major adverse cardiac and cerebral events at 30 days and to 
compare the two groups with respect to composite death, CVA, and AMI.
Results: The 30-day clinical outcomes were statistically not significantly different between 
the two groups. During 12 months follow up, the rate of mortality was not significantly 
different between the two groups (1.9% vs. 2.7%, p = 0.211). The rate of composite death, 
CVA, AMI was not significantly different in both groups (2.7% vs. 3.4%, p = 0.269). The rate 
of overall MACCE was 13.2% in the DES group and 3.8% in the CABG group (p < 0.001).
Conclusions: The rate of serious cardiovascular events, which includes death from any 
cause, CVA, and AMI were not significantly different between the two groups. However, 
overall major adverse cardiac and cerebral events were still significantly higher in patients 
with multivessel disease who treated with DES than CABG, because of the increased rate 
of repeat revascularization.
2:30 p.m.
1019-199 Oral Supplementation With Mixed Essential Amino 
Acids Protects The Human Heart From The Iatrogenic 
Ischemia/reperfusion Injury Associated With 
Cardioplegic Arrest Reducing Myocyte Cell Loss And 
Exerting Favorable Metabolic And Hemodynamic Effects
Carol Chen-Scarabelli, Giuseppe Faggian, Alessandro Mazzucco, Tiziano M. Scarabelli, 
St John Hospital/Wayne State University, Detroit, MI, University of Verona, Verona, Italy
Background & Aim: Cardioplegic arrest induces anaerobic metabolism, with enhanced 
glucose uptake and net production of lactate from glycolysis, as well as cardiac release of 
creatine kinase-MB (CK-MB) and apoptotic cell death, with decline in cardiac contractility. 
In this setting, one mechanism of cardiac adaptation is the uptake of essential amino 
acids (EAA), which correlates with 02 consumption. Here, we investigated metabolic, 
prosurvival and hemodynamic effects of EAA on patients undergoing on-pump CABG 
surgery in a double-blind placebo controlled study.
Methods: 56 patients with multiple-vessel coronary disease were randomly divided into 2 
groups. The treated group (24 patients) received 4 g of EAA (2 g b.i.d. per os) for 10 days 
prior to surgery. Cross-clamping time and mean number of grafts were not significantly 
different between the two groups. Myocardial arterial-venous difference (MAVD) in 
glucose, lactate, and CK-MB, as well as left ventricular stroke work index (LVSWI), as an 
indicator of global function of left ventricle, were evaluated preoperatively (PO), and 0, 
3, 6, 12, 24 and 48 hours after surgery (AS). Two biopsies were obtained from the right 
atrium of all patients at the start of CABG and 10 mins after release of aortic clamp.
Results: In the placebo group, cardioplegic arrest induced enhanced glucose extraction 
(MAVD: +35 ±2.2 mg/dl 3 h AS vs +18±1.8 mg/dl PO), lactate production (MAVD: +0.9±0.1 
mg/dl 3 h AS vs +3.8±0.4 mg/dl PO), CK-MB release (MAVD: -22±3.5 ng/ml 12 h AS vs -
1.4±0.4 ng/ml PO) and consistent reduction in LVSWI values during reperfusion (e.g. 48±2.9 
gm/m2 6 h AS vs 61±3.3 PO gm/m2). EAA supplements normalized glucose extraction 
(MAVD: 20±2.1 mg/dl 3 h AS), minimized lactate production (MAVD: 3.3±0.3 mg/dl 3 h AS) 
and CK-MB release (MAVD: 3.8±1.2 ng/ml 12 h AS), improved cardiac function following 
release of the aortic clamp (e.g. LVSWI 6 h AS: 60±2.8 gm/m2) and reduced TUNEL positive 
staining of myocytes (0.8±0.4% AS vs 4.3± 0.5% AS in placebo group) (all p<0.05).
Conclusions: EAA protect the heart exposed to cardioplegic arrest, reducing cardiac cell 
death, and exerting beneficial metabolic and hemodynamic effects.
2:30 p.m.
1019-200 The Changing Profile of First Re-operative Coronary Artery 
Bypass Surgery: Trends Over 14 Years in 470 Patients
Zefeng Zhang, Claudine Jurkovitz, Angela DiSabatino, Paul Kolm, Liping Zhao, James 
Bowen, Joan McKenna, Gerald Lemole, Kathleen McNicholas, William Weintraub, 
Michael Banbury, Christiana Care Health System, Newark, DE
Background: Re-operative coronary artery bypass grafting (CABG) is an increasing 
part of current surgical practice. Few data are available regarding the changing profile of 
patients undergoing re-operative CABG and trends of its outcomes.
Methods: Prospectively entered preoperative data of 470 patients undergoing first 
re-operative CABG at Christiana Care Health System, from 1993 to 2006, were 
retrospectively analyzed. Categorical and continuous variables were compared using the 
chi-square and analysis of covariance, respectively. 
Results: The mean age was 66.0 years and 80% were male. There was a statistically 
significant trend over time for patients to be older and sicker by multiple criteria, including 
hypertension, family history of cardiovascular disease, peripheral vascular disease, and 
renal failure. The presence of diabetes increased over time, although not statistically 
significant. Prior myocardial infarction, heart failure and ejection fraction remained 
similar over time. There were strong trends for the reduced rates over time in in-hospital 
mortality, post-operative myocardial infarction and stroke, with stroke reaching statistical 
significance (see Table).
Conclusions: Clinical outcomes after re-operative CABG appeared to be improved 
during the period from 1993 to 2006 despite increasing age and comorbidities among 
patients. The mechanisms of these improvements need to be further explored.
Variable 1993-1996 (n=194)
1997-2000 
(n=155)
2001-2006 
(n=121) p value
Age (years) 64.8 66.3 67.6 0.018
Female (%) 19.6% 20.0% 16.3% 0.79
Hypertension (%) 64.4% 70.3% 78.5% 0.03
Prior MI (%) 75.3% 71.0% 72.0% 0.64
Diabetes (%) 26.8% 30.3% 33.9% 0.403
Renal failure (%) 1.6% 0.7% 7.4% 0.001
In-hospital mortality 
(%) 10.82% 8.03% 4.96% 0.08
Post-operative MI 4.6% 1.3% 1.7% 0.11
Stroke (%) 5.7% 1.9% 0.8% 0.03
ACC.SYMPOSIUM / FEATURED ORAL ABSTRACT 
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644 
Antiplatelet Resistance: Is It Real and Is It 
Important?
Monday, March 26, 2007, 4:00 p.m.-5:30 p.m.
Room 217-218-219
4:30 p.m.
644-5 Clopidogrel Resistance Overcome by Reloading
Shlomi Matetzky, Paul Fefer, Boris Shenkman, Ibrahim Marai, Naphtali Savion, David Varon, 
Hanoch Hod, Sheba Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel 
Hashomer, Israel, Hebrew University Hadassah Medical School, Jerusalem, Israel
Background:Clopidogrel resistance has been found in up to 25% of treated patients and 
is associated with increased risk of recurrent cardiovascular events and periprocedural 
thrombotic complications. Although prior studies have suggested dose dependency of 
clopidogrel response, the effects of dose escalation in clopidogrel resistant patients 
have not been studied. The purpose of this study was to evaluate whether clopidogrel 
resistance can be overcome by increasing clopidogrel dose.
Methods: ADP-induced platelet aggregation was prospectively determined in 200 
consecutive acute coronary syndrome patients. All patients were treated with aspirin 
325mg loading and 100 mg/day thereafter and clopidogrel 300 mg loading and 75 mg/
day thereafter. Assessment of platelet function was performed on day IV. Twenty-four 
patients (12%) were found to have ADP-induced aggregation ≥80%. These patients were 
considered clopidogrel resistant and comprised the study group. Patients were reloaded 
with 600mg clopidogrel and 150mg/day for 4 weeks, after which the dose was reduced 
to 75mg/day. Platelet function was assessed 4 hours, 1 and 2 weeks post reloading and 
bi-weekly thereafter for a total of 12 weeks.
Results: In the entire group, ADP-induced platelet aggregation was significantly reduced 
4 hours post reloading (from 83±6% to 57±12%, p<0.01), as was arachidonic acid platelet 
aggregation (74±19% to 58±19%, p<0.01). Similarly, platelet aggregation under flow 
conditions, using Cone and Plate(let) technology(Impact-R), was significantly reduced. 
This reduction in platelet reactivity was maintained throughout the 12-week study period. 
Flow cytometry demonstrated a significant reduction in platelet activation 4 hours post 
loading, as evidenced by a reduction in fibrinogen binding (from 85±7% to 71±4%, 
p<0.05) and P-selectin expression (from 40±to 28±13%, p<0.05).
Conclusions: The results of this small series suggest that increasing the dose of 
clopidogrel may overcome clopidogrel resistance in at least some of these patients.
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825 
Chronic Ischemic Syndromes: 
Prevalence, Pathophysiology and 
Treatment
Monday, March 26, 2007, 4:00 p.m.-5:30 p.m.
Room 271-273
4:00 p.m.
825-3 Predictors of Persistent Angina Among Coronary 
Disease Patients
Karen P. Alexander, Patricia A. Cowper, Barbara L. Lylte, Judith A. Kempf, Eric D. 
Peterson, Duke Clinical Research Institute, Durham, NC
Background: A major goal of cardiac therapy is to relieve discomfort from angina, 
thereby improving quality of life; however symptom relief is not universal. The predictors 
of persistent angina across a broad cardiac population are unknown.
Methods: Patients catheterized at Duke Medical Center from 8/98- 4/01 with significant 
CAD and baseline angina were followed at 6 and 12 mo for symptoms with Seattle 
Angina Questionnaire (SAQ). Of survivors who completed 6 and 12 mo surveys (n= 
1,109), 18.7% (n=207) had persistent angina (PA) at 6 and 12 mo, 25.6% (n=284) had 
intermittent angina at 6 or 12 mo, and 55.7% (n=618) were angina free. Using logistic 
regression analysis, we examined predictors of PA also considering revascularization 
which occurred over time.
Results: Compared with those who were angina free, patients with PA were younger 
(63±11 v 67±10 yrs), more likely to be female (52 v 32%), nonwhite (30 v 20%), and 
obese (BMI >30= 43 v 32%) (all p<0.05). Patients with PA were also more likely to have 
COPD (21 v 11%), depression (11 v 5%), frequent angina at baseline (daily or weekly 
vs. monthly 71 v 42%), and single vessel disease (52 v 36%) (p<0.05). Patients with 
PA were less likely to undergo revascularization of any type (64 v 82%), specifically 
CABG (22 v 44%) between enrollment and 12 mo. After adjustment for patient factors 
and revascularization, younger patients (OR 0.96 per year), women (OR 2.6), with more 
frequent baseline angina (OR 4.8) or depression (OR 2.3) were more likely to have PA 
relative to their peers.
Conclusions: Angina persists in one in five CAD patients despite current therapy. 
These are often younger women with more frequent angina at baseline and no interval 
revascularization. Accordingly, they may gain particular benefit from more intensive anti-
anginal therapy as well as treatment for coexisting depression.
4:15 p.m.
825-4 Verapamil-SR Strategy Is Comparable to Atenolol 
Strategy at Reducing Cardiovascular Events in Patients 
With Prior Myocardial Infarction: An INVEST Substudy
Sripal Bangalore, Franz H. Messerli, Jerome D. Cohen, Peter H. Bacher, Giuseppe Mancia, 
Peter Kowey, Ann Hewkin, Annette Champion, Carl J. Pepine, St Lukes Roosevelt Hospital, 
New York, NY, University of Florida College of Medicine, Gainesville, FL
Background: In patients with prior myocardial infarction (MI), beta-blockers reduce 
reinfarction rates and mortality. However, despite evidence in favor of beta-blockers, 
some patients are unable to tolerate these drugs.The role of heart rate lowering calcium 
antagonist based strategy in patients post MI is not well defined.
Methods: We evaluated 7218 patients with prior MI enrolled in the INVEST equivalence trial 
who were randomized to verapamil SR (Ve) or atenolol (At) strategies and followed for 2.8 ± 
0.9 years. Patients could be randomized as early as 3 months after an MI. Primary outcome 
(PO) was a composite of time to first occurrence of death (all cause), nonfatal MI or nonfatal 
stroke. Secondary outcome was fatal and non fatal MI and fatal and non fatal stroke.
Results: At 2 yrs, the Ve and At strategies had comparable BP control. Incidence of the 
PO was equivalent between Ve and At strategies. There was no difference between the 
two groups for the end points of all-cause mortality and non fatal MI with a trend towards 
19% reduction in the risk of stroke in the Ve strategy. There was no difference between 
the two groups for the secondary end points as well (Figure). 
Conclusion: In patients with prior MI and hypertension, a verapamil SR based strategy 
is comparable to a beta-blocker strategy for the prevention of cardiovascular events, with 
a trend towards lesser risk of strokes in the verapamil SR group. A verapamil SR based 
strategy may thus be an acceptable alternative to a beta-blocker based strategy.
4:30 p.m.
825-5 Long-Acting Calcium Channel Blockers in Patients With 
Coronary Artery Disease: A Meta-Analysis of 39,652 
Patients
Sripal Bangalore, Sanobar Parkar, Naohiko Imai, Franz H. Messerli, St Lukes Roosevelt 
Hospital, New York, NY
Background: Prior studies on short acting calcium channel blockers (CCBs) have shown 
increased mortality in patients with coronary artery disease (CAD). However, the role of 
long acting CCBs in patients with CAD is unknown.
Methods: We conducted a MEDLINE, PUBMED search of studies using the terms: 
CCBs and CAD. The search was limited to randomized controlled trials in human 
subjects published in English language in patients with known CAD followed up for 
at least 1 year. Of the 96 studies, only 11 studies fulfilled the inclusion criteria. Only 
studies using long acting CCBs were included.
Results: A total of 19,464 patients on CCBs (amlodipine, verapamil SR, nifedipine GITS, 
nisoldipine) were compared against 20,188 patients on other therapy. The other therapy 
varied from an angiotensin converting enzyme (CAMELOT, JMIC-B) to beta blocker 
(INVEST, TIBET, JBCMI, APSIS) to a placebo (ACTION, CAMELOT, CRIS, NICOLE, 
PREVENT, CRIS).When compared to the other therapy, CCBs did not result in increased 
risk of death (event rate 6.4% both groups) or myocardial infarction (event rate 2.9% both 
groups). There was a 22% reduction in the risk of stroke and a trend towards reduction 
in the risk of heart failure in patients on CCBs compared to other therapy (Figure). There 
was no heterogeneity in this analysis.
Conclusions: In patients with CAD, long acting CCBs result in a 22% relative risk 
reduction for stroke with no increase in the risk of death or myocardial infarction when 
compared to the other therapy.
4:45 p.m.
825-6 The Oral Adenosine A1 Receptor Agonist, BAY 68-4986, 
Reduces Heart Rate at Peak Exercise in Patients With 
Chronic Stable Angina
Michal Tendera, Maciej Sosnowski, Ewa Gaszewska-Zurek, Zophia Parma, Dieter 
Neuser, Leo Seman, Silesian School of Medicine, Katowice, Poland, Bayer Healthcare, 
Wuppertal, Germany
Background: BAY 68-4986 is a novel small molecule adenosine A1 receptor agonist, 
with a structure that is not derived from adenosine. Pre-clinical studies demonstrated that 
treatment with BAY 68-4986 reduced heart rate in several animal models. Single-dose and 
multi-dose clinical trials in healthy males demonstrated safety and tolerance in humans.
Methods: In a randomized, double-blind, placebo-controlled, dose-escalating multi-
center study, patients with stable angina and definitive CHD were treated with BAY 68-
4986 at doses of 1, 2.5, 5, 10 and 20 mg vs placebo. Heart rate (HR) under equivalent 
work load was measured at baseline and after treatment at peak drug concentration. 
Other endpoints such as total exercise time at peak and trough, HR at equivalent work 
load at trough, total exercise time at peak and trough, time to angina onset at peak and 
trough, were also assessed. For each dose step subjects were randomized to either BAY 
68-4986 or matching placebo in a 5:1 ratio.
Results: Of 104 subjects enrolled, 63 were randomized, 62 were valid for intent-to-treat 
(ITT) analysis, and 52 were valid for per-protocol (PP) analysis. In both the PP and ITT 
analyses, HRs in the 10 mg dose cohort were significantly lower (PP, -17.2, p=0.0021; 
ITT, -16.4, p=0.0002) than placebo values at peak concentration of BAY 68-4986. The 
20 mg dose cohort demonstrated a trend (PP -10.7, p=0.1017; ITT -10.9, p=0.0320) at 
peak concentrations of BAY 68-4986. In PP, total exercise time at peak dose increased 
by 52 sec on 10 mg and by 81 sec on 20 mg of BAY 68-4986 (p=0.1304 and p=0.0205, 
respectively). Other endpoints all trended toward improvement with 10 and 20 mg doses 
of BAY 68-4986
Conclusions: The results of this study suggest that BAY 68-4986, an oral adenosine A1 
receptor agonist, may exert an anti-ischemic effect in patients with stable angina.
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825-7 Prevalence and Prognosis of Silent Ischemia in 
Outpatients With Stable Coronary Heart Disease: The 
Heart and Soul Study
Anil K. Gehi, Sadia Ali, Mary A. Whooley, Emory University Medical Center, Atlanta, GA, 
University of California San Francisco, San Francisco, CA
Background: Current guidelines do not recommend routine stress testing in patients with 
stable coronary heart disease (CHD) unless they have symptoms of angina. We sought to 
determine the prevalence and prognosis of silent ischemia in outpatients with stable CHD.
Methods: In a cohort of 938 outpatients with stable CHD, we measured self-reported 
angina using the Seattle Angina Questionnaire and inducible ischemia using treadmill 
stress echocardiography. We defined the presence of angina as once per week or 
more. Inducible ischemia was defined as the presence of echocardiographic wall motion 
abnormalities at peak exercise that were not present at rest. During an average 3 
(range 2 to 4) years of follow-up, blinded adjudicators reviewed medical records, death 
certificates, and coroner reports for CHD events (myocardial infarction or CHD death). 
We used logistic regression to evaluate the association of angina and ischemia with CHD 
events, adjusted for traditional CHD risk factors. Results are reported as odds ratios (OR) 
with 95% confidence intervals.
Results: Among the 938 study participants, 131 (14%) had angina without inducible 
ischemia, 188 (20%) had inducible ischemia without angina, and 40 (4%) had both angina 
and ischemia. CHD events occurred in 5% of participants without angina or ischemia, 
10% of those with angina alone, 18% of those with ischemia alone, and 28% of those 
with both angina and inducible ischemia (p<0.0001). After multivariable adjustment, the 
presence of angina alone was not associated with CHD events (OR 1.9; 0.8 - 4.0; p=0.1). 
However, the presence of ischemia without angina was strongly associated with CHD 
events (OR 2.7, 1.6-4.8, p<.001), and participants with both angina and ischemia had the 
highest odds of CHD events (OR 5.0, 2.2-11.6, p<.001).
Conclusions: We found that 20% of patients with stable CHD have inducible ischemia 
without angina, and that the presence of silent ischemia is associated with an almost 
3-fold odds of CHD events. These findings suggest it may be time to reconsider the 
potential benefit of routine stress testing in outpatients with stable CHD.
5:15 p.m.
825-8 Increased Red Blood Cell Aggregation and Blood 
Viscosity in Cardiac Syndrome X as a Cause of 
Microcirculatory Dysfunction
Byoung Kwon Lee, Tamas Alexy, Rosalinda Wenby, Azhil Durairaj, Anilkumar Mehra, Herbert 
J. Meiselman, University of Southern California, Keck School of Medicine, Los Angeles, CA
Background: Cardiac syndrome X (CSX) continues to be of basic science and clinical 
interest, yet the mechanism(s) involved have not been fully elucidated. However, it is well 
known that elevated RBC aggregation and blood viscosity can adversely affect in vivo 
microcirculatory blood flow: we thus tested the hypothesis that CSX is characterized by 
such hemorheological abnormalities.
Methods: Blood samples were obtained from adult angina patients at the LAC-USC 
Medical Center just prior to diagnostic cardiac angiography. Rheological measurements 
were carried out within six hours, with CSX subjects later identified based upon 
angiographically-normal coronary arteries, typical angina, and a positive stress test. 
Twenty-one CSX subjects were studied and compared to 21 age and sex matched 
controls without angina or clinical evidence of coronary arterial disease. Rheological 
measurements included whole blood viscosity (0.5 to 1500 sec-1 shear rate), yield shear 
stress, plasma viscosity, RBC aggregation via erythrocyte sedimentation rate (ESR) and by 
aggregation indices at stasis (M) and low shear (M1) using an automated aggregometer; 
clinical laboratory data and TIMI frame counts(CTFC) were also obtained.
Results: CSX patients had markedly abnormal blood rheology: 1) Higher RBC aggregation 
as judged by ESR (3-fold greater, p<0.001); 2) Enhanced RBC aggregation index at 
stasis (49% higher M, p<0.005) and at low shear (52% higher M1, p<0.005); 3) Elevated 
whole blood viscosity (p<0.001 at lower shear rates), plasma viscosity (1.66±0.11 vs. 
1.56±0.10 cP, p<0.001), and yield stress (38% higher, p=0.002). CSX patients had high 
WBC counts (7.6 vs. 5.8 x 109/L, p<0.05) and CRP levels (2.85±2.00 vs. 0.51±0.58 mg/dl, 
p<0.001), and a mean CTFC of 25.8 ± 5.6.
Conclusions: Our findings suggest that abnormal hemorheological parameters 
contribute importantly to the etiology of CSX, presumably via adversely affecting blood 
flow and RBC flux in the coronary microcirculation. Further, they indicate the possibility of 
therapeutic measures aimed at normalizing blood rheology (e.g., plasma phaeresis) and 
hence microcirculatory flow.
ACC.ORAL CONTRIBUTIONS
827 
Stem Cell Therapy for the Heart
Monday, March 26, 2007, 4:00 p.m.-5:30 p.m.
Room 278-281
4:00 p.m.
827-3 Mechanical Stretch Boosts Cardiomyogenic 
Differentiation of Normal and Genetically Modified 
Human and Murine Bone Marrow-Derived Mesenchymal 
Stem Cells
Arti A. Ramkisoensing, Daniël A. Pijnappels, John van Tuyn, Twan A.A.F. de Vries, Ernst 
E. van der Wall, Martin J. Schalij, Douwe E. Atsma, Arnoud van der Laarse, Leiden 
University Medical Center, Leiden, The Netherlands
Background: After stem cell transplantation in the infarcted heart, stem cells are exposed 
to stretch from the surviving myocardium. Not much is known about the effect of stretch 
on stem cell differentiation. Therefore, we subjected human and murine mesenchymal 
stem cells (hMSCs/mMSCs) with or without forced expression of the cardiomyogenic 
transcription factor myocardin (myoC_hMSCs/myoC_mMSCs) to passive mechanical 
stretch using collagen-coated stretch plates.
Methods: MSCs were seeded on 6-well flexible-bottom plates with a collagen (type 
I) coating and 0.1% gelatin. After adherence of cells, they were subjected to cyclic 
mechanical stretch using the Flexercell Strain Unit FX2000 (Flexcell Int. Corp, USA). 
Cells were stretched for 24 h once a week for a time period of 3 weeks. Control cells 
were grown in identical culture plates, but not subjected to stretch. Cardiomyogenic 
differentiation was analysed by immunohistochemical staining, reverse transcriptase 
polymerase chain reaction and Western Blotting.
Results: After forced expression of myocardin several cardiac genes, like α-actinin, atrial 
natriuretic polypeptide (ANP), Myosin, and GATA4, were expressed in MSCs. In stretched 
hMSCs α-actinin expression (+37%) was higher than in non-stretched hMSCs. In stretched 
myoC_hMSCs α-actinin (+70%), ANP (+75%) and Myosin (+81%) expression were 
significantly higher than in non-stretched myoC_hMSCs (p<0.05). In both stretched and 
control mMSCs none of the cardiac-specific proteins stained for were present. In stretched 
myoC_mMSCs the expression of α-actinin (+173%) and cardiac troponin I (+72%) was 
significantly higher than in non-stretched myoC_mMSCs (p<0.05). Western blot analysis 
and reverse transcriptase polymerase chain reaction confirmed the increased α-actinin 
expression in the stretched MSCs compared to non-stretched MSCs.
Conclusions: Mechanical stretch can play a pivotal role in boosting cardiomyogenic 
differentiation of hMSCs and mMSCs. Forced expression of myocardin results in expression 
of cardiac genes which are significantly upregulated under the influence of stretch.
4:15 p.m.
827-4 Survival and Maturation of Human Embryonic Stem 
Cell-Derived Cardiomyocytes Implanted Into Rat Hearts 
Exposed to Ischemia
Wangde Dai, Loren J. Field, Sharon L. Hale, Robert Zweigerdt, Ralph E. Graichen, 
Gregory L. Kay, Aarne J. Jyrala, Bruce Davidson, Martin Pera, Robert A. Kloner, Heart 
Institute of Good Samaritan Hospital, Los Angeles, CA, Es Cell International Pte Ltd, 
Helios, Singapore
Background: It is unknown whether human embryonic stem cells (hESCs) can be transported 
long distance, survive and mature in hearts with transient ischemia, as might occur in 
zones of hearts with ischemic cardiomyopathy. We investigated whether hESC-derived 
cardiomyocytes could survive shipment from a remote site and subsequent transplantation 
into the left ventricular wall of athymic nude rats exposed to transient ischemia.
Methods: hESCs (HES3)-derived cardiomyocytes expressing green fluorescent protein 
(GFP) were shipped (cooled but non-frozen) from Singapore to Los Angeles (3 days). The 
cells (2×106, n=10) or medium (n=10) were injected directly into the myocardium within 
ischemic risk area 5 minutes after left coronary artery occlusion in athymic nude rats; 
reperfusion was induced 10 minutes after injection. Hearts were harvested at either hours, 
1, 2 or 4 weeks after injection, and processed for detection of grafted cells. In order to 
assess whether the hESC might escape immune surveillance, 2×106 hESCs were injected 
into Sprague-Dawley rat hearts (n=2), and the hearts were harvested at 4 weeks.
Results: Even following 3 days of shipping, the cells actively and rhythmically contracted 
upon incubation at 37°C. H&E and immunohistochemical staining demonstrated sizable 
grafts in 9 out of 10 nude rat hearts in the cell group. The same cells that demonstrated GFP 
epifluorescence and positive staining for antibodies to GFP also stained positive for the 
muscle markers α-actinin and sarcomeric actin and exhibited cross striation (sarcomeres). 
No evidence of rejection was observed. In contrast, hESCs injection into immune competent 
Sprague-Dawley rats resulted in a brisk lymphocytic infiltrate typical of rejection.
Conclusions: hESCs-derived cardiomyocytes can survive several days of shipping, 
making an “off the shelf” approach to cardiac replacement therapy a potentially viable 
option. Grafted hESCs survived within the nude rat hearts subjected to ischemia/
reperfusion at 4 weeks after transplantation and matured toward an adult cardiomyocyte. 
However, hESCs did not escape immune surveillance in the xenograft setting in that they 
caused a rejection phenomenon in immune competent rats.
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827-5 Forced Myocardin Expression Enhances the 
Therapeutic Effect of Mesenchymal Stem Cells From 
Ischemic Heart Disease Patients After Acute Myocardial 
Infarction in NOD/SCID mice
Robert W. Grauss, Paul Steendijk, John van Tuyn, Elizabeth M. Winter, Arnoud van der 
Laarse, Adriana C. Gittenberger-de Groot, Ernst E. van der Wall, Antoine A.F. de Vries, Martin 
J. Schalij, Douwe E. Atsma, Leiden University Medical Center, Leiden, The Netherlands
Background: Human mesenchymal stem cells (hMSCs) can improve left ventricular (LV) function 
in myocardial infarction (MI) models, but show limited differentiation towards cardiomyocytes. We 
hypothesize that forced expression of the cardiac transcription factor Myocardin (Myoc) induces 
hMSCs to acquire a cardiomyocyte phenotype, and improves LV function in a mouse MI model.
Methods: hMSCs from patients with ischemic heart disease were transfected with GFP 
+ Myoc (hMSC
myoc) or GFP alone (hMSCGFP). After MI, hMSCmyoc (n=10), hMSCGFP (n=10) 
or medium only (n=11) were injected into the infarct area of immune-compromised NOD/
scid mice. Sham operated mice were used as baseline (n=12). At day 15 LV function was 
determined by pressure-volume loop measurements, followed by histological evaluation.
Results: At day 15, both hMSCGFP and hMSCmyoc increased ejection fraction as 
compared to medium (Table 1.). Moreover, Myoc transfection also decreased LV volumes 
and increased contractility (Table 1.). hMSCs
myoc, but not hMSCsGFP expressed the 
cardiomyocyte markers cardiac troponin I and Atrial Natriuretic Factor.
Conclusions: Transplantation of hMSC
myoc decreases LV remodelling and improves contractility, 
which was not observed after transplantation of hMSCGFP alone. Furthermore, forced expression of 
Myoc induced differentiation into a cardiomyocyte phenotype. These data suggest that hMSC
myoc 
may constitute an improved form of hMSC therapy for the treatment of IHD
5:00 p.m.
827-7 Hypoxic Preconditioning Promotes Bone Marrow 
Mesenchymal Stem Cells Survival by Enhancing Stem 
Cell Autocrine Action
Xinyang Hu, Shanping Yu, Jianan Wang, Jamie L. Fraser, Ling Wei, Medical University of 
South Carolina, charleston, SC, Zhejiang University, Hangzhou, People’s Republic of China
Background: Bone marrow stem cells (BMSCs) have shown potential for cardiac repair 
after myocardial infarction. It has been demonstrated that most stem cells die within 4 days 
after transplantation; Poor survival of implanted cells has hampered the progress of stem cell 
therapy. Therefore, cytoprotection is critical for improving the efficiency of cell therapy. Hypoxic 
preconditioning has been used as a mechanism for cardiomyocyte protection. The present 
study examined the hypothesis that hypoxic preconditioning promotes BMSC survival following 
transplantation into the ischemic heart.
Methods: BMSCs from green fluorescent protein (GFP)-transgenic mice were cultured under 
normoxia (N-BMSC) or hypoxia (0.5% O2) (H-BMSC) for 24 hours. Western blot analysis was 
performed to test the expression of growth factors. Cell death was analyzed in vitro using serum 
deprivation insult for 24 hours, and trypan blue and Caspase-3 staining were used to test for cell 
death and apoptosis. For in vivo experiment, myocardial infarction (MI) was induced by ligation 
of left ascending coronary artery, DAPI-labeled N-BMSCs or H-BMSCs were intramyocardially 
injected 30 minutes after MI, and the animals were sacrificed 24 hours after transplantation. 
Implanted cell apoptosis was identified by the ratio of Caspase-3 and DAPI co-labeled cells per 
total DAPI-positive cells.
Results: Western blot analysis showed that normoxically cultured BMSCs express angiopoietin-1, 
Flk-1, erythropoietin and its cognate receptor, H-BMSCs exhibit increased levels of these factors. 
Serum deprivation markedly increased cell death and apoptosis, which was significantly reduced 
in H-BMSC group compared with that of the N-BMSC group (P<0.05).The ratio of apoptotic 
implanted cells in the H-BMSC transplantation group (24.58±1.18%) was significantly reduced 
compared with that of the N-BMSC transplantation group (32.28±1.11%) (P<0.05).
Conclusions: These data indicate that hypoxic preconditioning significantly increases growth 
factor expression and enhance stem cell survival capacity under environmental insult.
5:15 p.m.
827-8 Electromechanical Assessment of Percutanous 
Intramyocardial Injection of Mesenchymal Vs. 
Mononuclear Bone-Marrow Derived Stem Cells in the 
Chronic Ischemic Myocardium
Korff T. Krause, Kai Jaquet, Stephan Geidel, Carsten Schneider, Carsten Schneider, 
Karl-Heinz Kuck, AK St. Georg, Hamburg, Germany
Background: Although clinical studies have shown that intramyocardial and intracoronary 
stem cell injection may improve myocardial function after acute myocardial infarction, the 
concept of cell injection therapy in ischemic heart disease remains controversial. We 
investigated the effects of different bone marrow derived stem cells in a porcine model of 
chronic progressive myocardial ischemia.
Methods: Endocardial left ventricular electromechanical mapping (NOGATM; BDS, 
USA), coronary and ventricular angiography were performed at week 2 and 6 in the 
ameroid constrictor model. At week two, 5 pigs received in vitro expanded mesenchymal 
stem cells (MSC), 6 pigs hematopoietic mononuclear bone marrow derived stem cells 
(MNC) and 6 pigs received placebo at 20 injection sites into the ischemic region of the 
myocardium by using using a percutaneous transendocardial injection catheter. Degree 
of fibrosis was detemined (Elastica-van-Gieson) by quantitative morphometric analysis 
of ischemic and non-ischemic regions and alpha smooth-musle-cell antigen positive 
(SMA+) vessels were counted per high power field (HPF).
Results: Endocardial electromechanical mapping showed a significantly reduced 
ischemic endocardial surface area of the MSC treated pigs compared to the control and 
the MNC group at week 6 after cell injection : control +17% vs. MNC +0,5% vs. MCS 
-12%; p=0,04. The difference of the standardized unipolar voltage (UV) at week 6 was: 
control -13% vs. MNC 0,0% vs. MSC +14%; p=0,04. In contrast to the control group there 
was significant less reduction of the unipolar voltage in the ischemic region in the MCS 
group. Morphometric quantitative histological analysis of the ischemic regions revealed 
17% myocardial fibrosis in the stem cell group vs. 29% in the control group (p>0,05). 
Conclusion: Assessment of left ventricular electromechanical mapping and post mortem 
histology showed that percutanous intramyocardial injection of mesenchymal stem cells 
has pronounced cardioprotective effects compared to injection of mononuclear stem cells 
in the chronic ischemic myocardium. 
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652-5 Transplanted Embryonic Stem Cells Following Mouse 
Myocardial Infarction Inhibit Apoptosis and Cardiac 
Remodeling
Dinender Kumar Singla, Timothy J. Kamp, University of Vermont, Colchester, VT, 
Universoty of Wisconsin, Madison, WI
Background: We have shown that transplanted embryonic stem (ES) cell following 
myocardial infarction (MI) differentiate into the major cell types in the heart and improve 
cardiac function. However, the extent of regeneration was relatively meager compared 
to the observed functional improvement. Therefore, we hypothesize that mechanisms in 
addition to regeneration contribute to the functional improvement. We examined the effect 
of mouse ES cells transplanted post-MI on cardiac apoptosis, hypertrophy and fibrosis.
Methods: We studied two ES cell lines, HM1 and R1, expressing eGFP and β-gal, 
respectively. MI was induced in C57BL/6 mice by LAD ligation and animals were divided 
into two groups: MI+medium and MI+ES cells. Three to five hr following coronary ligation, 
the thorax was re-opened and three intramyocardial injections of 10 μl of medium ±1x104 
ES cells were delivered into the heart. Histology, TUNEL staining and immunofluorescence 
were used to examine apoptosis, hypertrophy and fibrosis.
Results: Two weeks post-MI, ES cells transplanted hearts showed a significant decrease 
in cardiac apoptotic nuclei (mean±SE; MI+medium=12±1.5%; MI±ES cells=6.6±1%, 
p<0.05) per section are evaluated by TUNEL staining. TUNEL positive nuclei were also 
confirmed by co-labeling with caspase-3 antibody. Cardiac fibrosis observed in the MI+ES 
cell group was 57% less compared with MI+medium group (p<0.05) as seen with Mason’s 
Trichrome. Picrosirius red (PSR) staining confirmed a decreased amount of collagen 
present in the MI+ES cell group. Hearts transplanted with ES cells shows significant 
decrease in cardiac myocyte cell area (μm2) in the infarct and non-infarct regions of the 
heart (MI+ES cells; infarct zone= 626±47 (μm2) and non-infarct zone= 502±50 comapred 
with MI+medium; infarct zone= 750±72, non-infarct zone=601±50; mean±SE, p≤0.05), 
demonstrating decreased post-MI hypertrophy.
Conclusions: In conclusion, transplantation of ES cells post-MI significantly inhibits 
apoptosis, fibrosis and hypertrophy, and these beneficial effects contribute to the 
functional improvement observed in this form of cell therapy and are additional to direct 
cardiac regeneration from the transplanted ES cells.
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803-3 Remote Ischemic Preconditioning Is Induced by 
a Transferable Bloodborne Factor That Allows 
Interspecies Protection
Mikiko Shimizu, Michael Tropak, Jon Lee, Rick D. Bagshaw, John Callahan, Andrew N. 
Redington, Hospital for Sick Children, Toronto, ON, Canada, Tokyo Women’s Medical 
University, Heart Institute of Japan, Tokyo, Japan
Background: Remote ischemic preconditioning (rIPC) has been shown to protect hearts 
from ischemia-reperfusion (IR) injury in different mammalian species; suggesting a 
conserved protective mechanism. We have recently shown the presence of dialyzable 
circulating effector of rIPC in rabbit plasma using a Langendorff model. This study 
investigated the inter-species transferability of the circulating effector.
Methods: Human plasma dialysate was tested in isolated rabbit heart (Langendorff). 100 
ml of blood was taken from 4 healthy volunteers before and after rIPC. rIPC was induced 
by 4 cycles of 5 min upper limb IR, using blood pressure cuff. Following centrifugation, 
50 ml of plasma was dialyzed against 500 ml of water with 10-14 kDa membrane. Hearts 
were perfused for 30min with dialysate buffered with Kreb’s solution followed by 30min of 
LAD ligation and 2 hours of reperfusion. Infarct size was measured as % of area at risk 
(AAR) using Tetratrizolium staining. Paired t-test was used for comparison.
Results: All hearts survived the protocol without adverse effect by dialysate perfusion. 
AAR between groups was not significantly different (p>0.05). Infarct size was significantly 
reduced (p=0.026) in rIPC (10.6+/-1.3%) vs. control (29.0+/-4.7%) group.
Conclusions: Human blood dialysate contains a protective factor(s) which can provide 
potent protection against prolonged myocardial ischemia in a rabbit model. It appears that 
the circulating effector(s) of rIPC is conserved across mammalian species.
7:15 a.m.
803-4 Rapid Induction of Hypothermia Before Reperfusion 
Reduces Myocardial Infarct Size in Pigs
Matthias Gotberg, Goran K. Olivecrona, Henrik Engblom, Martin Ugander, Jesper van 
der Pals, Hakan Arheden, David Erlinge, Department of Cardiology, Lund University 
Hospital, Lund, Sweden, Department of Clinical Physiology, Lund University Hospital, 
Lund, Sweden
Background: Human trials have failed to reduce infarct size by inducing hypothermia 
in patients with myocardial infarction undergoing PCI. However, subgroup analysis 
displayed a reduction of infarct size in patients who achieved a target temperature of 
<35o C prior to reperfusion. The aim of our study was to investigate if rapidly induced 
hypothermia prior to reperfusion, compared to rapidly induced hypothermia immediately 
after reperfusion reduces infarct size.
Methods: Fourteen pigs (40-50kg) in a closed chest model were anesthetized and a 
temperature of 38 o C was established utilising an endovascular cooling catheter. The pigs 
were randomized to hypothermia before reperfusion (n=7) or to hypothermia immediately 
after reperfusion (n=7). Ischemia was induced by inflation of a PCI balloon in the mid 
LAD for 40 min. Hypothermia was induced after 25 min of ischemia and immediately 
after reperfusion in respective groups by infusion of 1000 ml of 8o C saline solution and 
endovascular cooling. Hypothermia was maintained for 30 min in both groups. Area at risk 
(AAR) was evaluated in vivo by single photon emission cardiac tomography (SPECT). 
Infarct size (IS) was evaluated by ex-vivo MRI.
Results: All pigs were cooled to <35o C in less than 10 min. Hypothermia before 
reperfusion reduced IS/AAR by 40% compared to the control group (44.3±5.2%; 
73.9±3.0%; p<0.001). Microvascular obstruction was seen in 6/7 pigs cooled after 
reperfusion vs. 0/7 pigs in the precooled group.
Conclusions: Short duration hypothermia before reperfusion reduces myocardial 
infarct size by 40% and protects the heart from microvascular obstruction (no-reflow) 
compared to hypothermia immediately after reperfusion. A combination of cold saline and 
endovascular cooling achieved a target temperature <35o C in less than 10 min suggesting 
it will enable patients to reach target temperature without delaying revascularization.
7:30 a.m.
803-5 Preconditioning-Like Cardioprotection by Regular 
Ethanol Consumption Lasts at Least 7 Days After 
Abstention and Is Associated With eNOS Upregulation
Kazuhiro Kaneda, Masami Miyamae, Shingo Sugioka, Chika Okusa, Yoshitaka 
Inamura, Naochika Domae, Vincent M. Figueredo, Junichiro Kotani, Department 
of Anesthesiology and Internal Medicine,Osaka Dental University, Osaka, Japan, 
Department of Cardiology, Albert Einstein Medical Center, Philadelphia, PA
Background: We previously found that regular ethanol consumption induces 
cardioprotection against ischemia-reperfusion (I-R) injury. It remains unclear how long 
this cardioprotection lasts after abstention. The present study was designed to determine 
the duration of ethanol-induced cardioprotection, and its relationship to inducible and 
endothelial nitric oxide synthase expression (iNOS and eNOS).
Methods: Isolated perfused hearts from control (CTL) and ethanol-treated (ETOH) guinea 
pigs were subjected to 30 min global ischemia and 120 min reperfusion. The ETOH group 
received 5% ethanol in their drinking water for 8 weeks. I-R was performed on ETOH 
hearts at 0, 4, 7 and 14 days after abstention. Contractile recovery was monitored by 
left ventricular developed (LVDP) and end-diastolic (LVEDP) pressures. Infarct size was 
determined by triphenyltetrazolium chloride staining. Coronary flow (CF) was measured 
by collecting effluent from the right ventricular outflow tract. The expression of iNOS and 
eNOS before ischemia was determined by western blot analysis.
Results: After I-R, ETOH at 0, 4 and 7, but not 14 days of abstention, had higher LVDP 
(62±5 mmHg, 63±5 mmHg, 53±4 mmHg, 38±4 mmHg vs 26±3 mmHg, respectively, 
p<0.05), and lower LVEDP (17±6 mmHg, 22±3 mmHg, 28±7 mmHg, 40±3 mmHg vs 59±5 
mmHg, respectively, p<0.05) compared to CTL. Infarct size was significantly reduced in 
ETOH at 0, 4 and 7, but not 14 days abstention, compared to CTL (24±3 %, 24±3 %, 
31±3 %, 38±2 % vs 47±3 %, respectively, p<0.05). Western blot analysis demonstrated 
upregulation of eNOS expression after abstention up to 7 days, but not 14 days. There 
was no correlation between ethanol-induced cardioprotection and iNOS expression. CF 
was similar among all groups throughout the experiment.
Conclusions: Chronic cardioprotection by regular ethanol consumption lasts for at least 
7 days after abstention and is associated with eNOS upregulation.
7:45 a.m.
803-6 Pretreatment With Epigallocatechin-3-Gallate, Green 
Tea Polyphenol, in Oral Uptake Attenuates Myocardial 
Ischemia/Reperfusion Injury in a Rat Heart Perfusion 
Model
Shigeki Yanagi, Kazuaki Matsumura, Kiyoaki Takaba, Atsushi Nagasawa, Tetsuya 
Kamitani, Suong-Hyu Hyon, Tadashi Ikeda, Masashi Komeda, Department of 
Cardiovascular Surgery, Kyoto University Graduate School of Medicine, Kyoto, Japan, 
Institute for Frontier Medical Sciences, Kyoto University, Kyoto, Japan
Background: In cardiac surgery, ischemia/reperfusion injury (IRI) has been a serious 
problem. Oxidative stress is an important factor of IRI. Epigallocatechin-3-gallate (EGCG), a 
major polyphenolic component of green tea, is a natural antioxidant, protecting cells against 
ischemic damages. We hypothesized that oral pretreatment with EGCG might attenuate 
myocardial IRI and maintain left ventricular (LV) function by reducing oxidative stress.
Methods: Thirty-six SD rats were divided into 3 groups (Gps, n=12 each). In Gp 
I and II (EGCG Gp), 1.0 and 0.1mM of EGCG, respectively, were administered orally 
supplemented with regular water for 2 weeks, while the regular water diet alone for 2 
weeks in Gp III (Control Gp). Subsequently, isolated hearts were subjected to warm 
(37°C) global ischemia for 30 min followed by 60 min of reperfusion using Langendorff 
perfusion apparatus.
Results: Gp I showed far better recovery of LV function than Gp II and III (Table). In Gp 
I and II, coronary flow was higher and heart weight after reperfusion was less increased 
than in Gp III. Oxidative stress as shown by 8-hydroxy-2’-deoxyguanosine (8-OHdG) was 
the lowest in Gp I. Western blot analysis showed that expression of NFkB and caspase-3 
were lower in Gp I than Gp III.
Conclusions: Oral pretreatment with EGCG attenuated myocardial IRI through anti-oxidative 
property and recovered LV function. EGCG pretreatment may be a novel and simple method 
of cardioprotection to prevent perioperative cardiac dysfunction in cardiac surgery. 
Results at 60 min after reperfusion
Gp I (1.0mM) Gp II (0.1mM) Gp III (Control)
% recovery of
LVDP (%) 85.3±8.2*† 62.1±3.8 63.0±12.7
+dp/dt (%) 86.6±5.7*† 65.4±5.1 63.5±11.3
- dp/dt (%) 81.2±6.3*† 62.7±5.5 62.5±11.6
CF (ml/min) 13.0±2.4 12.3±2.0 10.5±2.7
+HW (g) 0.33±0.09 0.38±0.17 0.44±0.11
8-OHdG(+)
cell ratio(%) 22.5±5.1*† 42.6±7.1 48.4±14.7
LVDP: left ventricular developed pressure, dp/dt: first derivative of left ventricular 
pressure,
CF : coronary flow , +HW : the increase of heart weight
*p<0.01 vs. Gp III , †p<0.01 vs. Gp II ; Data are shown in mean±standard deviation.
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803-7 Glucagon-Like-Peptide-1 Fused to Transferrin: A Novel 
Approach to Myocardial Reperfusion Injury
Muneaki Matsubara, Shinya Kanemoto, Michael A. Grosso, Earl Albone, Joseph H. 
Gorman, III, Robert C. Gorman, University of Pennsylvania, Philadelphia, PA, BioRexis 
Corporation, Philadelphia, PA
Background: Administration of glucose, K+ and insulin has demonstrated clinical 
efficacy in limiting myocardial reperfusion injury. Such therapy is often associated with 
hypoglycemia and is cumbersome to deliver. Glucagon-like peptide 1 (GLP1) is a insulin 
secretagogue not associated with hypoglycemia that has a half-life of minutes, severely 
limiting its clinical usefulness. The fusion GLP-1 to transferrin (GLP1-Tf) extends its 
functional half-life to days.
Methods: New Zealand rabbits (n= 32) underwent left thoracotomy, 30 min of myocardial 
ischemia and 3 hrs of reperfusion. Area at risk (AR) and infarct size as a percentage of AR 
(I/AR) were determined using a double staining technique. Ejection fraction (EF), fractional 
shortening (FS) and wall motion abnormality (WMA) were assessed by echocardiography. 
There were 3 experimental groups: Control (n=12) sham injection, Pre-Ischemic Rx (n=10) 
GLP1-Tf (10mg/kg) given subcutaneously 12 hrs prior to ischemia, Post-Ischemic Rx 
(n=10) GLP1-Tf (10mg/kg) given intravenously at the onset of reperfusion.
Results: I/AR in the treatment groups were significantly decreased compared to control. 
Global contractile function was improved in the treatment groups when compared to 
control at 3 hrs of reperfusion. 
*p<0.05 compared to control ; **p<0.01 compared to control
Group AR(% of LV) I/AR (%) EF(% change) FS(%change) WMA(%change)
GLP-1 level(ug/ml) 
after 3 hrs reperfusion
Control (n=12) 30.1±1.4 58.8±2.6 92.8±6.4 95.9±8.7 87.4±7.8 <0.009
Pre-Ischemic Rx 
(n=10) 29.4±1.4 45.7±1.9** 97.4±10.9 121.7±9.1 79.0±4.0 27.9±5.8**
Post-Ischemic 
Rx (n=10) 28.7±2.9 44.1±3.3** 103.2±10.3 147.8±23.4* 65.0±3.9* 239.8±25.7**
Conclusions: GLP1-Tf given either 12 hrs prior to the onset of ischemia or given at 
reperfusion reduces infarct size following myocardial ischemia-reperfusion and is an 
easily administered effective way for limiting myocardial reperfusion injury.
8:15 a.m.
803-8 Persistent Reduction in Myocardial Infarct Size After 
a Brief Intravenous Infusion of the Adenosine A2A 
Receptor Agonist ATL146e
Rajan A. Patel, Alexis Broisat, Hasan K. Kabul, Mirta Ruiz, N. Craig Goodman, Joseph 
M. DiMaria, Christopher M. Kramer, David K. Glover, Joel Linden, Geroge A. Beller, 
University of Virginia, Charlottesville, VA
Background. Reperfusion (RP) injury after myocardial infarction (MI) is characterized 
by intense inflammation causing additional myocyte injury, alterations in contractility, 
and microvascular dysfunction. The acute inflammatory response after MI lasts 24-48 
hrs. Adenosine infusion during RP after MI has been shown to reduce infarct size (IS). 
ATL146e is a highly selective adenosine A2A receptor agonist that decreased inflammation 
and IS at 2 hrs post-MI in dogs without the nonselective side effects of adenosine (e.g. 
hypotension, AV block). 
Hypothesis: The anti-inflammatory effects of a brief 2.5 hr infusion of ATL146e will result 
in smaller IS when examined at 48 hrs post-RP after MI in anesthetized dogs.
Methods: Twenty-five mongrel dogs underwent thoracotomy and LAD ligation for 90 min. 
Thirty minutes prior to RP, a 2.5 hr infusion of ATL146e (0.01 μg/kg/min) (n=13) or vehicle 
(n=12) was started. At 48 hrs post-MI, IS was assessed by ex vivo risk area and IS 
measurements after TTC histochemical staining.
Results: IS by TTC as a percentage of risk area was smaller in the ATL146e-treated vs. 
control dogs (16.7±3.7% vs 33.3±6.2%, p=0.027). 
Conclusion: The acute beneficial effect on IS of a 2.5 hr infusion of ATL146e during RP 
persists at 48 hrs after MI with no evidence of rebound injury. Thus, a rather short duration 
infusion of ATL146e, a highly selective and potent adenosine A2A receptor agonist, has 
significant potential as an IS-limiting agent in humans if used as an adjunct to coronary RP. 
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1025-69 Association of MTHFD1 G1958A and MTHFR 
C677T Polymorphisms With Serum Homocysteine 
Concentration and Cardiovascular Disease: The 
Normative Aging Study
Farbod Raiszadeh, Barry Shane, Patrick J. Stover, Augusto A. Litonjua, J. Michael Gaziano, 
Jacob Selhub, Katherine L. Tucker, Patricia A. Cassano, Division of Nutritional Sciences, 
Cornell University, Ithaca, NY, Harvard Medical School, Harvard University, Boston, MA
Background: Single nucleotide polymorphisms (SNPs) in genes coding for enzymes 
of the folate metabolic network are associated with disease. A well-known SNP in 
methylenetetrahydrofolate reductase (MTHFR C677T) is associated with higher 
plasma homocysteine concentration and greater risk of cardiovascular disease (CVD). 
Methylenetetrahydrofolate dehydrogenase (MTHFD1) catalyzes a prior step in folate 
metabolism, providing the substrate for MTHFR, and the MTHFD1 G1958A SNP is 
associated with an increased risk of neural-tube defects. Given that the MTHFD1 and 
MTHFR enzymes catalyze sequential steps in folate metabolism, the effect of MTHFR 
genotype on CVD risk may depend on the MTHFD1 genotype.
Methods: A matched case-control study nested within the Normative Aging Study cohort 
was designed to evaluate the association of both SNPs with plasma total homocysteine 
concentration and CVD risk, assessing gene-nutrient and gene-gene interactions.
Results: In regression models with homocysteine as an outcome, folate deficiency and 
the MTHFR 677 variant T allele were both associated with homocysteine (p<0.0001 and 
<0.001, respectively), and the effect of MTHFR genotype on homocysteine varied by folate 
status (p=0.01). No such interaction was observed for MTHFD1 genotype. In covariate-
adjusted, conditional logistic models, MTHFD1 GA/AA (vs. AA) had a small protective 
effect on CVD risk (OR 0.8; 95% CI 0.6, 1.1), regardless of folate status. A marginally 
statistically significant interaction between the two SNPs was observed (overall p=0.24, 
individual coefficient p values 0.09 and 0.35). The increased risk of CVD associated with 
the MTHFR TT genotype was limited to the subgroup of men with the MTHFD1 GA/AA 
genotype (OR 1.6, 95% CI 1.1, 2.4); there was little or no effect of MTHFR TT among men 
with the MTHFD1 GG genotype (OR 1.1, 95% CI 0.6, 2.2). Similarly, the increased CVD 
risk associated with the MTHFR C677T CT genotype was limited to the subgroup of men 
with MTHFD1 GA/AA genotype (OR 1.2; 95% CI 0.9, 1.7).
Conclusions: These findings suggest a gene-gene interaction between two genes 
of the folate metabolic network. The interaction does not appear to be mediated by 
homocysteine concentration.
10:00 a.m.
1025-70 Cardiac Side Population Cells Represent Endothelial 
Differentiation Potential
Seung-cheol choi, jihyun yoon, chi-yeon park, wan-joo shim, do-sun LIM, Department of 
Cardiology, College of Medicine, Korea University, Seoul, South Korea
Background: Recent studies have shown that side population (SP) cells, isolated from adult 
myocardium, represent a distinct cardiac progenitor cell population that exhibits functional 
cardiomyogenic differentiation. However, information on the intrinsic characteristics and 
endothelial potential of cardiac SP cells is limited. In this study, we demonstrate that cardiac 
SP cells have endothelial differentiation potential in vitro and in vivo.
Methods: RT-PCR/real-time PCR, immunocytochemistry and a laser Doppler perfusion 
image analyses were performed to examine endothelial potential of cardiac SP cells.
Results: Expression of early cardiac transcription factors such as GATA4, atrial natriuretic 
factor and Nkx2.5 was higher in freshly isolated adult heart-SP cells compared to the bone 
marrow-SP cells. Expression of CD31, vascular endothelial growth factor (VEGF) receptor-
1 (VEGFR1) and VEGFR-2, Tie1, and Tie2 mRNA was ~24.9, ~430, ~860, ~9.9 and ~188-
fold higher in adult heart-SP cells than in the bone marrow-SP cells, respectively. CD31 
or VEGF mRNA was expressed ~3.0- or ~4.2-fold in VEGF-treated adult heart-SP cells 
than control group. After treatment with VEGF for 28 days, cardiac SP cells differentiated 
into endothelial cells expressing von Willebrand factor. A laser Doppler perfusion image 
analyses revealed a significantly (P < 0.05) augmented ratio of ischemic/normal hindlimb 
blood flow in the adult heart-SP cell-transplanted group (n=30) compared with the saline-
treated controls (n=30) at postoperative days: 7, 14, 21 and 28. Most mice injected with 
saline typically had extensive limb necrosis whereas limb salvage occurred in 10 of 30 
animals and tip necrosis occurred 9 of 30 mice receiving adult heart-SP cells.
Conclusions: Cardiac SP cells may function as a cardiac progenitor cell population 
sharing the potential to transdifferentiate into angiogenic lineages, and they may 
contribute to regeneration of injured heart tissues.
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1025-71 Cytoplasmic Serine Hydroxymethyltransferase 
(cSHMT) and Methylene-tetrahydrofolate Reductase 
(MTHFR) Polymorphisms and Coronary Heart 
Disease Risk in US women
Farbod Raiszadeh, Amy R. Bentley, Jennifer K. Pai, Eric Rimm, David Hunter, Patrick 
Stover, Patricia A. Cassano, Cornell University, Ithaca, NY, Harvard University, Boston, MA
Background: Genetic variation in folate-regulating enzymes contributes to metabolic and 
nutritional influences on cardiovascular disease (CVD). A case-control study of men in the 
Normative Aging Study found the effect of a single nucleotide polymorphism (SNP) in the 
methylenetetrahydrofolate reductase (MTHFR C677T) gene depended on the presence 
of a SNP in the cytoplasmic serine hydroxymethyltransferase gene (cSHMT C1420T). 
The increased risk of CVD associated with the MTHFR C677T genotype was limited to 
men with the cSHMT TT genotype.
Methods: We studied this relation in a nested case-control of the Nurses’ Health Study 
(NHS) cohort. The full cohort comprised of 121,700 female nurses, established in 1976, 
followed biennially, and a subcohort of 32826 women who provided a blood sample was 
eligible for the case-control study. 249 CVD cases occurred and 2 controls were matched 
to each case on age and smoking status.
Results: The variant allele frequencies in controls were 29.8% and 30.9%, for cSHMT 
and MTHFR, respectively. A complete absence of double homozygotes (MTHFR TT/
cSHMT TT) among the cases precluded full quantification of the gene-gene interaction. 
However, the effect of MTHFR C677T CT (vs. CC) genotype on CVD risk differed 
substantially by cSHMT genotype (p=0.09). There was little or no effect of the MTHFR 
C677T CT genotype (vs. CC) in the cSHMT CC/CT subgroup (OR 1.1, 95% CI: 0.8, 1.5). 
Among women in the cSHMT TT subgroup, the MTHFR C677T CT genotype (vs. CC) 
was associated with a 3-fold increase in the risk of CVD (OR 2.7, 95% CI: 0.9, 8.8).
Conclusions: These results confirm prior findings reported for men in the Normative 
Aging Study. The absence of cases with the double homozygous genotype is likely 
due to the smaller number of cases in this study, given the expected prevalence of the 
joint homozygote genotype. These findings provide further evidence for a gene-gene 
interaction, which is of considerable interest given that cSHMT regulates a key intersection 
in folate metabolism and perturbations may affect homocysteine remethylation as well as 
DNA synthesis, repair, and methylation.
10:00 a.m.
1025-72 Low Carbohydrate Diet Reduces Myocardial Glycogen 
Stores And Impairs Cardiac Function During Ischemia
Steven G. Lloyd, Peipei Wang, University of Alabama at Birmingham, Birmingham, AL
Background: Obesity is a profound public healthy problem in the United States. Low 
carbohydrate diets (LCD) are popular, but their safety has not been adequately addressed. 
Myocardial glycogen may be an important energy source during ischemia. The impact of 
LCD on glycogen and the response to myocardial ischemia are unknown. We investigated 
the effect of LCD on glycogen levels and cardiac resistance to ischemic injury.
Methods: Rats were fed a LCD (60% kcal from fat / 30% protein / 10% carbohydrate) 
or a low fat diet (LFD; 16% / 19% / 65%) for two weeks (N=11-12 each diet). 6 rats from 
each diet were sacrificed for tissue and serum analysis; in the others, the heart was 
isolated and perfused with metabolic substrates and insulin at physiologic concentrations. 
Perfused hearts were subjected to 30 min of low flow ischemia (0.3ml/min) followed by 
60 min of reperfusion.
Results: Myocardial and liver glycogen was decreased in LCD (Fig A). Though LCD did 
not change cardiac systolic and diastolic function with normal perfusion, it did result in 
impaired left ventricular performance during ischemia, with worsened ischemic contracture 
as evidenced by the end diastolic pressure (EDP; Fig. B) and a 3-fold increase in injury as 
measured by lactate dehydrogenase release (Fig. C).
Conclusions: These results demonstrate that LCD impairs cardiac ischemic response 
compared to LFD, and suggest that glycogen stores play an important role in prevention 
of ischemic injury. 
10:00 a.m.
1025-73 The Lewis Null Blood Group is Associated with 
Proatherogenic Inflammatory Markers in Healthy Subjects.
Tamas Alexy, Howard N. Hodis, Wendy J. Mack, Eszter Pais, Herbert J. Meiselman, 
Timothy C. Fisher, USC Keck School of Medicine, Los Angeles, CA
Background: The NHLBI Family Heart Study and Copenhagen Male Study found that the 
Lewis blood group null (negative) phenotype, Le(a-b-) was associated with an approximately 
2-fold increase in the prevalence of ischemic heart disease (IHD) and the risk of an incident 
ischemic event compared to subjects with other Lewis types. The effect of Le(a-b-) was 
independent of “conventional” risk factors such hypertension, elevated triglycerides, high 
LDL, low HDL, obesity, etc. A structural similarity between sialyated Lewis antigens and the 
selectin ligand sialyl Lewis X suggested a possible link with inflammation.
Methods: To test this hypothesis, we studied 225 healthy subjects (70 male, 155 female 
mean age: 64±10 years) enrolled in an ongoing cardiovascular disease study. The study 
subjects were screened for any history of atherosclerotic disease on entry to the study, 
demographic data and “conventional” laboratory risk factors for atherosclerosis were 
measured, together with five non-specific markers of inflammation: ESR, CRP, fibrinogen, 
RBC aggregation (RCA) and plasma viscosity (PV). The baseline carotid intima-media 
thickness (IMT) was measured via ultrasound, and the Lewis red blood cell phenotype 
was determined by serology.
Results: Forty five of the 225 subjects (20%) had the Le(a-b-) phenotype. Each of the 
inflammatory markers was increased in Le(a-b-) relative to the other Lewis groups: PV 
(1.65 cP vs. 1.57 cP, p<.001), fibrinogen (4.20 vs. 3.66 g/L, p<.05), CRP (3.27 vs. 2.16 
mg/L, <0.05), RCA was increased by 27% (p<0.001), and ESR by 91% (29.3 vs. 15.5, 
p<.001). In 8 of 16 Le(a-b-) subjects the ESR exceeded 30mm/hr, compared to only 3 
of 53 with Lewis(b) subjects, and in 10 of 21 Le(a-b-) subjects CRP was above 3 mg/L 
compared to 5 of 53 with Lewis(b) subjects.
Conclusions: The large increase in ESR strongly supports the hypothesis that Le(a-b-) 
is a pro-inflammatory phenotype, and the elevation of fibrinogen and CRP are consistent 
with proatherogenic inflammation. Since the Lewis type is genetically determined, and 
can be identified long before the development of atherosclerosis, it could be useful as a 
risk marker for primary and secondary prevention of cardiovascular disease.
10:00 a.m.
1025-74 Predicting Value Of Early Period B-type Natriuretic 
Peptide For Left Ventricular Remodeling Following 
Prompt Reperfusion Therapy In Patients With Acute 
Myocardial Infarction.
Choe Hyun Min, Byung-Su Yoo, Min-Su Ahn, Kyung-Hoon Lee, Jang-Young Kim, 
Seung-Hwan Lee, Junghan Yoon, Kyung-Hoon Choe, Department of Cardiology, Wonju 
College of Medicine, Yonsei University, Won-ju City, Kang Won Do, South Korea
Background: The left ventricular(LV) remodeling is highly dynamic and occurs in a portion 
of patients with acute myocardial infarction(AMI). In spite of proper interventions, it is difficult 
to expect and prevent. Level of serum brain-type natriuretic peptide(BNP) is a good predictor 
of major adverse cardiac events following AMI. The aim of this study was to examine serial 
levels of BNP after onset of AMI and survey predictive factors of LV remodeling.
Methods: From April 2003 to June 2006, among 334 AMI patiients, we analyzed 131 
patients underwent echocardiography on 1 to 5th day(initial) and 6 to 9 months(follow-
up) and measurements of BNP(Triage®) on admission(≤24hr), early(24hr-6day), and 
long-term phase(6 to 9 months) after AMI. LV remodeling was defined as an increase 
in end-diastolic volume(LVEDV) ≥15% between initial and follow-up period. We 
divided them into remodeling and nonremodeling group and compared two groups.
Results: Mean age was 59.7±11.6.Primary PCI rate was 71.7%. Proportion of infarct-related 
artery(IRA) was LAD(n=64, 48.8%) and RCA(n=55, 41.9%). Mean symptom to reperfusion 
time was later in remodeling group(6.5±3.1 vs. 4.7±2.2 hours, p=0.000). According to IRA, 
mean level of BNP(anterior; 241.1±415.9 vs. lateral; 198.0±363.5 vs. inferior; 109.9±167.3 
pg/mL, p=0.019) and frequency of LV remodeling(anterior; 25(19.1%) vs. lateral;5(3.8%) 
vs. inferior;11(8.4%), p=0.040) were higher in anterior wall infarction. In remodeling group, 
mean level of BNP at early phase(371.6±458.7 vs 93.6 ±187.3 pg/mL, p=0.000) and wall-
motion score(31.9±11.4 vs. 26.4±5.2, p=0.000) were higher in remodeling group. Mean value 
of changed LVEDV between initial and follow-up period was 17.1±13.1mL. Multivariable 
regression analyses showed that level of BNP at early phase(odds ratio 0.996, p=0.003) 
and peak creatine kinase-MB(odds ratio 0.991, p=0.002) were the independent predictors of 
LV remodeling in patients with AMI. On ROC curve, the best value of BNP at early period in 
prediction of LV remodeling was 91.2 pg/mL (accuracy 78.0 %, p=0.000).
Conclusions: The level of BNP at early period(24hr-6day) could be useful predictors 
of LV remodeling after AMI.
10:00 a.m.
1025-75 Extracellular Matrix Protein, Fibulin-2, Enhances 
Acute Wound Healing after Experimental Myocardial 
Infarction in Mice
Takeshi Tsuda, Erhe Gao, Francois X. Sicot, Hailong Dong, Dessislava Markova, 
Xinliang Ma, Mon-Li Chu, Nemours Cardiac Center, Alfred I duPont Hospital for Children, 
Wilmington, DE, Thomas Jefferson University, Jefferson Medical College, Philadelphia, PA
Background: Acute wound healing is a critical process after myocardial infarction (MI) that 
determines the prognosis. Extracellular matrix (ECM) may provide structural integrity during 
tissue remodeling after injury, but little is known about its functional aspects. Fibulin-2 is an 
ECM protein up-regulated during connective tissue induction in the embryonic development 
and in the tissue remodeling after various injuries. However, the underlying role of fibulin-2 
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in wound repair is not well understood.
Methods: Fibuiln-2 null mutant mice (Fbln2-/-) were generated by gene targeting 
technique. There was no remarkable phenotypic anomaly in Fbln2-/- compared with wild 
type (WT). Experimental MI was induced by ligating distal left coronary artery in Fbln2-
/- and age-matched WT control mice. Left ventricular (LV) myocardial tissue and serum 
were obtained at both 24 and 72 hours after MI.
Results: Data are shown as Mean ± SEM. There was no death over 72 hours post-MI. Although 
the ischemic area was comparable between the two groups (35% of LV myocardium), the infarct 
area was significantly larger in Fbln2-/- than in WT at 72 hours (22.0 ± 1.8% vs. 14.3 ± 0.6%; p 
<0.001). Serum creatine kinase level was significantly higher in Fbln2-/- than in WT: 18.7 ± 2.8 
vs. 11.4 ± 0.9U/dl at 24 hours (p <0.005), and 7.9 ± 1.0 vs.3.7 ± 0.3U/dl at 72 hours (p <0.005). 
At 72 hours, the number of macrophages in the infarct border zone was significantly reduced 
in Fbln2-/- as compared with that in WT mice. The mRNA levels of TGF-β1, metalloproteinase 
(MMP)-9, brain naturiuric peptide, collagens type I and type III in the ischemic myocardium were 
all up-regulated from the control levels in both groups but were significantly lower in Fbln2-/- than 
in WT. Type I collagen deposition in the infarct border zone was remarkably reduced in Fbln2-/- 
compared with WT (%collagen deposition 3.68 ± 0.37% vs. 6.60 ± 0.58%; p <0.005).
Conclusions: The acute wound healing was remarkably delayed in Fbln2-/- after 
acute MI due to diminished reparative fibrosis in the infarct border zone. Our study 
demonstrated that fibulin-2 facilitates myocardial wound healing via modulating 
macrophage infiltration in the infarct border zone.
10:00 a.m.
1025-90 Protein Disulfide Isomerase (PDI) Prevents Apoptosis 
and Remodeling After Acute Myocardial Infarction
Anna Severino, Mara Campioni, Stefania Straino, Fadi N. Salloum, Maurizio C. 
Capogrossi, Filippo Crea, Antonio Abbate, Alfonso Baldi, Catholic University, Rome, 
Italy, Virginia Commonwealth University, Richmond, VA
Background. In response to a transmural myocardial infarction (MI), progressive remodelling in 
ventricular architecture occurs in infarcted and non-infarcted regions. A delicate balance between 
cell death and survival exists. Protein disulfide isomerase (PDI) is part of the unfolding protein 
response that in response to stress promotes cell survival. In the current study we tested whether 
PDI overexpression could favourably affect post-infarction remodelling.
Methods. Full length human PDI cDNA was isolated from Phoenix cell line total RNA by RT-
PCR. The cDNA was subcloned in pcDNA 3.1(+) expression vector. An initial thoracotomy was 
performed in 34 C57BL/6 mice. Seventeen received 4 intramyocardial injections in the anterior 
wall (2.5 μl per injection) of a solution containing PDI cDNA and 17 received saline solution. The 
chest was closed and the mice were allowed to recover. After 48 hours animals were re-operated 
and the left coronary artery was ligated. Transthoracic echocardiogram was performed on day 
7 to evaluate left ventricular end-diastolic diameter as in index of remodeling. The animals were 
thereafter sacrificed and the in situ end-labeling of DNA fragmentation (TUNEL) was used to 
calculate the apoptotic rate.
Results. Infarct size was significantly smaller in PDI-transfected mice (18±1% vs 43±1%, P<0.001). 
The apoptotic rate in the peri-infarct region was also significantly reduced (3.0±0.1% vs 1.0±0.1%, 
P<0.001). Compared to null-transfected animals, PDI-transfected mice had significantly smaller 
left ventricular end-diastolic diameter (2.50±0.02 mm vs 3.11±0.06 mm, P=0.009).
Conclusions. PDI over expression in a mouse model of AMI protects against apoptosis and 
adverse remodelling. Modulation of the unfolding protein response may prove useful for the 
prevention and treatment of heart failure.
10:00 a.m.
1025-91 Nicorandil Prevents Initial and Recurrent Events in 
Patients With Stable Angina Pectoris
Ian Ford, Neil Henderson, Henry Dargie, University of Glasgow, Glasgow, United Kingdom
Background: The Impact Of Nicorandil in Angina, a randomised double blind, placebo 
controlled trial in 5126 patients with stable angina pectoris, demonstrated a 17% 
(p=0.014) reduction in coronary heart disease death, non-fatal myocardial infarction or 
unplanned hospitalization for cardiac chest pain (average follow-up 1.6 years (range 1-
3 years) - 398 subjects with endpoints on placebo (P), 337 on nicorandil (N)). Including 
recurrent events there were 604 on P and 467 on N. Time-to-first event analysis 
undervalues the overall clinical benefit in preventing clinical events by 55%.
Methods: A recurrent event analysis was conducted including multiple occurrences of 
endpoints. Time to event curves were plotted for the first four events using the Kaplan-
Meier method (Fig 1a and 1b).
Results: The overall risk reduction for recurrent events (first 6 events) was 18%, 95% 
CI [8%, 27%], p=0.001. The numbers of events (subjects at risk) for the first to sixth 
events respectively were 398(2561), 107(343), 41(93), 24(38), 13(22) and 10(13) for P 
and 337(2565), 90(300), 23(68), 9(22), 3(9) and 2(2) for N.
Conclusions: The time to event curves demonstrate the increased hazard for each 
recurrent event type, each reduced by nicorandil treatment. This is supported by the 
significantly sharpened p-value. This study demonstrates the clinical benefits of nicorandil 
in preventing initial and recurrent cardiac events.
10:00 a.m.
1025-92 Rapamycin (Sirolimus) Administration in vivo Limits 
Post-Ischemic Myocardial Injury by MAPK Signaling in 
the Mouse Heart
Fadi N. Salloum, Evan D. Ownby, Anindita Das, Yuko Takenoshita, Antonio Abbate, 
George W. Vetrovec, Rakesh C. Kukreja, Virginia Commonwealth University Medical 
Center, Richmond, VA
Background: The therapeutic application of rapamycin, a potent inhibitor of downstream 
signaling from the mammalian target of rapamycin (mTOR) proteins, to drug eluting 
stents significantly reduced the degree of arterial restenosis. However, the effect of this 
antibiotic on cardiac tissue has not been fully examined. We hypothesized that acute 
inhibition of mTOR with rapamycin prior to ischemia/reperfusion (I/R) would attenuate 
myocardial infarction. We also theorized that similar to ischemic preconditioning, mitogen 
activated protein kinases (MAPK) are involved in this protection.
Methods and Results: Adult ICR mice (28-33g) were injected i.p. with rapamycin (0.25 
mg/kg) or vehicle 30 min prior to regional ischemia by left coronary artery ligation for 30 
min and reperfusion for 24 hr. At the end of reperfusion, hearts were collected for infarct 
size (IS) measurement using computer morphometry of tetrazolium chloride stained 
sections. Myocardial IS (mean ± SE) was significantly reduced in mice pretreated with 
rapamycin (Fig. 1A; 65% decline). Risk area was not different between groups (Fig. 1B). 
Moreover, WB analysis showed that rapamycin treatment caused an increase in pERK 
and pJNK 45 min later without affecting total ERK or JNK proteins (Fig. 1C).
Conclusion: These data provide evidence that acute systemic administration of 
rapamycin is effective against I/R injury through MAPK signaling. Rapamycin may be a 
useful therapeutic tool to suppress I/R injury in patients with cardiovascular disease. 
10:00 a.m.
1025-93 Fibroblast Growth Factors Promote Proliferation of Sca-
1+ Cardiac Stem Cells
Chi-yeon Park, Seung-cheol Choi, Wan-joo Shim, Do-sun Lim, College Of Medicine, 
Korea University, Seoul, South Korea
Background: Recent studies have reported the existence of resident cardiac stem cells 
(CSCs) that are clonogenic, self-renewing and multipotent, giving rise to myocytes, 
smooth muscle, and endothelial cells. However, little is known about factors regulating 
the proliferation of CSCs.
Methods: Stem cell antigen-1 (Sca-1)+ CSCs were isolated by sorting using the magnetic 
cell sorting system from heart of ICR mice. The purity of Sca-1+ cells was confirmed by 
flow cytometry. The effects of cytokines, growth factors and signal pathway inhibitors to 
the proliferation of Sca-1+ CSCs were assayed by BrdU labeling.
Results: Flow cytometry analysis showed that the puritiy of Sca-1+ CSCs was more 
than 87%. Among cytokines and growth factors examined in this study, bFGF and FGF4 
stimulated significantly the proliferation of Sca-1+ CSCs (control, 100±4.51 vs. bFGF, 
202.19±19.97 vs. FGF4, 160.57±5.92, P < 0.05, respectively). Two chemical signal 
transducer and activator of transcription 3 (STAT3) pathway inhibitors, piceatannol (JAK1/
STAT3 inhibitor) and AG490 (JAK2/STAT3 inhibitor) inhibitored both basic fibroblast growth 
factor (bFGF)- and FGF4-induced proliferation of Sca-1+ CSCs (bFGF+piceatannol, 
59.95% vs. bFGF+AG490, 75.13% vs. FGF4+piceatannol, 64.12% vs. FGF4+AG490, 
80.18%, respectively, P< 0.05). Moreover, phosphatidylinositol 3-kinase (PI3-K) inhibitor, 
LY294002 also inhibited both bFGF- and FGF4-induced proliferation of Sca-1+ CSCs 
(bFGF+LY294002, 71.91% vs. FGF4+LY294002, 86.16%). However, mitogen-activated 
protein kinase (MAPK) inhibitor PD98059 and a specific inhibitor of MEK (MAPK/ERK 
kinase), U0126 had no effect on the proliferation of Sca-1+ CSCs.
Conclusions: These data demonstrated that FGFs promote the proliferation of Sca-1+ 
CSCs through the activation of JAK/STAT3 and PI3-K signal pathway.
10:00 a.m.
1025-94 Use Of Low Molecular Weight Heparin Is Associated 
With Improved In-hospital Survival Of STEMI Patients 
Who Receive Reperfusion Therapy: Results From The 
Nationwide French FAST-MI Registry
Nicolas Danchin, Jean-Philippe Collet, Jean Marco, Bernard Charbonnier, Yves Cottin, 
Philippe Sans, Jacques Puel, Gilles Dentan, Jean-Pierre Cambou, Hopital Europeen 
Georges Pompidou, Paris, France
Background: There are conflicting results as regards the impact of low molecular weight 
heparin in STEMI patients. The aim is to compare in-hospital mortality in patients with 
STEMI according to type of heparin used.
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Methods: FAST-MI is a nationwide French registry carried out over a one-month period 
in the fall 2005 which included consecutive patients with AMI admitted to CCUs within 48 
hours from symptom onset at the 223 participating centers.
Results: Of the 1,711 patients with STEMI, 1,025 had reperfusion therapy with thrombolysis 
(45%) or primary PCI (55%). LMWH was used in the pre-hospital setting or within 48 hours 
of hospital admission in 56% of pts thrombolysed and 63% of those with primary PCI.
Baseline characteristics are reported in the Table 1.
In-hospital mortality was 2.0% in patients with LMWH vs 8.4% in those without (p<0.001). 
Major bleeding was found in 1.6% of patients with LMWH v 2.5% of those without.
Using multivariate logistic regression analysis, use of LMWH was associated with 
decreased hospital mortality (OR: 0.42; 95% CI: 0.19-0.89, p=0.02). When the analysis 
was restricted to patients who survived the first 2 days, in order to minimize bias, the 
positive impact of LMWH persisted (OR: 0.28; 95%CI: 0.18-0.75, p=0.01).
Conclusion: In this real world registry, the use of LMWH in patients undergoing 
reperfusion therapy with either thrombolysis or PCI for STEMI was associated with 
improved survival and slightly better safety as compared to the absence of LMWH.
Baseline characteristics: Table 1 
No LMWH LMWH P Value
Age (years) 63 +/-14 61 +/- 13 <0.05
Women (%) 23 24 NS
HTN (%) 47 42 NS
Current smoking (%) 42 43 NS
Diabetes (%) 19 14 NS
Prior MI (%) 11 10 NS
Prior CHF (%) 3 1 <0.05
Killip > 1 (%) 18.5 12 <0.02
Anterior MI (%) 41 36 NS
10:00 a.m.
1025-95 Clinical Outcomes of Drug Eluting Stents Versus Bare 
Metal Stents in Patients With Severe Renal Insufficiency
Michael Rosenblum, Jonathan Winston, Michael Robbins, Michael Kim, Mount Sinai 
Hospital, New York, NY
Background: Drug Eluting Stents (DES) have increasingly become standard of practice 
due to their decreased rates of in-stent thrombosis and target lesion revascularization in 
patients with normal and mildly decreased renal function. However, recent studies have 
failed to demonstrate these superior clinical outcomes in patients with moderate renal 
insufficiency. This study compared the clinical outcomes in patients with severe renal 
insufficiency treated with DES versus bare metal stents (BMS).
Methods: Between 2003 and 2006 we collected data on 4371 consecutive patients receiving 
DES and 1849 consecutive patients receiving BMS. Both groups were similar for angiographic 
and clinical variables. Clinical outcomes at 270 days and 365 days were then compared 
between patients receiving DES and BMS with varying creatinine clearance (CrCl).
Results: Target lesion revascularization (TLR) rates were significantly lower for DES in 
patients with CrCl > 60 (5% vs 9.3%; p < 0.0001). In patients with CrCl (21-40) and 
patients with CrCl < 20 or receiving dialysis, TLR rates were not significantly different 
between DES and BMS. There were no significant differences between Major Adverse 
Cardiac Events (MACE) or survival in patients with CrCl < 40.
Conclusion: While DES showed improved clinical outcomes in patients with normal renal 
function, they showed no increased benefit in patients with severe renal insufficiency. The 
benefit of DES over BMS does not appear to be present in patients with poor renal function. 
CrCl>60 CrCl>40 CrCl>20 CrCl<20 or dialysis
TLR 270 days
DES 3.7 (116/3080) 3.7 (28/759) 4.8 (16/337) 4.1 (8/195)
BMS 8.1 (95/1167) 6.3 (24/380) 7.4 (15/203) 5.1 (5/99)
p <0.0001 0.04 0.2 0.71
TLR 365 days
DES 5.0 (153/3080) 5.0 (38/759) 5.9 (20/337) 4.6 (9/195)
BMS 9.3 (109/167) 7.4 (28/380) 8.9 (18/203) 7.1 (7/99)
p <0.0001 0.11 0.2 0.38
10:00 a.m.
1025-96 Stent Implantation In Left Main Lesion Without Routine IABP 
Support; Risk Factors Related To Hemodynamic Instability
Ung Kim, Jong-seon Park, Sang-Hee Lee, Geu-ru Hong, Dong-gu Shin, Young-Jo Kim, 
Bong-seop Shim, Yoon-Kyung Cho, Chang-Wook Nam, Seung-Ho Hur, Kwon-Bae Kim, 
Dae-Kyung Kim, Sung-Man Kim, Doo-Il Kim, Dong-Soo Kim, Yeungnam University 
Hospital, Daegu, South Korea
Background: Percutaneous coronary intervention(PCI) of unprotected left main coronary 
artery(LMCA) stenosis is promising in drug-eluting stent era. However, data are lacking as 
to the characteristics of the patient’s hemodynamics during LMCA stenting. The purpose 
of this study was to find which risk factor is affecting hemodynamic stability during LMCA 
stenting and whether hemodynamic support is needed or not according to the risk factors
Methods: From July 2003 to January 2006, 98 patients(Male=59, Femal=39), who visited 
Yeungnam university hospital, Keimyung University Dongsan hospital and InJe University 
Baik hospital in Busan, with angiographically evaluated unprotected LMCA stenosis were 
enrolled in this study. Group 1 (n=75) was defined as patients had no hemodynamic 
changes during LMCA stenting. Group 2 (n=23) was defined as patients had hemodynamic 
change(BP<90mmHg) during LMCA stenting. All patients were deployed stents on LMCA 
lesions without hemodynamic support and clinical, angiographical, procedural outcomes 
were compared between two group after procedure.
Results: Baseline characteristics between two group were not different statistically. On 
the univariate analysis, Group2 had more patients diagnosed as MI than Group1 (39% 
vs 15%, P=0.017). Group 1 had more increased level of left ventricular(LV) ejection 
fraction than group 2(60±10 vs 47±11, p<0.05). In terms of lesion location in LMCA, 
group 2 had relatively more numbers of bifurcation lesion than group 1 ( 34% vs 78%, 
p<0.05). Group 2 needed more complex lesion techniques like kissing or crush stenting 
than group 1 ( 19% vs 48%, p<0.05). From the multivariate logistic regression analysis, 
presence of myocardial infarction (Odds Ratio(OR)=3.74, P=0.017), complex stenting 
procedure such as kissing or crushing (OR=3.99, P=0.007) bifurcation lesion (OR=4.58, 
P=0.004) and poor LV function (OR=9.95, P<0.001) were the independent predictors for 
the hemodynamic unstablility during LMCA stenting.
Conclusions: The most important risk factor for hemodynamic instability during LMCA 
stenting is LV function. We have to prepare for the hemodynamic support including IABP 
before procedure in this high risk patients.
10:00 a.m.
1025-111 Demand Ischemia is the Predominant Etiology of 
Perioperative Myocardial Infarction: Implications for 
Perioperative Risk Stratification
William L. Duvall, Brett Sealove, Chetan Pungoti, Daniel Katz, Valentin Fuster, Pedro 
Moreno, Michael Kim, Mount Sinai Medical Center, New York, NY
Background: The understanding of the pathophysiologic mechanisms of perioperative myocardial 
infarction (MI) is limited to 2 small autopsy studies suggesting a major role for plaque rupture and 
thrombosis. However, the perioperative period is characterized by increased cardiac metabolic 
demand that may lead to infarction in patients with otherwise stable obstructive disease.
Methods: Medical records and coronary angiograms from patients from 1998 to 2006 
who underwent noncardiac surgery complicated by a perioperative MI were reviewed. 
The culprit lesion was identified by EKG and left ventriculography criteria. Degree of 
stenosis, TIMI flow, ACC thrombus grade, calcification score, and lesion morphology 
were evaluated. Based on these criteria, MI’s were categorized as thrombotic, demand, 
or non-obstructive (normal angiograms without a culprit lesion).
Results: 54 patients (average age 70 yrs and 39% male), 81% of whom underwent an 
intermediate risk surgery with a 2% perioperative mortality were identified. The distribution 
of thrombotic, demand, and non-obstructive MI’s is displayed in the figure. There was no 
statistical difference in the occurrence of prolonged hypotension or tachycardia, nor was 
there any difference in the use of antiplatelets, beta-blockers, or statins.
Conclusion: This study identified demand ischemia as the predominant etiology of 
perioperative MI. As a result, preoperative risk stratification and risk reduction with beta-
blockers and even PCI should be emphasized. 
10:00 a.m.
1025-112 Diagnostic Performance of the Modified Rush 
Score Across Risk Strata and Pre-Specified Clinical 
Subgroups, is Superior to the TIMI Risk Score for 
Prediction of In-Hospital Mortality in Acute Coronary 
Syndromes (ACS)
Amit P. Amin, Sandeep Nathan, Arun Kumar, Patricia Vassallo, James E. Calvin, Rush 
University Medical Center, Chicago, IL, Cook County Hospital, Chicago, IL
Background: We previously developed the Modified Rush Score (MRS) and demonstrated its 
superiority to the TIMI Risk Score (TRS) for prediction of in-hospital ACS mortality. [JAMA 1995, 
JACC 2006]. We now test the utility of MRS in various patient (pt) subgroups.
Methods: Multicenter data from 3,468 ACS pts were analyzed. Calculation of MRS and TRS are 
as noted. [Fig. 1 inset] ROC analyses compared TRS and MRS overall and in subgroups of pts with 
DM, age≥75, ST depression, known CAD, troponin (cTn) positive, low, intermediate and high TRS
Results: In-hospital mortality was 3.4% (n=117). Mean TRS was 3.6 ± 1.2 and MRS 5.0 ± 
3.7. MRS showed high discriminant capacity for predicting mortality [ROC AUC (95% CI) 
0.74 (0.69-0.78) vs TRS 0.57 (0.52-0.62, p< 0.001)]. [Fig. 1] MRS independently predicted 
mortality (OR 1.94, (1.63-2.32, p<0.001)) when adjusted for all therapy variables. ROC 
AUC (95% CI) favored MRS over TRS in the following subgroups: cTn positive 0.71 (0.66-
0.75) vs 0.53 (0.47-0.59), p<0.001; DM 0.80 (0.73-0.87) vs 0.61 (0.52-0.70), p=0.0006; 
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Age≥75 0.66 (0.60-0.73) vs 0.48 (0.41-0.55), p<0.001; known CAD 0.74 (0.68-0.81) vs 
0.64 (0.57-0.70), p=0.004. MRS performed best in intermediate TRS pts [MRS: 0.72 
(0.67-0.77) vs TRS 3-5: 0.52 (0.46-0.57, p<0.001)].
Conclusions: MRS more effectively predicted in-hospital mortality in ACS than TRS 
overall as well as in the clinically relevant subgroups noted. MRS is particularly robust in 
the intermediate-risk pts in whom accurate risk stratification is critical.
10:00 a.m.
1025-114 Does Early Invasive Strategy Provide a Clinically 
Important Advantage Over Early Conservative Strategy 
in the Management of Acute Coronary Syndromes?
Jayanta R. Das, Melissa Joffe, George A. Diamond, Prediman K. Shah, Sanjay Kaul, 
Cedars-Sinai Medical Center, Los Angeles, CA
Background Early invasive (EI) management is the preferred strategy for acute coronary 
syndromes (ACS), primarily based on results of FRISC-II and TACTICS-TIMI18. However, 
the strength of evidence is based on conventional tests (P values, CIs) which rely heavily 
on statistical significance, but provide little guidance about clinical importance.
Objective To assess statistical and clinical significance of EI vs early conservative (EC) 
approach to management of ACS.
Methods We included studies with sample size exceeding 500. Posterior probabilities 
(Pr) that the relative risk difference (RRD) in outcomes is greater than putative threshold 
value for clinical importance (δ>0%, 10%, 20%) and “delta value” used for sample size 
estimation were derived from a Bayesian analysis using an uninformative prior and trial 
evidence summarized as odds ratio (OR).
Results Of the six trials, 3 were inconclusive (TIMI IIIB, RITA-3, ICTUS), 1 was against 
(VANQWISH) and 2 were in favor of EI strategy (FRISC II, TACTICS-TIMI 18) based on 
statistical significance. However, Pr for δ>10% ranged from 5% to 97%; for δ >20% from 
5 to 78%. Pr for δ >20% exceeded 50% in only one (FRISC- II) and Pr for delta value did 
not exceed 30% in any.
Conclusions The probability of a clinically important difference between EI vs EC 
strategy for ACS is far less than that implied by conventional statistical significance. 
Bayesian analysis provides a useful tool for judging the clinical importance of medical 
interventions, and should be utilized routinely. 
Trial
(follow-up) Sample Size
Primary 
end point
Odds Ratio
(95% CI)
Delta 
value
(RRD) 
Reported 
P value
Pr
δ>0%
Pr
δ>10%
Pr
δ>20%
Pr
δ>Delta
TIMI IIIB
1994
(6 weeks)
1,473
Death, MI, or
Recurrent
Ischemia
0.91 (0.67-
1.15) 30% 0.33 84% 52% 16% 1%
VANQWISH
1998
(1 year)
920 Death or MI 1.39 (1.01-1.91) 7.5% 0.05
98%*
(harm)
90%*
(harm)
72%*
(harm)
0%
(benefit)
FRISC II
1999
(6 months)
2,457 Death or MI 0.78 (0.59-0.98) 32% 0.031 98% 90% 60% 12%
FRISC II
(2 years) 2,457 Death or MI
0.73 (0.56-
0.89) 32% 0.03 100% 97% 78% 19%
TACTICS
2001
(6 months)
2,220
Death, MI, and
Recurrent 
Ischemia
0.8 (0.63-0.97) 22% 0.025 99% 85% 40% 30%
RITA-3
2002
(6 months)
1,810 Death or MI 0.97(0.65-1.28) 33% 0.58 71% 46% 20% 2%
RITA-3
2002
(5 years)
1,810 Death or MI 0.78 (0.61-0.99) 33% 0.044 98% 83% 42% 2%
ICTUS
2005
(1 year)
1200
Death, MI, or
Recurrent
Ischemia
1.07 (0.87-
1.33) 25% 0.33 26% 5% 0% 0%
10:00 a.m.
1025-115 Microvascular Endothelial Function Is Impaired 
In The Cutaneous Circulation In Patients With 
Coronary Artery Disease.
Sharad C. Agarwal, John Allen, Alan Murray, Ian F. Purcell, Freeman Hospital, 
Newcastle upon Tyne, United Kingdom
Background- Endothelial dysfunction (ED) is a diffuse process resulting in abnormal 
regulation of vascular tone and precedes overt coronary artery disease (CAD). Cutaneous 
laser Doppler (LDF) non-invasively measures microvascular endothelial dependent 
vasodilatation in response to physiological and pharmacological stimuli.
Methods- Cutaneous microvascular endothelial function was assessed by LDF in 
32 patients with CAD and 22 healthy controls. Endothelium dependent vasodilatory 
response was measured in response to localised heating of skin to 41ºC, transcutaneous 
1% acetylcholine(ACH) and reactive hyperaemia. Peak vasodilatation was assessed and 
expressed in arbitrary flux units (AFU).
Results- Subject details are in table 1. All patients with CAD received statins. The peak 
vasodilatation stimulated by ACh was significantly higher in the control group (median 
270, inter-quartile range (198 - 316) AFU) vs CAD group (median 182 (132 - 242) AFU), 
P=0.004. Peak vasodilatation by hyperthermia was also significantly higher in the control 
group (median 95, (75 - 137) AFU) vs patient group (median 56 (41 - 68) AFU), P<0.001. 
Response to reactive hyperaemia was significantly higher in the control group (median 
173 (128-202) AFU) vs patient group (126 (100-170) AFU), P=0.007.
Conclusion- Patients with CAD have microvascular endothelial dysfunction even when treated 
with statins. LDF is a simple non-invasive technique and has great potential in clinical practice.
Table 1: Subject characteristics 
Controls N=22 Coronary artery disease N=32 P value
Sex (Male) 17 (77%) 27 (84%) NS
Age (years) 54 ± 11 59 ± 8 NS
BMI (kg/m2) 26 ± 3 29 ± 4 0.001
Systolic BP (mmHg) 119±6 123±12 NS
Diastolic BP (mmHg) 75 ± 6 76 ± 6 NS
Total Cholesterol 5.1+0.6 4.4 +1.1 0.004
LDL 3 +0.5 2.3 +0.9 0.004
HDL 1.5 +0.5 1.1 +0.2 0.002
Triglycerides 1.62 +0.8 2.2 +1.5 0.07
Treatment Atenolol -1/22 (5%)
Beta Blockers - 24/32 (75%)
ACE inhibitors - 13/32 (41%)
Nitrate/ Nicorandil-17/32 (53 %)
Statins 32/32 (100%)
10:00 a.m.
1025-116 The Impact Of Aspirin Resistance On Long Term 
Cardiovascular Mortality In Patients With Non-st 
Elevation Acute Coronary Syndromes
Vasilios Tsirimpis, Michael N. Zairis, Stamatis Makrygiannis, Nikolaos Patsourakos, 
Konstantinos Kontos, Spyros Argyrakis, Evdokia Adamopoulou, Denis Xenos, 
Konstantinos Vogiatzidis, Maria Prodromiti, Stylianos Handanis, Stefanos G. Foussas, 
Cardiology Department, Tzanio Hospital, Piraeus, Greece
Background- There is scant data concerning the impact of aspirin resistance on long term 
mortality in pts with unstable coronary artery disease. We evaluated the predictive value 
of aspirin resistance for the incidence of long term cardiovascular death in pts with non-
ST elevation acute coronary syndromes (NSTACS). Methods-A total of 496 consecutive 
pts (age=69.8±12yrs, 70% males) who hospitalized in the first 24 hrs following index 
pain, were included. Platelets response to aspirin therapy was measured by the platelet 
function analyzer (PFA-100) closure time (CT). CT was measured upon presentation or 6 
hours after aspirin loading in pts with or without prior aspirin therapy respectively. Aspirin 
resistance was defined as a CT<193 sec based on the 90% central interval of normal. Pts 
were followed up for up to 2.5 years.
Results- A total of 121 (24.4%) pts had a CT<193 sec (aspirin resistants). By the end of 
follow up 53 (10.7%) pts died. Although there were not significantly differences between 
pts with or without aspirin resistance, the former were at significantly higher risk for 
cardiovascular death than the latter (21.5% vs 7.2%; RR=3.1; p<0.001) (Fig 1).
Conclusions-The present results have shown that aspirin resistance portends an 
increased risk for long term cardiovascular mortality in pts with NSTACS. 
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1025-117 Endothelial Dysfunction and Circulating Endothelial 
Progenitor Cells in Young People with Type 1 diabetes
Latika Sibal, Ali Aldibbiat, Sharad C. Agarwal, Jola U. Weaver, Salman Razvi, Crispian 
P. Oates, George Mitchell, James A. Shaw, Philip D. Home, Newcastle upon Tyne 
Hospitals, Newcastle upon Tyne, United Kingdom, School of Clinical Medical Sciences-
Diabetes, Newcastle upon Tyne, United Kingdom
Introduction:Type 1 diabetes is an important risk factor for cardiovascular disease (CVD) 
with a four-fold increased risk. Endothelial dysfunction precedes clinical CVD. Circulating 
endothelial progenitor cells (EPCs) play an important role in endothelial repair and are 
reduced in individuals at increased cardiovascular risk. We studied whether endothelial 
dysfunction in young people with Type 1 diabetes is associated with reduced EPCs and 
increased carotid intima-media thickness (CIMT).
Methods: We examined brachial artery flow-mediated dilatation (FMD) and CIMT, and 
quantified EPCs in 85 young people, mean age 25±5 (SD) yr, 47 with Type 1 diabetes 
and 38 healthy control subjects. Endothelium-dependent FMD and CIMT was assessed 
using high resolution ultra-sonography. EPCs were quantified by the expression of 
surface markers CD34, CD133, VEGFR-2 and VE-cadherin/CD144. Whole blood was 
labelled with fluorescent-tagged CD14, CD34, CD133, VEGFR2 and CD144 antibodies 
and analysed by flow-cytometry. EPC number (diabetes vs control) was determined as a 
percentage of cells in the (CD14+) monocyte gate.
Results: FMD was significantly impaired in the Type 1 diabetic people compared to healthy 
controls (4.1± 2.8 % vs 8.0± 3.0 %, p=0.0001). CIMT was increased in the diabetic people 
(0.60± 0.10 vs 0.50±0.07 mm, p<0.001). On flow-cytometry, there were significantly less 
CD34 and CD 133 positive cells in people with diabetes compared to controls (CD34: 
0.24 vs 0.34 %,p=0.030; CD133: 0.22 vs 0.37 %, p=0.030). There were no differences in 
the VEFGR2 and CD144 numbers. There was a significant positive correlation between 
CD133 numbers and the FMD in people with diabetes (r=0.28; p=0.011). CIMT negatively 
correlated with FMD (r=-0.412; p=0.010).
Conclusion: Our data suggests endothelial dysfunction in young people with Type 1 
diabetes is associated with increased CIMT. Circulating EPCs in Type 1 diabetes showed 
a trend towards lower numbers in comparison to healthy controls. This achieved statistical 
significance employing the CD34 and CD 133 marker.
10:00 a.m.
1025-132 Patients Transferred for Primary PCI in APEX-AMI 
(Assessment of Pexelizumab in Acute Myocardial 
Infarction) Trial Have Only Modest Symptom Onset to 
PCI Delays and Good Outcomes
Petr Widimsky, W. Douglas Weaver, Frans Van de Werf, Franz-Josef Neumann, Diego 
Ardissino, Amanda Stebbins, Arnoud van t’Hof, Torsten T. Nielsen, Paul W. Armstrong, 
Christopher B. Granger, for the APEX Investigators, Duke University Medical Center, 
Durham, NC, University of Alberta, Edmonton, AB, Canada
Background: Interhospital transfer for primary percutaneous coronary intervention (PCI) 
has been shown in randomized trials to result in good outcomes. The generalizability of 
these results remains uncertain, especially since registries show long delays in transfer.
Methods: The APEX-AMI trial database includes 5739 patients with STEMI treated with 
primary PCI at 296 hospitals in 17 countries in 2004 to 2006.
Results: Interhospital transfer occurred in 2315 (40%) pts, who had similar age, MI 
location, Killip Class as non-transfer pts. Non-U.S.pts were transferred more often (43.8%) 
than U.S. (32.5%). 30-day mortality was similar (and low) in both transfer (4.3%) and non-
transfer (3.8%) pts (p=0.29). Likewise, 30-day death, shock, and heart failure composite 
was similar (9.0 vs 9.1%). TIMI-3 flow was slightly lower in transfer (88.9%) than non-
transfer (90.7%). The median delay of transfer was 1.4 hrs, however, transferred pts 
were treated faster after arrival at the PCI center. Thus, the total ischemic time (symptom 
onset-to-balloon) in the transfer group was prolonged by only 36 min.
Conclusion: In this largest-ever primary PCI trial representing nearly 300 PCI hospitals, 
transfer patients had only modestly longer total ischemic times and low mortality that was 
non-significantly higher than non-transfer patients. These results derived from a clinical 
trial suggest that transfer can occur with only modest treatment delays (in contrast to 
many registries) and with good associated outcomes.
10:00 a.m.
1025-133 A Randomized, Double-Blind, Placebo-Controlled 
Study of the Safety and Efficacy of Intravenous MCC-
135 as an Adjunct to Primary Percutaneous Coronary 
Intervention in Patients with Acute Myocardial 
Infarction
Ik-Kyung Jang, Fred Senatore, Neil Weisman, Michael H. Picard, Michael R. Zile, 
Veronica Pettigrew, Steven Shen, Jun Tatsuno, Mark Hibberd, Frans J Th Wackers, 
EVOLVE Investigators, Massachusetts General Hospital, Boston, MA
Background: Calcium overload inside myocytes during ischemia and reperfusion not 
only affects myocardial function, but also may be related to myocyte necrosis and fatal 
arrhythmia. MCC-135 is the first in a new class of agents that modulate intracellular 
calcium overload. Pre-clinical experiments yielded promising results.
Methods: Patients with moderate to large ST elevation acute myocardial infarction (STEMI) 
were randomized into placebo, low dose, and high dose MCC-135 group. The target 
population was those with anterior MI and baseline thrombolysis in myocardial infarction 
(TIMI) grade flow 0 or 1. Cardiac markers were measured serially, left ventricular function 
and infarct size were evaluated by single photon emission computed tomography (SPECT). 
The primary endpoint was left ventricular ejection fraction (LVEF) on Day 5 determined by 
SPECT. Secondary endpoints included infarct size measured by SPECT and by serum 
cardiac markers. Patients were followed up to 30 days for adverse clinical events.
Results: Five hundred consecutive patients were enrolled. The LVEF on day 5 was 
47.0 ± 1.7% in the placebo group, 47.4 ± 1.7% in the low dose group, and 45.1 ± 
2.0% in the high dose group (p = 0.642). The infarct size on day 5 was not significantly 
different between the groups using both methods. The composite adverse clinical 
outcome occurred in 25.5% in the placebo group, in 19.2% in the low dose group, and 
in 34.2% in the high dose group (P = 0.276). A subgroups analysis including those with 
electrocardiographically large (sum of ST elevation > 10 mm) MI in large enrolled sites 
(number patients enrolled > 12) showed significantly higher LVEF in the low dose group 
compared to the placebo group.
Conclusion: In the overall population MCC-135 did not demonstrate significant benefit 
in preservation of LVEF and in reduction of infarct size. Ad-hoc analysis indicates that the 
low dose MCC-135 may have beneficial effect in high risk population.
10:00 a.m.
1025-134 Prehospital Wireless Transmission of STEMI 
Electrocardiograms Persistently Reduces Door-to-PCI 
Time below Those at Multiple Pre-Transmission Sites
George L. Adams, Benjamin A. Lee, Paul T. Campbell, Janet Patterson, B. Kevin 
Underhill, Nancy Yellin, Ginger LaMarr, Susan Dorroh, Debbie Rosenfelder, Charles 
Maynard, Galen S. Wagner, Duke University Medical Center, Durham, NC
Background: The ACC/AHA guidelines for door-to-PCI time (<90 minutes) in patients with 
ST-segment elevation myocardial infarction (STEMI) is a goal infrequently accomplished. 
The Timely Intervention in Myocardial Emergency - NorthEast (TIME-NE) study instituted 
prehospital transmission of electrocardiograms (ECG) to a cardiologist’s hand-held 
device, resulting in a reduction in door-to-PCI time, thus achieving the recommended 
ACC/AHA goal.
Methods: This formed the basis for a prospective multi-center study (n=4) that has 
enrolled 215 STEMI patients transported by emergency medical services (EMS) during 
the pre-intervention phase (transmission of ECG unavailable). This study determines if 
the presence of ECG transmission at the pilot site produces reperfusion times faster than 
those at the TIME-MC control sites awaiting transmission capability.
Results: During the TIME-MC control year, 215 patients were enrolled at 4 sites. During 
the TIME-NE follow-up year, 35 patients were enrolled. The median door-to-PCI time 
during the follow-up year was significantly less than the times at the TIME-MC sites.
Conclusion: NorthEast maintained door-to-PCI times below the ACC/AHA goal, but 
only one of the control sites met the guideline. All control sites have significantly longer 
times than the NE site. Pre-hospital ECG transmission directly to a cardiologist’s hand-
held device persistently reduces emergency department door-to-PCI time to achieve the 
recommended ACC/AHA goal for patients with STEMI. 
N ECG Transmission Door-to-Reperfusion Time (min) p Value
TIME-NE
NorthEast, NC 35 Y 58 ~
TIME-MC
Cincinnati, OH 68 N 93 <.0001
Durham, NC 83 N 101 <.0001
Pittsburgh, PA 43 N 100 <.0001
Salinas, CA 21 N 73 .005
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1025-135 Stabilization of Renal Function With Intraaortic Balloon 
Counterpulsation Therapy in Acute Myocardial Infarction 
Patients Undergoing Percutaneous Coronary Intervention
William Merhi, Talal Moukabary, Imran Memon, Simon Dixon, Cindy L. Grines, William 
Beaumont Hospital, Royal Oak, MI
Background: Intraaortic balloon pumping (IABP) has been postulated to impair renal function. 
However, we lack randomized data on their effect on renal function in acute myocardial infarction 
(AMI) patients undergoing Percutaneous Coronary Intervention (PCI). We tested the hypothesis 
that the IABPC therapy in AMI patients does not impair renal function.
Methods: Patients of the Primary Angioplasty in Myocardial Infarction Trial (PAMI-
II) were prospectively randomized to either IABP or no IABP. We performed 
a retrospective analysis of all patients in the PAMI-II database. We analyzed 
creatinine levels (Cr) at baseline, follow up, and discharge. We excluded patients 
with preexistent renal failure on dialysis and incomplete followup data.
Results: Data were available for 68 patients in the IABP arm and 64 in the no-IABP 
arm. There was no difference between the groups in contrast load, baseline creatinine, 
diabetes or hypertension or lowest blood pressure during hospitalization. The IABP arm 
had more patients with prior cerebrovascular accidents, prior PCI, and lower ejection 
fractions. There was no difference between the groups with respect to Cr on post-PCI day 
2 and 3. Patients in the IABP arm had a lower Cr on day 4: 1.4±1.2 vs. 1.7±1.8 (p=0.037). 
There was a trend toward fewer changes in Cr in the IABP arm.
Conculsion: IABP therapy does not appear to adversely affect renal function in patients 
with AMI undergoing PCI.
Creatinine Levels
Creatinine Levels -mg/dL No IABPC (N=64) IABPC (N=68) P Value
Baseline 1.6±1.7 1.3±1 0.59
Day 2 post PCI 1.6±1.7 1.3±1.1 0.49
Day 3 post PCI 1.7±1.7 1.3±1.1 0.11
Day 4 post PCI 1.7±1.8 1.4±1.2 0.037
At Discharge 1.7±1.7 1.4±1.2 0.066
10:00 a.m.
1025-136 Growth-differentiation Factor-15 For Risk Stratification 
And Selection Of Patients For An Early Invasive 
Treatment Strategy In Non-ST-elevation Acute Coronary 
Syndrome
Lars C. Wallentin, Tibor Kempf, Timo Peter, Helmut Drexler, Nina Johnston, Bo 
Lagerqvist, Bertil Lindahl, Kai C. Wollert, Uppsala Clinical Research Centre, Uppsala, 
Sweden, Dept. of Cardiology and Angiology, Hannover, Germany
Background: Retrospective evaluation in one trial indicates growth-differentiation factor-
15 (GDF-15) levels to be increased and independently related to outcome in non-ST-
elevation ACS. We aimed to prospectively verify the prognostic importance of GDF-15 
and to investigate the relations to the effects of an early invasive treatment strategy.
Methods: Levels of GDF-15 and other biomarkers were measured on admission 
in patients with non-ST-elevation ACS randomized to early invasive (N=1045) vs 
conservative (N=1034) treatment strategy in the FRISC-II trial. Previously established 
cut-off levels for GDF-15 were 1200 ng/L (90th percentile of matched healthy controls) and 
1800 ng/L (upper tertile in a previous non-ST-elevation ACS material).
Results: Outcome in relation to the randomized strategy and GDF-15 levels are shown in the table. 
Endpoint
Stratification 
according to 
GDF-15
Non-Invasive
% Events 
(Number of 
patients)
Invasive
% Events ( 
Number of 
patients)
Estmated 
Odds 
Ratio
(95% CI)
P-value*
Death/ Acute 
myocardial 
infarction at 2 
years
<1200 9.3 (400) 9.6 (416)
1.044 
(0.652 to 
1.669)
0.8584
1200-1800 16.5 (394) 11.2 (376)
0.637 
(0.420 to 
0.966)
0.0337
>1800 27.9 (240) 14.6 (253)
0.442 ( 
0.282-
0.693)
0.0004
In a multiple Cox regression analysis the following variables were significantly 
related to the rate of death or myocardial infarction at two years: current smoking, 
diabetes mellitus, previous myocardial infarction, Troponin-T level, GDF-15 level and a 
noninvasive treatment strategy. The only variable with a significant interaction with the 
effects of an invasive treatment strategy was GDF-15.
Conclusions: GDF-15 is a new and independent prognostic indicator in non-ST-elevation 
acute coronary syndrome that contributes to the identification of patients who benefit from 
an early invasive strategy.
10:00 a.m.
1025-137 Direct (Ambulance-based) Referral to CCU for Primary 
PCI Improves Door to Catheterization Time and Final 
TIMI Flow - Should We Bypass the ER?
Hatem Hamood, Arie Shefer Shefer, Nabeel Makhoul, Amin Hassan Hassan, Erez 
Geler, Uri Rosenschein, Bnai-Zion Mediacl Center,Rappaport Faculty of Medicine,Techn
ion,Israel, Haifa, Israel, Magen David Adom, Haifa, Israel
Background: One of the major factors in the outcome of Acute STEMI patients (pts) is 
time- dependent reperfusion of the infarct-related coronary artery. Randomized clinical trials 
have shown that failure to restore TIMI grade-3 Flow results in reduced outcomes. Today, 
Primary PCI has become the reperfusion strategy of choice when it is performed in the right 
time window. The objective of this study is to compare the strategy of direct referral to ICCU 
vs indirect ER-based referral strategy of STEMI pts who were referred to Primary PCI.
Methods and Results: Since September 2003, we introduced a 24 hour/7 day a week 
service of Primary PCI in STEMI. All data were collected consecutively (n=151). Direct 
ambulance-based referral was in 56(37.1%) patients, while indirect ER-based referral 
was in the other 95 (62.9%) patients. Door-to-Catheterization time (D2C), Mean Final 
TIMI Flow and TIMI-3 Flow rate are shown herein: 
Direct-based 
referral(n=56)
Indirect ER-based 
referral(n=95) P value
D2C time (min) 19.5±20.8 96.6±73.8 P< 0.00001
Mean Final TIMI 
Flow 3 2.73 P< 0.002
Final TIMI-3 Flow 
(%) 100 84 P< 0.002
Conclusions:
Direct ambulance-based referral strategy shortens significantly Door-to-Catheterization 
delay time and improves final culprit vessel patency as measured by TIMI-3 flow when 
compared to Indirect ER-based referral strategy.
10:00 a.m.
1025-138 Efficacy and Safety of Fondaparinux in Elderly Patients 
with ST Segment Elevation Myocardial Infarction: Data 
from the OASIS 6 Trial
Ron J. Peters, Tjeerd van Rees Vellinga, Jean Pierre Bassand, Rizwan Afzal, Susan 
Chrolavicius, Chris Granger, Andrzej Budaj, Keith Fox, Shamir Mehta, Salim Yusuf, McMaster 
University, Hamilton, ON, Canada, academic medical center, amsterdam, The Netherlands
Introduction. In the OASIS 6 trial, fondaparinux (fonda) 2.5 mg/day subQ was compared 
to placebo (stratum 1) or i.v. unfractionated heparin (stratum 2) in a wide range of patients 
presenting with acute ST-segment elevation myocardial infarction (STEMI). Overall, fonda 
significantly reduced mortality and reinfarction at 30 days (9.7 vs 11.2%, p=0.008) without 
increasing bleeding or strokes. There was no apparent benefit in patients undergoing 
primary percutaneous coronary intervention (PPCI). Since the risks of both ischemic and 
hemorrhagic events are higher in elderly patients, we analysed our results regarding this 
particular subgroup.
Methods and results. Of the12,086 patients included, 2015 were 75 years of age or 
older. Overall, the treatment benefits of fondaparinux were similar regardless of age for 
the primary endpoint (Death/MI at 30 days) or for severe bleeding (table). Similarly, at 9 
and 180 days there was no interaction of treatment effect and age. 
Death/MI
at 30 days n
Control
(n) %
Fonda
(n) % HR 95% CI
P value for 
interaction
Age <75 years 10071 (446) 8.8 (378) 7.5 0.85 0.74-0.97
0.8923
Age ≥75 years 2015 (231) 23.2 (207) 20.3 0.86 0.72-1.04
Severe 
hemorrhage
at 30 days
Age <75 years 10071 (59) 1.2 (48) 1.0 0.82 0.56-1.20
0.7117
Age ≥75 years 2015 (27) 2.9 (20) 2.1 0.72 0.56-1.20
There was consistent benefit in both strata of the study. Similarly, in patients undergoing 
thrombolytic therapy or no reperfusion therapy there was consistent benefit of fondaparinux 
compared to control (UFH or placebo) regardless of age. In the PPCI subgroup there was 
no apparent benefit of fonda in either age group.
Conclusion. In patients with STEMI not undergoing PPCI, there is consistent benefit in 
older and younger patients from fondaparinux, which significantly reduces mortality and 
reinfarction without increasing bleeding and strokes.
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1025-153 Long-Term Follow-Up of Patients With ST-Segment 
Elevation Myocardial Infarction Treated With Sirolimus-
Eluting Stents
Anuj R. Shah, Himanshu Tandon, Sachin Navare, Aziz Maksoud, Zulfqar Mirza, Jeff 
Mather, Roger Mennett, Roger Mennett, Francis Kiernan, Raymond McKay, Hartford 
Hospital, University of Connecticut, Hartford, CT
Background: Although previous studies have documented short-term safety and efficacy 
of sirolimus-eluting stents in the setting of ST-segment elevation myocardial infarction 
(STEMI), the long-term outcome of this treatment modality has not been fully described.
Methods: In-hospital, 9-month, 18-month and 24-month clinical outcomes were assessed 
in 559 patients (pts) with STEMI without cardiogenic shock who were treated with primary 
percutaneous coronary intervention (PCI) with one or more sirolimus-eluting stents at a large 
tertiary center between 3/2003 and 6/2006. The study group consisted of 393 males and 166 
females with a mean age of 60.6±13.3 yrs. Cardiac risk factors included diabetes (20.2%), 
hyperlipidemia (56.4%), hypertension (60.1%) and current smoking (40.4%). GP IIb/IIIa 
inhibitors were utilized in 94.1% of pts. TIMI 3 flow in the infarct vessel was achieved in 98.2% 
of pts. All pts were treated with aspirin and clopidogrel for a minimum of 6 months.
Results: Table
Conclusions: Sirolimus-eluting stent placement in the setting of STEMI has good long 
term outcomes up to 2 years.
In-Hospital and Long-term Outcomes of Patients with STEMI treated with 
Sirolimus Eluting Stent PCI
In-Hospital
Mortality 2.0%
Stent Thrombosis 0.9%
9-Month
Mortality 2.0%
Recurrent MI 1.3%
Repeat TL PCI 1.8%
18-Month
Mortality 0.0%
Recurrent MI or PCI 0.0%
24-Month
Mortality 1.8%
Recurrent MI 0.0%
Repeat TL PCI 0.0%
10:00 a.m.
1025-154 The Fate Of Adipose Stromal Cells Following 
Intracoronary And Retrograde Venous Myocardial 
Delivery In A Swine Infarct Model
Dongming Hou, Todd J. Brinton, Brian Johnstone, Dongni Feng, Jinglin Li, Eyas Al-
Shaykh Youssef, Pamela Rogers, William F. Fearon, Alan C. Yeung, Paul Yock, Keith L. 
March, ICVBM, KI of cardiology, Indianapolis, IN
Background: Recent studies suggest that transplantation of progenitor cells may 
improve left ventricular function after acute myocardial infarction (MI). The efficacy of 
percutaneously delivered cells is likely to depend on the delivery efficiency, which in 
turn is a product of delivery modality and cell type. Preliminary studies suggest that 
pluripotent adipose stromal cells (ASC) may be effective for myocardial restoration 
following infarction. We evaluated the short-term fate of ASCs after intracoronary (IC) 
and retrograde coronary venous (RCV) delivery in a swine MI model.
Methods: 12 Yorkshire swine were randomly assigned to two groups. An anterior infarct 
was created in each animal by 45 min balloon occlusion of the proximal LAD just distal 
to the 1st septal branch. 6 days after infarct, 10 million Indium-111 labeled porcine ASC 
were delivered by either IC or RCV. The index of microcircularory resistance (IMR) was 
measured using a pressure wire technique in each pig pre and post cell delivery. The 
animals were sacrificed 1 hr (n=6) or 24hrs (n=6) after delivery. Quantitative assessment of 
delivery distribution was performed using gamma-emission counting of multiple organs.
Results: Quantitative analysis of delivery distribution demonstrated a trend toward higher 
myocardium retention following IC delivery at 1 hr post delivery (74 ± 5.4% vs 34 ± 17%;p 
= 0.07) but no significant difference at 24 hr (23 ± 5.6% 20 ± 8.2%; p > 0.05). Importantly, 
the majority of ASCs redistributed to the lungs by 24 hr using either method (59 ± 3.2% 
vs 70 ± 6.5%; p > 0.05). There was no significant change in IMR following cell delivery 
using either delivery method.
Conclusions: IC and RCV delivery of ASCs demonstrated similar cardiac targeting at 
24 hr, despite a trend toward higher retention after acute IC delivery. The majority of 
ASC delivered by both methods was retained in the lungs. No significant impact on the 
coronary microcirculation following delivery of 10 million cells via IC or RCV delivery. The 
clinical implications of these findings are potentially significant, as these proangiogenic 
cells may have undesirable effects in non-target organs. We are conducting long-term 
follow-up studies to further assess safety.
10:00 a.m.
1025-155 Soluble CXCL16 Independently Predicts Long Term 
Mortality in Acute Coronary Syndromes
Kenneth Caidahl, Anna M. Jansson, Thor Ueland, Camilla Smith, Arne Yndestad, 
Torbjorn Omland, Marianne Hartford, Pål Aukrust, Karolinska Institutet, Stockholm, 
Sweden, Rikshospitalet, Oslo, Norway
Background: CXCL16/SR-PSOX is an interferon-gamma-regulated chemokine and 
scavenger receptor for OxLDL, expressed in atherosclerotic lesions. Proteolytic cleavage 
of membrane bound CXCL16 releases soluble CXCL16 which may promote migration of 
effector T cells and a proatherogenic inflammatory response. However, CXCL16 might be 
atheroprotective, as knock-out mice (CXCL16-/- ) have increased macrophage recruitment 
and an accelerated atherosclerosis. We hypothesized that in humans long-term outcome 
after an acute coronary event would be associated with soluble CXCL16 concentrations.
Methods: We assessed the association between circulating CXCL16 levels obtained within 24 
hrs following admission and time to death in 1351 patients (median age 67 yrs, 30% female) 
admitted to a Scandinavian teaching hospital with a diagnosis of unstable angina, non-ST-
elevation myocardial infarction (NSTEMI) or ST-elevation myocardial infarction (STEMI).
Results: During a median follow-up time of 81 months, 377 patients died. Increased 
levels of CXCL16 were prognostically unfavourable; Q4 vs. Q1 associated with a doubled 
mortality (hazard ratio 2.1, 95% CI 1.6 - 2.8; p<0.0001) After adjustment for age, gender, 
previous MI, angina, chronic heart failure, diabetes, hypertension, current smoking, index 
diagnosis, heart rate, peak CK-MB, troponin T, estimated creatinine clearance, and 
Killip class in a multivariable Cox proportional hazards regression model, logarithmically 
transformed CXCL16 levels remained a strong independent indicator of long-term 
mortality (hazard ratio 1.21 (95% CI 1.09 - 1.36 per 1 SD increase in CXCL16; p<0.001). 
After further adjustment for C-reactive protein (CRP) and proB-type natriuretic peptide 
(proBNP) in the subset of patients in whom these measures were available (n=1016; 249 
deceased), CXCL16 still provided significant additional prognostic information (hazard 
ratio 1.16 (95% CI 1.00 - 1.33; p=0.04).
Conclusions: In patients with an acute coronary syndrome, CXCL16 levels obtained within 
24 hrs of admission are associated with long-term mortality. This relationship is independent 
of index diagnosis and conventional risk factors, including CRP and proBNP.
10:00 a.m.
1025-156 Bare Metal Stent Implantation is Independent Predictor 
of Cardiac Death After Percutaneous Interventions on 
Unprotected Left Main Coronary Artery
Albert E. Alahmar, Elved B. Roberts, Mohammed Andron, Mohaned Egred, Kashif 
Bashir, Mark Jackson, Nick D. Palmer, Raphael A. Perry, Cardiothoracic Centre 
Liverpool, Liverpool, United Kingdom
Background: : the incidence of cardiac death following percutaneous coronary 
intervention of de novo lesions in unprotected left main coronary arteries(ULMCA) 
remains relatively high.
Aim: to identify significant clinical, angiographic, and procedural predictors of cardiac 
death following percutaneous coronary intervention of ULMCA.
Methods: We identified all patients (total number 77) who were treated with percutaneous 
intervention for de novo lesions in ULMCA in our institution between January 2001 and 
December 2005. The two indications for percutaneous interventions were patients’ refusal 
of surgery, or patients’ preference. We have excluded the 7 patients who presented in 
cardiogenic shock. Out of the 70 patients included in this analysis, 39 were elective and 
31 were acute presented with non ST elevation myocardial infarction. There were 33 
males and 37 females. 17(24%) patients were diabetics, 39 were hypertensive, and 40 
were smokers. Seven(10%) patients had left ventricle ejection fraction (LVEF) of <35%. 
Lesions were located at the ostium of the left main coronary artery in 11 patients, in the 
body in 13, and at the distal bifurcation in 46 patients. Median reference vessel diameter 
was 3.5 (IQR 3.37- 4.0). All patients were treated with stent implantation, 17 with Cypher, 
21 with Taxus, and 32 with bare metal stents (BMS).
Results: During hospitalisation 2 patients died of myocardial infarctions. Mean follow-up 
was 605 ± 319 days, during which additional 10 cardiac deaths occurred. Cox proportional 
hazards model with the use of the stepwise procedure was used to assess the correlates 
of cardiac death among multiple clinical (age, sex, presence of diabetes), procedural 
(acute or elective), and angiographic (lesion location, LVEF, type of stent) variables. The 
two independent predictors of cardiac death were the use of BMS (OR 3.67; 95% CI 1.04-
12.69 P=0.043), and LVEF<35% (OR 10.62; 95% CI 2.65-42.54 P=0.001).
Conclusions: In our series, the implantation of BMS and significant impairment of left 
ventricle were the most important predictors of cardiac death following percutaneous 
coronary intervention of ULMCA.
10:00 a.m.
1025-157 LV Dyssynchrony After MI Predicts Long Term Cardiac 
Events. A Real-Time 3D Echo Study
Federico M. Asch, Szymon Bieganski, Julio A. Panza, Neil J. Weissman, Washington 
Hospital Center, Washington, DC, Medstar Research Institute, Washington, DC
Background: The prevalence and prognostic value of Left ventricular mechanical 
dyssynchrony (LVMD) in patients with acute myocardial infarction (AMI) is unknown. Real 
time 3D echo (RT3DE) is a novel method for detecting dyssynchrony, particularly sensitive 
due to its ability to evaluate the entire heart (16 segments) in real time. We aimed to test 
whether LVMD assessed by RT3DE has predictive value for cardiac events after an AMI.
Methods: We prospectively enrolled patients admitted for ST elevation AMI in a single 
institution. A RT3DE was performed within 48hs of admission and analyzed in a TomTec 
workstation with semi-automated endocardial detection by a reader blinded to the clinical 
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data. Peak systole for each of the 16 segments was defined as the time between the 
beginning of the QRS and the moment of minimal segmental volume. Dyssynchrony index 
(DI) was defined as the standard deviation of timing for peak systole in all 16 segments 
and reported as % of the cardiac cycle length to adjust for different heart rates. LVMD 
was defined as a DI > 7.5% (assuming a normal value of 5.4% from a similar population 
without AMI previously reported), which divided the cohort in halves (15 patients with 
and 15 without LVMD). A combined end-point of death, re-AMI, re-hospitalization and 
re-revascularization was evaluated at 27.4±8 months of follow up.
Results: Thirty patients were enrolled (age 60.2±12), 73% male, with EF 42.1±8.1%. AMI 
involved the anterior wall in 40% and QRS duration was 88.6±13.9. DI was 7.6±2.7. All were 
revascularized and received the same anti-ischemic medications (aspirin, clopidogrel, beta 
blockers, ACE inhibitors and statins). There was no statistical difference between groups 
regarding time to follow up, age, EF and end diastolic volume. A total of 9 patients reached 
the combined endpoint, 7 in the group with LVMD and 2 in the group without (p=0.04). Two 
were deaths, 1 re-AMI, 1 re-hospitalization and 5 revascularizations.
Conclusions: In our small population, LVMD early after AMI as assessed by RT3DE 
was an independent predictor of cardiac events in the long term. Larger studies are 
warranted to confirm our findings.
10:00 a.m.
1025-158 Impact Of Admission Blood Glucose On Outcome 
Of Non-diabetic Patients With Acute ST-elevation 
Myocardial Infarction: Results From 5866 Patients From 
The ACOS Registry
Christoph K. Naber, Rajendra H. Metha, Claus Juenger, Raimund Erbel, Anselm Gitt, 
Uwe Zeymer, Jochen Senges, West German Heart Center Essen, Essen, Germany, 
Cardiology Clinic/Cardiovascular Research Institute, Ludwigshafen, Germany
Background: High glucose levels cause an adverse short-term outcome in diabetics 
and non-diabetics with acute coronary syndromes (ACS). However, the relationship of 
admission glucose to long-term outcomes is less well described. We aimed to investigate 
if admission blood glucose levels impacted long-term outcomes of non-diabetic patients 
with ST-elevation myocardial infarction (STEMI).
Methods: We evaluated consecutive STEMI patients without diabetes from the German 
Acute Coronary Syndromes (ACOS) Registry. Clinical endpoints were long term mortality 
and composite of death, reinfarction, stroke or rehospitalization (MACCE). Patients were 
categorized based on their admission blood glucose level.
Results: Of 5866 patients with STEMI, 36.9% had a blood glucose <120 mg/dl (A), 33.1% 
120-150 mg/dl (B), and 30.0% >150 mg/dl (C). Admission blood glucose was significantly 
related to increased risk of not only in-hospital death (OR C vs. A: 2.86; 95%CI 2.13-3.82, 
p<0.0001) and MACCE (OR C vs. A: 1.88; 95%CI 1.52-2.33; p<0.0001), but this risk 
persisted beyond the acute phase during long term follow up (mean 380 d) in patients 
discharged alive (death OR C vs. A: 1.11; 95%CI 0.79-1.56, p=0.08; MACCE OR C vs. A: 
1.46; 95%CI 1.04-2.03; p<0.0001; Figure).
Conclusions: High blood glucose levels at admission to hospital are an independent 
predictor of long-term mortality in STEMI patients. They should be incorporated into the 
risk stratification of STEMI patients and may be an important target for risk modulation. 
10:00 a.m.
1025-159 The SIRIUS Study: 5-Year Outcomes
Martin B. Leon, Jeffrey W. Moses, David R. Holmes, Jr., Dean J. Kereiakes, Sidney A. 
Cohen, Donald Cutlip, Columbia University, New York City, NY
Control/Tracking Number:
Activity: Abstract
Current Date/Time:
The SIRIUS Study: Five-Year Outcomes
Background: The SIRIUS Study is a multi-center, double-blind, randomized study comparing 
the Sirolimus-eluting stent (CYPHER®) to a bare metal Bx VELOCITY™ control (BX) in the 
treatment of patients with de novo native coronary artery lesions. Analysis of the primary 
endpoint of target vessel failure (TVF) at 9 months demonstrated the safety and effectiveness 
of the CYPHER® stent. Long-term follow-up is planned annually out to 5 years.
Methods: 4 5 years clinical follow-up for surviving patients that were enrolled at 53 centers 
is currently underway. Target lesion revascularization (TLR), TVF and major adverse cardiac 
events (MACE) continue to be adjudicated by an independent clinical events committee.
Results: TLR, TVF and MACE rates reported at 1, 2, and 3 4 years are summarized below.
1 Year 2 Year 4 Year
CYPHER®
(n=533)
BX
(n=525) p-value
CYPHER®
(n=533)
BX
(n=525) p-value
CYPHER®
(n=533)
BX
(n=525) p-value
TLR 4.9% 20.0% <0.0001 5.8% 21.3% <0.0001 7.9% 23.8% <0.0001
TVF 9.8% 24.8% <0.0001 12.0% 26.7% <0.0001 18.6% 32.0% <0.0001
MACE 8.3% 22.3% <0.0001 10.1% 24.4% <0.0001 16.3% 30.5% <0.0001
Conclusions: Data up to the 34-year follow up of the SIRIUS study demonstrates maintenance 
of the highly significant differences in clinical outcomes between CYPHER® and BX, with a 
trend for an increase in this difference over time. Increments in target vessel revascularization 
and MACE are similar in both arms, reflecting non-target lesion atherosclerotic disease 
progression. Completed 45-year follow-up clinical data will be presented.
10:00 a.m.
1025-174 Aspirin Resistance And Long Term Prognosis After 
Successful Coronary Stenting
Nikolaos Patsourakos, Michael N. Zairis, Stamatis Makrygiannis, Demetrios Beldekos, 
John Hatzissavas, Evdokia Adamopoulou, Anastassios Theodosis-Georgilas, 
Constantine Fakiolas, Evangelos Pissimissis, Christopher Olympios, Spyros Argyrakis, 
Stefanos G. Foussas, Cardiology Department, Tzanio Hospital, Piraeus, Greece
Background- We evaluated the impact of aspirin resistance on the incidence of 1-year 
death following elective coronary stenting (CS). 
Methods-A total of 612 consecutive pts who underwent elective CS for stable or unstable coronary 
artery disease were studied. All patients preloaded with aspirin and 300mg of clopidogrel at least 
24 hrs before the procedure. Platelets response to aspirin therapy was measured preproceduraly 
by the platelet function analyzer (PFA-100) closure time (CT). Patients were divided into 3 groups 
according to the tertiles of preprocedural values of PFA-100 CT. 
Results- By the 1-year 47 (4.7%) pts died. Although, there were not significant differences 
in baseline clinical, angiographic and CS related data among the 3 groups, patients at 
the first tertile of preprocedural values of PFA-100 CT (lower response to aspirin therapy) 
had the higher risk of 1-year death than those in the second (10.2% vs 2.4; RR=4.9; 
p=0.001) or third (10.2% vs 1.5; RR=5.2; p<0.001) tertile (Fig 1). Conclusions-The 
present results have shown that attenuated platelets response to therapy with aspirin 
portend an increased risk for 1-year death after CS. 
10:00 a.m.
1025-175 A Gender-specifc Difference In Vasodilating Capacity 
Of Coronary Arteries: Comparison Between 
Postmenopausal Women And Age-matched Men 
Tetsuro Kataoka, Shuichi Hamasaki, Sanemasa Ishida, Masakazu Ogawa, Keishi Saihara, 
Hideki Okui, Naoya Oketani, Hitoshi Ichiki, Yuichi Ninomiya, So Kuwahata, Shoji Fujita, 
Chuwa Tei, Graduate School of Medicine, Kagoshima University, Kagoshima, Japan
Background: Postmenopause is recognized as a risk factor for the development of 
cardiovascular disease. However, it remained unclear whether the vasodilating capacity 
of the coronary arteries is influenced by gender. Thus, we here compared the difference in 
coronary vascular function between the postmenopausal women and age-matched men.
Methods: Coronary vascular function was examined in 46 postmenopausal women (69±8 
yrs.). Age-matched 47 men (68±4 yrs.) served as control subjects. Vascular reactivity was 
assessed by intra-coronary administration of papaverine (12.5 mg/20 sec), acetylcholine 
(Ach) (3μg/2min), and nitroglycerin (200μg/20 sec) using a Doppler guidewire.
Results: Left ventricular mass and basal coronary blood flow were similar when comparing 
the two groups (408±156 g vs. 467±174 g, p=NS; 98±64 ml/min vs. 84±42 ml/min, p=NS). 
The percent increases in coronary blood flow evoked by papaverine and acetylcholine in 
postmenopausal women was significantly reduced when compared with those in men 
(164±107% vs. 230±124%, p<0.01; 34±60% vs. 70±86%, p<0.05, respectively), whereas the 
percent changes in coronary diameter evoked by acetylcholine and nitroglycerin were similar 
when comparing the two groups (3±12% vs. 9±14%, p=NS; 13±11% vs 17±21%, p=NS).
Conclusions: This study suggests that endothelium-dependent and -independent vasodilation 
of the resistance coronary artery are impaired in postmenopausal women, which may be 
affected by gender-specifc difference of the resistance coronary vasodilating function.
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1025-176 Adult Treatment Panel III 2001 But Not International 
Diabetes Federation 2005 Criteria of the Metabolic 
Syndrome Predict Future Vascular Events Among 
Women Undergoing Coronary Angiography
Christoph H. Saely, Lorena Koch, Fabian Schmid, Thomas Marte, Stefan Aczel, Peter 
Langer, Guenter Hoefle, Heinz Drexel, VIVIT Institute, Feldkirch, Austria, Academic 
Teaching Hospital Feldkirch, Feldkirch, Austria
Background: The International Diabetes Federation (IDF) has recently established a 
worldwide consensus definition of the metabolic syndrome (MetS). The purpose of this 
study was to prospectively evaluate the cardiovascular risk associated with the IDF 
and Adult Treatment Panel III (ATPIII) MetS definitions in women undergoing coronary 
angiography for the evaluation of stable coronary artery disease.
Methods: In a prospective study on 241 women undergoing coronary angiography for the 
evaluation of stable coronary artery disease we recorded vascular events over 4 years.
Results: From the women enrolled in our study, 34.9% (n = 84) had the MetS according 
to the ATP III definition and 47.8% (n = 115) according to the IDF definition. Concordance 
between the definitions was moderate (Cohen-Kappa coefficient = 0.537; p <0.001). The 
MetS as defined by the ATP III criteria significantly predicted vascular events (adjusted 
hazard ratio = 2.133 [1.111-4.094]; p = 0.023) but the MetS as defined by IDF criteria 
did not (adjusted hazard ratio = 1.214 [0.635-2.319]; p = 0.558). Accordingly, event-free 
survival was significantly lower among women who fulfilled the ATP III but not the IDF 
criteria than among those who met the IDF but not the ATP III criteria (p = 0.035).
Conclusions: Among women undergoing coronary angiography for the evaluation of 
CAD, the ATP III and the IDF definitions of the MetS do not identify the same patient 
populations. The ATP III definition of the MetS confers a significantly higher risk of 
vascular events than the IDF definition.
10:00 a.m.
1025-177 Clinical Significance of Urinary 8-iso-prostaglandinF2α 
Concentration in Patients with Coronary Vasospastic 
Angina Pectoris
Takashi Hitsumoto, Mao Takahashi, Takuo Iizuka, Kouji Shirai, Toho University Sakura 
Hospital, Sakura, Japan
Background: > Oxidative stress may promote endothelial dysfunction through increased 
production of reactive oxygen species that inactivate nitric oxide. On the other hand, 8-iso-
prostaglandinF2α, a representative isoprostane, has been reported to be a reliable marker 
for oxidative stress in vivo. Furthermore, F2-isoprostane is known to be a vasoconstrictive 
property. The purpose of this study is to clarify the relationship between urinary 8-iso-
prostaglandinF2α (U-8-iso) concentration and coronary vasospastic angina pectoris.
Methods: 156 subjects (male/female: 82/74, mean age: 61±10years) without angiographically 
demonstrable coronary atherosclerosis were enrolled. Coronary vasospasm was defined as 
a marked luminal narrowing or total occlusion provoked by the intracoronary administration of 
acetylcholine. U-8-iso concentration was measured by enzyme immunoassay methods.
Results: U-8-iso concentration was higher in 58 subjects with coronary vasospasm 
than in 98 subjects with a negative response (129±43 vs 99±38pg/mg Cr, p<0.0001), 
furthermore, the patients with multiple vessel spasms had significantly high U-8-
iso concentration compared with single vessel spasm (145±51 vs 118±35pg/mg Cr, 
p=0.01). Multiple regression analysis revealed that only U-8-iso concentration was an 
independent variable for presence of coronary vasospasm among the factors which 
influenced coronary vasospasm such as smoking, HDL-cholesterol concentration and 
insulin resistance (t value=3.9, p=0.0002).
Conclusions: Theses results indicate that high U-8-iso concentration is an important risk 
factor for coronary vasospastic angina pectoris.
10:00 a.m.
1025-178 Do Drug Eluting Stents Impact Survival in Patients With 
Chronic Renal Insufficiency
Michael C. Kim, Michael J. Robbins, Michael Rosenblum, Persis Bhandri, Samin K. 
Sharma, Annapoorna S. Kini, Mount Sinai Medical Center, New York, NY
Background: Patients with Chronic Renal Insufficiency (CRI) especially on dialysis 
undergoing Percutaneous Coronary Intervention (PCI) have poor survival and higher 
cardiac event at follow-up. Drug Eluting Stent (DES) use in these patients reduces target 
vessel revascularization (TLR), but survival benefit when compared to patients with 
normal renal function is not know.
Methods: We analyzed all stable patients who underwent PCI with DES. Patients 
were grouped in four groups, according to the values of the estimated serum creatinine 
clearance (SCL, in ml/min): I normal SCL ≥60, II SCL 40 to 59, III SCL 20 to 39, IV SCL 
<19 or dialysis. All patients received DES and Plavix was continued for one year.
Results: A total of 6200 patients were analyzed, gp I 4231, gp II 1135, gp III 540, gp IV 
294. Procedural and clinical success (procedural success without Q-wave MI, urgent 
revascularization, death) were similar in all groups. TLR at 9 months was 4.8%, 4.9%, 
6.2% and 4.6% (p=0.72) respectively. MACE (MI with CK-MB >3x, urgent revascularization 
or death) at 12 months was 6.2%, 8.7%, 16.6% 17.4% (p< 0.0001) respectively. Survival 
decreased with worsening renal function as shown in the graph.
Conclusions: CRI patients undergoing PCI continue to have poor long-term survival 
despite DES use. Therefore in these high-risk patients aggressive secondary 
cardiovascular risk factor modification with tight blood-pressure, glycemic and lipid 
control is mandated to improve survival. 
10:00 a.m.
1025-179 Relationship Between Intensive Statin Therapy and 
Cardiovascular Outcomes in Patients With Stable 
Coronary Artery Disease: A Meta-Analysis of 
Randomized Clinical Trials
Taral Patel, Ali Usmani, Anthony A. Bavry, Arman T. Askari, Cleveland Clinic, Cleveland, OH
Background: The benefit of statin therapy targeting a low density lipoprotein level (LDL-
C) of 100 mg/dL in patients with stable coronary artery disease is well established. That 
a mortality benefit exists with intensive statin therapy, targeting even lower LDL-C levels, 
remains controversial.
Methods: We performed a meta-analysis to determine the overall efficacy and safety 
of high-dose statin therapy in patients with stable coronary artery disease. Prospective 
randomized trials with the following criteria were included: trials enrolling patients with 
stable coronary artery disease; randomization to high-dose vs. low-dose statin or 
placebo; and > 6 month clinical outcome data available. The primary endpoint was all-
cause mortality and secondary endpoints were cardiovascular (CV) mortality, non-fatal 
myocardial infarction (MI), stroke, and revascularization. Safety endpoints included liver 
function test (LFT) abnormalities and rhabdomyolysis.
Results: A total of eleven trials were included in the analysis. Mean LDL-C levels were 
reduced by 39% to 86 mg/dL in the high-dose arm and 13% to 122 mg/dL in the control 
arm. Relative risk estimates for all of the endpoints are displayed in Table 1.
Conclusion: Whereas no mortality benefit was found, there were significant reductions in 
non-fatal MI, stroke, and revascularization with high-dose compared with low-dose statin 
or placebo in this patient population. A significant increase in the risk of LFT abnormalities 
was also demonstrated.
Outcomes
Endpoints Relative Risk 95% CI p-value
All-Cause Mortality 0.97 0.88 - 1.07 0.52
CV Mortality 0.92 0.81 - 1.06 0.24
Non-fatal MI 0.80 0.72 - 0.89 < 0.0001
Stroke 0.82 0.71 - 0.96 0.014
Revascularization 0.81 0.75 - 0.88 < 0.0001
LFT abnormalities 5.14 3.50 - 7.54 < 0.0001
Rhabdomyolysis 0.87 0.28 - 2.69 0.81
10:00 a.m.
1025-180 Bridging of Chronically Anticoagulated Patients 
With Low Molecular Weight Heparin Prior to Cardiac 
Catheterization: Experience in 203 Patients From the 
Brave-registry
Heyder Omran, Harald Schmidt, Christoph Hammerstingel, Giso von der Recke, Dep of 
Medicine MHV Bonn, Bonn, Germany
Background: It is recommended to discontinue oral anticoagulation (OAC) in chronically 
anticoagulated patients (pts) with mechanical heart valve replacement (MVR) and/or atrial 
fibrillation (AF) and concomitant thromboembolic (TE) risk factors prior to interventions 
with high risk of bleeding. To prevent TE complications, pts should receive weight 
adapted bridging therapy with unfractioned heparin intravenously. Low molecular weight 
heparin (LMWH) have a higher bioavailability and more predictive anticoagulatory effect, 
therefore, effective anticoagulant therapy can be achieved by subcutaneous application 
of LMWH. The aim of this registry was to assess the safety and practicability of bridging 
therapy with LMWH in patients on OAC undergoing cardiac catheterization.
Methods: Consecutive chronically anticoagulated pts with MVR and AF and an indication 
for interruption of OAC were included in the registry. Pts at high TE-risk (patients with 
MVR, patients with AF and several concomitant risk factors) received weight adapted 
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enoxaparin s.c. twice a day (1mg/kgBW/12h). The remaining patients (n = 62) received 
enoxaparin in half therapeutic dosage. Procedures were performed at INR<1.5. After the 
procedure OAC was reintroduced under LMWH therapy until effective INR was reached. 
All pts were followed up regarding bleeding complications, occurance of clinical signs of 
thromboembolism and other adverse events under LMWH-therapy.
Results: 203 pts were included in the study. 31 had MVR and 172 patients AF. The 
average age was 72.3±10.5 years; the mean treatment time 7.2 ± 5.1 d. Of the 203 
procedures 72 were coronary interventions. Minor bleeding occurred in 7% of patients. 
Neither major bleedings nor thromboembolic complications evolved due to bridging 
therapy. 1 patient had a pseudoaneurysm of the brachial artery.
Conclusions: Bridging therapy with low molecular weight heparin (enoxaparin) is safe 
and feasible in a large cohort of patients with chronic oral anticoagulation undergoing 
elective cardiac catheterization. A dose adjusted treatment according to the individual 
thromboembolic risk resulted in a low complication rate.
10:00 a.m.
1025-195 Drug Eluting Stents in the Elderly: Long-Term Clinical 
Outcomes of Octogenarians in the DESIRE Registry
Amanda Sousa, Adriana Moreira, Galo Maldonado, Manuel Cano, Fausto Feres, Luiz 
Mattos, Alexandre Abizaid, Leandro Lasave, Andrea Abizaid, J.Eduardo Sousa, Hospital 
do Coração, Sao paulo, Brazil, Institute Dante Pazzanese de Cardiologia, Brazil
Background: Elderly patients (P) after bare metal stents (BMS) traditionally experience 
higher rates of procedural complications and worse long-term outcomes compared to 
younger P. This study sought to evaluate the long-term clinical follow-up (FU) after drug 
eluting stents (DES) in octogenarians compared to septuagenarians and P < 70 y old.
Methods: 1,559 P were included in the DESIRE (Drug Eluting Stents in the Real World) Registry 
for an elective DES implantation between 9/2002 - 9/2006. Of these, 1,347 P (86.4%) completed 6 
mo FU and were divided into 3 groups (G) according to age (GI: < 70 y; GII: 70-79 y; GIII: > 80 y). 
The baseline and procedural characteristics as well as the outcomes are in the table.
Table: Baseline and Outcomes 
Group
Variables
GI < 70 y
(n = 890)
GII 70 - 79 y
(n = 336)
GI > 80 y
(n = 121) P
Mean age (y) 57.69 ± 7.47 74.2 ± 2.8 83 ± 3.4 <0.001
Female (%) 18.1 32.7 37.2 <0.001
Diabetes (%) 30.3 30.06 20.66 0.08
AMI prior 20.6 19.34 17.36 0.354
Hypertension 75.9 80.3 84.3 0.014
Hypercholesterolemia 64.38 60.42 48.76 0.0013
Unstable angina (%) 27.7 28.0 35.5 0.158
Multivessel disease (%) 53.1 57.2 64.5 0.014
Treated lesions/P 1.32 1.40 1.47
DES/P 1.43 1.52 1.62
% FU 97.0 96.7 97.5
Mean FU (y) 1.2 ± 1.0 1.1 ± 1.0 1.1 ± 1.0
Cumulative MACE
Cardiac death (%) 1.46 2.1 6.6* 0.001
MI Q 0.33 0.3 0 0.58
MI ñ Q 1.46 1.2 0.8 0.53
MI 1.79 1.49 0.8 0.42
TVR PCI 2.7 1.5 0.8 0.096
TVR CABG (%) 0.7 0.6 0 0.435
TVR 3.37 2.08 0.8 0.065
MACE (%) 6.7 5.6 8.2 0.891
In the multivariate logistic regression analysis, the age was the only independent predictor 
of cardiac death (OR1.06 95%CI 1.03-1.12, p=0.001)
Conclusions: DES in octogenarians have a higher incidence of MACE (8.2%) due to a 
higher mortality rate (6.6%) compared to younger patients in a long-term follow-up. Older 
age was the only independent predictor of outcome by multivariate analysis. However, 
this incidence is far lower than the observed in the historical series with BMS.
10:00 a.m.
1025-196 Therapeutic Hypothermia for Out-of Hospital Cardiac 
Arrest May Not Improve Survival when Utilized in an 
Unselected Population
Andrea C. Hall, Brian E. Gulbis, Aamer Abbas, Wing Y. Liu, Carmen W. Landrau, Manuel 
M. Reyes, Coung T. Pham, Husnu E. Kaynak, James J. McCarthy, David E. Persse, 
Stefano Sdringola, H. Vernon Anderson, Richard W. Smalling, Ali E. Denktas, The 
University of Texas Health Science Center, Houston,TX, Memorial Hermann Heart and 
Vascular Institute, Houston,TX
Background: Sudden cardiac death (SCD) is a major cause of mortality in the United States 
and in-hospital mortality for successfully resuscitated patients remains high. Therapeutic 
hypothermia trials which have shown improved survival to discharge have had highly selective 
study populations. Our hospital, has initiated routine therapeutic hypothermia in SCD patients 
in an attempt to improve survival. We sought to establish whether this intervention significantly 
decreased mortality in routine SCD care. 
Methods: We evaluated patients with out-of-hospital cardiac arrest between 2004-2006 
excluding only those with arrest in the emergency room or those transferred from another 
center. We compared therapeutic hypothermia vs. conventional care in terms of patient 
baseline characteristics; age, gender, initial arrest rhythm, witness status, bystander CPR, 
downtime, and vasopressor use. Mortality was evaluated as the primary outcome. 
Results: In 92 consecutive patients evaluated, in hospital mortality was 51%. Demographics 
included mean age: 59yr, downtime: 22min, length of stay: 9.7 days, VT/VF: 66%, witnessed 
arrest: 84% and use of vasopressors: 45%. Hypothermia was initiated in 58.7% of patients. 
Demographics were similar between therapeutic hypothermia and usual care groups except 
witnessed arrest was higher in the hypothermia group (90.7% vs. 73.7% -p< 0.05). Mortality 
was not statistically different between the hypothermia and usual care groups (53.7% 
vs. 47.4%). Length of stay was 10.1 for hypothermia vs. 9.1 days for usual care (p=NS). 
Vasopressor use was not significantly different, however vasopressors initiated > 6 hours 
after admission was higher in the therapeutic hypothermia group (20.4% vs. 5.3%, p < 0.05). 
Conclusion: In a consecutive population of patients with out of hospital cardiac arrest, 
therapeutic hypothermia did not decrease mortality. The criteria for initiation of treatment 
and type and timing of cooling used were variable. Further studies should be performed to 
evaluate the different modes and timing of hypothermia induction as well as specific criteria 
for patient subsets most likely to benefit from hypothermia.
10:00 a.m.
1025-197 Differences in Invasive Therapies and In-Hospital 
Mortality Between Patients With and Without ST-
Segment Elevation Myocardial Infarction Complicated 
by Cardiogenic Shock
Hani Jneid, George V. Moukarbel, Marwan Refaat, Omeed Zardkoohi, Andrew O. 
Maree, Jean-Pierre Awaida, Marc J. Semigran, Marc J. Semigran, Herman K. Gold, 
Eugene V. Pomerantsev, Igor F. Palacios, Massachusetts General Hospital and Harvard 
Medical School, Boston, MA
Background: Previous studies reported differences in the medical care of patients with and without 
ST-segment elevation myocardial infarction (MI) complicated by cardiogenic shock (CS). It is unclear 
whether the improvement in MI management has mitigated these differences between patients.
Methods: We compared invasive therapies and in-hospital mortality in patients presenting to our 
center with acute MI complicated by CS between March 2003 and September 2006.
Results: The study population consisted of 76 patients with non-ST segment myocardial infarction 
(NSTEMI) and 122 patients with ST-segment elevation myocardial infarction (STEMI). NSTEMI 
patients had a higher risk profile compared with STEMI patients and were less likely to undergo early 
cardiac catheterization or revascularization (Table). NSTEMI patients had also lower rates of PCI or 
any revascularization during the index hospitalization. Higher in-hospital mortality was observed in 
NSTEMI compared with STEMI patients (47 vs. 32%, P = 0.035); however, after adjusting for either 
revascularization or PCI in a logistic regression model, the difference in mortality was attenuated and 
was no longer statistically signifcant.
Conclusion: NSTEMI patients presenting with CS were less likely to undergo invasive therapies 
and had higher in-hospital mortality compared with their STEMI counterparts. Differences in hospital 
mortality appear to be primarily related to lower revascularization rates in the NSTEMI patients. 
Overall rate (N) % NSTEMI % (N) STEMI %  (N) P-value
Baseline 
Characteristics 
and
Co-morbidities
Age (years) [Mean ± SD] 68.3 ± 12.6 70.5 ± 11.3 66.9 ± 13.3 0.074
Female gender 37.9 % (75) 34.2 % (26) 40.2 % (49) 0.45
Diabetes 32.3 % (64) 46.1 % (35) 23.8 % (29) 0.0017
Hyperlipidemia 67.9 5 % (133) 79.7 % (59) 60.7 % (74) 0.007
History of Renal Failure 21.7 % (43) 34.2 % (26) 13.9 % (17) 0.0013
Peripheral Arterial Disease 24.4 % (48) 39.5 % (30) 14.9 % (18) 0.0001
Cerebrovascular Disease 24.4 % (48) 23.7 % (18) 11.6 % (14) 0.0001
History of Chronic Obstructive Pulmonary disease 15.7 % (31) 27.6 % (21) 8.3 % (10) 0.0005
Previous Coronary Artery Bypass Graft (CABG) 15.2 % (30) 31.6% (24) 4.9% (6) < 0.0001
Current smoker 23.1 % (45) 12.2 % (9) 29.8 % (36) 0.005
Multi vessel CAD 70.5 % (124) 81.1 % (52) 64.3 % (72) 0.025
Frequency 
and Timing 
of Invasive 
strategies
Early cardiac catheterization (within 6 h after 
symptom onset) 50.3 % (93) 31.8 % (21) 60.5% (72) 0.0002
PCI 80.1 % (157) 65.3 % (75) 89.3 % (121) < 0.0001
CABG 5.6 % (11) 6.7 % (5) 4.9 % (6) 0.75
Revascularization 81.6 % (160) 68 % (51) 90.1 % (109) 0.0002
Use of Intra-aortic Balloon Pump 85.2 % (156) 80.3 % (53) 88.0 % (103) 0.19
Revascularization on 1st day of admission 89.3 % (142) 76 % (38) 95.4 % (104) 0.0005
Outcome In-Hospital Mortality 38 % (75) 47.4 % (36) 32.0 % (39)
-Unadjusted P
= 0.035
-Adjusted for 
revascularization 
or PCI à P >
0.05
10:00 a.m.
1025-198 Patients Treated With Clopidogrel Before Coronary 
Artery Bypass Grafting Surgery: Detrimental or Merely 
a Bother?
Nachum Nesher, Steve K. Singh, Nimesh D. Desai, Maria E. Lagopoulos, Jeri Y. Sever, 
Fuad Moussa, George T. Christakis, Bernard S. Goldman, Gideon N. Cohen, Stephen 
E. Fremes, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
Background: Clopidogrel is used in managing acute coronary syndromes and frequently 
administered prior to angiography. These patients may subsequently be referred for 
coronary artery bypass graft (CABG) surgery, where increases in bleeding risks are 
balanced with risks of ongoing ischemia by CABG delay. Our study aimed to analyze 
outcomes in those that received clopidogrel pre-CABG versus those who did not.
Methods: 386 consecutive patients (04/2005-08/2006) undergoing urgent isolated CABG 
at our institution were reviewed: 235 did not receive clopidogrel pre-CABG, 151 did. The 
latter all received intraoperative anti-fibrinolytics. The primary endpoint was the combined 
outcome of in hospital death, massive transfusion or blood loss.
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Results: Patient/operative characteristics were comparable between the two groups, 
except pre-operative MI (69% vs 47%), NYHA class 3-4 (94% vs 82%), prior PCI (23% 
vs 13%) and cross-clamp time (96+31 vs 89+27 minutes), were higher in the clopidogrel 
group (p<0.05). There was no difference in the combined endpoint frequency in the 
clopidgrel versus no-clopidogrel groups (38% vs 30%, p=0.1). No differences were noted 
in early mortality, bleeding, use of blood products, renal failure, early MI or other early 
outcomes between the two groups, even after adjustment for time interval between last 
drug dose and operation. After multivariable regression analysis, significant independent 
predictors of outcomes did not include the use of clopidogrel or the duration it was 
stopped pre-CABG. Pre-operative hemoglobin was the only independent predictor of 
our combined endpoint. Older age, pre-operative LV dysfunction and peripheral vascular 
disease were independent predictors of early mortality. Chest reopening was infrequent 
and no independent predictors were yielded by multivariable analysis.
Conclusions: Clopidogrel or the time it was stopped pre-operatively were not significant 
independent risk factors of poor outcomes in patients requiring urgent CABG. We hypothesize 
that practice measures, such as the use of anti-fibrinolytic agents, may ameliorate the adverse 
impact of clopidogrel without increased renal or other adverse consequences.
10:00 a.m.
1025-199 Excision of the Left Atrial Appendage is Not Associated 
with Increased Incidence of Postoperative Bleeding 
after Cardiac Surgery When Compared to Exclusion.
Anne S. Kanderian, Gosta B. Pettersson, A. Marc Gillinov, Allan L. Klein, Cleveland 
Clinic, Cleveland, OH
Background: Left atrial appendage (LAA) elimination is performed in patients undergoing cardiac 
surgery, and consists of either excision (LAA removal) or exclusion (LAA remains attached). 
Excision of the LAA is performed by scissors or a stapling device. Exclusion of the LAA is done by 
suturing or stapling the base of the LAA. LAA excision is more effective than exclusion; however a 
concern exists for increased postoperative bleeding. The aim of this study was to determine if LAA 
excision was associated with increased postoperative bleeding compared to exclusion.
Methods: 2545 patient underwent surgical LAA elimination from 1993-2004. 895 patients 
had excision (464 scissors, 431 stapler) and 1650 had exclusion (1346 suture, 304 stapler). 
Postoperative bleeding after open-heart surgery was defined as mediastinal bleeding which 
required surgical exploration. Categorical variables were compared using Fisher exact test.
Results: Of the 2545 patients, 93 (3.7%) had postoperative bleeding. 28 (3.1%) had LAA excision 
(19 scissors, 9 stapler) and 65 (3.9%) had LAA exclusion (55 suture, 10 stapler), p=0.352. There 
were no significant differences between the varying techniques (figure).
Conclusions: LAA excision is not associated with increased postoperative bleeding after cardiac 
surgery. There appears to be a trend towards reduced postoperative bleeding with staple excision 
of the LAA (2.1%). Therefore, we advocate that when indicated, surgeons should excise the LAA 
during cardiac surgery. 
10:00 a.m.
1025-200 Outcomes of Coronary Artery Bypass Surgery 
Compared to Percutaneous Coronary Intervention 
With Drug-Eluting Stents for Unprotected Left Main 
Coronary Artery Disease
Gautam Kedia, Gilbert Chang, Michael Broukhim, Michael S. Lee, L. Iri 
Kupferwasser, James Mirocha, Gregory P. Fontana, Alfredo Trento, Prediman K. 
Shah, Raj R. Makkar, Cedars-Sinai Medical Center, Los Angeles, CA
Background: Coronary artery bypass graft (CABG) surgery remains the predominant 
means of revascularization for unprotected left main coronary artery (ULMCA) disease. 
Percutaneous coronary intervention (PCI) for ULMCA disease has increased with the 
advent of drug-eluting stents (DES). The objective of this study was to compare CABG 
surgery to PCI with DES for ULMCA disease.
Methods: Beginning April 2003, we followed the first 123 patients who underwent CABG 
surgery and the first 100 patients who underwent PCI with DES for ULMCA disease.
Results: The mean Parsonnet score was 14 ± 10 in the CABG group and 18 ± 11 in the 
PCI group (p=0.002). High surgical risk patients (Parsonnet score ≥15) comprised 46% of 
the CABG group and 64% of the PCI group (p=0.01). Overall freedom from major adverse 
cardiac and cerebrovascular events (MACCE) was greater in the CABG group (p=0.003), 
and there was greater, but not statistically significant, freedom from death in the CABG 
group (p=0.09). The estimated freedom from MACCE at 12 and 24 months was 87 ± 3% 
and 84 ± 3% in the CABG group and 75 ± 5% and 63 ± 8% in the DES group. The estimated 
freedom from death at 12 and 24 months was 89 ± 3% and 87 ± 3% in the CABG group 
and 87 ± 4% and 74 ± 8% in the DES group. In the statistical trend test analysis, both 
MACCE (p<0.0001) and mortality (p=0.0002) were lowest in low surgical risk PCI patients, 
followed by low surgical risk CABG patients, high surgical risk CABG patients, and finally 
high surgical risk PCI patients. Multivariable Cox proportional hazards regression revealed 
lower ejection fraction and higher Parsonnet score to be independent predictors of death, 
and higher Parsonnet score, male sex and PCI to be independent predictors of MACCE.
Conclusions: Patients undergoing ULMCA PCI had a greater baseline surgical risk 
compared to CABG patients, suggesting selective referral of high surgical risk patients to 
the less invasive PCI strategy. Overall, MACCE was higher in PCI patients, and survival, 
though not statistically significant, tended to be greater in CABG patients. Low surgical 
risk patients had excellent outcomes after ULMCA PCI. Ongoing randomized trials should 
clarify the role of PCI of ULMCA disease in the DES era.
ACC.ORAL CONTRIBUTIONS
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Acute Myocardial Infarction: Predictors of 
Long-term Outcomes
Tuesday, March 27, 2007, 11:00 a.m.-12:30 p.m.
Room 275-276-277
11:00 a.m.
843-3 Is There a Gap in Long-Term Clinical Outcome in 
Patients With Complicated Versus Noncomplicated 
Acute Myocardial Infarction Who Survived 
Hospitalization?
Tina L. Pinto Slottow, Daniel H. Steinberg, Probal Roy, Aamir Javaid, Ashesh Buch, 
Rebecca Torguson, Kimberly Smith, Zhenyi Xue, Natalie Gevorkian, Augusto D. 
Pichard, Lowell Satler, William O. Suddath, Kenneth Kent, Ron Waksman, Washington 
Hospital Center, Washington, DC
Background: Patients with complicated ST elevation myocardial infarction (STEMI) continue to 
be a therapeutic challenge. This study aimed to determine whether intensive medical care can 
minimize the gap in late clinical outcome of patients with and without complicated STEMI.
Methods: Records of 438 consecutive patients with STEMI who underwent primary or 
facilitated PCI and intensive medical therapy starting from April 2003 were analyzed. The 
201 patients who presented with cardiogenic shock, developed acute renal failure, or had 
a large infarct size (CPK-MB fraction ≥75 ng/mL) were identified as complicated and their 
outcome was compared to the 237 patients with non-complicated STEMI.
Patient characteristic (%) Complicated Non-Complicated p value
Congestive heart failure 26.9 12.6 <0.001
Chronic renal insufficiency 37.4 8.1 <0.001
Cardiogenic shock 42.3 0 <0.001
Maximum CPK-MB (ng/mL) 124.2 15.6 <0.001
In-hospital Events N=201 N=237
Length of stay (days) 8.2 3.4 <0.001
ICU stay (days) 4.8 1.4 <0.001
In-hospital acute renal failure 21.6 2.4 <0.001
Reinfarction 3.7 0 <0.001
Death 22.4 0.8 <0.001
30 Days N=168 N=234
Death out-of-hospital 1.3 1.3 _
Myocardial infarction 2.4 1.3 0.458
TLR 1.8 0.4 0.313
Subacute thrombosis 1.0 0.4 0.596
1 year N=162 N=234
Death out-of-hospital 12.2 7.0 0.084
Myocardial infarction 3.9 4.5 0.794
TLR 6.5 4.9 0.506
Late thrombosis 0 0 _
Results: Baseline demographic characteristics of the groups were similar. Complicated 
STEMI patients had higher in-hospital mortality, reinfarction, and renal failure rates 
and longer ICU stays (p<0.001). Despite that, following discharge, the complicated 
STEMI group had similar out-of-hospital death, reinfarction, revascularization, and stent 
thrombosis at 30 days and 1 year when compared to non-complicated STEMI. (Table)
Conclusions: In the era of primary and facilitated PCI, patients who survive to hospital 
discharge do well regardless of the severity of their initial presentation with similar rates of 
out-of-hospital death, reinfarction, revascularization and stent thrombosis. 
11:15 a.m.
843-4 Predictors of Long-Term Outcome Among Patients With 
ST Elevation Myocardial Infarction Complicated by Shock
Mandeep Singh, Jennifer White, David Hasdai, Patricia K. Hodgson, Peter B. Berger, 
Eric J. Topol, Robert M. Califf, David R. Holmes, Jr., Mayo Clinic, Rochester, MN, Duke 
Clinical Research Institute, Durham, NC
Background: Patients with cardiogenic shock have high early mortality (in-hospital and 
30-day), but there is little data from which to estimate long-term prognosis among those 
who survive beyond 30 days. We sought to determine factors that predicted long-term 
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outcome among 30-day survivors of cardiogenic shock.
Methods: We analyzed baseline, in-hospital, and survival data from US patients with STEMI 
and cardiogenic shock enrolled in the Global Utilization of Streptokinase and TPA for Occluded 
Coronary Arteries-I trial and compared them with patients without shock in the same trial.
Results: Of the 22,883 US patients with data, shock occurred in 1891 (8.3%); 953 
(50.4%) of them survived 30 days and 527 (27.8%) survived 11 years. Of 20,992 US 
patients without shock, 20,360 (96.9%) survived 30 days and 14,763 (70.3%) survived 
11 years. The Kaplan-Meier mortality rate estimate was 44.8% (95% CI 41.6, 47.9) in 
patients with shock and 30.6% (95% CI 29.9, 31.2) without shock. After the first year, 
the annual mortality was 2-4% regardless of whether patients did or did not have shock. 
Using Cox proportional hazards models we were able to predict long-term outcome in 
30-day survivors from their baseline demographic and in-hospital complication data. 
The strongest predictors were increasing age, diabetes mellitus, hypertension, previous 
myocardial infarction, current smoking, anterior infarct, higher Killip class, and heart 
rate. Cardiogenic shock was a predictor of long-term survival. Revascularization during 
the index hospitalization was associated with reduced risk of death (HR 0.76, 95% CI 
0.72,0.80, P=<0.0001).
Conclusions: The mortality of shock is very high within the first 30 days; after one year, 
annual mortality of 2% and 4% approximates patients without shock.
11:30 a.m.
843-5 Fasting Glucose in Acute Myocardial Infarction: 
Incremental Value for Long-Term Mortality and 
Relationship With Left Ventricular Systolic Function
Doron Aronson, Haim Hammerman, Michael Kapeliovich, Rafael Beyar, Walter 
Markiewicz, Mahmoud Suleiman, Rambam Medical Center, Haifa, Israel
Background: Hyperglycemia is a common metabolic disorder among patients (pts) with 
acute myocardial infarction (AMI) and is associated with adverse prognosis. However, 
whether the association between stress hyperglycemia and adverse outcome is partly 
mediated through the acute reduction in left ventricular systolic performance remains 
controversial.
Methods: We prospectively studied the relationship between fasting glucose (FG) and 
long-term mortality in nondiabetic pts (n=1101) with AMI. FG was determined ≥8 hours 
fast within 24h of admission. The median duration of follow-up was 24 months (range, 6 
to 48). FG was categorized into 4 groups: normal (<110 mg/dl) and tertiles of elevated FG. 
LVEF was classified as normal (≥ 55%), mildly reduced (45-54%), moderately reduced 
(30-44%) and severely reduced (<30%) using echocardiography.
Results: The Figure shows that for each level of LVEF mortality was lowest among pts 
in the lowest FG category and highest in pts in the highest FG category. In a multivariate 
Cox mode, adjusting for clinical variables and LVEF, the adjusted hazard ratio for mortality 
in tertiles of elevated FG compared to normal FG were as follows: 1sr tertile 1.8 [95% CI 
1.0 to 3.3; P = 0.05]; 2nd tertile 2.9 [95% CI 1.8 to 4.7; P < 0.0001]; and 3rd tertile 4.2 
[95% CI 2.7 to 6.5; P < 0.0001].
Conclusions: FG is a simple robust tool for predicting long-term mortality in nondiabetic 
pts with AMI. FG provides incremental prognostic information when added to clinical 
variables and LVEF. 
11:45 a.m.
843-6 High-Risk Patients Benefit Most From Angiotensin- 
Converting Enzyme Inhibition After an Acute 
Myocardial Infarction
Christos Milonas, Tomas Jernberg, Johan Lindback, Stefan Agewall, Lars Wallentin, 
Ulf Stenestrand, Department of Cardiology, Karolinska University Hospital, Karolinska 
Institutet, Stockholm, Sweden, Sweden
Background: There is a controversy whether all patients with acute myocardial infarction 
(AMI) benefit from angiotensin converting enzyme inhibition (ACEI). Large clinical trials 
have come to somewhat conflicting conclusions and reliable observational studies in 
unselected patient materials are scarce. We examined the association between ACEI 
treatment and one-year mortality in a large, unselected population of AMI patients.
Methods: The study was based on a prospective cohort of 99 128 patients with AMI 
registered in the Register of Information and Knowledge about Swedish Heart Intensive 
Care Admissions (RIKS-HIA) at 74 hospitals from 1995 to 2003. Information about 
mortality was obtained from the Swedish National Cause of Death register. The association 
between ACEI treatment at discharge and one-year mortality was evaluated using Cox 
regression analyses adjusting for 41 different covariates possible to be associated with 
ACEI treatment and mortality.
Results: A total of 42 639 (43%) patients received ACEI at hospital discharge. After 
adjusting for 41 covariates, ACEI treatment was independently associated with a reduced 
one-year mortality (RR[95%CI]: 0,87[0.83-0.91]). This association was most evident in 
patients with previous myocardial infarction (0,82[0.76-0.89]), heart failure (0,81[0.76-
0.85]), depressed left ventricular ejection fraction (<40%) (0,69[0.56-0.84]), elevated 
levels of creatinine (0,72[0.60-0.87]) and higher age (>80) (0,81[0.75-0.87]).
Conclusions: In patients with AMI, treatment with ACEI is associated with a reduced 
one-year mortality. The reduction of mortality is largest in patients with characteristics 
indicating a higher risk.
Noon
843-7 Outcomes After Acute Myocardial Infarction in 
Systemic Lupus Erythematosus as Compared to 
Diabetes Mellitus
AMBER M. SHAH, Mansi A. Shah, Eswar Krishnan, The Reading Hospital and Medical 
Center, West Reading, PA
Background: Both diabetes mellitus (DM) and systemic lupus erythematosus (SLE) are 
associated with premature atherosclerosis. However, outcomes after acute myocardial 
infarction (AMI) in SLE patients have so far not been compared in detail with DM patients 
and controls. We performed this study to compare in-hospital mortality and length of stay 
(LOS) post-AMI in SLE patients, DM patients and controls.
Methods: We utilized the nationwide inpatient sample (NIS), which is 20% sample of all 
hospitalizations in the United States from 1993 to 2002 to identify patients hospitalized 
for AMI (n= 709,690), including 2065 SLE patients and 186,028 DM patients. Prolonged 
LOS was defined as LOS ≥ 6 days. Patients with both SLE and DM were excluded due 
to small numbers. In-hospital mortality rates and prolonged LOS were compared in SLE, 
DM and control patient sub-groups. Hazard ratio for death was calculated using the Cox 
Proportional hazards model. Odds ratio for prolonged LOS was calculated using logistic 
regression. Adjustment for age, gender, race, congestive heart failure and socioeconomic 
status was performed.
Results: In-hospital mortality rate was 6.1% in SLE patients, 4.3% in DM patients, and 
3.05% in controls (p < 0.001). In non-DM patients, multivariate adjusted hazard ratio for 
death with SLE was 1.75 (95% Confidence interval (CI): 1.44- 2.14). In patients without 
SLE, multivariate adjusted hazard ratio for death with DM was 0.95 (95% CI: 0.92 - 0.97).
Mean LOS was 5.3 ± 2.7 days in SLE patients, 5.4 ± 2.7 days in DM patients, and 4.9 ± 
2.5 days in controls (p < 0.001). In non-DM patients, multivariate adjusted odds ratio for 
prolonged LOS with SLE was 1.38 (95% CI: 1.24- 1.53). In non-SLE patients, multivariate 
adjusted odds ratio for prolonged LOS with DM was 1.18 (95% CI: 1.17 - 1.20).
Conclusions: SLE, like DM, increases the risk of poor in-hospital outcomes after AMI. 
Aggressive prevention, evaluation and treatment of coronary heart disease and AMI in 
SLE patients is strongly recommended.
12:15 p.m.
843-8 In-Hospital Mortality Predictors in Patients With ST-
Elevation Acute Myocardial Infarction: Substudy of 
RENASICA Mexican Registry
Carlos Martinez, Carlos Jerjes - Sanchez, Jesus Martinez, Marco Antonio Ramos, 
Guillermo Llamas, Alfonso Treviño, Octavio Gonzalez, Jorge Cortez, on the belhaf 
RENASICA II investigators, Sociedad Mexicana de Cardiologia, Mexico, DF, Mexico
Background: ST elevation (STE) myocardial infarction (MI) mortality markers has been 
studied extensively in developed countries. The hospital course of patients with STE MI 
from developing countries is less well established.
Methods: RENASICA registry was analyzed to know in - hospital outcome in STE MI . 
It was a prospective registry of the Mexican Cardiology Society designed to reflect an 
unbiased and representative population with final diagnosis of ACS. Patients were enrolled 
in 66 primary and tertiary Mexican hospitals and for quality control criteria of Alpert were 
used. The hospitals varied in terms of access to on-site cardiac catheterization, number of 
acute care beds and the type of practice setting with an aim of establishing a representative 
rather than a selective study population.
Results: 8, 098 patients with final diagnosis of ACS were included; 4,555 of them with STE 
MI were analysed in this substudy. Patients were young (62 + 12 ), male (77%), anterior 
MI (56%), Killip class I (74%), phamacologic (37%) and mechanical (15%) reperfusion, 
mortality (10%). A logistic regression showed predictors of mortality: Age > 65 yrs old 
(adjusted OR 2.4, 95% CI 1.9 - 3.1, p < 0.001), female (OR 1.6, CI 1.2 - 2.0, p 0.0002), Killp 
& Kimball 2 (OR 2.5, CI 1.5 - 4.0, p 0.0002), KK 3 (OR 4.1, CI 2.4 - 7.1, p < 0.0001), KK 4 
(OR 10.6, CI 6.0 - 18.4, p < 0.0001), ST depression > 3 leads (OR 3.4, CI 1.5 - 7.7, p 0.003), 
LBBB (OR 1.7, CI 1.1 - 2.5, p 0.007), RBBB (OR 1.7, CI 1.1 - 2.4, p 0.003), high - degree 
AV block (OR 2.9, CI 2.2 - 92.1, p 0.004), unsuccessful PTCA (OR 14.5, CI 2.2 - 92.1, p 
0.004). In-hospital outcome was improved by: LMWH (OR 0.47, CI 0.28 - 0.80, p = 0.005), 
ST regression (OR 0.26, CI 0.10 - 0.69, p = 0.007) BB (OR 0.49, CI 0.30 - 0.80, p = 0.005), 
PTCA plus stent (OR 0.10, CI 0.02 - 0.46, p = 0.003), primary PTCA (OR 0.03, CI 0.008 
- 0.15, p = 0.0001), and non-urgent CBAG (OR 0.07, CI 0.006 - 0.90, p = 0.004)
Conclusions: The largest ACS registry in Latin-America provides important and reliable 
information on the outcome and quality of care, identifying areas to improve. RENASICA II 
broadens our knowledge about how reperfusion and antithrombotic approaches modify the 
outcome and what needs to be improved in the real practice in Mexico.
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844 
New Concepts in Acute Myocardial 
Infarction
Tuesday, March 27, 2007, 11:00 a.m.-12:30 p.m.
Room 278-281
11:00 a.m.
844-3 Meta-Analysis of 1,193 Patients Shows That Late 
Percutaneous Coronary Intervention for the Occluded 
Infarct-Related Artery Improves Survival
Darryn Appleton, Antonio Abbate, Venkat Ramachandran, Pierfrancesco 
Agostoni, Michael Lipinski, George W. Vetrovec, Giuseppe Biondi-Zoccai, Virginia 
Commonwealth University, Richmond, VA
Background: There is ongoing uncertainty about the risk-benefit ratio of late percutaneous 
coronary intervention (PCI) in stable patients with persistent infarct-related artery occlusion. 
We performed a meta-analysis of randomized controlled trialscomparing PCI with best 
medical therapy (medical Rx) in such patients aimed at assessing impact on mortality.
Methods: PubMed, CENTRAL, and mRCT were searched for eligible studies according to 
the following inclusion criteria: comparison of late PCI vs conservative medical management 
in hemodynamically stable patients presenting, late (>12 hours following onset of symptoms) 
with AMI. Exclusion criteria included: non-randomized treatment allocation, cardiogenic 
shock, recurrent symptoms, failed fibrinolysis or other indications to early catheterization. 
Random-effect odds ratios (OR) were pooled for the dichotomous clinical outcomes of all-
cause mortality. Power and heterogeneity analyses were also performed.
Results: We combined data from 8 studies enrolling 1193 patients, with median time from 
AMI to randomization of 8 days (range 1-42), and median follow-up time of 12 months (range 
3-60). Six hundred and one patients were randomized to PCI and 592 to medical treatment. 
There were 22 (3.7%) and 43 (7.3%) deaths in the 2 groups, respectively. Overall, PCI was 
associated with significantly greater survival (Peto OR 0.49 [0.30-0.81], P for effect=0.005, P 
for heterogeneity=0.53).
Conclusions: While waiting for larger randomized studies, pooled data from the largest 
cohort to date of patients randomized to late PCI versus best conservative treatment for post-
infarction IRA occlusion suggest that PCI is associated with improved survival.
11:15 a.m.
844-4 Myocardial Perfusion in ST-Elevation Myocardial Infarction 
Patients Following Primary Percutaneous Coronary 
Intervention: Insights From the Electrocardiography/
Angiography Substudy of APEX AMI
Paul W. Armstrong, Yuling Fu, Sorin J. Brener, Thomas G. Todaro, David J. Moliterno, David 
R. Holmes, Jr., Peter X. Adams, Cynthia M. Westerhout, Galen S. Wagner, Christopher B. 
Granger, APEX AMI Investigators, University of Alberta, Edmonton, AB, Canada
Background: The optimal approach to assessing myocardial perfusion after PCI 
for STEMI is unclear.
Methods: APEX AMI evaluated pexelizumab efficacy in 5,745 pts with ST-elevation 
myocardial infarction (STEMI) undergoing primary PCI < 6 hours of symptoms. A 
preplanned substudy of APEX examined the relative prognostic utility of post-PCI TIMI 
flow grade and ST-resolution acquired in separate core laboratories in 1016 patients. ST-
resolution was derived from post-PCI ECGs (Schroeder) attained 33min [median, IQR 
(20-57min)] after PCI.
Results: The 30-day mortality (primary outcome) was 2.1% and the key secondary 
outcomes of CHF & shock were 3.7% and 2.8%, respectively. The figure shows composite 
30-day death/CHF/shock according to ST-resolution versus TIMI flow grade immediately 
following PCI. Whereas TIMI flow separated the 30-day composite (overall rate: 6.8%) 
in pts with no (<30%; p=0.029) and partial (30 to >70%; p=0.001) ST-resolution, no 
additional partitioning of the composite occurred with complete resolution.
Conclusion: These data, acquired from the largest trial of systematically-studied primary 
PCI STEMI population to date, demonstrate that irrespective of TIMI flow post PCI, 
complete ST-resolution affords an excellent 30-day outcome. By contrast, with progressive 
declines in ST-resolution, TIMI flow grade provides additional prognostic insight, confirming 
the critical importance of achieving both epicardial and myocardial reperfusion.
11:30 a.m.
844-5 Enoxaparin Versus Unfractionated Heparin With 
Fibrinolysis for ST-Elevation Myocardial Infarction In 
Patients ≥75 Years Compared With <75 Years
Harvey D. White, Amy Shui, Ashok J. Jacob, Nina Gotcheva, Leonid Polonetsky, Elliott 
M. Antman, Eugene B. Braunwald, Green Lane Cardiovascular Service, Auckland City 
Hospital, Auckland, New Zealand, TIMI Study Group, Cardiovascular Division, Brigham 
and Women’s Hospital, Boston, MA
Background: Elderly patients with ST elevation myocardial infarction (STEMI) account 
for much of the mortality and adverse effects of fibrinolytic and antithrombotic therapies.
Methods: In the double blind EXTRACT-TIMI 25 trial, subcutaneous enoxaparin (ENOX) 
for the duration of hospitalization was compared to unfractionated heparin (UFH) in 
conjunction with fibrinolysis. We tested a novel dosing regimen of ENOX in patients aged 
≥ 75 years (n = 2532). Compared to treatment of patients < 75 years (n = 17947) no IV 
bolus was given and the subcutaneous dose was reduced from 1.0mg/kg to 0.75mg/kg, 
12 hourly. UFH was given as a weight adjusted regimen to an aPTT of 1.5-2.0 x control. 
The primary end point was death or non fatal reMI at 30 days.
Results: Death or reMI occurred in 9.9% UFH vs 7.9% ENOX in patients < 75 years (ARD= 
absolute risk difference 2.0%) and 26.3% UFH vs 24.8% ENOX in patients ≥ 75 years (ARD 
1.5%). The number of patients needed to prevent one event was similar in both age groups; 
50 in younger and 67 in older patients. Major bleeding was higher with ENOX in younger 
patients, 1.1% UFH vs 1.9% ENOX, p<0.0001 and similar in the elderly, 2.9% UFH vs 3.3% 
ENOX, p=0.53. Intracranial hemorrhage rates were similar in younger, 0.5% UFH vs 0.7% 
ENOX, p=0.06 and older patients, 1.7% UFH vs 1.6% ENOX, p=0.85.
Conclusions: A strategy of adjunctive therapy with ENOX in patients receiving fibrinolysis 
for STEMI provides a consistent treatment benefit in younger and older patients and is 
preferred to UFH across the age spectrum. 
11:45 a.m.
844-6 A Phase III International, Multi-Center, Prospective, 
Randomized, Double-Blind, Placebo-Controlled Study 
to Assess the Safety and Efficacy of Nitric Oxide 
Synthase Inhibition With Tilarginine Acetate Injection in 
Patients With Cardiogenic Shock Complicating Acute 
Myocardial Infarction, or TRIUMPH Study
Judith S. Hochman, TRIUMPH Steering Committee and Investigators, New York 
University School of Medicine, New York, NY
Background: The TRIUMPH Study tested whether nitric oxide synthase inhibition with NG-
monomethyl-L-arginine (tilarginine,TAI) would reduce 30-day mortality from 50% to 37.5% 
in patients with refractory cardiogenic shock (CS) despite an open infarct related artery.
Methods: Patients with CS due to LV failure (EF <40%) and Systolic BP (SBP) <100mmHg 
despite vasopressor support for at least 1 hour post open artery were randomized to TAI 
1mg/kg bolus and 1mg/kg/hr for 5 hours or matching placebo. SBP, 30-day and 6-month 
mortality rates were compared, stratified by age <75 vs ≥ 75 yrs. A total of 398 (planned 
658) patients were randomized and 383 received study drug after persistent shock 
was reconfirmed, prior to drug administration. The DSMB recommended termination of 
enrollment due to futility based on prespecified stopping rules after review of 317 subjects.
Results: Average age was 64.3 +/- 13.3 yrs, 28% were women and mean EF was 26.0 +/- 
7.9%. There was a significantly greater rise in SBP at 2 hrs in the TAI group compared to 
placebo, among those aged < 75 yrs (table). Interim DSMB review found that 30-day and 6-
month mortality rates overall and stratified by age were similar in the 2 groups. Rates of adverse 
events, CS resolution and causes of death were similar. Final data will be presented. 
Conclusion: Based on interim data, TAI resulted in a significant rise in BP in patients <75 
yrs. Despite promising earlier study results and an increase in BP, TAI had no effect on 
mortality in high-risk patients with persistent CS. 
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Baseline + change
Systolic Blood Pressure 
(mmHg)
Mortality 
(all p=NS)
30 days 6 month
Placebo TAI p Value Placebo TAI Placebo TAI
All Pts
(n=317)
85
+7
87
+12 <0.001
44.5 %
(n=69)
46.3 %
(n=75)
All Pts
(n=140)
54.4 %
(n=37)
54.2 %
(n=39)
Pts <75
(n=236)
86
+5
89
+12 <0.001
38.5 %
(n=45)
37.0 %
(n=44)
Pts <75
(n=103)
47.9 %
(n=23)
43.6 %
(n=24)
Pts >=75
(n=81)
83
+13
83
+10 0.57
63.2 %
(n=24)
72.1 %
(n=31)
Pts >=75
(n=37)
70.0 %
(n=14)
88.2 %
(n=15)
Noon
844-7 Acute Myocardial Infarction and Pregnancy: Clinical 
Profile, Treatment, and Outcome
Uri Elkayam, Arie Roth, University of Southern California, Los Angeles, CA
Background: Clinical profile, treatment and outcome of patients with AMI during 
pregnancy and the peripartum in the current era are poorly described.
Methods: Review of 103 patients with document pregnancy related AMI diagnosed 
between 1995 and 2006 and 125 cases diagnosed prior to 1995.
Results:
Conclusions: Pregnancy related AMI occurs mostly in multiparous women at any age. The 
location of AMI is anterior in >70% and coronary dissection is the cause in ~30% of the 
cases. Patients diagnosed in the last decade compared to those diagnosed prior to 1995, had 
higher incidence of diagnostic cardiac catherization and treatment with coronary reperfusion 
by either thrombolytic therapy or percutaneous intervention and significantly better outcome 
with lower rate of cardiogenic shock as well as maternal and fetal mortality.
12:15 p.m.
844-8 Association of Methamphetamine Abuse With ST-
Elevation Myocardial Infarction
Jonathan Schwartz, Katie M. Menssen, Charlene R. Boisjolie, Daniel T. O’Laughlin, 
Timothy D. Henry, Minneapolis Heart Institute Foundation at Abbott Northwestern 
Hospital, Minneapolis, MN
Background: An epidemic of methamphetamine use has plagued the United States in 
recent years, particularly in the Midwest and rural communities. The physiologic effects 
of methamphetamine are strikingly similar to cocaine, and cocaine has been associated 
with a wide spectrum of cardiovascular disease. Virtually no data exist regarding 
methamphetamine use and cardiovascular disease other than in isolated case reports.
Methods: We developed a standardized protocol for PCI in STEMI including transfer 
from 30 community and rural hospitals in Minnesota with a comprehensive database and 
long term follow-up. After recognizing an association of methamphetamine with STEMI 
patients, we reviewed the medical history for drug abuse of 1042 consecutive patients 
admitted with STEMI from March 2003 to April 2006.
Results: We identified 23 of 1042 STEMI patients (2.2%) with confirmed or suspected 
methamphetamine abuse by medical records. Patients with methamphetamine abuse 
were younger (mean age, 44.0±10.6 years vs. 62.3±14.6 years, p<0.001) than the control 
STEMI patients, 100% had a history of smoking, and 100% of identified/suspected users 
were hypertensive (including 1 pt with an aortic dissection). 70% of identified patients 
had confirmed STEMI, while 30% were false positive. History was frequently positive 
for multiple drug use and the confirmation of drug use often came following the initial 
presentation, at a subsequent hospitalization, or through a family member.
Conclusions: Methamphetamine, like cocaine, appears associated with STEMI in 
young patients. The incidence of methamphetamine-related STEMI would likely be 
higher if a systematic history of drug use or toxicology had been utilized. In light of the 
methamphetamine epidemic in the US, attention should be focused on determining the 
frequency and pathophysiology of methamphetamine associated cardiovascular disease.
ACC.ORAL CONTRIBUTIONS
847 
Challenges in Acute Myocardial Infarction
Tuesday, March 27, 2007, 2:00 p.m.-3:30 p.m.
Room 228-229-230
2:00 p.m.
847-3 Differential Predictors For Subacute, Late And Very 
Late Drug-eluting Stent Thrombosis. Results From The 
Multicenter “ESTROFA” Study
Jose M. de la Torre Hernandez, Felipe Hernandez, Marcelo San Martin, Iñigo Lozano, Juan 
Sanchis, Armando Perez de Prado, Jose R Rumoroso, Juan M Ruiz Nodar, Javier Rodriguez 
Collado, Josefa Mauri, Jose A Diarte, Jose M Hernandez, Jose R Lopez Minguez, Eduardo 
Pinar, Jose M Vazquez, Fernando Alfonso, ESTROFA group, Santander, Spain
Background: Late stent thrombosis (LST), specially very LST (> 6 months after 
procedure), is a particular serious complication of drug eluting stents (DES). The 
incidence of these events and their predictors are not completely elucidated. 
Moreover, these predictors could be different to those described for acute-
subacute thrombosis (SAT).
Methods: We have performed a registry involving 16 Spanish centers in order to 
collect detailed data regarding angiographically documented DES thrombosis.
Results: From a total cohort of 11000 patients treated with DES since june 2002, 
136 cases presented angiographic evidence of stent thrombosis (1.23%). The ST 
were: 76 SAT and 60 LST (among these 48 were very LST). These LST events 
occurred at 13±10 months (1-46) after procedure. LST rate for Taxus was 0,53% 
and 0,57% for Cypher. Antiplatelet treatment discontinuation was a common 
observation in all periods, 30% in SAT and 38% in LST. Other independent 
predictors for SAT were the following: renal failure, stent implantation in STEMI or 
in ACS, stent implanted in left anterior descending artery, stent diameter ≤2.5mm, 
longer stent, stent under-expansion by angiography, female sex and Cypher 
stent. For LST only stent implantation in STEMI (OR 7; 95%CI 3.6-13; p<0.0001) 
and stent implanted in left anterior descending artery (OR 4.2; 95%CI 2.2-8.1; 
p<0.0001) were identified as independent predictors along with antiplatelet 
therapy discontinuation. These same predictors were also found for very LST: 
implantation in STEMI (OR 6.2; 95%CI 3,2 -12; p<0,0001) and stent in left anterior 
descending artery (OR 3.6; 95%CI 1.7-7.3; p<0,001).
Conclusions: LST and very LST after DES implantation although not frequent are 
no a rarity and may occur over an extended period of time after procedure. Many 
of the variables involved in SAT are not predictive for LST. DES implantation in a 
setting of STEMI, stent in left anterior descending artery and antiplatelet therapy 
cessation resulted strong predictors for these late events.
2:15 p.m.
847-4 Does Epo Reduce Enzymatic Infarct Size In Non-STE 
ACS ?; Results From A Pilot Trial
A. Liem, A. Woestijne van de, J. W. Jukema, A. Laarse van der, A. H. Zwinderman, D. J. 
Veldhuisen van, Oosterscheldeziekenhuizen, Goes, The Netherlands, Leiden University 
Medical Center, Leiden, The Netherlands
Background: The purpose of this study is to determine the effect of erythropoietin (EPO) 
on myocardial damage in patients with non-STE-ACS and to assess the safety of this 
treatment. Earlier experimental studies have suggested that acute EPO administration 
may be beneficial by inhibiting apoptosis and by increasing angiogenesis.
Methods: Patients with ACS and cTnI concentration ≥ 0.20 μg/L were randomly assigned to 
a single i.v. dose of 40,000IU Epoietin-alpha or a matching placebo. Myocardial infarct size 
is estimated on cumulative release and peak values of CK, CK-MB
mass
 and cTnI. Patients 
were followed for at least three months for the occurrence of death, stroke or ACS.
Results: A total of 51 patients were included, 26 received EPO and 25 placebo. Patients 
were well-matched at baseline; Q72 CK-MB value with EPO vs placebo was 480 ± 123 
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vs 497 ± 119 ug/l (p =0.99). Cumulative 72h CK enzyme release(Q72) values were also 
comparable, as well as maximal values and time to maximal values of cTnI, CK and CK-
MB. In addition, during hospital stay there were no differences in complications such as 
heart failure, interventions or use of concomitant medication. We found a small increase 
in systolic blood pressure 2-4 hours after epo iv (p =0,019) compared to placebo which 
was not accompanied by any side-effects. During 1 year follow-up there was no effect on 
major adverse clinical endpoints [MACE] ACS, stroke, death).
Conclusions: The findings of this pilot study suggest that EPO administration using 
Epoietin-alpha in patients with non-STE ACE is safe and feasible. Larger studies will be 
needed to examine its potential effect on cardiac function and clinical endpoints
2:30 p.m.
847-5 The Impact of IIb/IIIa GP Receptor Inhibitors and 
Clopidogrel Treatment on 30-day and One-year All-
cause Mortality of Patients with STEMI Treated by 
Primary PCI. On behalf of the STEMI 2003 Registry 
Collaborators.
Adam Witkowski, Paweł Maciejewski, Wojciech Wasek, Maciej Niewada, Bogusław 
Kaminski, STEMI 2003 Registry Collaborators, Institute of Cardiology, Warsaw, Poland, 
Postgraduate Medical School, Warsaw, Poland
Background: The treatment with IIb/IIIa GP receptor inhibitors (GPIIb/IIIa) as adjunctive 
therapy to primary angioplasty (PPCI) in patients (pt) with STEMI lowers the incidence 
of major adverse cardiac events in short-term follow-up. However, its value in all-cause 
mortality reduction, particularly in the long-term follow-up, remains unproved. The role of 
Clopidogrel (Cl) is even less well established in PPCI.
Methods: The study group consisted of 7193 consecutive pts with STEMI treated by 
PPCI in 38 centres in 2003 in Poland. The demographic, clinical and angiographic 
characteristics as well as periprocedural data had been collected prospectively in the 
national data base. The primary end-points of the study was 30-day and one-year all-
cause mortality. To identify independent variables associated with the study end points, 
logistic regression analysis was performed. The data of 48 variables were analysed.
Results: 4291 pts received GPIIb/IIIa in Cath-Lab before/during PPCI and 4291 did not. 
4256 pts were treated with 300 mg loading dose of Cl administered at the time of PPCI. The 
30-day and one-year all-cause mortality of the entire cohort was 7% and 11%, respectively. 
30-day and one-year all-cause mortality was independently, significantly reduced with 
antiplatelet therapy of GPIIb/IIIa and Cl facilitating PPCI (OR 0.69, 95% CI 0.55-0.86, 
p<0.01 and OR 0.76, 95% CI 0.63-0.90, p<0.01, respectively for GPIIb/IIIa; and OR 0.56, 
95% CI 0.42-0.77, p<0.001 and OR 0.68, 95% CI 0.52-0.87, p<0.001, respectively for Cl). 
However, we did not observed further all-cause mortality reduction among pt who received 
combined treatment with GPIIb/IIIa and Cl in comparison to pt treated with GPIIb/IIIa or Cl 
only (log rank p=NS for GPIIb/IIIa+Cl vs GPIIb/IIIa and GPIIb/IIIa+Cl vs Cl, respectively).
Conclusions: In this non-randomized, large-cohort, real-life registry we observed the 
strong relation between the use of GPIIb/IIIa and Cl and the reduction of all-cause 
mortality in the setting of PPCI in the long-term follow-up. The use of GPIIb/IIIa on the top 
of Cl did not further reduce mortality.
2:45 p.m.
847-6 Continuation of Warfarin at Hospital Discharge in 
Patients With Acute Coronary Syndromes on Chronic 
Warfarin Anticoagulation
Tracy Y. Wang, Lee A. Robinson, Matthew T. Roe, Fang-Shu Ou, Eric D. Peterson, E. 
Magnus Ohman, W. Brian Gibler, Sidney C. Smith, Jr., Richard C. Becker, Duke Clinical 
Research Institute, Durham, NC
Background: Current ACC/AHA guidelines provide several recommendations for 
warfarin use. However, with increased frequency of percutaneous coronary interventions 
(PCI) with stenting and consequent mandate for concomitant aspirin and clopidogrel use, 
underutilization of warfarin may emerge in routine clinical practice.
Methods: We evaluated patients (pts) with ACS in the CRUSADE initiative (2003-2006) 
who were receiving warfarin at the time of hospital admission. Pt characteristics were 
analyzed to determine factors associated with warfarin withholding at discharge.
Results: Among 5673 pts previously on home warfarin, 1357 (23.9%) did not receive 
warfarin at discharge. Factors associated with a decision not to administer warfarin at 
discharge included discharge clopidogrel use, in-hospital RBC transfusion, non-white race, 
and prior stroke (Table). Notably, age, sex, and in-hospital PCI were not determinants of 
discharge warfarin use. In a subset of 1247 pts who underwent PCI with stenting, 66.4% 
continued warfarin at discharge, 60.1% were prescribed triple therapy (aspirin, clopidogrel 
and warfarin) and 31.4% were prescribed aspirin and clopidogrel without warfarin.
Conclusions: Use of warfarin therapy at discharge is influenced primarily by concomitant 
medication use and to a lesser extent by clinical bleeding risk and demographic factors. 
Whether triple therapy is safe or withholding warfarin represents an error of omission in 
some pts with ACS requires further investigation. 
Factors associated with the decision not to continue warfarin at discharge
Variable Adjusted Odds Ratio 95% CI Chi-square P value
Discharge clopidogrel 3.11 2.44-3.95 85.87 <0.001
RBC transfusion 1.72 1.18-2.52 7.88 0.005
Non-white 1.47 1.15-1.89 9.33 0.002
Prior stroke 1.22 1.01-1.49 4.15 0.042
PCI 1.04 0.83-1.30 0.10 0.758
Age (per 10 yr increase) 1.02 0.94-1.11 0.24 0.623
Male 1.02 0.86-1.21 0.04 0.850
RBC = red blood cell; PCI = percutaneous coronary intervention.
Other variables in the model include BMI, hypertension, diabetes, dyslipidemia, 
current/recent smoking, prior MI, PCI, CABG or CHF, renal disease, family history of 
CAD, systolic BP and HR on admission, signs of CHF, positive cardiac markers, and 
in-hospital cath or CABG.
3:00 p.m.
847-7 Hospital Discharge Status Following Percutaneous 
Coronary Intervention for ST-Elevation Myocardial 
Infarction in Octogenarians
Ellen Christiansen, Katie M. Menssen, David M. Larson, Elizabeth Z. Grey, Norma L. 
Thiessen, Robert G. Hauser, Timothy D. Henry, Minneapolis Heart Institute Foundation 
at Abbott Northwestern Hospital, Minneapolis, MN
Background: Recent registry data from the US and Europe indicate that up to one 
third of eligible STEMI patients do not receive reperfusion therapy. Advanced age is the 
most common reason for “eligible but untreated” patients. This may be due to a lack of 
PCI availability and risk of bleeding from fibrinolysis in elderly patients. While PCI is the 
preferred method of reperfusion in STEMI, there is limited data on outcomes in the elderly 
and basically no data regarding their functional recovery following PCI for STEMI.
Methods: We developed a standardized protocol to increase the access to PCI in STEMI 
patients including transfer from 30 community and rural hospitals throughout Minnesota. 
We determined the in-hospital mortality, length of stay, and discharge status of 160 patients 
≥80 (14.3%) in 1,121 consecutive STEMI patients (STE or LLBB <24 hours after symptoms) 
with no exclusions including cardiogenic shock and out of hospital cardiac arrest.
Results: In-hospital mortality was 18/160 (11.3%) compared to 1.9% in patients <70 and 
5.9% in patients 70-79 (p<0.001). The strongest predictor of mortality was cardiogenic 
shock [11/34 (32.4%) versus 7/126 (5.6%), p<0.0001]. Ten patients resided in a skilled 
nursing facility (NH) at the time of STEMI presentation. Of the 131 patients who were in 
independent or assisted living prior to hospital admission and survived, 123 (93.8%) were 
discharged to a similar living situation. Only 16 (12.2%) required a temporary NH placement 
for rehabilitation. The median length of stay was 4 days for all patients ≥80 years
Conclusions: Octogenarians with STEMI who are treated with PCI utilizing a standardized 
protocol including transfer from non-PCI hospitals have relatively low mortality, short 
length of stay and 94% return to their prior living situation. This approach to increase 
timely access to PCI in elderly STEMI patients should also decrease the incidence of 
“eligible but untreated”.
3:15 p.m.
847-8 Differences in Early Mortality, Treatment, and 
Procedures by Age and Race for Women with Acute 
Myocardial Infarction, 2000 through 2006
Judith H. Lichtman, Lori S. Parsons, Laura Grosso, Norrina B. Allen, Charles V. Pollack, 
Jr., Harlan M. Krumholz, Yale School of Medicine, New Haven, CT
Background: Little is known about how patterns of initial treatment, utilization 
of procedures, and early mortality compare for women with AMI by race and age 
subgroups.
Methods: The study included women with AMI from the National Registry of Myocardial 
Infarction (NRMI) July 2000 to March 2006. Outcomes included in-hospital mortality, 
aspirin (within 24 hrs), reperfusion and beta blockers (ideal patients within 24 hrs), 
coronary angiography (ideal pts), and CABG. Stepwise logistic regression compared 
outcomes by race (Black/White) within age groups (<55, 55-64, 65-74, 75-84, 85+), 
adjusted for demographic, clinical, treatment and hospital factors.
Results: Among 187,624 women with AMI (168,037 White; 19,587 Black), CVD risk 
factors were more common for Black women, particularly in the younger age groups. 
In risk-adjusted analyses, Black women were more likely to die in the hospital than 
White women (OR 1.10, 95% CI: 1.04, 1.16), but this increase was marked for Black 
women <55 years of age (OR 1.45, 1.19-1.78). Black women were less likely to receive 
reperfusion therapy and coronary angiography (OR 0.84, 0.72-0.99 and OR 0.81, 0.72-
0.91 respectively), despite being ideal candidates for these procedures. This trend was 
seen across all age categories but was significant for Black women aged 65-74.
Conclusion: Young Black women are at particularly high risk for in-hospital mortality as 
compared to White women. Across all age groups Black women had a lower likelihood of 
receiving invasive treatment. 
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851 
Treatment Complications and Outcomes 
in Acute Coronary Syndrome Care
Tuesday, March 27, 2007, 2:00 p.m.-3:30 p.m.
Room 275-276-277
2:00 p.m.
851-3 Beneficial Effects Of Optimized Antithrombotic Therapy 
With Aspirin, Clopidogrel And Enoxaparin Versus 
Standard Therapy In Non-ST-elevation Acute Coronary 
Syndromes In Clinical Practice
Tobias Heer, Uwe Zeymer, Claus Juenger, Anselm K. Gitt, Harm Wienbergen, Martin 
Gottwik, Ralf Zahn, Jochen Senges, Herzzentrum Ludwigshafen, Ludwigshafen, 
Germany, Klinikum Nuernberg, Nuremberg, Germany
Background: Until recently the combination of aspirin and unfractionated heparin (UFH) 
constituted the standard antithrombotic therapy in patients with non-ST-elevation acute 
coronary syndromes (NSTE ACS). Randomized clinical trials showed a further reduction 
in ischemic events when clopidogrel was added, or when enoxaparin was given instead 
of UFH. Aim of this analysis of ACOS, an acute coronary syndromes registry, was to 
to evaluate the efficacy of the new antithrombotic and antiplatelet regimen with aspirin, 
clopidogrel and enoxaparin in NSTE ACS in clinical practice.
Methods: We analyzed data of 2956 consecutive patients with NSTE ACS, which were 
prospectively enrolled in ACOS (acute coronary syndromes registry) between 6/00 until 
the end of 11/02, and were either treated with the combination of aspirin, clopidogrel and 
enoxaparin or with aspirin and UFH.
Results: The univariate analysis for clinical characteristics and hospital outcome is 
shown in the table. After adjustment for age, gender, diabetes, prior CABG or PCI, renal 
insufficiency, cardiogenic shock and acute PCI <= 48 hours, hospital mortality was lower 
with optimized antithrombotic therapy compared to standard therapy, odds ratio 0,46, 
95% confidence interval, 0.23-0.99.
Conclusions: In clinical practice optimized antithrombotic therapy with aspirin, 
clopidogrel and enoxaparin in NSTE ACS patients is associated with a lower hospital 
mortality compared to standard therapy with aspirin and UFH.
Patients with NSTE ACS
Variable Aspirin, clopidogrel and 
enoxaparin Aspirin and UFH p Value
n 479 2558
Age, years, mean 67.5 69.1
Women (%) 33.6 36.6 0.22
Diabetes mellitus (%) 30.9 30.4 0.82
Cardiogenic shock (%) 1.0 5.2 <0.001
Reperfusion (%) 42.4 15.5 <0.001
Hospital mortality (%) 1.9 5.5 <0.001
Reinfarction, non-fatal 
(%) 0.9 5.3 <0.001
Stroke, non-fatal 0.4 0.8 0.4
2:15 p.m.
851-4 Bleeding Complications Are a Major Driver of Resource 
Use Among Patients With Acute Coronary Syndromes
Sunil V. Rao, Padma Kaul, Lawrence Liao, Daniel B. Mark, Eric L. Eisenstein, Paul 
W. Armstrong, Magnus Ohman, Christopher B. Granger, Robert M. Califf, Robert A. 
Harrington, The Duke Clinical Research Institute, Durham, NC
Background: Bleeding complications are associated with poor outcomes among patients 
with acute coronary syndromes (ACS). There are no data on the impact of bleeding 
events on resource use such as length of stay and cost.
Methods: Using data from the economics and quality of life substudy of the GUSTO IIb 
trial of patients with non ST-segment elevation ACS (N=1235), we assessed the effect 
of GUSTO bleeding on resource use defined by hospital length of stay (LOS) and costs. 
Linear regression was used to determine the independent effect of bleeding severity on 
LOS and total costs. Costs were transformed to reflect 2006 dollars.
Results: 37% of the patients in the study had at least one bleeding event. There was 
a stepwise increase in LOS, hospital costs, and physician costs as bleeding severity 
worsened (Table). After cardiac procedures, bleeding was the most powerful predictor of 
total costs (cost of each moderate/severe bleeding event $3770). Moreover, bleeding was 
the most powerful predictor of LOS (mild bleeding increased LOS 0.83 days; moderate/
severe bleeding increased LOS 6.60 days)(model R2=0.87).
Conclusions: Bleeding is a common complication among patients with ACS and is major 
driver of LOS and costs. Minimizing bleeding complications for ACS patients can result in 
substantial savings to the healthcare system.
Table. LOS and costs by worsening GUSTO bleeding severity 
No bleeding
(N=780)
Mild bleeding
(N=282)
Moderate bleeding
(N=156)
Severe bleeding
(N=17)
Total LOS (days) 5.3 6.9 15.0 16.4
ICU LOS (days) 2.7 3.8 8.9 11.2
Hospital costs $11,447 $17,271 $36,651 $56,921
Physician costs $2,835 $4,403 $9,147 $9,643
Total costs $14,282 $21,674 $45,798 $66,564
2:30 p.m.
851-5 Outcome in Acute Coronary Syndrome Patients 
Managed Surgically Based on Clopidogrel Exposure 
and Delay to Surgery: A Report From the ACUITY Trial
Ramin Ebrahimi, Frederick Feit, Steven Manoukian, A. Michael Lincoff, Cornelius Dyke, 
Bernard Gersh, Roxana Mehran, Jeffery Moses, Gregg Stone, University of California 
Los Angeles/Greater Los ANgeles VA Medical Center, LA, CA, Columbia University 
Medical Center, New York, NY
Background: Clopidogrel (Clop) is often used prior to angiography in non ST elevation 
acute coronary syndrome (ACS) pts. This practice delays coronary artery bypass surgery 
(CABG) due to concerns over increased bleeding. We evaluated Clop exposure and time 
to CABG on 30 day outcomes in pts from the ACUITY trial.
Methods: ACUITY randomized 13,819 ACS pts to 3 upstream pharmacologic regimens 
prior to angiography. Use of Clop, as well as referral to and timing of CABG were at 
investigator discretion. Clop exposure was defined as any Clop use during the index 
hosp. prior to CABG. Time to CABG was defined as the time from last Clop to CABG. 
Patients were divided into 4 groups: Any Clop exposure (Any +Clop), Clop exposure and 
time to CABG <120 hrs (+Clop, ≤120), Clop exposure and time to CABG >120 hrs (+Clop, 
>120) and no Clop exposure (-Clop).
Results: 1539 pts (11.1%) underwent CABG, 708 of whom (46%) had Clop exposure 
prior to CABG. Baseline characteristics including incidence of elevated troponin and ECG 
changes were similar except weight (84.0 kg for -Clop vs. 81.0 kg for +Clop, ≤120 p= 
0.01) and incidence of prior CABG (6.2% for +Clop, ≤120 vs. 3.7% for -Clop, p=0.04).
Conclusions: Clop exposure prior to CABG in pts with ACS is associated with less 
composite ischemia without a significant increase in major bleeding. Among Clop+ pts, 
CABG within 5 days is associated with a slight increase in major bleeding compared to 
waiting >5 days, but not significantly greater than if not exposed to Clop.
Thirty Day Results for ACUITY CABG patients 
Any 
+Clop
N=708
- Clop 
(C)
N= 830
P1 
value
+Clop, ≤120 
(A)
N= 450
+Clop, >120 
(B)
N= 258
P2 
value
Hospital stay (mean 
days) 14.8 11.2 <0.001 13.4 17.3 <0.001
Pre CABG stay (mean 
days) 6.2 3.8 <0.001 3.2 11.5 <0.001
Post CABG stay (mean 
days) 8.4 7.1 <0.001 10.0 5.6 0.006
Net Clin Outcome 15.4% 19.0% 0.06 17.8% 11.2% 0.02
Composite ischemia 12.4% 17.1% 0.01 15.1% 7.8% 0.004
All Major bleeds Post 
CABG 50.3% 50.2% 0.99 54.0% 43.8% 0.009
Reop for Bleed 1.3% 1.4% 0.77 1.6% 0.8% 0.37
Transfusion 38.3% 37.8% 0.86 42.7% 30.6% 0.002
Chest Tube
Output 24 hr (mean) 704.9 ml
688.7 
ml 0.16 724.7 ml 668.3 ml 0.15
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851-6 Platelet Function in Clopidogrel-Treated Patients With 
Acute Coronary Syndrome
Dirk Sibbing, Olga von Beckerath, Albert Schömig, Adnan Kastrati, Nicolas von 
Beckerath, Deutsches Herzzentrum Muenchen, Muenchen, Germany
Background: Percutaneous coronary intervention (PCI) in patients that present with 
an acute coronary syndrome (ACS) is associated with an increased risk of thrombotic 
complications. ACS enhances platelet activation and it is not known whether pretreatment 
with clopidogrel is sufficient to suppress platelet function in patients with ACS. The aim of 
this study was to assess platelet function in patients with and without an ACS prior to PCI 
and after pretreatment with a single dose of 600 mg clopidogrel.
Methods: Blood samples of 402 patients prior to PCI with (n=119) or without (n=283) 
ACS were collected at least 2 hours after administration of 600 mg clopidogrel. Maximal 
platelet aggregation in response to ADP (5 and 20 μM), collagen (4 μg/ml) and TRAP (25 
μM) was measured with optical aggregometry. Surface expression of glycoprotein IIb/IIIa 
(CD61) and P-selectin (CD62) was assessed with flow cytometry at baseline and after 
stimulation with ADP.
Results: Agonist-induced platelet aggregation did not differ significantly between 
patients with and without ACS (P≥0.15). Parameters of platelet activation 
(CD61 and CD62 surface expression) were significantly higher in ACS patients 
at baseline and after stimulation with 5 and 20 μM ADP (see Fig.) (P<0.0001). 
Conclusions: Patients with ACS continue to exhibit increased platelet reactivity even 
after pretreatment with 600 mg of clopidogrel. This finding supports the need of additional 
platelet function inhibition during PCI in patients with ACS. 
3:00 p.m.
851-7 Upstream Therapy With Bivalirudin is as Safe and 
Effective as Heparin for Patients With Acute Coronary 
Syndrome Undergoing Coronary Artery Bypass 
Surgery: A Report From the ACUITY Trial.
Ramin Ebrahimi, Steven Manoukian, Frederick Feit, A. Michael Lincoff, Cornelius Dyke, 
Bernard Gersh, Roxana Mehran, Jeffery Moses, Gregg Stone, UCLA/Greater Los Angeles 
VA Medical Center, Los Angeles, CA, Columbia University Medical Center, New York, NY
Background: Various anticoagulation strategies are utilized in Non-ST elevation 
acute coronary syndromes (ACS) patients treated medically or with percutaneous 
revascularization. The impact of upstream use of different antithrombotic and antiplatelet 
agents on coronary artery bypass surgery (CABG) outcomes has not been widely 
studied. We compared the safety and efficacy of different pharmacologic strategies in 
ACS patients undergoing CABG in the ACUITY trial.
Methods: In ACUITY 13,819 ACS pts were randomly assigned to one of three 
pharmacologic strategies prior to angiography: heparin (unfractionated or enoxaparin) + a 
glycoprotein IIb/IIIa inhibitor (Hep+GPI), bivalirudin + a glycoprotein inhibitor (BIV+GPI), or 
bivalirudin alone (BIV). All patients received heparin for procedural anticoagulation during 
CABG. Adverse outcomes assessed included composite ischemia (death, myocardial 
infarction, unplanned revascularization), major bleeding, net clinical outcomes (ischemia 
or bleeding), transfusion, and chest tube output.
Results: CABG was performed in 1539 (11.1%) pts (84.9% on-pump, 15.1% off-
pump). Baseline demographics and the incidence of on- and off-pump CABG were not 
significantly different between the three groups. Mean time to CABG after randomization 
was 4.5 ± 5.0 days. 
ACUITY 30 Day Results for CABG Patients
Hep + GPI
n=549
Biv + GPI
n= 499
Biv
n= 491
Net Clinical Outcome 18.2% 16.0% 17.7%
Composite Ischemia 15.1% 13.6% 16.1%
Non-CABG Major Bleeding 4.2% 3.6% 2.0%*
All Major Bleeding 52.6% 54.7% 55.6%
Any Blood Transfusion 39.2% 42.3% 43.0%
24hr Chest Tube Output (mean mL) 702.8 681.3 702.5
* p=0.05, Biv alone versus Hep + GPI
Conclusion: In patients with ACS undergoing CABG, upstream BIV alone results in 
similar protection from ischemic complications, major bleeding and net clinical outcomes 
at 30 days compared as Hep+GPI.
3:15 p.m.
851-8 Erythropoietin Predicts The Presence Of Coronary 
Artery Collaterals in ST-segment Elevation Myocardial 
Infarction
Helina Kassahun, Glenn A. Hirsch, James Harkness, Gary Gerstenblith, Susan N. 
Townsend, Steven P. Schulman, Johns Hopkins Medical Institutions, Baltimore, MD
Background: The presence of collaterals to the infarct-related artery (IRA) may influence the 
clinical course in patients with acute myocardial infarctions. In basic laboratory models coronary 
artery collateral vessels derive from endothelial progenitor cells (EPCs) and erythropoietin 
(EPO) is one mediator of EPC elaboration. We assessed the relationship between EPO and 
collaterals and compared this association with that of other postulated correlates in patients 
presenting with first acute ST-segment elevation myocardial infarction (MI).
Methods: The presence of collaterals to the IRA was assessed in 154 consecutive subjects 
with first MI undergoing cardiac catheterization and related to serum EPO levels, using the 
natural log to normalize the data for regressions, as well as to other variables previously 
identified or hypothesized as influencing collateral formation, including age, diabetes, 
smoking status, and glomerular filtration rate (GFR), as determined by the MDRD formula.
Results: The subjects were 69% male with an average age of 60.4 ± 13 years. Forty-nine 
percent had collaterals to the IRA. Mean serum EPO was 27.8 ± 35 μU/mL, hemoglobin 
14.0 ± 2.1 g/dL, and GFR 94.8 ± 33 mL/min. Significant univariate predictors of the 
presence of collaterals to the IRA were the log EPO level (OR 1.50, 95% CI 1.04-2.19), 
age per 10 years (OR 0.72, 95% CI 0.55-0.92), GFR per 10 ml/min (OR 1.14, 95% CI 
1.03-1.27). By multivariate regression only the log EPO level (OR 1.64, 95% CI 1.08-
2.50) was a significant predictor of coronary artery collateral status with age per 10 years 
of borderline statistical significance (OR 0.72, 95% CI 0.52-1.00, p=0.047).
Conclusions:In patients presenting with first MI, increasing serum EPO levels at the 
time of initial hospitalization significantly predict the presence of collaterals to the IRA, 
even after multivariable adjustment. The mechanism may be related to EPO-mediated 
increases in circulating EPCs. Thus, in some patients with acute ischemic syndromes, the 
potential benefits of EPO may extend beyond an influence on red blood cell mass alone.
